Compensation Committee Interlocks and Insider Participation
Dr. Adler and Messrs. Smith and Trotman were members of the Compensation Committee for all of 2016. None of these individuals are or
were a current or former executive officer or employee of WebMD or had any relationships in 2016 requiring disclosure by WebMD under the SECs rules requiring disclosure of certain relationships and related-party transactions.
None of WebMDs executive officers served as a director or a member of a compensation committee (or other committee serving an
equivalent function) of any other entity, the executive officers of which served as a director or member of the WebMD Compensation Committee during 2016.
Compensation Discussion and Analysis
Introduction
. The Compensation Discussion and Analysis contains a description of the specific types
of compensation that WebMD pays, a discussion of our compensation policies, information regarding how the compensation of our Named Executive Officers for 2016 was determined under those policies, and other information that we believe may be useful
to investors regarding compensation of our Named Executive Officers and other employees. Under applicable SEC rules, our Named Executive Officers for this Proxy Statement include each person who served as Chief Executive Officer during 2016, each
person who served as Chief Financial Officer during 2016 and the next three most highly compensated executive officers for 2016, and consist of the following persons:
|
|
|
Steven L. Zatz, M.D., who has served as our Chief Executive Officer since September 2016 and, prior to that, served as our President;
|
|
|
|
Blake DeSimone, who has served as our Chief Financial Officer since September 2016;
|
|
|
|
Martin J. Wygod, our Chairman of the Board;
|
|
|
|
Michael B. Glick and Douglas W. Wamsley, each of whom serves as Co-General Counsel of WebMD;
|
|
|
|
David J. Schlanger, who served as our Chief Executive Officer until September 2016; and
|
|
|
|
Peter Anevski, who served as our Chief Financial Officer until September 2016.
|
Overview of Types of Compensation Used by WebMD
.
The compensation of our Named Executive
Officers and our other executive officers has consisted primarily of some or all of the following, as determined by the Compensation Committee:
|
|
|
Supplemental Bonus Plan (SBP) contributions, which are cash amounts contributed to a trust, which distributes such amounts, with interest earned, after
a specified date if the executive officer remains employed through the specified date;
|
|
|
|
additional or special bonuses to provide recognition for specific accomplishments or at the time of a promotion, if determined by the Compensation
Committee to be appropriate;
|
|
|
|
grants of options to purchase shares of WebMD Common Stock, subject to vesting based on continued employment, with an exercise price that is equal to
the fair market value of WebMD Common Stock on the grant date; and
|
|
|
|
grants of shares of WebMD Restricted Stock, subject to vesting based on continued employment and/or achievement of certain performance criteria.
|
A discussion of how each of the above types of compensation was used for 2016 follows under the heading
Use of Specific Types of Compensation for 2016. The compensation of our other employees generally consists of the same types of compensation, with the specific types and amounts determined by our Chief Executive Officer and
other members of our senior management, in light of the policies described under
22
Overview of Compensation Policies below. In addition, some employees are compensated partially based on commissions or similar arrangements not used at the senior
management level.
We have not offered any retirement plans to our executive officers other than a 401(k) plan that is
generally available to our employees. We refer to the WebMD 401(k) Savings Plan as the 401(k) Plan. Subject to the terms of the 401(k) Plan, WebMD matches, in cash, 50% of amounts contributed to that Plan by each Plan participant, up to 6% of
eligible pay. The matching contribution made by WebMD is subject to vesting, based on continued employment, with 50% scheduled to vest on each of the first and second anniversaries of an employees date of hire (with employees vesting
immediately in any matching contribution made after the second anniversary). Named Executive Officers who have elected to contribute to the 401(k) Plan received matching contributions on the same basis as other participants.
In determining the forms of compensation to be used by WebMD, the Compensation Committee considers various factors, including the
effectiveness of the incentives provided, tax and accounting considerations, the compensation practices of other companies and the expectations of our employees and our investors. In addition, the Compensation Committee believes that it is important
that compensation be understood by the employees who receive it and by our companys investors. See Overview of Compensation Policies below for additional discussion of the goals of our compensation programs and how they
are implemented. The Compensation Committee believes that our compensation programs, including the types of equity awards that we use, are effective forms of compensation and well understood. Taken as a whole, our compensation programs are intended
to provide incentives to employees, at various levels of seniority and responsibility, to work to achieve revenue and earnings growth for WebMD in both the short-term and the long-term. The Compensation Committee believes that, in light of the
specific forms of compensation that WebMD uses and the specific businesses in which WebMD is engaged, our compensation programs and practices are unlikely to cause our employees to take unnecessary or excessive risks to achieve that growth and that
WebMDs internal controls and compliance programs provide reasonable mitigation for the risks inherent in providing incentives for such growth.
Outreach to Investors in Connection with the 2016 Say-on-Pay Vote and Key Changes Made in Response.
At our 2016 Annual Meeting of Stockholders, the ballot included an
advisory vote on executive compensation, commonly known as a Say-on-Pay vote. Approximately 67.5% of the votes cast were FOR the compensation of the executive officers as disclosed in the Executive Compensation
section of the proxy statement for the 2016 Annual Meeting. Although Say-on-Pay votes are not binding, the Compensation Committee took this result, and input from stockholders (as described below) into consideration in connection with
its implementation of our executive compensation program since the 2016 Annual Meeting and intends to continue to consider the outcome of annual advisory votes and related input from stockholders when making future executive compensation decisions.
WebMD has sought and received input from its stockholders regarding WebMDs compensation practices as part of the process of soliciting proxies for our past several Annual Meetings of Stockholders, including the 2016 Annual Meeting of
Stockholders. In each of the past three years, we have made efforts to reach out to those we believed held 0.5% or more of our Common Stock (which, in the aggregate, generally represented at least 50% of our outstanding Common Stock) and spoke to
all holders who indicated a willingness to provide their views. We also have regular contact with our stockholders at other points in the year, including at investor conferences and in meetings and telephone calls, during which we address areas of
interest to them, including corporate governance and executive compensation, and seek their views on those and other matters. In particular, stockholders that we spoke to in connection with and following the 2016 Annual Meeting:
|
|
|
expressed a preference that WebMD begin to use performance-based restricted stock as a component of its equity grants, beginning with the most senior
executives and later extending to other senior executives;
|
|
|
|
requested that WebMD continue, in 2017 and future years, the policy begun for 2016 to have an annual bonus program for its executive officers that
relies primarily on pre-set financial goals in determining annual cash bonuses and to include appropriate disclosure regarding how annual bonuses were calculated under the 2016 Bonus Program in this Proxy Statement for the 2017 Annual Meeting (and
similar disclosure regarding future programs in future proxy statements);
|
23
|
|
|
indicated their belief that WebMD should adopt a clawback policy; and
|
|
|
|
noted that, while they were generally satisfied with the stockholdings of WebMDs directors and officers, they believed that a formal policy
regarding those holdings should be adopted.
|
WebMDs Compensation Committee has, since the 2016 Annual
Meeting;
|
|
|
included performance-based restricted stock as a component of the equity grants made on November 2, 2016 for our Chief Executive Officer and
Chairman of the Board and expects to expand this practice to additional executive officers if grants are made in the future, as more fully described in Use of Specific Types of Compensation for 2016 Grants of Options,
Restricted Stock and Performance-Based Restricted Stock in 2016 below;
|
|
|
|
established a structure for WebMDs 2017 Bonus Program for Executive Officers similar in approach to the 2016 Bonus Program, as more fully
described in 2017 Bonus Program at the end of this Compensation Disclosure and Analysis section;
|
|
|
|
caused there to be included, in this Proxy Statement, disclosure of the pre-set financial goals that applied under the 2016 Bonus Program and how the
bonuses under that Program were determined (see Use of Specific Types of Compensation for 2016 2016 Bonus Program below);
|
|
|
|
adopted a clawback policy, as more fully described in Clawback Policy below; and
|
|
|
|
adopted formal stock ownership guidelines applicable to our executive officers and non-employee directors, as more fully described in
Stock Ownership Guidelines below.
|
The Compensation Committee also took input from
stockholders into account in other decisions it has made in recent years, including:
|
|
|
making a commitment that none of the 1,700,000 shares added to the 2005 Plan at the 2015 Annual Meeting would be available for future grants to members
of WebMDs Board of Directors or to WebMDs executive officers, except in the case of a new hire who joins WebMD as an executive officer;
|
|
|
|
implementing the 2016 Bonus Program;
|
|
|
|
retaining an independent compensation consultant to assist in implementing the bonus plan structure and other matters relating to the compensation of
WebMDs executive officers, as more fully described in Corporate Governance Committees of the Board of Directors Compensation Committee above; and
|
|
|
|
implementing the policies and procedures described below under Specific Policies and Practices to Protect Stockholder Interests in Connection
with Our Equity Compensation Plans below.
|
Overview of Compensation
Policies
. The Compensation Committees guiding philosophy is to establish a compensation program that is:
|
|
|
Competitive with the market in order to help attract, motivate and retain highly qualified employees and executives.
We
seek to attract and retain talent by offering competitive base salaries, annual cash incentive opportunities, and the potential for long-term rewards through equity-based awards, such as stock options and restricted stock. Our employees and
executives are highly sought after by other companies because of WebMDs leadership position in providing health and wellness content and tools through the Internet and mobile applications. In New York City, where our headquarters is located,
competition for talent is especially intense. Our writers and editors, our software developers and other technical personnel, our sales and marketing personnel, and our executives are recruited for positions at numerous other Internet and
information technology companies, particularly those focused on health, wellness and related areas, with offers coming to them from our existing competitors and from other established companies as well as from venture capital backed companies and
other start-ups.
|
|
|
|
Performance-based to link executive pay to company performance over the short term and long term and to facilitate shareholder value creation.
It is WebMDs practice to provide compensation opportunities that are linked to our companys performance and the individuals performance. Through annual and
|
24
|
long-term incentives, a major portion of the total potential compensation of WebMDs executive officers (and other members of senior management) is placed at risk in order to motivate them
to improve the performance of our businesses and to increase the value of our company.
|
|
|
|
Achievement of short-term goals is rewarded through annual cash bonuses. For 2016, our Compensation Committee implemented a new annual bonus program
for executive officers (which we refer to as the 2016 Bonus Program), with pre-set financial goals that were intended to more closely tie annual bonus compensation to WebMDs performance, as described under Use of Specific Types of
Compensation for 2016 2016 Bonus Program below. The Compensation Committee has adopted a similar program for 2017 (which we refer to as the 2017 Bonus Program and which is described at the end of this Compensation Discussion and
Analysis) and expects to continue to implement, for future years, annual bonus programs that rely primarily on pre-set financial goals for determining the amounts of the bonuses for WebMDs executive officers.
|
|
|
|
Achievement of long-term objectives is encouraged through grants of nonqualified stock option and restricted stock awards that are generally subject to
vesting over a three or four year period. The compensation that employees receive from equity awards increases when the price of WebMD Common Stock increases, which rewards employees for increasing shareholder value. The vesting schedules applicable
to these equity awards are intended to promote retention of employees during the vesting period. The equity compensation is offered in lieu of higher cash compensation in order to align the interests of our employees with the long-term interests of
our stockholders. We generally use two types of long-term incentives: non-qualified stock options and restricted stock. Stock options are granted with an exercise price that is equal to the fair market value of WebMD Common Stock on the grant date.
Thus, participants in our equity plans (including the Named Executive Officers) will realize value on their stock options only if the price of WebMD Common Stock increases after the grant date. The Compensation Committee believes that WebMDs
equity compensation encourages employees to focus on the long-term performance of our company. Starting in November 2016 with grants to our Chief Executive Officer and our Chairman of the Board, the Compensation Committee has granted
performance-based restricted stock, as described in Use of Specific Types of Compensation for 2016 Grants of Options, Restricted Stock and Performance-Based Restricted Stock in 2016 below, a form of compensation that the
Compensation Committee believes can further align the interests of our executives with those of our stockholders. The Compensation Committee expects to expand this practice to additional executive officers if grants are made in the future.
|
|
|
|
Designed to foster a long-term commitment by management.
The Compensation Committee believes that there is great value to our company in having
a team of long-tenured, seasoned executives and managers. Our compensation practices are designed to foster a long-term commitment to WebMD by our management team. Our recently adopted Stock Ownership Guidelines are intended to further this
objective.
|
Roles of Compensation Consultant and of Management.
As discussed more fully in
Corporate Governance Committees of the Board of Directors Compensation Committee above, the Compensation Committee retained the Arthur J. Gallagher & Co. (which we refer to as Gallagher) Human Resources &
Compensation Consulting Practice in late 2015 to assist it in implementing the compensation policies described above and making specific decisions relating to executive compensation. Gallagher provides information, analysis and advice that assists
the Compensation Committee in the performance of its duties. Since its engagement, Gallagher has assisted the Compensation Committee by working with it to develop a peer group of other public companies for use in its analyses (described in the next
section below), by benchmarking WebMDs executive compensation against such peer group and by assisting in implementing bonus programs and making other determinations regarding the compensation of WebMDs executive officers described in
this Compensation Discussion and Analysis. Going forward, the Compensation Committee expects to request information and advice from Gallagher when it deems appropriate in order to assist it in structuring and evaluating WebMDs executive
compensation programs and practices. However, the Compensation Committees decisions about
25
executive compensation, including the specific types and amounts of compensation to be paid to executive officers, will continue to be its own and may reflect factors and considerations other
than information and advice provided by Gallagher.
With respect to 2016 compensation, the Compensation Committee considered
recommendations made by the Chairman of the Board and the Chief Executive Officer with respect to determinations of the types and amounts of compensation to be paid to the other executive officers, and also discussed with them the types and amounts
they believed would be appropriate to pay each of them in light of the amounts being recommended for, and paid to, the other WebMD executive officers. The key compensation decisions for 2016 for which the Chairman of the Board and the Chief
Executive Officer provided input to the Compensation Committee relating to WebMDs executive officers included the amounts of the portion of the annual bonuses for 2016 based on individual goals and the equity grants made to executive officers
in November 2016, as more fully described under Use of Specific Types of Compensation for 2016 below. In addition, the Chairman of the Board and the Chief Executive Officer have discussions, from time to time, with the
Compensation Committee and the full Board of Directors regarding compensation policies generally, compensation planning and other compensation matters unrelated to specific compensation decisions and give their views on these matters to the members
of the Compensation Committee and the full Board. The Compensation Committee seeks the input from the Chairman of the Board and the Chief Executive Officer because they believe that understanding managements views regarding managements
own performance helps the Compensation Committee apply the compensation policies discussed earlier in this section to specific compensation decisions. However, all the decisions regarding the compensation paid to executive officers of WebMD for 2016
were made by the Compensation Committee.
Peer Group.
As noted above, Gallaghers engagement by the
Compensation Committee has included working with the Committee to develop a peer group of other public companies for use in Gallaghers analyses for the Committee. In late 2015, Gallagher recommended, and our Compensation Committee approved,
the following peer company group (which we refer to as the Peer Group):
|
|
|
|
|
Name of Company
|
|
GICS Code
|
|
Industry Group
|
Advisory Board Co.
|
|
20202020
|
|
Research & Consulting Services
|
Angies List, Inc.
|
|
45101010
|
|
Internet Software & Services
|
athenahealth, Inc.
|
|
35103010
|
|
Healthcare Technology
|
Bankrate, Inc.
|
|
45101010
|
|
Internet Software & Services
|
Blucora, Inc.
|
|
45101010
|
|
Internet Software & Services
|
Constant Contact, Inc.
|
|
45101010
|
|
Internet Software & Services
|
CoStar Group Inc.
|
|
45101010
|
|
Internet Software & Services
|
DHI Group Inc.
|
|
45101010
|
|
Internet Software & Services
|
Everyday Health, Inc.
|
|
45101010
|
|
Internet Software & Services
|
E.W. Scripps Class A
|
|
25401020
|
|
Broadcasting
|
Healthways, Inc.
|
|
35102015
|
|
Healthcare Services
|
Media General, Inc.
|
|
25401020
|
|
Broadcasting
|
Meredith Corp.
|
|
24301040
|
|
Publishing
|
Monster Worldwide, Inc.
|
|
45101010
|
|
Internet Software & Services
|
Nexstar Broadcasting Group
|
|
25401020
|
|
Broadcasting
|
Pandora Media, Inc.
|
|
45101010
|
|
Internet Software & Services
|
Press Ganey Holdings, Inc.
|
|
35103010
|
|
Healthcare Technology
|
Yelp Inc.
|
|
45101010
|
|
Internet Software & Services
|
Zillow Group, Inc.
|
|
45101010
|
|
Internet Software & Services
|
26
In February 2017, the Peer Group was revised to remove Constant Contact, Everyday Health
(which was acquired by J2 Global Inc., a company that was added to the Peer Group as noted below), Media General (which was acquired by Nexstar Broadcasting, a company that remains in the Peer Group), Monster Worldwide, and Press Ganey Holdings
since those companies had been acquired by other companies and to add the following companies:
|
|
|
|
|
Name of Company
|
|
GICS Code
|
|
Industry Group
|
Gray Television Inc.
|
|
25401020
|
|
Broadcasting
|
J2 Global Inc.
|
|
45101010
|
|
Internet Software & Services
|
XO Group Inc.
|
|
45101010
|
|
Internet Software & Services
|
The Peer Group is intended to include companies that have business models similar to WebMDs and/or
are likely to compete with WebMD for talent. Accordingly, the Peer Group consists primarily of companies that rely on advertising and sponsorship for revenue or that provide services to employers and health plans that are similar to the services we
provide under our
WebMD Health Services
brand. Some of those companies have the same GICS Code as WebMD (Internet Software and Services), but that GICS Code also includes numerous Internet-related companies that have very different
capabilities and sources of revenue than WebMD. Accordingly, the Peer Group also includes companies outside the Internet Software and Services industry group that publish or broadcast content and derive revenue primarily from advertisers and
sponsors. Another reason to include these companies is that they are increasingly using the Internet to reach their audiences, even if their original business involved other media. The Peer Group was also intended to have median revenue and market
capitalization that were reasonably close to WebMDs revenue and market capitalization. In addition to information and analyses based on compensation practices of the Peer Group, Gallagher also provides information and analyses to the
Compensation Committee based on the compensation and corporate governance practices of larger groupings of public companies, including companies included in the Russell 3000 in the same industry group as WebMD.
Our Compensation Committee reviewed information and analyses provided by Gallagher regarding the compensation practices of the Peer Group
in connection with the Committees determinations regarding the compensation of WebMDs executive officers for 2016, but did not use that information and those analyses to benchmark to any particular level.
Specific Policies and Practices to Protect Stockholder Interests in Connection with Our Equity Compensation
Plans
. The Compensation Committee has implemented, in the 2005 Plan and in WebMDs agreements relating to equity compensation, the following policies and practices to protect our stockholders interests:
|
|
|
20% Sublimit for Full Value Awards
. In 2010, the Compensation Committee implemented a sublimit on the number of shares
available for grants of restricted stock and similar types of awards for which no exercise or purchase price is payable (often referred to as full value awards) so that only 20% of the shares available for grant could be used for full
value awards. The same 20% sublimit applies to the shares added to the 2005 Plan since then.
|
|
|
|
Minimum Vesting Period for Full Value Awards
. The 2005 Plan provides that, for full value awards, the vesting period
shall occur over at least a three-year period for awards with time-based vesting conditions, and shall be at least one year for awards with performance-based vesting conditions, with limited exceptions.
|
|
|
|
No Liberal Share Counting
. Shares tendered or held back upon exercise of a stock option to cover the exercise price or
tax withholding or for tax withholding on vesting of restricted stock are not returned to the pool of shares available for issuance.
|
|
|
|
No Annual Evergreen Provision
. The 2005 Plan authorizes only a fixed number of shares, and stockholder
approval is required for any increase in the number of shares.
|
|
|
|
No Discounted Stock Options
. All stock options must have an exercise price equal to or greater than the fair market value
of our Common Stock on the date of grant.
|
|
|
|
No Repricing
. The 2005 Plan prohibits the repricing of stock options without stockholder approval.
|
27
|
|
|
Impact of a Change of Control on Equity Awards
. Under the 2005 Plan, vesting of equity awards on a
Change of Control applies only to grants to our Non-Employee Directors, which our Board believes is consistent with good corporate governance. Under the provisions of the 2005 Plan, there is no effect on grants made to WebMD officers and
other employees as a result of a Change of Control. Certain of our executive officers and other senior officers are parties to employment agreements or equity award agreements that contain specific provisions relating to a change of
control. For additional information, see Compensation Following Termination of Employment or a Change of Control and Employment Agreements with Named Executive Officers below.
|
|
|
|
Anti-Hedging Policy
. Our existing policies relating to trading in WebMD securities by WebMDs executive officers and
other senior executives prohibit hedging transactions with respect to their holdings in WebMD securities.
|
Stock Ownership Guidelines
. In 2017, the Compensation Committee adopted stock ownership guidelines
for our executive officers and Non-Employee Directors in order to further align their interests with those of our stockholders and in response to investor input requesting adoption of such guidelines. These guidelines require our executive officers
and Non-Employee Directors to achieve an ownership level, within five years of the adoption of the guidelines, that the Compensation Committee believes to be appropriate for their specific positions. The table below sets forth the applicable stock
ownership guidelines:
|
|
|
Executive Officer/Director
|
|
Stock Ownership Guideline
|
CEO
|
|
5 times Base Salary
|
Chairman of the Board
|
|
5 times Base Salary
|
All other executive officers
|
|
2 times Base Salary
|
Non-employee Directors
|
|
3 times Base Annual Retainer
|
Once a Non-Employee Director or executive officer meets the ownership level set forth in the table, the ownership
guideline becomes a requirement to hold the number of shares that such individual held at the time of meeting the guidelines, and the individual is permitted to sell shares that he or she owns that exceed that. As of April 18, 2017, all of our
executive officers met the applicable stock ownership guidelines and all of our
Non-Employee
Directors met the applicable stock ownership guidelines, other than the two Non-Employee Directors most recently
added to the Board.
Clawback Policy
. In 2017, the Compensation Committee adopted a clawback policy in light of
the fact that WebMD had begun to base executive officer bonuses (starting in 2016) primarily on pre-set financial goals and in response to investor input requesting adoption of such a policy. The compensation programs covered under this policy
currently include: the 2016 Bonus Program and the performance-based restricted stock issued in November 2016. Going forward, the 2017 Bonus Program, any future performance-based restricted stock and any other compensation that is determined based on
our financial performance will be covered by the Clawback Policy. Under the Clawback Policy, in the event of a financial restatement arising out of any willful act or omission that constitutes fraud or intentional misconduct by an executive officer
of WebMD, the Compensation Committee shall have the authority to require relinquishment (clawback) by such executive officer of previously awarded bonuses or performance-based restricted stock to the extent such compensation would not have been
earned based on the restated financial results.
Use of Specific Types of Compensation for 2016
Base Salary.
The Compensation Committee reviews the base salaries of our executive officers from time to time and in connection
with changes in position. In November 2016, the annual salary rate of Dr. Zatz was increased from $500,000 to $575,000 following his promotion to Chief Executive Officer and the salary of Mr. DeSimone was increased from $367,500 to
$400,000 following his promotion to Chief Financial Officer. Also, in November 2016, the annual salary rate for Messrs. Glick and Wamsley was increased from $350,000 to $375,000. The Compensation Committee considers various factors when it
contemplates an adjustment to base salary, including: the executives individual performance, scope of responsibility and changes in that scope
28
(including as a result of promotions), tenure, prior experience and market practice. WebMDs senior management considers similar factors in determining whether to make adjustments to
salaries of other employees.
2016 Bonus Program
. The 2016 Bonus Program was adopted by the Compensation Committee in
April 2016. The participants in the 2016 Bonus Program were the executive officers of WebMD at the time of adoption. Under the 2016 Bonus Program, 70% of each participants maximum potential bonus (or 60% in the case of Mr. Wygod) was
based upon the level of achievement of pre-set goals for revenues and Adjusted EBITDA for 2016; and 30% of their maximum potential bonus (or 40% in the case of Mr. Wygod) was based upon individual performance of each participant in 2016. In March
2017, the Compensation Committee approved the following annual cash bonuses under the 2016 Bonus Program for the participants listed below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Title
|
|
Maximum
Potential
Bonus for
2016
|
|
|
Actual 2016
Bonus
|
|
|
Actual Bonus as a
Percent of Maximum
Potential Bonus
|
|
Steven L. Zatz, M.D.
|
|
Chief Executive Officer
|
|
$
|
862,500
|
|
|
$
|
537,317
|
|
|
|
62
|
%
|
Michael Glick
|
|
Executive Vice President &
Co-General Counsel
|
|
$
|
262,500
|
|
|
$
|
163,531
|
|
|
|
62
|
%
|
Douglas Wamsley
|
|
Executive Vice President &
Co-General Counsel
|
|
$
|
262,500
|
|
|
$
|
163,531
|
|
|
|
62
|
%
|
Martin Wygod
|
|
Chairman of the Board
|
|
$
|
720,000
|
|
|
$
|
453,621
|
|
|
|
63
|
%
|
The maximum potential bonuses for the above participants under 2016 Bonus Program were the following
percentages of their salary: 150% for Dr. Zatz; 70% for Messrs. Glick and Wamsley; and 147% for Mr. Wygod. The actual amounts paid under the 2016 Bonus Program to the participants were determined as follows:
|
|
|
Portion Based on Pre-Set Financial Goals
. Under the 2016 Bonus Program: 70% of each participants maximum potential
bonus (or 60% in the case of Mr. Wygod) was based upon the level of achievement of pre-set goals for revenues and Adjusted EBITDA for 2016, divided as follows:
|
|
|
|
Pre-Set Revenue Goals
. Up to 40% (or 35% in the case of Mr. Wygod) of each participants maximum potential
bonus under the 2016 Bonus Program was payable based on the level of revenue of WebMD for 2016, with no payment for revenue below $680 million and a maximum payment for revenue of $732 million or more. Actual revenue for 2016 was $705 million and
resulted in payment of 50.3% of the potential maximum payment for this portion of the bonus.
|
|
|
|
Pre-Set Adjusted EBITDA Goals
. Up to 30% (or 25% in the case of Mr. Wygod) of each participants maximum
potential bonus under the 2016 Bonus Program was payable based on the level of Adjusted EBITDA of WebMD for 2016, with no payment for Adjusted EBITDA below $215 million and the maximum payment for Adjusted EBITDA of $247.5 million or more. Actual
Adjusted EBITDA for 2016 was $230.6 million and resulted in payment of 45.6% of the maximum payment for this portion of the bonus.
|
For purposes of the 2016 Bonus Program, Adjusted EBITDA is used with the same meaning as used in Annex C to this Proxy Statement (the MD&A Annex), which also contains a reconciliation of
net income to Adjusted EBITDA for 2016, and as discussed in Annex G to this Proxy Statement (Explanation of Non-GAAP Financial Measures).
|
|
|
Portion Based on Individual Performance
. Up to 30% of each participants maximum potential bonus (or 40% in the case
of Mr. Wygod) under the 2016 Bonus Program was payable based on individual performance and was determined by the Compensation Committee in its discretion; provided, however, that no such bonuses would have been payable if revenue had been less
than $680 million or Adjusted EBITDA had been less than $215 million (the respective minimum amounts needed for a payment to be made pursuant to the portions of the 2016 Bonus Program described above). The Compensation Committee determined to pay
95% of the maximum payment for this portion of the bonus for the Named Executive Officers, other than to Mr. Wygod for whom it was 85% of such maximum. Among the factors
|
29
|
considered by the Compensation Committee in the determination of the portion of the bonuses payable for individual performance to each of the participants were their respective contributions with
respect to the following in 2016:
|
|
|
|
the changes in executive management in September 2016, which resulted in a smooth transition when Dr. Zatz became Chief Executive Officer of WebMD
and Mr. DeSimone became Chief Financial Officer of WebMD without disruption to relations with clients, employees or strategic partners;
|
|
|
|
product development and enhancement initiatives during the year, including the launch of
MedscapeTV
, the launch of
WebMDRx
,
Medscape
Consult
reaching over 200,000 physicians in its first 12 months, development of voice recognition applications for Google Home and Amazon Alexa, significant progress in converting consumer and professional sites to responsive design, significant
progress on relaunch of WebMDs Symptom Checker, and improvements to WebMDs technology infrastructure;
|
|
|
|
efforts to respond to changes made by Google in how it presents health search results, which caused a decline in traffic being referred by Google
searches to many health information Websites, including WebMD consumer sites; this included efforts to continue to grow traffic in areas of most value to sponsors through content development and newsletters and other cross-promotion efforts, which
more than offset the impact of the Google changes in these important areas; and
|
|
|
|
continued improvements in the monetization of Medscapes content offerings for physicians outside the United States.
|
The bonuses paid under the 2016 Bonus Program were approximately 23% to 27% lower than the total bonuses for these individuals for 2015 (which, for that
year, included both an amount paid in cash and an amount contributed to the Supplemental Bonus Trust). No bonuses were payable to any of the participants in the 2016 Bonus Program outside of that program.
Mr. DeSimone became Chief Financial Officer and an executive officer of WebMD in September 2016, after the 2016 Bonus Program was
implemented. The Compensation Committee determined, in its discretion, that Mr. DeSimones bonus for 2016 was $202,000. The Compensation Committee took into consideration similar factors as those applicable to the bonus payments to the
participants in the 2016 Bonus Program and also took into consideration Mr. DeSimones taking on the role of Chief Financial Officer and the smooth transition that was achieved.
David Schlanger, former Chief Executive Officer of WebMD, was entitled to receive the amount of his bonus, as determined by the
Compensation Committee under the 2016 Bonus Program, as part of his severance. Mr. Schlangers bonus under the 2016 Bonus Program was determined by the Compensation Committee to be $266,983, which represented the amount calculated based
solely on WebMDs level of achievement of revenue and Adjusted EBITDA.
Grants of Options, Restricted Stock and
Performance-Based Restricted Stock in 2016
. The Compensation Committee does not make equity grants to our executive officers on an annual or other pre-determined basis. In determining whether and when to make equity
grants, the Compensation Committee considers the history of prior grants made to individual executive officers, their vesting status and the retention value of those grants. In addition, the Compensation Committee considers factors similar to those
it considers in its decisions relating to cash compensation, as described above, including factors relating to individual and company performance. Finally, the Compensation Committee typically makes larger grants to the executive officers it
believes have the greatest potential to affect the value of our company and improve results for stockholders. The Compensation Committee approved the following grants of shares of WebMD Restricted Stock and options to purchase WebMD Common Stock to
Named Executive Officers on November 2, 2016:
30
|
|
|
|
|
|
|
|
|
|
|
Named Executive Officer
|
|
Title
|
|
Number of Shares of
WebMD Restricted Stock
|
|
|
Number of Shares of
WebMD Common Stock
Underlying Option
Grant
|
|
Steven L. Zatz, M.D.
|
|
Chief Executive Officer
|
|
|
30,000
|
|
|
|
150,000
|
|
Blake DeSimone
|
|
Executive Vice President and
Chief Financial Officer
|
|
|
16,000
|
|
|
|
80,000
|
|
Michael B. Glick
|
|
Executive Vice President and
Co-General Counsel
|
|
|
15,000
|
|
|
|
75,000
|
|
Douglas W. Wamsley
|
|
Executive Vice President and
Co-General Counsel
|
|
|
15,000
|
|
|
|
75,000
|
|
Martin J. Wygod
|
|
Chairman of the Board
|
|
|
25,000
|
|
|
|
100,000
|
|
The shares of WebMD Restricted Stock and the options were granted under the 2005 Plan. The options were granted with an
exercise price of $49.00 per share, the closing price of WebMD Common Stock on the date of grant. The options are scheduled to expire on the tenth anniversary of the date of grant. For the grants of both the WebMD Restricted Stock and the options,
one-third of the amount granted is scheduled to vest on each of the second through fourth anniversaries of the date of grant, other than the grants made to Mr. DeSimone which are scheduled to vest in equal annual installments of 25% commencing on
the first anniversary of the date of grant.
Also on November 2, 2016, the Compensation Committee approved the grant of
30,000 shares of performance-based restricted stock to Dr. Zatz and 25,000 shares of performance-based restricted stock to Mr. Wygod under the 2005 Plan. The grants will vest and be earned so long as the executive is employed at the end of
the performance period, December 31, 2019, and only to the extent that the Compensation Committee determines that the performance criteria have been satisfied, except as described below. The performance criteria are based on average Adjusted
EBITDA during the performance period of January 1, 2016 through December 31, 2019. The Compensation Committee will determine average Adjusted EBITDA (which may be equitably adjusted by the Compensation Committee for certain extraordinary
corporate events so as not to enlarge or dilute the awards) within 45 days after WebMDs filing of its audited financial statements for 2019. Satisfaction of a threshold level of average Adjusted EBITDA will result in the vesting of 50% of the
shares subject to the award (15,000 for Dr. Zatz and 12,500 for Mr. Wygod), with vesting of up to an additional 50% of the shares determined based on linear interpolation for levels of average Adjusted EBITDA between that threshold and the
higher level required to achieve vesting of all of the shares.
For additional information regarding the November 2, 2016
grants, including a description of the provisions regarding the effect of termination of employment, see Employment Agreements with Named Executive Officers below and the tables included below, including the table titled Grants of
Plan-Based Awards in 2016 below, and the related notes and commentary that accompany those tables. As of the date of the filing of this Proxy Statement, no grants of WebMD Restricted Stock or options to purchase WebMD Common Stock had been
granted to any of our executive officers since the November 2, 2016 grants.
Generally, for our Named Executive Officers,
the most significant form of compensation is the options to purchase WebMD Common Stock granted to them under the 2005 Plan. Our employees (including our Named Executive Officers) receive value from stock options only if the price of WebMD Common
Stock increases over the price on the grant date, which rewards employees for increasing stockholder value and aligns their interests with the long-term interests of our stockholders. These options vest over time (generally over a period of three to
four years) and the vesting schedules applicable to these option grants are intended to promote retention of employees during the vesting period. However, as required under applicable SEC rules, in calculating the dollar value of grants contained in
this Proxy Statement (including in the Summary Compensation Table), WebMD includes the full grant date fair value of option grants (estimated using the Black-Scholes Option Pricing Model) as compensation in the year in which the grant is made and no
compensation for such grants in any other year, regardless of the vesting schedule of the grant. Similarly, the full fair value of a grant of shares of WebMD Restricted Stock is required to be reported in the year of grant and no compensation for
such grants in any other year, regardless of the vesting schedule. The Compensation Committee considers the vesting schedule of these grants to be an important term of such grants and believes that it is appropriate, in its consideration of the
timing
31
and amount of specific grants it approves, to view the value of such grants to be compensation provided over a period of time as the options vest, rather than assigned solely to the year of
grant.
Application of Compensation Policies to Individual Named Executive Officers
. Differences
in compensation among our Named Executive Officers result from a number of factors and may vary from year to year. The key factors that may create differences in compensation are differences in:
|
|
|
the position and level of responsibility of the individual Named Executive Officers and changes in position or level of responsibility;
|
|
|
|
our need to induce specific individuals to join WebMD at the time of their initial hiring; and
|
|
|
|
our need to motivate and retain specific individuals at other specific points in time.
|
In general, larger equity grants are made to our most senior executive officers because they have the greatest potential to affect the value of our
company and to improve results for stockholders. Similarly, a greater portion of their total cash compensation is likely to come from their annual bonus.
The key individualized determinations with respect to the Named Executive Officers for 2016 were in connection with the grants of options and shares of WebMD Restricted Stock in November 2, 2016, as
described under Grants of Options, Restricted Stock and Performance-Based Restricted Stock in 2016 above, and the portion of the bonus determination process for 2016 based on individual performance, as described in
2016 Bonus Program above. In determining the size of the grants to Dr. Zatz and Mr. DeSimone in November 2016 and the other changes to their terms of employment made at that time, the Compensation Committee took into
consideration that, in September 2016, Dr. Zatz had been promoted to Chief Executive Officer and that Mr. DeSimone had been promoted to Chief Financial Officer, with no changes made in their compensation at the time of such promotions. In
determining to grant performance-based restricted stock only to Dr. Zatz and Mr. Wygod in November 2016, the Compensation Committee believed that it was appropriate, as a first step toward including this type of restricted stock in WebMDs
executive compensation more generally, to begin with the two most highly compensated Named Executive Officers.
Benefits and
Perquisites
. The limited perquisites (or perks) received by our Named Executive Officers in 2016 are described in the footnotes to the Summary Compensation Table. Our executive officers are generally eligible
to participate in our benefit plans on the same basis as our other employees, including matching contributions to the 401(k) Plan and company-paid group term life insurance, the cost of which is listed in those footnotes to the Summary Compensation
Table. For the past several years, we have maintained a sliding scale for the cost of employee premiums for our health plan, under which employees with higher salaries pay a higher premium amount. Our executive officers (as part of a larger group of
employees generally having a title of Vice President or higher or a salary of $180,000 or more) receive company-paid supplemental disability insurance, the cost of which is listed in the footnotes to the Summary Compensation Table.
Compensation Following Termination of Employment or a Change of Control
Overview.
WebMD does not offer any retirement plans to our executive officers, other than a 401(k) plan
generally available to our other employees. Accordingly, the payment and benefit levels for WebMDs Named Executive Officers applicable upon a termination or a change of control result primarily from provisions in the employment agreements or
specific equity award agreements between WebMD and the individual Named Executive Officers. The employment agreements with our Named Executive Officers are described under the heading Employment Agreements with Named Executive Officers
below and summaries of the types of provisions relating to post-termination compensation contained in those agreements are included in this section under the headings Employment Agreement Provisions Regarding Termination Benefits
and Employment Agreement Provisions Regarding Change of Control Benefits below. The Compensation Committee has generally been willing to include provisions relating to potential terminations and changes of control in connection
with the renewal of or extensions to an employment agreement with an existing executive officer that are similar to those in the existing employment agreement with that executive officer.
32
In determining whether to approve executive officer employment agreements (or amendments of
or extensions to those agreements), the Compensation Committee considers our need for the services of the specific individual and the alternatives available to us, as well as potential alternative employment opportunities available to the individual
from other companies. In considering whether to approve employment agreement terms that may result in payments and other benefits for executives that could become payable following a termination or change of control, the Compensation Committee
considers both the costs that could be incurred by our company, as well as the benefits to our company, including benefits to our company from post-termination confidentiality, non-solicit and non-compete obligations imposed on the executive and
provisions relating to post-termination services that may be required of the executive. In the case of potential payments and other benefits that could become payable following a change of control, the Compensation Committee considers whether those
provisions would provide appropriate benefit to an acquirer and to WebMD, in light of the potential cost to be incurred, given that such provisions encourage our executives to remain employed while a change of control transaction is pending and
provide for a transition period following consummation of a change of control.
Employment Agreement Provisions Regarding
Termination Benefits
. Certain of the employment agreements with our Named Executive Officers provide, or have provided, for some or all of the following to be paid or provided to the executive officer if he or she is
terminated without cause or resigns for good reason (the definitions of which are typically set forth in the applicable employment agreement), dies or ceases to be employed as a result of disability:
|
|
|
continuation of cash compensation (including salary and, in some cases, an amount based on past bonuses) for a period following termination and, if the
termination follows a change of control, payment of amounts previously contributed by WebMD on his or her behalf to WebMDs Supplemental Bonus Plan;
|
|
|
|
continuation or acceleration of vesting and/or exercisability of some or all options or restricted stock; and
|
|
|
|
continued participation in certain of our health and welfare insurance plans or payments in respect of COBRA premiums.
|
The amount and nature of these benefits vary by individual, with the most senior of executive officers typically receiving more of these
benefits and receiving them for longer periods. These benefits also vary depending on the reason for the termination and whether the termination follows a Change of Control (as more fully described under Employment Agreement Provisions
Regarding Change of Control Benefits below). See Employment Agreements with Named Executive Officers below for a description of the specific provisions that apply to specific Named Executive Officers and Potential Payments
and Other Benefits Upon Termination of Employment or a Change of Control below for a sample calculation, based on applicable SEC rules, of the amounts that would have been payable if termination for specified reasons had occurred on
December 31, 2016. No such post-termination benefits apply if a Named Executive Officer is terminated for cause. The Compensation Committee believes that the protections provided to executive officers by the types of employment agreement
provisions described above are appropriate for the attraction and retention of qualified and talented executives and consistent with good corporate governance.
Employment Agreement Provisions Regarding Change of Control Benefits
. The Compensation Committee believes that executives should generally not be entitled to severance
benefits solely as a result of the occurrence of a change of control, but that it is appropriate to provide for such benefits if a change of control is followed by a termination of employment or other appropriate triggering event. See
Employment Agreement Provisions Regarding Termination Benefits above. However, the Compensation Committee has approved the following exceptions for certain of the Named Executive Officers:
|
|
|
With respect to Dr. Zatz and Mr. DeSimone, each may resign from employment after the first anniversary of a Change of Control of WebMD and
receive the same benefits, under his employment agreement, as if he resigned for Good Reason following a Change of Control. Such benefits include the components described above: rights to cash severance, rights to company paid COBRA premiums and
rights to continued vesting and exercisability of certain options and to acceleration of certain shares of WebMD Restricted Stock (including the performance-based restricted stock granted in November 2016), as described more fully below under
Employment Agreements with Named Executive Officers Steven L. Zatz, M.D. and Blake DeSimone (which also provides descriptions of the defined terms used in their respective employment agreements).
|
33
|
|
|
With respect to Mr. Wygod, the vesting of all WebMD Restricted Stock (including the performance-based restricted stock granted in November 2016)
and options to purchase WebMD Common Stock outstanding at the time of a Change of Control (as defined in the HLTH 2000 Plan held by Mr. Wygod, which definition is substantially the same as the definition in the 2005 Plan) will accelerate on the
date of the Change of Control. If Mr. Wygods employment terminates for any reason (other than for Cause) thereafter, such options will remain outstanding through the remainder of their terms. For additional information, including
regarding his rights to cash severance and benefits on termination, see Employment Agreements with Named Executive Officers Martin J. Wygod below (which also provides descriptions of the defined terms used in his employment
agreement).
|
In the negotiations with those Named Executive Officers regarding their employment agreements, the Compensation
Committee recognized that, for those individuals, a change of control is likely to result in a fundamental change in the nature of their responsibilities. Accordingly, under their employment agreements, the Compensation Committee approved the
specific Named Executive Officers having, following a change of control, the rights described above. The Compensation Committee believed that the rights provided were likely to be viewed as appropriate by a potential acquiror in the case of those
specific individuals. In addition, the Compensation Committee sought to balance the rights given to the Named Executive Officers with certain requirements to remain employed for a transition period or to provide transitional services in types and
amounts likely to be viewed as reasonable by a potential acquiror.
Our employment agreements with Messrs. Glick and Wamsley do
not provide rights to receive any compensation as a result of a change of control, unless the change of control is followed by a termination of employment (including a termination by the executive for Good Reason under the terms of his
employment agreement). However, as more fully described under Employment Agreements with Named Executive Officers below, a change of control followed by such a termination would result in enhanced compensation for the executive beyond
what would apply in the case of a similar termination that was not preceded by a change of control. Such enhancements include continuation of vesting and exercisability of certain options and acceleration of vesting of certain shares of WebMD
Restricted Stock. Similar provisions are contained in employment agreements with other key employees of WebMD who are not executive officers.
If the benefits payable to Mr. Wygod in connection with a change of control would be considered an excess parachute payment under Section 280G of the Internal Revenue Code of 1986 (Section
280G) and subject to the excise tax imposed under Section 4999 of the Code, WebMD has agreed to make an additional payment to him so that the net amount of such payment (after taxes) that he receives is sufficient to pay the excise tax
due. No other Named Executive Officer has the right to receive any tax gross-up payments from WebMD.
Deductibility of
Compensation
.
Section 162(m) of the Internal Revenue Code generally limits the ability of a publicly held corporation to deduct compensation in excess of $1 million per year paid to certain executive
officers. It is the policy of the Compensation Committee to structure, where practicable, compensation paid to its executive officers so that it will be deductible under Section 162(m) of the Code. Accordingly, WebMDs equity plans under
which awards are made to officers and directors are generally designed with the intent that compensation attributable to stock options granted will be tax deductible by WebMD. However, cash bonuses for WebMDs executive officers and grants of
restricted stock do not qualify as performance-based within the meaning of Section 162(m) and, therefore, are subject to its limits on deductibility. In determining that the compensation of WebMDs executive officers for 2016 was
appropriate under the circumstances and in the best interests of WebMD and its stockholders, the Compensation Committee considered the amount of net operating loss carryforwards available to WebMD to offset income for Federal income tax purposes.
See Note 11 to the Consolidated Financial Statements included in Annex A this Proxy Statement.
34
2017 Bonus Program for Executive Officers.
For 2017, the Compensation
Committee has implemented an annual bonus program (which we refer to as the 2017 Bonus Program) for WebMDs executive officers that relies primarily on pre-set financial goals for determining the amount of their bonuses for 2017, which will be
determined and paid in early 2018. The 2017 Bonus Program is generally similar in design to the 2016 Bonus Program, with the following terms:
|
|
|
Up to 70% (or 60% in the case of Mr. Wygod) of each executive officers maximum potential bonus for 2017 will be based on pre-set financial goals,
as follows:
|
|
|
|
40% (or 35% in the case of Mr. Wygod) of each executive officers maximum potential bonus for 2017 will be payable based on the extent to which
revenue for 2017 exceeds a specified minimum threshold; and
|
|
|
|
up to 30% (or 25% in the case of Mr. Wygod) of the maximum potential bonus will be payable based on the extent to which Adjusted EBITDA for 2017
exceeds a specified minimum threshold.
|
|
|
|
In addition, if the minimum financial thresholds for revenue and EBITDA are met, the remaining 30% of the maximum potential bonus (or 40% in the case
of Mr. Wygod) will be eligible for payment, subject to the Compensation Committee determining, in its discretion, that certain individual goals have been met by the respective executive officers. The individual goals relate to various operational,
product-related and strategic matters. No bonus will be payable for meeting individual goals if the minimum thresholds for both revenue and Adjusted EBITDA are not met.
|
|
|
|
The target bonus for each Named Executive Officer under the 2017 Bonus Program, which would be achieved for meeting targets set by the Compensation
Committee when the 2017 Bonus Program was adopted, will be the following percentages of their annual base salary: 120% for Dr. Zatz; 56% for Messrs. DeSimone, Glick and Wamsley; and 118% for Mr. Wygod.
|
|
|
|
The maximum bonus for each Named Executive Officer under the 2017 Bonus Program, which would be achieved for exceeding, by a specified amount, the
targets set by the Compensation Committee, will be the following percentages of their annual base salary: 150% for Dr. Zatz; 70% for Messrs. DeSimone, Glick and Wamsley; and 147% for Mr. Wygod.
|
The Compensation Committee expects to continue to implement, for future years, annual bonus programs that rely primarily on pre-set
financial goals for determining the amounts of the bonuses for WebMDs executive officers.
Executive Compensation
Tables
This section provides information, in tabular formats specified in applicable SEC rules, regarding the amounts of
compensation paid to our Named Executive Officers and related information. See Compensation Discussion and Analysis Introduction above for an explanation regarding the determination, under applicable SEC rules, of who is a
Named Executive Officer of WebMD for 2016. As permitted by the SEC rules relating to the executive compensation tables, the following tables reflect only the types of compensation paid to our Named Executive Officers. For example, since
our only retirement plan is a 401(k) plan, we do not include tables applicable to other types of retirement plans. Descriptions of the material terms of each Named Executive Officers employment arrangements and related information is provided
under Employment Agreements with Named Executive Officers below.
35
Summary Compensation Table
Table
.
The following table presents information regarding the amount of the total
compensation of our Named Executive Officers for services rendered during the years covered, as well as the amount of the specific components of that compensation. The compensation reported in the table reflects all compensation to the Named
Executive Officers from our company and any of our subsidiaries.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
|
(b)
|
|
|
(c)
|
|
|
(d)
|
|
|
(e)
|
|
|
(f)
|
|
|
(g)
|
|
|
(h)
|
|
|
(i)
|
|
Name and Principal
Position
(1)
|
|
Year
|
|
|
Salary($)
(2)
|
|
|
Bonus($)
(3)(4)
|
|
|
Stock
Awards
($)
(5)
|
|
|
Option
Awards
($)
(5)
|
|
|
Non-Equity
Incentive
Plan
Compensation
($)
(4)
|
|
|
All Other
Compen-
sation ($)
|
|
|
Total
($)
|
|
Steven L. Zatz, M.D.
|
|
|
2016
|
|
|
|
510,962
|
|
|
|
433,313
|
(6)
|
|
|
2,940,000
|
|
|
|
2,292,855
|
|
|
|
291,504
|
|
|
|
26,237
|
(7)
|
|
|
6,494,871
|
|
Chief Executive Officer
|
|
|
2015
|
|
|
|
500,000
|
|
|
|
646,629
|
(6)
|
|
|
1,719,600
|
|
|
|
1,378,880
|
|
|
|
|
|
|
|
24,995
|
(7)
|
|
|
4,270,104
|
|
|
|
2014
|
|
|
|
500,000
|
|
|
|
658,523
|
(6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24,845
|
(7)
|
|
|
1,183,368
|
|
|
|
|
|
|
|
|
|
|
Blake DeSimone
|
|
|
2016
|
|
|
|
370,394
|
|
|
|
229,638
|
(8)
|
|
|
784,000
|
|
|
|
1,222,856
|
|
|
|
|
|
|
|
8,490
|
(9)
|
|
|
2,615,378
|
|
Executive VP and
CFO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Michael B. Glick
|
|
|
2016
|
|
|
|
353,558
|
|
|
|
134,813
|
(10)
|
|
|
735,000
|
|
|
|
1,146,428
|
|
|
|
88,718
|
|
|
|
20,646
|
(11)
|
|
|
2,479,163
|
|
Executive VP and
|
|
|
2015
|
|
|
|
350,000
|
|
|
|
227,113
|
(10)
|
|
|
687,840
|
|
|
|
732,530
|
|
|
|
|
|
|
|
19,405
|
(11)
|
|
|
2,016,888
|
|
Co-General Counsel
|
|
|
2014
|
|
|
|
350,000
|
|
|
|
300,016
|
(10)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19,229
|
(11)
|
|
|
669,245
|
|
|
|
|
|
|
|
|
|
|
Douglas W. Wamsley
|
|
|
2016
|
|
|
|
353,558
|
|
|
|
134,813
|
(12)
|
|
|
735,000
|
|
|
|
1,146,428
|
|
|
|
88,718
|
|
|
|
6,041
|
(13)
|
|
|
2,464,558
|
|
Executive VP and
|
|
|
2015
|
|
|
|
350,000
|
|
|
|
227,113
|
(12)
|
|
|
687,840
|
|
|
|
732,530
|
|
|
|
|
|
|
|
6,041
|
(13)
|
|
|
2,003,524
|
|
Co-General Counsel
|
|
|
2014
|
|
|
|
350,000
|
|
|
|
300,016
|
(12)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,015
|
(13)
|
|
|
656,031
|
|
|
|
|
|
|
|
|
|
|
Martin J. Wygod
|
|
|
2016
|
|
|
|
490,000
|
|
|
|
394,800
|
(14)
|
|
|
2,450,000
|
|
|
|
1,528,570
|
|
|
|
208,821
|
|
|
|
9,481
|
(15)
|
|
|
5,081,672
|
|
Chairman of the Board
|
|
|
2015
|
|
|
|
490,000
|
|
|
|
590,031
|
(14)
|
|
|
2,579,400
|
|
|
|
|
|
|
|
|
|
|
|
13,998
|
(15)
|
|
|
3,673,429
|
|
|
|
2014
|
|
|
|
490,000
|
|
|
|
742,040
|
(14)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16,832
|
(15)
|
|
|
1,248,872
|
|
|
|
|
|
|
|
|
|
|
David J. Schlanger
|
|
|
2016
|
|
|
|
383,654
|
|
|
|
187,500
|
(16)
|
|
|
|
|
|
|
|
|
|
|
266,983
|
|
|
|
769,613
|
(17)
|
|
|
1,607,750
|
|
Former CEO
|
|
|
2015
|
|
|
|
525,000
|
|
|
|
655,331
|
(16)
|
|
|
1,719,600
|
|
|
|
1,378,880
|
|
|
|
|
|
|
|
26,993
|
(17)
|
|
|
4,305,804
|
|
|
|
|
2014
|
|
|
|
525,000
|
|
|
|
617,518
|
(16)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24,950
|
(17)
|
|
|
1,167,468
|
|
|
|
|
|
|
|
|
|
|
Peter Anevski
|
|
|
2016
|
|
|
|
328,558
|
|
|
|
127,500
|
(18)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
452,940
|
(19)
|
|
|
908,998
|
|
Former CFO
|
|
|
2015
|
|
|
|
425,000
|
|
|
|
445,427
|
(18)
|
|
|
1,719,600
|
|
|
|
1,378,880
|
|
|
|
|
|
|
|
21,980
|
(19)
|
|
|
3,990,887
|
|
|
|
|
2014
|
|
|
|
425,000
|
|
|
|
457,516
|
(18)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,780
|
(19)
|
|
|
903,296
|
|
(1)
|
Positions listed are as of December 31, 2016. See Compensation Discussion and Analysis Introduction above for an explanation regarding the
determination, under applicable SEC rules, of who is a Named Executive Officer of WebMD for 2016 and regarding changes in the positions held by the Named Executive Officers during 2016.
|
(2)
|
Because of changes in salary during 2016, the amounts for 2016 in Column (c) are not equal to the annual salary rate for certain of the Named Executive Officers.
The annual salary rates, as of December 31, 2016, for the Named Executive Officers who were employees of WebMD at that time were as follows: Dr. Zatz, $575,000; Mr. DeSimone, $400,000; Messrs. Glick and Wamsley, $375,000; and
Mr. Wygod, $490,000.
|
(3)
|
The amounts reported in Column (d) include, to the extent applicable to the individual Named Executive Officers, with respect to the years listed: discretionary
annual cash bonuses for that year, which were paid in March of the following year; and amounts released from the Supplemental Bonus Trust during that year, which were based on contributions made in March of the prior year, with respect to the bonus
process for the fiscal year prior to that contribution, except for the release to Mr. DeSimone reflected in Column (d), which occurred in September 2016 based on a contribution made in March 2016, the scheduled release date since
Mr. DeSimone did not become an executive officer until after such release. For additional information, see Background Information Regarding the Summary Compensation Table Supplemental Bonus Plan (SBP) below and the
applicable footnotes below that provide a breakdown, for each year, of the total amount in Column (d) for the respective Named Executive Officers.
|
(4)
|
For Dr. Zatz and Messrs. Glick, Wamsley and Wygod, their annual bonuses for 2016 were determined under WebMDs 2016 Bonus Program for Executive Officers,
with: a portion of their annual cash bonus for 2016 being based on pre-set financial goals and, in accordance with applicable SEC rules, reported in Column (g) as Non-Equity Incentive Plan Compensation; and a portion being based on individual
goals and determined by the Compensation Committee in its discretion and, in accordance with applicable SEC rules, reported in Column (d). For Mr. Schlanger, his entire annual cash bonus for 2016 was based on the pre-set financial goals under
the 2016 Bonus Program for Executive Officers and is reported in Column (g).
|
36
(5)
|
The amounts reported in Columns (e) and (f) above reflect the grant date fair value, in the year of grant, for the WebMD Restricted Stock and options to
purchase WebMD Common Stock awarded, if any, to the respective Named Executive Officers, computed in accordance with FASB ASC Topic 718. See Note 8 (Stock-Based Compensation) to the Consolidated Financial Statements included in Annex A to this Proxy
Statement for an explanation of the methodology and assumptions used in determining the fair value of these awards. The actual amounts, if any, ultimately realized by our Named Executive Officers from these grants depend on the price of WebMD Common
Stock at the time of vesting of restricted stock or at the time of exercise of vested stock options, as the case may be.
|
(6)
|
For 2016,
consists of:
(a) $245,813 portion of annual bonus for 2016 determined by the Compensation Committee, in its discretion, based on
individual goals; and (b) a Supplemental Bonus Plan distribution of $187,500, released in March 2016 based on a contribution to the Plan made in connection with his 2014 bonus.
For 2015,
consists of:
(a) an annual
bonus for 2015 of $490,000; and (b) a Supplemental Bonus Plan distribution of $156,629, released in March 2015 based on a contribution to the Plan made in connection with his 2013 bonus.
For 2014, c
onsists of
: (a) an
annual bonus for 2014 of $437,500; and (b) a Supplemental Bonus Plan distribution of $221,023, released in March 2014 based on a contribution to the Plan made in connection with his 2012 bonus.
|
(7)
|
For 2016,
consists of:
(a) $3,564 for company-paid group term life insurance; (b) $2,723 for company-paid supplemental disability;
(c) an automobile allowance of $12,000; and (d) $7,950 in company matching contributions under the 401(k) Plan.
For 2015,
consists of:
(a) $2,322 for company-paid group term life insurance; (b) $2,723 for
company-paid supplemental disability; (c) an automobile allowance of $12,000; and (d) $7,950 in company matching contributions under the 401(k) Plan.
For 2014
, consists of
: (a) $2,322 for company-paid group term
life insurance; (b) $2,723 for company-paid supplemental disability insurance; (c) $7,800 in company matching contributions under the 401(k) Plan; and (d) an automobile allowance of $12,000.
|
(8)
|
Mr. DeSimone was not an executive officer of WebMD when the 2016 Bonus Program for Executive Officers was established in April 2016 and was not included in that
Program
.
Accordingly, the amount in Column (d) consists of: (a) his annual cash bonus for 2016 of $202,000, which was determined by the Compensation Committee in its discretion; and (b) a Supplemental Bonus Plan distribution of
$27,638 released in September 2016 based on a contribution to the Plan made in March 2016 in connection with his 2015 bonus. September 2016 was the scheduled release date for Mr. DeSimone since he did not become an executive officer until after
such release. For additional information, see Background Information Regarding the Summary Compensation Table Supplemental Bonus Plan (SBP) below.
|
(9)
|
Consists of:
(a) $540 for company-paid group term life insurance; and (b) $7,950 in company matching contributions under the 401(k) Plan.
|
(10)
|
For 2016,
consists of:
(a) $74,813 portion of annual bonus for 2016 determined by the Compensation Committee, in its discretion, based on
individual goals; and (b) a Supplemental Bonus Plan distribution of $60,000, released in March 2016 based on a contribution to the Plan made in connection with his 2014 bonus.
For 2015,
consists of:
(a) an annual bonus
for 2015 of $157,500; and (b) a Supplemental Bonus Plan distribution of $69,613, released in March 2015 based on a contribution to the Plan made in connection with his 2013 bonus.
For 2014
, consists of
: (a) an annual
bonus for 2014 of $140,000; and (b) a Supplemental Bonus Plan distribution of $160,016, released in March 2014 based on a contribution to the Plan made in connection with his 2012 bonus.
|
(11)
|
For 2016,
consists of:
(a) $3,564 for company-paid group term life insurance; (b) $3.932 for company-paid supplemental disability;
(c) an automobile allowance of $5,200; and (d) $7,950 in company matching contributions under the 401(k) Plan.
For 2015,
consists of:
(a) $2,322 for company-paid group term life insurance; (b) $3,933 for
company-paid supplemental disability; (c) an automobile allowance of $5,200; and (d) $7,950 in company matching contributions under the 401(k) Plan.
For 2014
, consists of
: (a) $2,322 for company-paid group term
life insurance; (b) $3,907 for company-paid supplemental disability insurance; (c) an automobile allowance of $5,200; and (d) $7,800 in company matching contributions under the 401(k) Plan.
|
(12)
|
For 2016,
consists of:
(a) $74,813 portion of annual bonus for 2016 determined by the Compensation Committee, in its discretion, based on
individual goals; and (b) a Supplemental Bonus Plan distribution of $60,000, released in March 2016 based on a contribution to the Plan made in connection with his 2014 bonus.
For 2015,
consists of:
(a) an annual bonus
for 2015 of $157,500; and (b) a Supplemental Bonus Plan distribution of $69,613, released in March 2015 based on a contribution to the Plan made in connection with his 2013 bonus.
For 2014
, consists of
: (a) an annual
bonus for 2014 of $140,000; and (b) a Supplemental Bonus Plan distribution of $160,016, released in March 2014 based on a contribution to the Plan made in connection with his 2012 bonus.
|
(13)
|
For 2016,
consists of:
(a) $2,322 for company-paid group term life insurance; and (b) $3,719 for company-paid supplemental disability.
For 2015,
consists of:
(a) $2,322 for company-paid group term life insurance; and (b) $3,719 for company-paid supplemental disability.
For 2014
, consists of
: (a) $2,322 for company-paid group
term life insurance; and (b) $3,693 for company-paid supplemental disability insurance.
|
(14)
|
For 2016,
consists of:
(a) $244,800 portion of annual bonus for 2016 determined by the Compensation Committee, in its discretion, based on
individual goals; and (b) a Supplemental Bonus Plan distribution of $150,000, released in March 2016 based on a contribution to the Plan made in connection with his 2014 bonus.
For 2015,
consists of:
(a) an annual
bonus for 2015 of $420,000; and (b) a Supplemental Bonus Plan distribution of $170,031, released in March 2015 based on a contribution to the Plan made in connection with his 2013 bonus.
For 2014, c
onsists of
: (a) an
annual bonus for 2014 of $350,000; and (b) a Supplemental Bonus Plan distribution of $392,040, released in March 2014 based on a contribution to the Plan made in connection with his 2012 bonus.
|
(15)
|
For 2016,
consists of:
(a) $4,944 for company-paid group term life insurance; and (b) $4,537 for company-paid supplemental disability.
For 2015,
consists of:
(a) $9,461 for company-paid group term life insurance; and (b) $4,537 for company-paid supplemental disability.
For 2014
, consists of:
(a) $5,707 for company-paid
supplemental disability insurance; and (b) $11,125 for company-paid group term life insurance.
|
37
(16)
|
For 2016,
the amount reported is a Supplemental Bonus Plan distribution of $187,500, released in March 2016 based on a contribution to the Plan
made in connection with his 2014 bonus.
For 2015,
consists of:
(a) an annual bonus for 2015 of $490,000; and (b) a Supplemental Bonus Plan distribution of $165,331, released in March 2015 based on a contribution to the
Plan made in connection with his 2013 bonus.
For
2014, c
onsists of
: (a) an annual bonus for 2014 of $437,500; and (b) a Supplemental Bonus Plan distribution of $180,018, released in March 2014 based on a
contribution to the Plan made in connection with his 2012 bonus.
|
(17)
|
For 2016,
consists of:
(a) $1,697 for company-paid group term life insurance; (b) $3,782 for company-paid supplemental disability;
(c) an automobile allowance of $8,769; (d) $7,950 in company matching contributions under the 401(k) Plan; (e) $537,415 for the aggregate amount of the severance payable to him (some of which is payable in 2017); and (f) a
Supplemental Bonus Plan distribution in September 2016 of $210,000 based on a contribution to that Plan made in connection with his 2015 bonus, as provided in the severance agreement entered into with him in connection with his leaving WebMD in
September 2016.
For 2015,
consists of:
(a) $2,322 for company-paid group term life insurance; (b) $4,721 for company-paid supplemental disability; (c) an automobile allowance of $12,000; and (d) $7,950 in
company matching contributions under the 401(k) Plan.
For 2014
, consists of
: (a) $2,322 for company-paid group term life insurance; (b) $4,128 for company-paid supplemental disability insurance; (c) an automobile
allowance of $12,000; and (d) $6,500 in company matching contributions under the 401(k) Plan.
|
(18)
|
For 2016,
the amount reported is a Supplemental Bonus Plan distribution released in March 2016 based on a contribution to the Supplemental Bonus Plan made
in connection with his 2014 bonus.
For 2015,
consists of:
(a) an annual bonus for 2015 of $297,500; and (b) a Supplemental Bonus Plan distribution of $147,927, released in March 2015 based on a contribution to the Plan
made in connection with his 2013 bonus.
For 2014
, consists of
: (a) an annual bonus for 2014 of $297,500; and (b) a Supplemental Bonus Plan distribution of $160,016, released in March 2014 based on a contribution to the
Plan made in connection with his 2012 bonus.
|
(19)
|
For 2016,
consists of:
(a) $623 for company-paid group term life insurance; (b) $2,115 for company-paid supplemental disability;
(c) an automobile allowance of $8,000; (d) $5,322 in company matching contributions under the 401(k) Plan; and (e) $436,880 for the aggregate amount of the severance payable to him (some of which is payable in 2017).
For 2015,
consists of:
(a) $810 for company-paid group term life insurance; (b) $2,820 for company-paid supplemental disability; (c) an automobile allowance of $10,400; and (d) $7,950 in company matching contributions under
the 401(k) Plan.
For 2014,
consists of
: (a) $810 for company-paid group term life insurance; (b) $1,770 for company-paid supplemental disability insurance; (c) an automobile allowance of $10,400; and
(d) $7,800 in company matching contributions under the 401(k) Plan.
|
Background Information Regarding
the Summary Compensation Table
General
. The Summary Compensation Table above quantifies
the amount or value of the different forms of compensation earned by or awarded to our Named Executive Officers by WebMD and provides a dollar amount for total compensation for each year covered. As contemplated by applicable SEC rules, the Summary
Compensation Table does not include information for 2014 or 2015 for Mr. DeSimone since he was not a Named Executive Officer for those years.
2016 Bonuses
. As more fully described in Compensation Discussion and Analysis Use of Specific Types of Compensation for 2016 2016 Bonus Program
above, the Compensation Committee adopted the 2016 Bonus Program for Executive Officers in April 2016. The participants in the Program were Dr. Zatz and Messrs. Anevski, Glick, Wamsley, Schlanger and Wygod, the individuals who were executive
officers of WebMD at that time. Under the 2016 Bonus Program: 70% of each participants maximum potential bonus (or 60% in the case of Mr. Wygod) was based upon the level of achievement of pre-set goals for revenues and Adjusted EBITDA for
2016 (and that portion of the bonus is reported, for those who received it, is reported in Column (g) of the Summary Compensation Table as Non-Equity Incentive Plan Compensation; and 30% of their maximum potential bonus (or 40% in
the case of Mr. Wygod) was based upon individual performance of each Named Executive Officer in 2016 (and that portion of the bonus, for those who received it, is reported in Column (d) of the Summary Compensation Table).
2014 and 2015 Bonuses
. For 2015 and 2014, WebMD paid annual cash bonuses to its executive officers, the amounts of which were
determined by the Compensation Committee in its discretion and are reflected solely in Column (d) of the Summary Compensation Table.
No Special Bonuses
. In certain past years, WebMD has paid additional or special bonuses to provide recognition for specific accomplishments or at the time of a promotion, if
determined by the Compensation Committee to be appropriate and in amounts determined by the Compensation Committee in its discretion. No such additional or special bonuses were paid to any of the Named Executive Officers for any of the years covered
in the Summary Compensation Table.
Supplemental Bonus Program (SBP)
. SBP Contributions are cash
amounts contributed by WebMD for the Named Executive Officers (and certain other WebMD employees) to a trust (the Supplemental Bonus Trust),
38
which distributes such amounts, with actual interest earned, if the employee remains employed through a specified date. The purpose of the SBP is to create additional retention incentives for our
executive officers and other key employees in connection with our annual bonus process. Because SBP Contributions are forfeitable until a specified date, they are reflected in Column (d) of the Summary Compensation Table as compensation based
on the release date, not the date of contribution or the fiscal year for which they were earned, as required by applicable SEC rules. In considering the annual decisions made by the Compensation Committee regarding discretionary bonuses, the amount
authorized for a particular year includes the bonus payable for that year plus the amount, if any, of the SBP Contribution made at the same time to the Supplemental Bonus Trust (but not the amount released as a result of decisions made in prior
years). Accordingly, amounts reported in Column (d) of the Summary Compensation Table for a particular year will generally not correspond to the amounts authorized by the Compensation Committee for that same year because, under applicable SEC
rules, we include SBP distributions but not SBP Contributions in Column (d) for that year.
No SBP Contributions were made
by WebMD on behalf of any of the Named Executive Officers in connection with the bonuses for 2016, though SBP Contributions were made for certain other members of management. The Compensation Committee will determine, in its discretion, whether to
use the SBP in future years and, if so, which individuals will receive a portion of their bonus in the form of SBP Contributions, the specific portion and the applicable date or dates for release from the Supplemental Bonus Trust. SBP Contributions
were made by WebMD on behalf of Named Executive Officers in connection with the annual bonus processes for 2012 through 2015. The following describes the history of contributions made and related releases, to the extent relevant to the years covered
by the Summary Compensation Table:
|
|
|
2015 SBP Contributions and Related Distributions in March 2017
. In March 2016, the Compensation Committee approved the contribution, made in
March 2016, to the Supplemental Bonus Trust of SBP Contributions for 2015 (which we refer to as the 2015 SBP Contributions), including: a $210,000 contribution for Mr. Schlanger (who was then Chief Executive Officer); a $210,000 contribution
for Dr. Zatz; a $127,500 contribution for Mr. Anevski (who was then Chief Financial Officer); a $67,500 contribution for Mr. Glick; a $67,500 contribution for Mr. Wamsley; and a $180,000 contribution for Mr. Wygod. For
these executive officers, the 2015 SBP Contributions represented 30% of their total bonuses for 2015. In order to receive the applicable payment from the Supplemental Bonus Trust for the 2015 SBP Contributions, these executive officers (and certain
other senior executives who are SBP participants) were required to be employed by WebMD on March 1, 2017, subject to limited exceptions for death, disability, or certain terminations of employment in connection with a Change of Control of WebMD
(as defined in the 2005 Plan), a sale of a subsidiary or division or, in the discretion of the governing committee, certain other reductions in force or position eliminations or as specifically provided in each individuals employment
agreement. The Supplemental Bonus Trust distributed the 2015 SBP Contributions, together with actual net interest earned on the respective amounts, to the eligible executive officer SBP participants (and certain other eligible senior executive SBP
participants) in March 2017, while the distribution to other eligible participants (which included Mr. DeSimone since he was not yet an executive officer) was made in September 2016. Mr. Schlanger received a distribution of the 2015
SBP Contribution made on his behalf as part of his severance compensation in September 2016. Mr. Anevski did not receive any distribution of the 2015 SBP Contribution made on his behalf. For the amounts that were forfeitable until March 1,
2017 for Dr. Zatz and Messrs. Glick, Wamsley and Wygod, they would be reflected in a future Summary Compensation Table as compensation in 2017 if the recipient is a Named Executive Officer for that year.
|
|
|
|
2014 SBP Contributions and Related Distributions in March 2016.
In February 2015, the Compensation Committee approved the contribution, made in
March 2015, to the Supplemental Bonus Trust of SBP Contributions for 2014 (which we refer to as the 2014 SBP Contributions), including: a $187,500 contribution for Mr. Schlanger; a $187,500 contribution for Dr. Zatz; a $127,500
contribution for Mr. Anevski; a $60,000 contribution for Mr. Glick; a $60,000 contribution for Mr. Wamsley; and a $150,000 contribution for Mr. Wygod. For these executive officers, the 2014 SBP Contributions represented 30% of
their total bonuses for 2014. The Supplemental Bonus Trust distributed the 2014 SBP Contributions, together with actual net interest earned on the respective amounts, to the Named Executive
|
39
|
Officers and to other eligible SBP participants in March 2016 and the amounts of the distributions to the respective Named Executive Officers are included in the Summary Compensation Table in
Column (d) as compensation in 2016, the year in which they ceased to be forfeitable.
|
|
|
|
2013 SBP Contributions and Related Distributions in March 2015
. In February 2014, the Compensation Committee approved the contribution, made in
March 2014, to the Supplemental Bonus Trust of SBP Contributions for 2013 (which we refer to as the 2013 SBP Contributions), including: a $165,300 contribution for Mr. Schlanger; a $156,600 contribution for Dr. Zatz; a $147,900
contribution for Mr. Anevski; a $69,600 contribution for Mr. Glick; a $69,600 contribution for Mr. Wamsley; and a $170,000 contribution for Mr. Wygod. For these executive officers, the 2013 SBP Contributions represented between
26% and 28% of their total bonuses for 2013. The Supplemental Bonus Trust distributed the 2013 SBP Contributions, together with actual net interest earned on the respective amounts, to the Named Executive Officers and to other eligible SBP
participants in March 2015 and the amounts of the distributions to the respective Named Executive Officers are included in the Summary Compensation Table in Column (d) as compensation in 2015, the year in which they ceased to be forfeitable.
|
|
|
|
2012 SBP Contributions and Related Distributions in March 2014
. In February 2013, the Compensation Committee approved the contribution, made in
March 2013, to the Supplemental Bonus Trust of SBP Contributions for 2012 (which we refer to as the 2012 SBP Contributions), including: a $180,000 contribution for Mr. Schlanger; a $221,000 contribution for Dr. Zatz; a $160,000
contribution for Mr. Anevski; a $160,000 contribution for Mr. Glick; a $160,000 contribution for Mr. Wamsley; and a $392,000 contribution for Mr. Wygod. For these individuals, the 2012 SBP Contributions represented 80% of their
total bonuses for 2012, except for Mr. Schlanger, whose 2102 SBP Contribution represented 75% of his total bonus for 2012. At the time the 2012 SBP Contributions were made, Messrs. Schlanger and Anevski were not yet executive officers of WebMD.
The Supplemental Bonus Trust distributed the 2012 SBP Contributions, together with actual net interest earned on the respective amounts, to the Named Executive Officers and to other eligible SBP participants in March 2014 and the amounts of the
distributions to the respective Named Executive Officers are included in the Summary Compensation Table in Column (d) as compensation in 2014, the year in which they ceased to be forfeitable.
|
Any SBP Contributions that are forfeited for failure to meet the employment condition by an SBP participant are shared by the remaining
SBP participants for that year, other than SBP participants who are executive officers at the time of the distribution; provided, however, that: (a) with respect to 2014 SBP Contributions, only the Chief Executive Officer and the Chairman of
the Board were not eligible to receive any portion of such forfeitures; and (b) with respect to 2015 SBP Contributions, all executive officers and certain other senior management employees were not eligible to receive any portion of such
forfeitures.
Stock Options and Restricted Stock.
Under applicable SEC rules, the Summary Compensation Table reflects
the full amount of the grant date fair value of option grants and restricted stock grants in the year in which the grant is made and no amount of compensation in any other year, regardless of the vesting schedule of the grant. As a result, the
compensation of our executive officers reported in the Summary Compensation Table may vary greatly from year to year, depending on which years grants were made to specific WebMD executive officers and the size of the grants made. In addition, grants
made to an executive officer at the time he or she joins WebMD or at the time he or she is first promoted to an executive officer position may be larger than grants made in that year to existing executive officers with comparable responsibilities
and may not be indicative of the compensation for such individual in future years. The Compensation Committee considers the vesting schedule of grants made under equity compensation plans to be an important term of such grants and believes that it
is appropriate, in its consideration of the timing and amount of specific grants it approves, to view the value of such grants to be compensation provided over a period of time as the options vest, rather than assigned solely to the year of grant.
The amounts reported in the Summary Compensation Table for stock awards and option awards reflect a specific method of
valuation of those awards, as more fully described in Note 8 (Stock-Based Compensation) to the Consolidated Financial Statements included in Annex A to this Proxy Statement, and do not reflect income or cash received by our Named Executive Officers.
The actual amounts, if any, ultimately realized by our Named Executive Officers from equity grants will depend on the price of our Common Stock at the time of vesting of restricted stock or at the time of exercise of vested stock options, as the
case may be.
40
Grants of Plan-Based Awards in 2016
Table
.
The following table presents information regarding the plan-based awards granted by
WebMD to our Named Executive Officers during 2016. The Grant Date and Approval Date in Column (b) applies to the information in Columns (e) through (j).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
|
(b)
|
|
|
(c)
|
|
|
(d)
|
|
|
(e)
|
|
|
(f)
|
|
|
(g)
|
|
|
(h)
|
|
|
(i)
|
|
|
(j)
|
|
Name
|
|
Grant
Date
and
Approval
Date
|
|
|
Estimated
Future
Payouts
Under
Non-Equity
Incentive
Plan
Awards
(1)
|
|
|
Estimated
Future
Payouts
Under
Equity
Incentive Plan
Awards
(2)
|
|
|
All Other
Stock
Awards:
Number of
Shares of
Stock
(#)
|
|
|
All
Option
Awards:
Number
of
Securities
Underlying
Options
(#)
|
|
|
Exercise or
Base Price
of Option
Awards
($/Sh)
|
|
|
Grant
Date
Fair
Value of
Stock
and
Option
Awards
($)
(3)
|
|
|
|
Threshold
($)
|
|
|
Maximum
($)
|
|
|
Threshold
(#)
|
|
|
Maximum
(#)
|
|
|
|
|
|
Steven L. Zatz, M.D.
|
|
|
11/02/16
|
|
|
|
|
|
|
|
603,750
|
|
|
|
15,000
|
|
|
|
30,000
|
|
|
|
30,000
|
|
|
|
150,000
|
|
|
|
49.00
|
|
|
|
5,232,855
|
|
Blake DeSimone
|
|
|
11/02/16
|
|
|
|
n/a
|
|
|
|
n/a
|
|
|
|
|
|
|
|
|
|
|
|
16,000
|
|
|
|
80,000
|
|
|
|
49.00
|
|
|
|
2,006,856
|
|
Michael B. Glick
|
|
|
11/02/16
|
|
|
|
|
|
|
|
183,750
|
|
|
|
|
|
|
|
|
|
|
|
15,000
|
|
|
|
75,000
|
|
|
|
49.00
|
|
|
|
1,881,428
|
|
Douglas W. Wamsley
|
|
|
11/02/16
|
|
|
|
|
|
|
|
183,750
|
|
|
|
|
|
|
|
|
|
|
|
15,000
|
|
|
|
75,000
|
|
|
|
49.00
|
|
|
|
1,881,428
|
|
Martin J. Wygod
|
|
|
11/02/16
|
|
|
|
|
|
|
|
432,000
|
|
|
|
12,500
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
100,000
|
|
|
|
49.00
|
|
|
|
3,978,570
|
|
David J. Schlanger
|
|
|
|
|
|
|
|
|
|
|
551,250
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Peter Anevski
|
|
|
|
|
|
|
|
|
|
|
297,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
These columns show the range of potential annual cash bonuses for the respective Named Executive Officers, other than Mr. DeSimone, based on achievement of pre-set
financial goals under the 2016 Bonus Program, as more fully described under Compensation Discussion and Analysis Use of Specific Types of Compensation for 2016 2016 Bonus Program above. No bonuses would have been payable
for financial performance below the thresholds for revenue and Adjusted EBITDA set by the Compensation Committee. From those thresholds to the maximums, potential payouts increased linearly from zero to the respective amounts for each Named
Executive Officer in Column (d). See Column (g), titled Non-Equity Incentive Plan Compensation, in the Summary Compensation Table above for the amounts actually paid, in March 2017, under the 2016 Bonus Program based on pre-set financial
goals. Mr. DeSimone was not a participant in the 2016 Bonus Program because he was not yet an executive officer at the time the 2016 Bonus Program was adopted.
|
(2)
|
For information regarding the vesting and other terms of the performance-based restricted stock granted to Dr. Zatz and Mr. Wygod and the method for
determining the future payout in shares of WebMD Common Stock from those Awards, see footnote (9) to Outstanding Equity Awards at End of 2016 table below and Compensation Discussion and Analysis Use of Specific Types of
Compensation for 2016 Grants of Options, Restricted Stock and Performance-Based Restricted Stock in 2016 above.
|
(3)
|
The amounts reported in Column (j) have been calculated in accordance with FASB ASC Topic 718 and reflect the fair value of each equity award based on the grant
date fair market value of WebMD Common Stock. See Note 8 (Stock-Based Compensation) to the Consolidated Financial Statements included in Annex A to this Proxy Statement for an explanation of the methodology and assumptions used in determining the
fair value of these awards. The actual amounts, if any, ultimately realized by our Named Executive Officers from these grants depend on the price of our Common Stock at the time of vesting of restricted stock or at the time of exercise of vested
stock options, as the case may be. The amounts reported in Column (j) for Dr. Zatz and Mr. Wygod are calculated using the maximum number of shares, as set forth in Column (f), subject to the grants of performance-based restricted
stock made to them on November 2, 2016. For additional information, see Compensation Discussion and Analysis Use of Specific Types of Compensation for 2016 Grants of Options, Restricted Stock and Performance-Based Restricted
Stock in 2016 above.
|
Additional Information Regarding Stock Awards and Option Awards
.
Each option to purchase WebMD Common Stock granted to a Named Executive Officer in 2016 was granted under the 2005 Plan. All option grants to Named Executive Officers were made with a per-share exercise price equal to the
fair market value of a share of WebMD Common Stock on the grant date. For these purposes, and in accordance with the terms of the 2005 Plan and WebMDs option grant practices, the fair market value is equal to the closing price of a share of
WebMD Common Stock on the Nasdaq Global Select Market on the grant date. See Outstanding Equity Awards at End of 2016 below for information regarding the vesting schedule for the grants. Each such stock option granted to our Named
Executive Officers in 2016 has a term of 10 years. For information regarding the effect on the vesting and exercisability of these stock options as a result of the death, disability or termination of employment of a Named Executive Officer or a
change of control of WebMD, see Potential Payments and Other Benefits Upon Termination of Employment or a Change of Control and Employment Agreements with Named Executive Officers below. If a Named Executive Officers
employment were terminated for cause, outstanding stock options (whether vested or unvested) would immediately terminate.
Each
share of WebMD Restricted Stock granted to a Named Executive Officer in 2016 was granted under the 2005 Plan. Grants of shares of WebMD Restricted Stock are subject to certain restrictions, including
41
restrictions on transferability, until they vest. See Outstanding Equity Awards at End of 2016 below for information regarding the vesting schedule for the grants. For information
regarding the effect on the vesting of shares of WebMD Restricted Stock as a result of the death, disability or termination of employment of a Named Executive Officer or a change of control of WebMD, see Potential Payments and Other Benefits
Upon Termination of Employment or a Change of Control and Employment Agreements with Named Executive Officers below. If a Named Executive Officers employment were terminated for cause, unvested shares of WebMD Restricted
Stock would be forfeited. Prior to vesting, holders of shares of WebMD Restricted Stock have voting power with respect to those shares, but do not have the right to receive dividends, if any, that are declared on those shares.
The 2005 Plan is administered by the Compensation Committee of the WebMD Board. The Compensation Committee has authority to interpret the
plan provisions and make all required determinations under the 2005 Plan. This authority includes making required proportionate adjustments to outstanding awards upon the occurrence of certain corporate events such as reorganizations, mergers and
stock splits, and making provision to ensure that any tax withholding obligations incurred in respect of awards are satisfied. Awards granted under the 2005 Plan are generally transferable only to a beneficiary of a plan participant upon his or her
death or to certain family members or family trusts. However, the Compensation Committee may establish procedures for the transfer of awards to other persons or entities, provided that such transfers comply with applicable laws. For additional
information regarding the 2005 Plan, see Proposal 4 below, under the caption Summary of the 2005 Plan.
42
Outstanding Equity Awards at End of 2016
The following table presents information regarding the outstanding equity awards held by each Named Executive Officer as of
December 31, 2016, including the vesting dates for the portions of these awards that had not vested as of that date.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
|
(b)
|
|
|
(c)
|
|
|
(d)
|
|
|
(e)
|
|
|
(f)
|
|
|
(g)
|
|
|
(h)
|
|
|
(i)
|
|
|
(j)
|
|
|
(k)
|
|
|
|
Option Awards
(1)
|
|
|
Stock Awards
(2)
|
|
|
|
|
|
|
|
Name
|
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable
|
|
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable
|
|
|
Option
Exercise
Price
($)
|
|
|
Option
Grant
Date
|
|
|
Option
Expiration
Date
|
|
|
Number of
Shares of
Stock That
Have Not
Vested
(#)
|
|
|
Stock
Award
Grant
Date
|
|
|
Market
Value of
Shares of
Stock
That
Have Not
Vested
($)
(3)
|
|
|
Equity
Incentive
Plan
Awards:
Number
of
Unearned
Shares
That
Have
Not
Vested
(#)
|
|
|
Equity
Incentive
Plan
Awards:
Market
Value of
Unearned
Shares
That
Have
Not
Vested
($)
(3)
|
|
S. Zatz
|
|
|
|
|
|
|
150,000
|
(6)
|
|
|
49.00
|
|
|
|
11/02/16
|
|
|
|
11/02/26
|
|
|
|
30,000
|
(6)
|
|
|
11/02/16
|
|
|
|
1,487,100
|
|
|
|
30,000
|
(9)
|
|
|
1,487,100
|
|
|
|
|
|
|
|
|
80,000
|
(4)
|
|
|
42.99
|
|
|
|
3/25/15
|
|
|
|
3/25/25
|
|
|
|
40,000
|
(4)
|
|
|
3/25/15
|
|
|
|
1,982,800
|
|
|
|
|
|
|
|
|
|
|
|
|
225,000
|
|
|
|
75,000
|
(5)
|
|
|
33.40
|
|
|
|
8/11/13
|
|
|
|
8/11/23
|
|
|
|
12,500
|
(5)
|
|
|
8/11/13
|
|
|
|
619,625
|
|
|
|
|
|
|
|
|
|
|
|
|
40,000
|
|
|
|
|
|
|
|
13.15
|
|
|
|
11/14/12
|
|
|
|
11/14/22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
75,000
|
|
|
|
|
|
|
|
36.62
|
|
|
|
7/23/11
|
|
|
|
7/23/21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
B. DeSimone
|
|
|
|
|
|
|
80,000
|
(5)
|
|
|
49.00
|
|
|
|
11/02/16
|
|
|
|
11/02/26
|
|
|
|
16,000
|
(5)
|
|
|
11/02/16
|
|
|
|
793,120
|
|
|
|
|
|
|
|
|
|
|
|
13,750
|
|
|
|
41,250
|
(5)
|
|
|
44.28
|
|
|
|
6/30/15
|
|
|
|
6/30/25
|
|
|
|
11,250
|
(5)
|
|
|
6/30/15
|
|
|
|
557,663
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
M. Glick
|
|
|
|
|
|
|
75,000
|
(6)
|
|
|
49.00
|
|
|
|
11/02/16
|
|
|
|
11/02/26
|
|
|
|
15,000
|
(6)
|
|
|
11/02/16
|
|
|
|
743,550
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42,500
|
(4)
|
|
|
42.99
|
|
|
|
3/25/15
|
|
|
|
3/25/25
|
|
|
|
16,000
|
(4)
|
|
|
3/25/15
|
|
|
|
793,120
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
|
|
|
25,000
|
(6)
|
|
|
38.65
|
|
|
|
12/18/13
|
|
|
|
12/18/23
|
|
|
|
5,000
|
(6)
|
|
|
12/18/13
|
|
|
|
247,850
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
|
|
|
|
|
|
|
46.81
|
|
|
|
6/28/10
|
|
|
|
6/28/20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
D. Wamsley
|
|
|
|
|
|
|
75,000
|
(6)
|
|
|
49.00
|
|
|
|
11/02/16
|
|
|
|
11/02/26
|
|
|
|
15,000
|
(6)
|
|
|
11/02/16
|
|
|
|
743,550
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42,500
|
(4)
|
|
|
42.99
|
|
|
|
3/25/15
|
|
|
|
3/25/25
|
|
|
|
16,000
|
(4)
|
|
|
3/25/15
|
|
|
|
793,120
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
|
|
|
25,000
|
(6)
|
|
|
38.65
|
|
|
|
12/18/13
|
|
|
|
12/18/23
|
|
|
|
5,000
|
(6)
|
|
|
12/18/13
|
|
|
|
247,850
|
|
|
|
|
|
|
|
|
|
|
|
|
15,000
|
|
|
|
|
|
|
|
36.62
|
|
|
|
7/23/11
|
|
|
|
7/23/21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
M. Wygod
|
|
|
|
|
|
|
100,000
|
(6)
|
|
|
49.00
|
|
|
|
11/02/16
|
|
|
|
11/02/26
|
|
|
|
25,000
|
(6)
|
|
|
11/02/16
|
|
|
|
1,239,250
|
|
|
|
25,000
|
(9)
|
|
|
1,239,250
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60,000
|
(4)
|
|
|
3/25/15
|
|
|
|
2,974,200
|
|
|
|
|
|
|
|
|
|
|
|
|
16,667
|
|
|
|
16,667
|
(6)
|
|
|
38.65
|
|
|
|
12/18/13
|
|
|
|
12/18/23
|
|
|
|
16,667
|
(6)
|
|
|
12/18/13
|
|
|
|
826,183
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
D. Schlanger
|
|
|
|
|
|
|
20,000
|
(7)
|
|
|
42.99
|
|
|
|
3/25/15
|
|
|
|
6/23/17
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,250
|
(8)
|
|
|
33.40
|
|
|
|
8/11/13
|
|
|
|
11/09/17
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
P. Anevski
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Each grant reported in the table above was granted under, and is subject to, the 2005 Plan. The option expiration date shown in Column (f) above is the normal
expiration date, and the last date that the options may be exercised, except that the dates listed for Mr. Schlanger represent the last date that the options may be exercised pursuant to the Separation Agreement entered into with him in
September 2016. For each Named Executive Officer, the unexercisable options shown in Column (c) above are also unvested. Unvested options are generally forfeited if the Named Executive Officers employment terminates, except to the extent
otherwise provided in an employment agreement. For information regarding the effect on vesting of options as a result of the death, disability or termination of employment of a Named Executive Officer or a change of control of WebMD, see
Compensation Discussion and Analysis Compensation Following Termination of Employment or a Change of Control above and Potential Payments and Other Benefits Upon Termination of Employment or a Change of Control below.
The exercisable options shown in Column (b) above, and any unexercisable options shown in Column (c) above that subsequently become exercisable, will generally expire earlier than the normal expiration date if the Named Executive
Officers employment terminates, except as otherwise specifically provided in the Named Executive Officers employment agreement or a related separation agreement. For a description of the material terms of each Named Executive
Officers employment agreement and the letter agreement entered into with Mr. Schlanger in connection with his leaving WebMD, see Employment Agreements with Named Executive Officers below.
|
(2)
|
Unvested shares of restricted stock are generally forfeited if the Named Executive Officers employment terminates, except to the extent otherwise
provided in an employment agreement or award agreement. The stock awards held by our Named Executive Officers are subject to accelerated or continued vesting in connection with a change of control of WebMD and upon certain terminations of
employment, as discussed above under Compensation Discussion and Analysis Compensation Following Termination of Employment
|
43
|
or a Change of Control and described below under Employment Agreements with Named Executive Officers and Potential Payments and Other Benefits Upon Termination of
Employment or a Change of Control. Except as otherwise indicated in those sections, unvested stock awards will generally be forfeited if a Named Executive Officers employment terminates.
|
(3)
|
The market or payout value of stock awards reported in Columns (i) and (k) is computed by multiplying the respective number of shares of WebMD Restricted
Stock reported in Columns (g) and (j) by $49.57, the closing market price of WebMD Common Stock on December 30, 2016, the last trading day of 2016.
|
(4)
|
Vesting schedule: 50% of the original amount granted on each of the second and third anniversaries of the date of the grant.
|
(5)
|
Vesting schedule: 25% of the original amount granted on each of the first, second, third and fourth anniversaries of the date of the grant.
|
(6)
|
Vesting schedule: 1/3 of the original amount granted on each of the second, third and fourth anniversaries of the date of grant.
|
(7)
|
All shares outstanding vested on March 25, 2017.
|
(8)
|
All shares outstanding are scheduled to vest on August 11, 2017.
|
(9)
|
The grants of shares of performance-based restricted stock made to Dr. Zatz and Mr. Wygod on November 2, 2016 will vest and be earned so long as the
executive is employed at the end of the performance period, December 31, 2019, and only to the extent that the Compensation Committee determines that the performance criteria have been satisfied, except as described in Employment
Agreements with Named Executive Officers Steven L. Zatz, M.D. and Martin J. Wygod below. The performance criteria are based on Average Adjusted EBITDA during the performance period of January 1, 2016 through
December 31, 2019. The Compensation Committee will determine Average Adjusted EBITDA (which may be equitably adjusted by the Compensation Committee for certain extraordinary corporate events so as not to enlarge or dilute the awards) within 45
days after WebMDs filing of its audited financial statements for 2019. Satisfaction of a threshold level of Average Adjusted EBITDA will result in the vesting of 50% of the shares subject to the award (15,000 for Dr. Zatz and 12,500 for
Mr. Wygod), with vesting of up to an additional 50% of the shares determined on a pro-rated basis for levels of Average Adjusted EBITDA between that threshold and the higher level required to achieve vesting of all of the shares. For additional
information regarding the performance-based restricted stock, see Compensation Discussion and Analysis Use of Specific Types of Compensation for 2016 Grants of Options, Restricted Stock and Performance-Based Restricted Stock in
2016 above.
|
Option Exercises and Stock Vested in 2016
The following table presents information regarding the exercise of options to purchase WebMD Common Stock by our Named Executive Officers
during 2016 and regarding the vesting during 2016 of WebMD Restricted Stock previously granted to the Named Executive Officers. Please note that the amounts reported for Value Realized in Columns (c) and (e) represent gain over
a period of years; we do not consider all such gain to be 2016 compensation and, under applicable SEC rules, none of such gain is included in 2016 compensation in the Summary Compensation Table (which, instead, requires that we report the fair
value, as of the grant date, of the grants made in 2016).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
|
(b)
|
|
|
(c)
|
|
|
(d)
|
|
|
(e)
|
|
|
|
Option Awards
|
|
|
Stock Awards
|
|
Name
|
|
Number of Shares
Acquired on Exercise
(#)
|
|
|
Value Realized on
Exercise
($)
|
|
|
Number of Shares
Acquired on Vesting
(#)
|
|
|
Value Realized on
Vesting
($)
(1)
|
|
Steven L. Zatz, M.D.
|
|
|
|
|
|
|
|
|
|
|
22,500
|
|
|
|
1,229,875
|
|
Blake DeSimone
|
|
|
|
|
|
|
|
|
|
|
3,750
|
|
|
|
217,913
|
|
Michael B. Glick
|
|
|
45,000
|
|
|
|
1,479,077
|
|
|
|
12,000
|
|
|
|
662,200
|
|
Douglas W. Wamsley
|
|
|
85,000
|
|
|
|
2,066,600
|
|
|
|
10,000
|
|
|
|
535,300
|
|
Martin J. Wygod
|
|
|
191,666
|
|
|
|
4,544,240
|
|
|
|
41,667
|
|
|
|
2,412,934
|
|
David J. Schlanger
|
|
|
337,500
|
|
|
|
6,704,028
|
|
|
|
34,792
|
|
|
|
1,951,278
|
|
Peter Anevski
|
|
|
180,000
|
|
|
|
3,684,858
|
|
|
|
12,500
|
|
|
|
789,000
|
|
(1)
|
The dollar amounts shown in Column (c) above for option awards are determined by multiplying (i) the number of shares for which the option was exercised by
(ii) the difference between (1) the per-share closing price of WebMD Common Stock on the date of exercise (or, for any shares sold on the date of exercise, the actual sale price received) and (2) the exercise price of the options. The
dollar amounts shown in Column (e) above for stock awards were determined by multiplying the number of shares that vested by the per-share closing price of WebMD Common Stock on the vesting date.
|
44
Potential Payments and Other Benefits Upon Termination of Employment or a Change of Control
Background and Assumptions
. In this section, we provide tables containing estimates
(rounded to the nearest $1,000) of (a) amounts that may become payable to our Named Executive Officers as a result of a termination of employment under specific circumstances or as a result of a change of control and (b) the value of other
benefits they may become entitled to receive as a result of such termination or change of control under employment agreements and equity grant agreements. For a general discussion of matters relating to compensation that may become payable by WebMD
after termination of employment or a change of control, see Compensation Discussion and Analysis Compensation Following Termination of Employment or a Change of Control above, and for a detailed description of the applicable
provisions of the employment agreements of our Named Executive Officers, see Employment Agreements with Named Executive Officers below. Under those agreements, the amount and types of payment and other benefits vary depending on whether
the termination is as a result of death or disability, is with or without Cause, is a resignation with or without Good Reason and/or is in connection with a Change of Control. The terms used in the tables have the meanings given to them in each
Named Executive Officers employment agreement, as described under Employment Agreements with Named Executive Officers below. In estimating, solely for purposes of the tables below, the amount of any potential payments to Named
Executive Officers and the value of other benefits they may become entitled to receive:
|
|
|
We have assumed, as prescribed by applicable SEC rules, that the applicable triggering event (i.e., termination of employment or change of control)
occurred on December 31, 2016 and, accordingly, we have used
|
|
|
|
a price per share of WebMD Common Stock of $49.57 (the closing price per share on the last trading day of 2016), including for calculating the value of
WebMD Restricted Stock and the amount realizable from exercise of options to purchase WebMD Common Stock, and
|
|
|
|
the employment agreement terms and annual salary rate in effect, for the respective Named Executive Officers, on that date.
|
|
|
|
We have treated the right to continue to vest in options after termination as if the vesting had accelerated to December 31, 2016.
|
|
|
|
We have assumed that, as of December 31, 2016, any required transition periods, following a Change of Control, before a Named Executive Officer
can resign for Good Reason (or otherwise unilaterally resign) have been met and that the Named Executive Officer is entitled, as of December 31, 2016, to any cash payments, any continuation of vesting and exercisability of options, any
acceleration of vesting of restricted stock and any other benefits as if the transition period had already been completed.
|
|
|
|
The amount of the bonus for 2016 to be included in or otherwise used to determine Cash Severance for purposes of these tables is the actual
amount for 2016, even though it was not determined until March 2017.
|
|
|
|
In the column entitled Permanent Disability or Death, the amounts reflect provisions contained in certain employment agreements and the
fact that WebMDs equity plans generally provide for acceleration of vesting of awards in the event of a termination of employment as a result of death or disability. In addition, the Supplemental Bonus Plan provides that any award thereunder
will be paid in the event of a termination as a result of death or disability.
|
|
|
|
In the row entitled Health and Welfare Benefits Continuation in each of the tables in this section, the amounts are based upon the current
cost to our company of these benefits per employee (with an estimate for individual coverage after expiration of the applicable COBRA period for Mr. Wygod) and are net of amounts that the executives would continue to be responsible for. Under
his employment agreement, Mr. Wygod is eligible to continue to participate in our health and welfare plans (or comparable plans) for three years. For Dr. Zatz and Messrs. DeSimone, Wamsley and Glick, we include only the COBRA premium that
would have applied upon a termination on December 31, 2016. In addition, we have not
|
45
|
made any reduction in the applicable amounts included in the tables below to reflect the fact that the obligation to continue benefits or reimbursement ceases in the event the executive becomes
eligible for comparable coverage with a subsequent employer.
|
|
|
|
For purposes of calculating amounts payable upon termination without cause following a change of control of WebMD, we have treated Supplemental Bonus
Plan awards held in the Supplemental Bonus Trust as of December 31, 2016 as payable to the applicable participants as of that date, in accordance with the terms of their respective employment agreements and the Supplemental Bonus Plan.
|
|
|
|
We have assumed that the Named Executive Officers had no accrued and unused vacation on December 31, 2016.
|
If the benefits payable to Mr. Wygod in connection with a change of control would be considered an excess parachute payment under
Section 280G and subject to the excise tax imposed under Section 4999 of the Code (which we refer to as the Section 280G Excise Tax), WebMD has agreed to make an additional payment to him so that the net amount of such payment (after
taxes) that he receives is sufficient to pay the Section 280G Excise Tax due. We note that the determination of whether a payment is a parachute payment is a facts and circumstances test. For purposes of the tables below, we have
calculated the Section 280G Excise Tax (and related gross-up payment, if any) on the basis of IRS regulations and Rev. Proc. 2003-68 and have assumed that Mr. Wygods outstanding equity awards would be accelerated and terminated in
exchange for a cash payment upon the change of control. The value of this acceleration (and thus the amount of the additional payment) would be slightly higher if the accelerated awards were assumed by the acquiring company rather than terminated
upon the transaction. For purposes other than calculating the Section 280G Excise Tax, we have calculated the value of any option or stock award that may be accelerated in connection with a change of control to be the amount Mr. Wygod can
realize from such award as of December 31, 2016: for options, that is the market price of the shares that would be received upon exercise, less the applicable exercise price; and for restricted stock, that is the market value of the shares that
would vest. No other Named Executive Officer has the right to receive any tax gross-up payments from WebMD.
The employment by
WebMD of Messrs. Anevski and Schlanger terminated in September 2016. For a description of the severance arrangements with each of them, see Employment Agreements with Named Executive Officers David Schlanger and Peter
Anevski below and for information regarding their severance payments see the Summary Compensation Table above.
Tables
. Assuming employment was terminated on December 31, 2016 for the respective Named
Executive Officers, the following tables provide information regarding the estimated dollar value, using the methodologies and assumptions described above, of the payments and benefits they would be entitled to receive.
Steven L. Zatz, M.D.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Executive Benefits and
Payments
|
|
Voluntary
Termination
for Good
Reason
|
|
|
Voluntary
Termination
in Connection
with a
Change of
Control
|
|
|
Other
Voluntary
Termination
|
|
|
Permanent
Disability
or Death
|
|
|
Involuntary
Termination
for Cause
|
|
|
Involuntary
Termination
without
Cause
|
|
|
Termination of
Employment
without Cause or
for Good
Reason
Following a
Change of
Control
|
|
Cash Severance
|
|
|
1,112,000
|
|
|
|
1,322,000
|
|
|
|
-0-
|
|
|
|
210,000
|
|
|
|
-0-
|
|
|
|
1,112,000
|
|
|
|
1,322,000
|
|
Stock Options
|
|
|
-0-
|
|
|
|
1,298,000
|
|
|
|
-0-
|
|
|
|
1,825,000
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
1,825,000
|
|
Restricted Stock
|
|
|
-0-
|
|
|
|
3,594,000
|
|
|
|
-0-
|
|
|
|
4,461,000
|
(1)
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
5,577,000
|
|
Health and Welfare Benefits Continuation
|
|
|
27,000
|
|
|
|
27,000
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
27,000
|
|
|
|
27,000
|
|
280G Tax Gross-Up
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
Other
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
TOTAL
|
|
|
1,139,000
|
|
|
|
6,241,000
|
|
|
|
-0-
|
|
|
|
6,496,000
|
|
|
|
-0-
|
|
|
|
1,139,000
|
|
|
|
8,751,000
|
|
(1)
|
Includes vesting of 7,500 shares of performance-based restricted stock granted on November 2, 2016 (25% of the total grant of 30,000 shares).
|
46
Blake DeSimone
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Executive Benefits and
Payments
|
|
Voluntary
Termination
for Good
Reason
|
|
|
Voluntary
Termination
in Connection
with a
Change of
Control
|
|
|
Other
Voluntary
Termination
|
|
|
Permanent
Disability
or Death
|
|
|
Involuntary
Termination
for Cause
|
|
|
Involuntary
Termination
without
Cause
|
|
|
Termination of
Employment
without Cause or
for Good
Reason
Following a
Change of
Control
|
|
Cash Severance
|
|
|
602,000
|
|
|
|
602,000
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
602,000
|
|
|
|
602,000
|
|
Stock Options
|
|
|
-0-
|
|
|
|
264,000
|
|
|
|
-0-
|
|
|
|
264,000
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
264,000
|
|
Restricted Stock
|
|
|
-0-
|
|
|
|
1,351,000
|
|
|
|
-0-
|
|
|
|
1,351,000
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
1,351,000
|
|
Health and Welfare Benefits Continuation
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
280G Tax Gross-Up
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
Other
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
TOTAL
|
|
|
602,000
|
|
|
|
2,217,000
|
|
|
|
-0-
|
|
|
|
1,615,000
|
|
|
|
-0-
|
|
|
|
602,000
|
|
|
|
2,217,000
|
|
Michael B. Glick
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Executive Benefits and
Payments
|
|
Voluntary
Termination
for Good
Reason
|
|
|
Voluntary
Termination
in Connection
with a
Change of
Control
|
|
|
Other
Voluntary
Termination
|
|
|
Permanent
Disability
or Death
|
|
|
Involuntary
Termination
for Cause
|
|
|
Involuntary
Termination
without
Cause
|
|
|
Termination of
Employment
without Cause or
for Good
Reason
Following a
Change of
Control
|
|
Cash Severance
|
|
|
539,000
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
68,000
|
|
|
|
-0-
|
|
|
|
539,000
|
|
|
|
606,000
|
|
Stock Options
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
595,000
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
595,000
|
|
Restricted Stock
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
1,785,000
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
1,785,000
|
|
Health and Welfare Benefits Continuation
|
|
|
1,000
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
1,000
|
|
|
|
1,000
|
|
280G Tax Gross-Up
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
Other
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
TOTAL
|
|
|
540,000
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
2,448,000
|
|
|
|
-0-
|
|
|
|
540,000
|
|
|
|
2,987,000
|
|
Douglas W. Wamsley
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Executive Benefits and
Payments
|
|
Voluntary
Termination
for Good
Reason
|
|
|
Voluntary
Termination
in Connection
with a
Change of
Control
|
|
|
Other
Voluntary
Termination
|
|
|
Permanent
Disability
or Death
|
|
|
Involuntary
Termination
for Cause
|
|
|
Involuntary
Termination
without
Cause
|
|
|
Termination of
Employment
without Cause or
for Good
Reason
Following a
Change of
Control
|
|
Cash Severance
|
|
|
539,000
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
68,000
|
|
|
|
-0-
|
|
|
|
539,000
|
|
|
|
606,000
|
|
Stock Options
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
595,000
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
595,000
|
|
Restricted Stock
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
1,785,000
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
1,785,000
|
|
Health and Welfare Benefits Continuation
|
|
|
26,000
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
26,000
|
|
|
|
26,000
|
|
280G Tax Gross-Up
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
Other
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
TOTAL
|
|
|
565,000
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
2,448,000
|
|
|
|
-0-
|
|
|
|
565,000
|
|
|
|
3,012,000
|
|
47
Martin J. Wygod
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Executive Benefits and
Payments
|
|
Voluntary
Termination
for Good
Reason
|
|
|
Voluntary
Termination
in Connection
with a
Change of
Control
|
|
|
Other
Voluntary
Termination
|
|
|
Permanent
Disability or
Death
|
|
|
Involuntary
Termination
for Cause
|
|
|
Involuntary
Termination
without
Cause
|
|
|
Termination of
Employment
without Cause or
for Good
Reason
Following a
Change of
Control
|
|
Cash Severance
(1)
|
|
|
5,725,000
|
|
|
|
5,905,000
|
|
|
|
5,725,000
|
|
|
|
5,905,000
|
|
|
|
-0-
|
|
|
|
5,725,000
|
|
|
|
5,905,000
|
|
Stock Options
|
|
|
239,000
|
|
|
|
239,000
|
|
|
|
-0-
|
|
|
|
239,000
|
|
|
|
-0-
|
|
|
|
239,000
|
|
|
|
239,000
|
|
Restricted Stock
|
|
|
6,279,000
|
|
|
|
6,279,000
|
|
|
|
-0-
|
|
|
|
6,279,000
|
|
|
|
-0-
|
|
|
|
6,279,000
|
|
|
|
6,279,000
|
|
Health and Welfare Benefits Continuation
|
|
|
57,000
|
|
|
|
57,000
|
|
|
|
57,000
|
|
|
|
57,000
|
|
|
|
-0-
|
|
|
|
57,000
|
|
|
|
57,000
|
|
280G Tax Gross-Up
(2)
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
Other
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
|
|
-0-
|
|
TOTAL
|
|
|
12,300,000
|
|
|
|
12,480,000
|
|
|
|
5,782,000
|
|
|
|
12,480,000
|
|
|
|
-0-
|
|
|
|
12,300,000
|
|
|
|
12,480,000
|
|
(1)
|
As more fully described under Employment Agreements with Named Executive Officers Martin J. Wygod below, in connection with the Merger of HLTH and
WebMD in 2009, Mr. Wygod agreed to remain executive Chairman of the Board following the consummation of the Merger, notwithstanding the terms of his employment agreement at the time, which provided for him to receive the cash severance reported
in this table in connection with such consummation. Accordingly, his agreement was amended to provide that he may resign with or without Good Reason and receive such cash severance, which consists of salary and bonus for three years, with
(a) the annual salary amount being $975,000, the salary in effect immediately prior to the Merger and (b) the annual bonus amount being $933,333, determined by averaging the bonus amounts received by Mr. Wygod for the three years
prior to the Merger.
|
(2)
|
We have assumed, solely for purposes of preparing this table, that the salary continuation portion of the severance is the only portion of the benefits that constitutes
reasonable compensation for the restrictive covenants to which the executive is bound following the termination of employment. Accordingly, we have not treated the salary continuation portion as a parachute payment for purposes of
Section 280G. Such assumption may change at the time of an actual change of control.
|
Employment Agreements with Named
Executive Officers
The following are summaries of the employment agreements with our Named Executive Officers. The
agreements provide the general framework and some of the specific terms for the compensation of the Named Executive Officers. Approval of the Compensation Committee is required prior to WebMD entering into employment agreements with its executive
officers or any amendments to those agreements. However, some of the decisions relating to the compensation of our Named Executive Officers for a specific year made by the Compensation Committee are implemented without changes to the general terms
of employment set forth in those agreements. Those decisions in 2016 and their implementation are noted below and are more fully discussed earlier in this Executive Compensation section.
Some of the employment agreement summaries below refer to the definition of Change of Control used in the 2005 Plan. That
definition is described above under the heading Non-Employee Director Compensation Option Grants.
Steven L. Zatz, M.D.
We are party to an employment agreement with Steven L. Zatz, M.D., who serves as our Chief Executive Officer, which was entered into on November 3, 2016 (the Zatz Agreement), following
his appointment to that position in September 2016. The following is a description of the Zatz Agreement, along with a summary of compensation decisions made with respect to Dr. Zatz for 2016:
|
|
|
Dr. Zatzs base salary rate under the Zatz Employment Agreement is $575,000 per year, an increase from his prior base salary rate of $500,000
per year. For a discussion of the $537,317 annual bonus awarded to Dr. Zatz for 2016, see Compensation Discussion and Analysis Use of Specific Types of Compensation for 2016 2016 Bonus Program above.
|
48
|
|
|
On November 2, 2016, the Compensation Committee granted to Dr. Zatz 30,000 shares of WebMD Restricted Stock and options to purchase 150,000
shares of WebMD Common Stock with an exercise price of $49.00 per share, the closing price of WebMD Common Stock on the date of grant. The options are scheduled to expire on the tenth anniversary of the date of grant. For the grants of both the
WebMD Restricted Stock and the options, one-third of the amount granted is scheduled to vest on each of the second, third and fourth anniversaries of the date of grant. For information regarding prior grants to Dr. Zatz, see Executive
Compensation Tables above.
|
|
|
|
Also on November 2, 2016, the Compensation Committee granted to Dr. Zatz 30,000 shares of performance-based restricted stock that will vest
and be earned so long as he is employed at the end of the performance period, December 31, 2019, and only to the extent that the Compensation Committee determines that the performance criteria have been satisfied, except as described below. The
performance criteria are based on Average Adjusted EBITDA during the performance period of January 1, 2016 through December 31, 2019. The Compensation Committee will determine Average Adjusted EBITDA (which may be equitably adjusted by the
Compensation Committee for certain extraordinary corporate events so as not to enlarge or dilute the awards) within 45 days after WebMDs filing of its audited financial statements for 2019. Satisfaction of a threshold level of Average Adjusted
EBITDA will result in the vesting of 50% of the shares subject to the award, with vesting of up to an additional 50% of the shares determined on a pro-rated basis for levels of Average Adjusted EBITDA between that threshold and the higher level
required to achieve vesting of all of the shares. For additional information regarding the performance-based restricted stock, see Compensation Discussion and Analysis Use of Specific Types of Compensation for 2016 Grants of
Options, Restricted Stock and Performance-Based Restricted Stock in 2016 above.
|
|
|
|
In the event of the termination of Dr. Zatzs employment by WebMD without Cause or by him for Good Reason, he would be entitled to the
following under the Zatz Agreement:
|
|
|
|
to continue to receive his base salary for one year from the date of termination;
|
|
|
|
to receive certain amounts in respect of COBRA premiums until the earlier of one year following his termination and the date upon which he receives
comparable coverage under another plan; and
|
|
|
|
if the date of termination is on or after July 1 and before bonuses for that year are paid, to receive the bonus he would have received for that
year, payable at the time bonuses for that year are paid to other executives.
|
In addition to the payments
described above, if following a Change of Control of WebMD, (a) WebMD terminates Dr. Zatz without Cause or he resigns for Good Reason or (b) if he resigns after one year following a Change of Control, he would be entitled to the
following:
|
|
|
WebMD Restricted Stock and options to purchase WebMD Common Stock that were granted to him on or before November 2, 2016, other than the grants made on
March 25, 2015 discussed below, will be deemed fully vested and the options will remain outstanding for one year from the date of termination;
|
|
|
|
the performance-based restricted stock described above will be deemed fully vested and earned; and
|
|
|
|
to receive the amount, if any, contributed by WebMD on his behalf to WebMDs Supplemental Bonus Plan for the most recent year, if not previously
distributed to him.
|
|
|
|
With respect to the grants of WebMD Restricted Stock and of options to purchase WebMD Common Stock made to Dr. Zatz on March 25, 2015, those
grants would be deemed fully vested on the date of termination and the options would remain outstanding for the remainder of their term, but only if there was a termination by WebMD without Cause or by Dr. Zatz for Good Reason after a Change of
Control. Accelerated vesting of the March 25, 2015 grants will not occur upon a resignation by Dr. Zatz following a Change in Control unless that resignation is for Good Reason (as defined in his employment agreement).
|
|
|
|
For purposes of the Zatz Agreement:
|
|
|
|
Change of Control has the same definition used in the 2005 Plan;
|
49
|
|
|
Cause includes (i) continued willful failure to perform duties after 30 days written notice, (ii) willful misconduct or violence
or threat of violence that would harm WebMD, (iii) a breach of a material WebMD policy, the employment agreement or the Trade Secret and Proprietary Information Agreement (as described below) that remains unremedied after 30 days written
notice, or (iv) conviction of a felony in respect of a dishonest or fraudulent act or other crime of moral turpitude; and
|
|
|
|
Good Reason means resignation of employment within one year of the occurrence of any of the following conditions or events: (i) a
material reduction in base salary, (ii) WebMD removing him from the position of Chief Executive Officer (except on or following a Change of Control, so long as he is working on the transition or in a senior capacity), or (iii) any material
breach of the employment agreement by WebMD; provided that he has provided written notice to WebMD within 90 days after the occurrence of such condition or event claimed to be Good Reason and WebMD has failed to remedy such condition or event within
30 days of receipt of such written notice.
|
Dr. Zatz is also a party to a related Restrictive Covenant
Agreement that contains confidentiality obligations that survive indefinitely. The agreement also includes non-solicitation provisions that prohibit him from hiring WebMDs employees who were employed during the one year period prior to his
termination of employment or soliciting any of WebMDs clients or customers with whom he had a relationship or about whom he obtained confidential information during the time he was employed by WebMD, and non-competition provisions that
prohibit him from being involved in a business that competes with WebMDs business or that competes with any other business engaged in by any affiliates of WebMD if he is directly involved in such business. The non-solicitation and
non-competition obligations end on the first anniversary of the date his employment ceases. Post-employment payments and benefits that may become due to Dr. Zatz would be subject to his continued compliance with the covenants contained in the
Zatz Agreement and the Restrictive Covenant Agreement.
Blake DeSimone
We are party to an employment agreement with Blake DeSimone, who serves as our Chief Financial Officer, which was entered into on
November 3, 2016 (the DeSimone Agreement), following his appointment to that position in September 2016. The following is a description of the DeSimone Agreement, along with a summary of compensation decisions made with respect to
Mr. DeSimone for 2016:
|
|
|
Mr. DeSimones base salary rate under the DeSimone Agreement is $400,000 per year, an increase from his prior base salary rate of $367,500
per year. For a discussion of the $202,000 annual bonus awarded to Dr. Zatz for 2016, see Compensation Discussion and Analysis Use of Specific Types of Compensation for 2016 2016 Bonus Program above.
|
|
|
|
On November 2, 2016, the Compensation Committee granted to Mr. DeSimone 16,000 shares of WebMD Restricted Stock and options to purchase
80,000 shares of WebMD Common Stock with an exercise price of $49.00 per share, the closing price of WebMD Common Stock on the date of grant. The options are scheduled to expire on the tenth anniversary of the date of grant. For the grants of both
the WebMD Restricted Stock and the options, 25% of the amount granted is scheduled to vest on each of the first through fourth anniversaries of the date of grant. For information regarding prior grants to Mr. DeSimone, see Executive
Compensation Tables above.
|
|
|
|
In the event of the termination of Mr. DeSimones employment by WebMD without Cause or by him for Good Reason, he would be entitled to the
following under the DeSimone Agreement:
|
|
|
|
to continue to receive his base salary for one year from the date of termination;
|
|
|
|
to receive certain amounts in respect of COBRA premiums until the earlier of one year following his termination and the date upon which he receives
comparable coverage under another plan; and
|
|
|
|
if the date of termination is on or after December 31 and before bonuses for that year are paid, to receive the bonus he would have received for
that year, payable at the time bonuses for that year are paid to other executives.
|
50
In addition to the payments described above, if following a Change of Control of WebMD,
(a) WebMD terminates Mr. DeSimone without Cause or he resigns for Good Reason or (b) if he resigns after one year following a Change of Control, he would be entitled to the following:
|
|
|
WebMD Restricted Stock and options to purchase WebMD Common Stock that were granted to him on or before November 2, 2016 will be deemed fully
vested and the options will remain outstanding for one year from the date of termination; and
|
|
|
|
to receive the amount, if any, contributed by WebMD on his behalf to WebMDs Supplemental Bonus Plan for the most recent year, if not previously
distributed to him.
|
|
|
|
For purposes of the DeSimone Agreement, the definitions of Change of Control, Cause and Good Reason are
substantially the same as those contained in the Zatz Agreement described above, except that they reference Mr. DeSimones position and responsibilities where applicable.
|
Mr. DeSimone is also a party to a related Trade Secret and Proprietary Information Agreement that contains confidentiality
obligations that survive indefinitely. The agreement also includes non-solicitation provisions that prohibit him from hiring WebMDs employees who were employed during the one year period prior to his termination or soliciting any of
WebMDs clients or customers during the time he was employed by WebMD, and non-competition provisions that prohibit him from being involved in a business that competes with WebMDs business or that competes with any other business engaged
in by any affiliates of WebMD if he is directly involved in such business. The non-solicitation and non-competition obligations end on the first anniversary of the date his employment ceases. Post-employment payments and benefits that may become due
to Mr. DeSimone would be subject to his continued compliance with the covenants contained in the DeSimone Agreement and the Trade Secret and Proprietary Information Agreement.
Michael B. Glick
We are party to an employment agreement with Michael Glick, which was entered into on February 11, 2011, and amended on March 5, 2013 and November 2, 2016 (as amended, the Glick
Agreement). The following is a description of the Glick Agreement, along with a summary of compensation decisions made with respect to Mr. Glick for 2016:
|
|
|
Mr. Glicks base salary rate is $375,000 per year. It was increased, effective November 3, 2016, from $350,000 per year. For a discussion of
the $163,531 annual bonus awarded to Mr. Glick for 2016, see Compensation Discussion and Analysis Use of Specific Types of Compensation for 2016 2016 Bonus Program above.
|
|
|
|
On November 2, 2016, the Compensation Committee granted to Mr. Glick 15,000 shares of WebMD Restricted Stock and options to purchase 75,000
shares of WebMD Common Stock with an exercise price of $49.00 per share, the closing price of WebMD Common Stock on the date of grant. The options are scheduled to expire on the tenth anniversary of the date of grant. For the grants of both the
WebMD Restricted Stock and the options, one-third of the amount granted is scheduled to vest on each of the second, third and fourth anniversaries of the date of grant. For information regarding prior grants to Mr. Glick, see Executive
Compensation Tables above.
|
|
|
|
Under the Glick Agreement, in the event of a termination of Mr. Glicks employment by WebMD without Cause or by him for Good Reason,
Mr. Glick would be entitled to the following: to continue to receive his base salary for one year from the date of termination; to receive certain amounts in respect of COBRA premiums until the earlier of one year following his termination and
the date upon which he receives comparable coverage under another plan; and if the date of termination is on or after July 1 of that year and before bonuses for that year are paid, to receive the bonus he would have received for that year,
payable at the time bonuses for that year are paid to other executives. If such termination occurs following a Change of Control (as defined in the 2005 Plan) of WebMD:
|
|
|
|
the remaining unvested portion, as of the date of termination, of the WebMD Restricted Stock and the WebMD options granted to him on November 2,
2016 would vest upon such termination and the options will remain outstanding until the first anniversary of the date of termination;
|
51
|
|
|
the remaining unvested portion, as of the date of the termination, of the WebMD Restricted Stock and the WebMD options granted to him on March 25,
2015 would vest upon such termination and the options would remain outstanding through the original 10 year term;
|
|
|
|
the final vesting of the WebMD Restricted Stock granted to him on December 18, 2013 would be accelerated to the date of termination and the
options subject to the final vesting of the grant made to him on that date would remain outstanding and vest on December 18, 2017; and
|
|
|
|
he would be entitled to receive the Supplemental Bonus Plan contribution made by WebMD on his behalf for the most recent year, if not previously
distributed to him.
|
|
|
|
For purposes of the Glick Agreement, the definitions of Change of Control, Cause and Good Reason are substantially
the same as those contained in the Zatz Agreement described above, except that they reference Mr. Glicks position and responsibilities where applicable.
|
Mr. Glick is also a party to a related Trade Secret and Proprietary Information Agreement that contains confidentiality obligations
that survive indefinitely. The agreement also includes non-solicitation provisions that prohibit him from hiring WebMDs employees or soliciting any of WebMDs clients or customers with whom he had a relationship during the time he was
employed by WebMD, and non-competition provisions that prohibit him from being involved in a business that competes with WebMDs business or that competes with any other business engaged in by any affiliates of WebMD if he is directly involved
in such business. The non-solicitation and non-competition obligations end on the first anniversary of the date his employment ceases. Post-employment payments and benefits that may become due to Mr. Glick would be subject to his continued
compliance with the covenants contained in the Glick Agreement and the Trade Secret and Proprietary Information Agreement.
Douglas W. Wamsley
We are party to an employment agreement with Douglas Wamsley, which was entered into on July 14, 2005, and amended on each of December 14, 2008, March 5, 2013 and November 3, 2016 (as
amended, the Wamsley Agreement). The following is a description of the Wamsley Agreement, along with a summary of compensation decisions made with respect to Mr. Wamsley for 2016:
|
|
|
Mr. Wamsleys base salary rate is $375,000 per year. It was increased, effective November 3, 2016, from $350,000 per year. For a
discussion of the $163,531 annual bonus awarded to Mr. Wamsley for 2016, see Compensation Discussion and Analysis Use of Specific Types of Compensation for 2016 2016 Bonus Program above.
|
|
|
|
On November 2, 2016, the Compensation Committee granted to Mr. Wamsley 15,000 shares of WebMD Restricted Stock and options to purchase 75,000
shares of WebMD Common Stock with an exercise price of $49.00 per share, the closing price of WebMD Common Stock on the date of grant. The options are scheduled to expire on the tenth anniversary of the date of grant. For the grants of both the
WebMD Restricted Stock and the options, one-third of the amount granted is scheduled to vest on each of the second, third and fourth anniversaries of the date of grant. For information regarding prior grants to Mr. Wamsley, see Executive
Compensation Tables above.
|
|
|
|
Under the Wamsley Agreement, in the event of a termination of Mr. Wamsleys employment by WebMD without Cause or by him for Good Reason,
Mr. Wamsley would be entitled to the following: to continue to receive his base salary for one year from the date of termination; to receive certain amounts in respect of COBRA premiums until the earlier of one year following his termination
and the date upon which he receives comparable coverage under another plan; and if the date of termination is on or after July 1 of that year and before bonuses for that year are paid, to receive the bonus he would have received for that year,
payable at the time bonuses for that year are paid to other executives. If such termination occurs following a Change of Control (as defined in the 2005 Plan) of WebMD:
|
|
|
|
the remaining unvested portion, as of the date of termination, of the WebMD Restricted Stock and the WebMD options granted to him on November 2,
2016 would vest upon such termination and the options will remain outstanding until the first anniversary of the date of termination;
|
52
|
|
|
the remaining unvested portion, as of the date of the termination, of the WebMD Restricted Stock and the WebMD options granted to him on March 25,
2015 would vest upon such termination and the options would remain outstanding through the original 10 year term;
|
|
|
|
the final vesting of the WebMD Restricted Stock granted to him on December 18, 2013 would be accelerated to the date of termination and the
options subject to the final vesting of the grant made to him on that date would remain outstanding and vest on December 18, 2017; and
|
|
|
|
he would be entitled to receive the Supplemental Bonus Plan contribution made by WebMD on his behalf for the most recent year, if not previously
distributed to him.
|
|
|
|
For purposes of the Wamsley Agreement, the definitions of Change of Control, Cause and Good Reason are
substantially the same as those contained in the Zatz Agreement described above, except that they reference Mr. Wamsleys position and responsibilities where applicable.
|
Mr. Wamsley is also a party to a related Trade Secret and Proprietary Information Agreement that contains confidentiality
obligations that survive indefinitely. The agreement also includes non-solicitation provisions that prohibit him from hiring WebMDs employees or soliciting any of WebMDs clients or customers with whom he had a relationship during the
time he was employed by WebMD, and non-competition provisions that prohibit him from being involved in a business that competes with WebMDs business or that competes with any other business engaged in by any affiliates of WebMD if he is
directly involved in such business. The non-solicitation and non-competition obligations end on the first anniversary of the date his employment ceases. Post-employment payments and benefits that may become due to Mr. Glick would be subject to
his continued compliance with the covenants contained in the Wamsley Agreement and the Trade Secret and Proprietary Information Agreement.
Martin J. Wygod
Mr. Wygod entered into an employment agreement
with HLTH dated as of August 3, 2005, which was amended on each of February 1, 2006, December 1, 2008 (the 2008 Amendment), December 29, 2008 and July 9, 2009 (the 2009 Amendment). WebMD assumed
the employment agreement upon the closing of the Merger in October 2009 and it has been further amended, since then, on September 21, 2011, September 25, 2011 and May 8, 2013 (as amended, the Wygod Agreement). The following is
a description of the Wygod Agreement, along with a summary of compensation decisions made with respect to Mr. Wygod for 2016:
|
|
|
Mr. Wygods base salary rate is $490,000 per year. No change has been made to this rate since September 2011. For a discussion of the
$453,621 annual bonus awarded to Mr. Wygod for 2016, see Compensation Discussion and Analysis Use of Specific Types of Compensation for 2016 2016 Bonus Program above.
|
|
|
|
On November 2, 2016, the Compensation Committee granted to Mr. Wygod 25,000 shares of WebMD Restricted Stock and options to purchase 100,000
shares of WebMD Common Stock with an exercise price of $49.00 per share, the closing price of WebMD Common Stock on the date of grant. The options are scheduled to expire on the tenth anniversary of the date of grant. For the grants of both the
WebMD Restricted Stock and the options, one-third of the amount granted is scheduled to vest on each of the second, third and fourth anniversaries of the date of grant. For information regarding prior grants to Mr. Wygod, see Executive
Compensation Tables above.
|
|
|
|
Also on November 2, 2016, the Compensation Committee granted to Mr. Wygod 25,000 shares of performance-based restricted stock that will vest
and be earned so long as he is employed at the end of the performance period, December 31, 2019, and only to the extent that the Compensation Committee determines that the performance criteria have been satisfied, except as described below. The
performance criteria are based on Average Adjusted EBITDA during the performance period of January 1, 2016 through December 31, 2019. The Compensation Committee will determine Average Adjusted EBITDA (which may be equitably adjusted by the
Compensation Committee for certain extraordinary corporate events so as not to enlarge or dilute the awards) within 45 days after WebMDs filing of its audited
|
53
|
financial statements for 2019. Satisfaction of a threshold level of Average Adjusted EBITDA will result in the vesting of 50% of the shares subject to the award, with vesting of up to an
additional 50% of the shares determined on a pro-rated basis for levels of Average Adjusted EBITDA between that threshold and the higher level required to achieve vesting of all of the shares. For additional information regarding the
performance-based restricted stock, see Compensation Discussion and Analysis Use of Specific Types of Compensation for 2016 Grants of Options, Restricted Stock and Performance-Based Restricted Stock in 2016 above.
|
|
|
|
The 2008 Amendment extended the employment period, under the employment agreement, through December 31, 2012 and thereafter on a month-to-month
basis. A non-renewal by WebMD would be treated as a termination without Cause (as that term is described below) and have the consequences described below. Pursuant to the 2008 Amendment, upon the closing of the Merger,
(i) Mr. Wygods employment would have terminated, (ii) Mr. Wygod would have become a non-executive Chairman of the Board of WebMD and (iii) Mr. Wygod would have been entitled to receive the cash severance and
benefits provided in the employment agreement (described below). However, HLTH, WebMD and Mr. Wygod agreed, in the 2009 Amendment, that Mr. Wygod would continue to serve as executive Chairman of the Board of WebMD following the Merger. The
2009 Amendment also provided that Mr. Wygod would continue to have the right, if his employment were to terminate for any reason, to receive the severance he would have received under the 2008 Amendment had he become a non-employee Chairman of
the Board of WebMD upon the closing of the Merger, as had originally been contemplated. Accordingly, upon any such termination, Mr. Wygod would be entitled to the following severance benefits:
|
|
|
|
a severance payment of $975,000 (Mr. Wygods base salary prior to the Merger), per year payable for three years following the date of termination
in equal installments at the same time as WebMDs payroll practices (for an aggregate of $2,925,000); provided that the first six months of severance shall be delayed for six months and will be paid in a lump sum after such six month period in
accordance with Section 409A of the Internal Revenue Code;
|
|
|
|
a bonus payment in the amount of $933,333.34 (the average of the three annual bonuses prior to the closing date of the Merger) for each of the three
calendar years following the date of termination (for an aggregate of $2.8 million), with the payments to be made at such time as bonuses are paid to executive officers generally for each such year; and
|
|
|
|
continued participation in WebMDs health, dental, vision and life insurance plans in which he participates on the date of termination (or
reasonably equivalent plans) for three years from the date of termination (or, if earlier, until eligible for comparable coverage with a subsequent employer).
|
|
|
|
If Mr. Wygods employment is terminated by WebMD without Cause, by Mr. Wygod for Good Reason or as a result of death or disability, the
vesting of all of his options and restricted stock (including the performance-based restricted stock granted on November 2, 2016) would accelerate, his options would remain outstanding for three years (but in no event longer than the expiration
of the original term) and the Compensation Committee shall determine the extent to which the performance criteria for the performance-based restricted stock have been satisfied at the end of the year in which the termination occurred. In the event
of a Change in Control, Mr. Wygods equity would fully vest (including the performance-based restricted stock granted on November 2, 2016, with the performance criteria and the employment condition being deemed fully satisfied) and,
if his employment terminates after that, his options would remain outstanding through the expiration of the original term. In addition, all cash amounts payable to Mr. Wygod in connection with his termination on or following a Change in Control
are required to be placed in a rabbi trust.
|
|
|
|
In addition, if the termination by WebMD without Cause or the resignation by him for Good Reason occurs following a Change of Control of WebMD,
Mr. Wygod shall be entitled to receive the Supplemental Bonus Plan contribution made by WebMD on his behalf for the most recent year, if not previously distributed to him.
|
|
|
|
For purposes of the Wygod Agreement: (a) Cause includes a final court adjudication that Mr. Wygod (i) committed fraud or a
felony directed against WebMD or an affiliate relating to his employment, or
|
54
|
(ii) materially breached any of the material terms of the Wygod Agreement; and (b) the definition of Good Reason includes the following conditions or events: (i) a
material reduction in title or responsibility that remains in effect for 30 days after written notice, (ii) a final court adjudication that WebMD materially breached any material provisions of the Wygod Agreement, (iii) failure to serve on
WebMDs Board or Executive Committee of WebMDs Board, or (iv) the occurrence of a Change in Control (as defined in the HLTH 2000 Plan, which definition is substantially the same as the definition in the 2005 Plan) of WebMD.
|
|
|
|
The Wygod Agreement contains confidentiality obligations that survive indefinitely and non-solicitation and non-competition obligations that continue
until the third anniversary of the date his employment has ceased. Post-employment payments and benefits that may be due to Mr. Wygod under the Wygod Agreement are subject to his continued compliance with these covenants.
|
|
|
|
The Wygod Agreement contains a tax gross-up provision relating to any excise tax that Mr. Wygod incurs by reason of his receipt of any payment
that constitutes an excess parachute payment as defined in Section 280G. Any excess parachute payments and related tax gross-up payments made to Mr. Wygod will not be deductible by WebMD for federal income tax purposes.
|
David J. Schlanger
WebMD entered into an employment agreement with Mr. Schlanger, effective in May 2013 when Mr. Schlanger became Interim Chief Executive Officer of WebMD, and it was amended on August 11,
2013 when he became Chief Executive Officer (as amended, the Schlanger Employment Agreement). Subject to continued compliance with the applicable restrictive covenants, Mr. Schlanger was entitled to receive the following severance
compensation pursuant to the terms of the Schlanger Employment Agreement when he left WebMD by mutual agreement in September 2016:
|
|
|
salary continuation for one year, at his annual base salary rate of $525,000 per year;
|
|
|
|
his annual bonus for 2016, as determined by the Compensation Committee, at the time that annual bonuses are regularly paid to other executive officers
in March 2017; and
|
|
|
|
reimbursement of his COBRA premiums on a tax neutral basis for continuation of his health coverage for up to one year or, if earlier, until he was no
longer eligible for COBRA or he becomes eligible for coverage from a subsequent employer.
|
In addition,
pursuant to a letter agreement entered into between Mr. Schlanger and WebMD effective September 16, 2016 (the Departure Date), Mr. Schlanger was entitled, subject to compliance with restrictive covenants, to receive the
following additional severance compensation:
|
|
|
the release of the contribution of $210,000 made by WebMD in March 2016 on behalf of Mr. Schlanger to the Supplemental Bonus Trust in connection
with his 2015 annual bonus;
|
|
|
|
the following scheduled vestings of options to purchase WebMD Common Stock previously granted to Mr. Schlanger (with the remaining unvested
options being terminated): (i) the vesting on March 25, 2017 of 20,000 of the 40,000 options scheduled to vest on that date and (ii) the vesting on August 11, 2017 of 6,250 of the 75,000 options scheduled to vest on that date;
and
|
|
|
|
acceleration to the Departure Date of the vesting of: (i) 10,000 of the 20,000 shares of restricted WebMD Common Stock scheduled to vest on
March 25, 2017 (with the remaining unvested shares being forfeited) and (ii) 1,042 of the 12,500 shares of restricted WebMD Common Stock scheduled to vest on August 11, 2017 (with the remaining unvested shares being forfeited);
provided that Mr. Schlanger may not sell, transfer or pledge any of the shares for which vesting was accelerated until the originally scheduled vesting date.
|
The post-employment payments and benefits due to Mr. Schlanger are subject to his continued compliance with the restrictive
covenants applicable to him, including confidentiality obligations that survive indefinitely and
55
non-solicitation provisions that prohibit him from hiring WebMDs employees or soliciting any of WebMDs clients or customers with whom he had a relationship during the time he was
employed by WebMD, and non-competition provisions that prohibit him from being involved in a business that competes with WebMDs business or that competes with any other business engaged in by any affiliates of WebMD if he is directly involved
in such business. The non-solicitation and non-competition obligations end on the first anniversary of the Departure Date.
Peter Anevski
In connection with Mr. Anevski becoming Chief Financial Officer of WebMD in May 2013, the Compensation Committee approved the terms of an employment agreement between WebMD and Mr. Anevski.
Subject to continued compliance with the restrictive covenants in his employment agreement, Mr. Anevski was entitled to receive the following severance compensation pursuant to the terms of the employment agreement following his termination
without cause in September 2016:
|
|
|
salary continuation for one year, at his annual base salary rate of $425,000 per year;
|
|
|
|
reimbursement of his COBRA premiums for continuation of his health coverage for up to one year or, if earlier, until he is no longer eligible for COBRA
or he becomes eligible for coverage from a subsequent employer.
|
The post-employment payments and benefits
due to Mr. Anevski are subject to his continued compliance with the restrictive covenants applicable to him, including confidentiality obligations that survive indefinitely and non-solicitation provisions that prohibit him from hiring
WebMDs employees or soliciting any of WebMDs clients or customers with whom he had a relationship during the time he was employed by WebMD, and non-competition provisions that prohibit him from being involved in a business that competes
with WebMDs business or that competes with any other business engaged in by any affiliates of WebMD if he is directly involved in such business. The non-solicitation and non-competition obligations end on the first anniversary of the date he
ceased to be employed by WebMD.
56
FINANCIAL STATEMENTS
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTAL DATA
All other schedules not listed above have been omitted as not applicable or because the required
information is included in the Consolidated Financial Statements or in the notes thereto. Columns omitted from the schedule filed have been omitted because the information is not applicable.
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
1
REPORT OF MANAGEMENT ON INTERNAL CONTROL OVER FINANCIAL
REPORTING
Management of WebMD Health Corp. is responsible for establishing and maintaining adequate internal control over
financial reporting. Internal control over financial reporting is defined in
Rules 13a-15(f)
and
15d-15(f)
promulgated under the Securities Exchange Act of 1934
(the Exchange Act) as a process designed by, or under the supervision of, a companys principal executive and principal financial officers and effected by its board of directors, management and other personnel, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes those policies and
procedures that:
|
|
|
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the
company;
|
|
|
|
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
|
|
|
|
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the companys assets
that could have a material effect on the financial statements.
|
Internal control over financial reporting
includes the controls themselves, monitoring and internal auditing practices and actions taken to correct deficiencies as identified.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject
to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
WebMD management assessed the effectiveness of WebMDs internal control over financial reporting as of December 31, 2016. In making this assessment, WebMD management used the criteria set forth
in
Internal Control
Integrated Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on that assessment and those criteria, WebMD management concluded that
WebMD maintained effective internal control over financial reporting as of December 31, 2016.
Ernst & Young
LLP, the independent registered public accounting firm that audited and reported on the Companys consolidated financial statements as of December 31, 2016 and 2015 and for each of the three years in the period ended December 31,
2016, has audited the Companys internal control over financial reporting as of December 31, 2016, as stated in their report which appears on page 3.
March 1, 2017
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
2
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Stockholders of WebMD Health Corp.
We have audited WebMD Health Corp.s internal control over financial reporting as of December 31, 2016, based on criteria established in Internal ControlIntegrated Framework issued by the
Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). WebMD Health Corp.s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of
the effectiveness of internal control over financial reporting included in the accompanying Report of Management on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the companys internal control over
financial reporting based on our audit.
We conducted our audit in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our
audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk,
and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
A companys internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles. A companys internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that,
in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance
regarding prevention or timely detection of unauthorized acquisition, use or disposition of the companys assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections
of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
In our opinion, WebMD Health Corp. maintained, in all material respects, effective internal control over financial reporting as of
December 31, 2016, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public
Company Accounting Oversight Board (United States), the consolidated balance sheets of WebMD Health Corp. as of December 31, 2016 and 2015, and the related consolidated statements of operations, comprehensive income, equity and cash flows for
each of the three years in the period ended December 31, 2016 of WebMD Health Corp. and our report dated March 1, 2017 expressed an unqualified opinion thereon.
/s/ Ernst & Young LLP
New York, New York
March 1, 2017
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
3
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Stockholders of WebMD Health Corp.
We have audited the accompanying consolidated balance sheets of WebMD Health Corp. as of December 31, 2016 and 2015, and the related consolidated statements of operations, comprehensive income,
equity, and cash flows for each of the three years in the period ended December 31, 2016. Our audits also included the financial statement schedule listed in the Index at Item 15(a). These financial statements and schedule are the
responsibility of the Companys management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position
of WebMD Health Corp. at December 31, 2016 and 2015, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2016, in conformity with U.S. generally accepted accounting
principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), WebMD Health
Corp.s internal control over financial reporting as of December 31, 2016, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013
framework) and our report dated March 1, 2017 expressed an unqualified opinion thereon.
/s/
Ernst & Young LLP
New York, New York
March 1, 2017
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
4
WEBMD HEALTH CORP.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2016
|
|
|
2015
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
492,424
|
|
|
$
|
641,165
|
|
Accounts receivable, net of allowance for doubtful accounts of $1,532 at December 31, 2016 and $1,040 at December 31,
2015
|
|
|
179,454
|
|
|
|
174,313
|
|
Investments
|
|
|
498,500
|
|
|
|
|
|
Prepaid expenses and other current assets
|
|
|
15,294
|
|
|
|
18,998
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
1,185,672
|
|
|
|
834,476
|
|
Property and equipment, net
|
|
|
83,296
|
|
|
|
81,027
|
|
Goodwill
|
|
|
202,980
|
|
|
|
202,980
|
|
Intangible assets, net
|
|
|
7,774
|
|
|
|
10,894
|
|
Deferred tax assets, net
|
|
|
14,544
|
|
|
|
15,694
|
|
Other assets
|
|
|
6,920
|
|
|
|
10,852
|
|
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
$
|
1,501,186
|
|
|
$
|
1,155,923
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accrued expenses
|
|
$
|
78,597
|
|
|
$
|
80,664
|
|
Deferred revenue
|
|
|
105,310
|
|
|
|
102,715
|
|
2.25% convertible notes due 2016, net
|
|
|
|
|
|
|
102,523
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
183,907
|
|
|
|
285,902
|
|
2.50% convertible notes due 2018, net
|
|
|
398,066
|
|
|
|
396,281
|
|
1.50% convertible notes due 2020, net
|
|
|
295,432
|
|
|
|
294,266
|
|
2.625% convertible notes due 2023, net
|
|
|
351,190
|
|
|
|
|
|
Other long-term liabilities
|
|
|
28,731
|
|
|
|
23,246
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
Stockholders equity:
|
|
|
|
|
|
|
|
|
Preferred stock, 50,000,000 shares authorized; no shares issued and outstanding
|
|
|
|
|
|
|
|
|
Common stock, $0.01 par value per share, 650,000,000 shares authorized; 57,437,992 shares issued at December 31, 2016 and
December 31, 2015
|
|
|
574
|
|
|
|
574
|
|
Additional
paid-in
capital
|
|
|
9,303,783
|
|
|
|
9,238,444
|
|
Treasury stock, at cost; 20,698,568 shares at December 31, 2016 and 20,621,216 shares at December 31,
2015
|
|
|
(747,225
|
)
|
|
|
(678,069
|
)
|
Accumulated other comprehensive income
|
|
|
502
|
|
|
|
357
|
|
Accumulated deficit
|
|
|
(8,313,774
|
)
|
|
|
(8,405,078
|
)
|
|
|
|
|
|
|
|
|
|
Stockholders equity
|
|
|
243,860
|
|
|
|
156,228
|
|
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY
|
|
$
|
1,501,186
|
|
|
$
|
1,155,923
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes.
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
5
WEBMD HEALTH CORP.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
Revenue
|
|
$
|
705,046
|
|
|
$
|
636,399
|
|
|
$
|
580,449
|
|
Cost of operations
|
|
|
266,654
|
|
|
|
247,311
|
|
|
|
224,094
|
|
Sales and marketing
|
|
|
145,962
|
|
|
|
138,025
|
|
|
|
136,160
|
|
General and administrative
|
|
|
91,141
|
|
|
|
91,580
|
|
|
|
94,119
|
|
Depreciation and amortization
|
|
|
30,792
|
|
|
|
30,521
|
|
|
|
29,811
|
|
Interest income
|
|
|
2,545
|
|
|
|
51
|
|
|
|
69
|
|
Interest expense
|
|
|
24,496
|
|
|
|
23,123
|
|
|
|
24,686
|
|
Loss on convertible notes
|
|
|
|
|
|
|
2,058
|
|
|
|
|
|
Gain on investments
|
|
|
|
|
|
|
139
|
|
|
|
|
|
Other expense
|
|
|
1,712
|
|
|
|
4,100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before income tax provision
|
|
|
146,834
|
|
|
|
99,871
|
|
|
|
71,648
|
|
Income tax provision
|
|
|
55,530
|
|
|
|
35,847
|
|
|
|
30,707
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
91,304
|
|
|
|
64,024
|
|
|
|
40,941
|
|
Income from discontinued operations, net of tax
|
|
|
|
|
|
|
|
|
|
|
1,122
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
91,304
|
|
|
$
|
64,024
|
|
|
$
|
42,063
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic income per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
2.41
|
|
|
$
|
1.75
|
|
|
$
|
1.08
|
|
Income from discontinued operations
|
|
|
|
|
|
|
|
|
|
|
0.03
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
2.41
|
|
|
$
|
1.75
|
|
|
$
|
1.11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted income per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
1.97
|
|
|
$
|
1.48
|
|
|
$
|
0.97
|
|
Income from discontinued operations
|
|
|
|
|
|
|
|
|
|
|
0.03
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
1.97
|
|
|
$
|
1.48
|
|
|
$
|
1.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares outstanding used in
computing per share amounts:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
37,854
|
|
|
|
36,600
|
|
|
|
37,869
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
54,179
|
|
|
|
52,653
|
|
|
|
45,614
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes.
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
6
WEBMD HEALTH CORP.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
Net income
|
|
$
|
91,304
|
|
|
$
|
64,024
|
|
|
$
|
42,063
|
|
Other comprehensive income (loss), net of tax:
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized gains (losses), net of tax
|
|
|
145
|
|
|
|
(619
|
)
|
|
|
976
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other comprehensive income (loss), net of tax
|
|
|
145
|
|
|
|
(619
|
)
|
|
|
976
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income
|
|
$
|
91,449
|
|
|
$
|
63,405
|
|
|
$
|
43,039
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes.
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
7
WEBMD HEALTH CORP.
CONSOLIDATED STATEMENTS OF EQUITY
(In thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
`
|
|
Stockholders Equity
|
|
|
|
Common Stock
|
|
|
Additional
Paid-In
Capital
|
|
|
Treasury Stock
|
|
|
Accumulated
Other
Comprehensive
Income
|
|
|
Accumulated
Deficit
|
|
|
Total
Stockholders
Equity
|
|
|
|
Shares
|
|
|
Amount
|
|
|
|
Shares
|
|
|
Amount
|
|
|
|
|
Balances at December
31, 2013
|
|
|
57,437,992
|
|
|
$
|
574
|
|
|
$
|
9,273,712
|
|
|
|
18,281,498
|
|
|
$
|
(572,221
|
)
|
|
$
|
|
|
|
$
|
(8,511,165
|
)
|
|
$
|
190,900
|
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42,063
|
|
|
|
42,063
|
|
Other comprehensive income, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
976
|
|
|
|
|
|
|
|
976
|
|
Issuance of stock for option exercises and other issuances
|
|
|
|
|
|
|
|
|
|
|
(105,382
|
)
|
|
|
(2,356,573
|
)
|
|
|
112,898
|
|
|
|
|
|
|
|
|
|
|
|
7,516
|
|
Tax benefit realized from issuances of common stock
|
|
|
|
|
|
|
|
|
|
|
14,239
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,239
|
|
Stock-based compensation expense
|
|
|
|
|
|
|
|
|
|
|
32,231
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32,231
|
|
Repurchase of shares through tender offers
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,000,000
|
|
|
|
(97,588
|
)
|
|
|
|
|
|
|
|
|
|
|
(97,588
|
)
|
Purchases of treasury stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,160,070
|
|
|
|
(128,748
|
)
|
|
|
|
|
|
|
|
|
|
|
(128,748
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances at December
31, 2014
|
|
|
57,437,992
|
|
|
|
574
|
|
|
|
9,214,800
|
|
|
|
21,084,995
|
|
|
|
(685,659
|
)
|
|
|
976
|
|
|
|
(8,469,102
|
)
|
|
|
61,589
|
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
64,024
|
|
|
|
64,024
|
|
Other comprehensive loss, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(619
|
)
|
|
|
|
|
|
|
(619
|
)
|
Issuance of stock for option exercises and other issuances
|
|
|
|
|
|
|
|
|
|
|
(19,135
|
)
|
|
|
(1,152,246
|
)
|
|
|
35,996
|
|
|
|
|
|
|
|
|
|
|
|
16,861
|
|
Tax benefit realized from issuances of common stock
|
|
|
|
|
|
|
|
|
|
|
39,002
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
39,002
|
|
Correcting adjustment to prior years tax benefits realized from issuances of common stock
|
|
|
|
|
|
|
|
|
|
|
(29,499
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(29,499
|
)
|
Stock-based compensation expense
|
|
|
|
|
|
|
|
|
|
|
33,276
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
33,276
|
|
Purchases of treasury stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
688,467
|
|
|
|
(28,406
|
)
|
|
|
|
|
|
|
|
|
|
|
(28,406
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances at December
31, 2015
|
|
|
57,437,992
|
|
|
|
574
|
|
|
|
9,238,444
|
|
|
|
20,621,216
|
|
|
|
(678,069
|
)
|
|
|
357
|
|
|
|
(8,405,078
|
)
|
|
|
156,228
|
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
91,304
|
|
|
|
91,304
|
|
Other comprehensive income, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
145
|
|
|
|
|
|
|
|
145
|
|
Issuance of stock for option exercises and other issuances
|
|
|
|
|
|
|
|
|
|
|
(17,781
|
)
|
|
|
(2,378,866
|
)
|
|
|
64,900
|
|
|
|
|
|
|
|
|
|
|
|
47,119
|
|
Tax benefit realized from issuances of common stock
|
|
|
|
|
|
|
|
|
|
|
54,258
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
54,258
|
|
Stock-based compensation expense
|
|
|
|
|
|
|
|
|
|
|
28,862
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28,862
|
|
Repurchase of shares through tender offers
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,000,000
|
|
|
|
(110,413
|
)
|
|
|
|
|
|
|
|
|
|
|
(110,413
|
)
|
Purchases of treasury stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
456,218
|
|
|
|
(23,643
|
)
|
|
|
|
|
|
|
|
|
|
|
(23,643
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances at December
31, 2016
|
|
|
57,437,992
|
|
|
$
|
574
|
|
|
$
|
9,303,783
|
|
|
|
20,698,568
|
|
|
$
|
(747,225
|
)
|
|
$
|
502
|
|
|
$
|
(8,313,774
|
)
|
|
$
|
243,860
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes.
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
8
WEBMD HEALTH CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
91,304
|
|
|
$
|
64,024
|
|
|
$
|
42,063
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations, net of tax
|
|
|
|
|
|
|
|
|
|
|
(1,122
|
)
|
Depreciation and amortization
|
|
|
30,792
|
|
|
|
30,521
|
|
|
|
29,811
|
|
Non-cash
interest, net
|
|
|
3,906
|
|
|
|
4,172
|
|
|
|
4,511
|
|
Non-cash
stock-based compensation
|
|
|
29,329
|
|
|
|
33,743
|
|
|
|
32,546
|
|
Deferred income taxes
|
|
|
1,083
|
|
|
|
(7,713
|
)
|
|
|
14,717
|
|
Loss on convertible notes
|
|
|
|
|
|
|
2,058
|
|
|
|
|
|
Gain on investments
|
|
|
|
|
|
|
(139
|
)
|
|
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(5,141
|
)
|
|
|
(37,507
|
)
|
|
|
(12,574
|
)
|
Prepaid expenses and other, net
|
|
|
4,039
|
|
|
|
(4,132
|
)
|
|
|
(673
|
)
|
Accrued expenses and other long-term liabilities
|
|
|
3,246
|
|
|
|
9,606
|
|
|
|
(380
|
)
|
Deferred revenue
|
|
|
2,595
|
|
|
|
12,930
|
|
|
|
4,637
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by continuing operations
|
|
|
161,153
|
|
|
|
107,563
|
|
|
|
113,536
|
|
Net cash used in discontinued operations
|
|
|
|
|
|
|
|
|
|
|
(384
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
161,153
|
|
|
|
107,563
|
|
|
|
113,152
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases of property and equipment
|
|
|
(29,785
|
)
|
|
|
(48,372
|
)
|
|
|
(23,194
|
)
|
Purchases of investments
|
|
|
(1,446,410
|
)
|
|
|
|
|
|
|
|
|
Maturities and sales of investments
|
|
|
948,078
|
|
|
|
139
|
|
|
|
|
|
Partial redemption of cost-method investment
|
|
|
2,599
|
|
|
|
|
|
|
|
|
|
Cash paid in business combination
|
|
|
|
|
|
|
|
|
|
|
(3,182
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
|
(525,518
|
)
|
|
|
(48,233
|
)
|
|
|
(26,376
|
)
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from exercise of stock options
|
|
|
65,309
|
|
|
|
21,939
|
|
|
|
40,602
|
|
Cash used for withholding taxes due on stock-based awards
|
|
|
(17,599
|
)
|
|
|
(6,438
|
)
|
|
|
(33,385
|
)
|
Net proceeds from issuance of convertible notes
|
|
|
350,394
|
|
|
|
|
|
|
|
|
|
Maturity and repurchases of convertible notes
|
|
|
(102,682
|
)
|
|
|
(151,038
|
)
|
|
|
|
|
Repurchase of shares through tender offers
|
|
|
(110,413
|
)
|
|
|
|
|
|
|
(97,588
|
)
|
Purchases of treasury stock
|
|
|
(23,643
|
)
|
|
|
(28,406
|
)
|
|
|
(128,748
|
)
|
Excess tax benefit on stock-based awards
|
|
|
54,258
|
|
|
|
39,002
|
|
|
|
14,239
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) financing activities
|
|
|
215,624
|
|
|
|
(124,941
|
)
|
|
|
(204,880
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net decrease in cash and cash equivalents
|
|
|
(148,741
|
)
|
|
|
(65,611
|
)
|
|
|
(118,104
|
)
|
Cash and cash equivalents at beginning of period
|
|
|
641,165
|
|
|
|
706,776
|
|
|
|
824,880
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period
|
|
$
|
492,424
|
|
|
$
|
641,165
|
|
|
$
|
706,776
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes.
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
9
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(In thousands, except share and per share data)
1. Background and
Basis of Presentation
Background
WebMD Health Corp. (the Company or WebMD) is a Delaware corporation that was incorporated on May 3, 2005. The Company completed an initial public offering on
September 28, 2005. The Companys Common Stock trades under the symbol WBMD on the Nasdaq Global Select Market. The Company generates revenue from the advertising and sponsorship services of
The WebMD Health Network
and
related operations, from the services it markets to employers and health plans under the
WebMD Health Services
brand and from certain information services, each of which is described below and discussed further under Presentation of
Segment Information in Note 2.
Advertising and Sponsorship
.
The WebMD Health Network
includes:
www.WebMD.com
, the Companys primary Website for consumers and related mobile apps;
www.Medscape.com
, the Companys primary Website for physicians and other healthcare professionals and related mobile apps; and other sites
and apps through which the Company provides branded health and wellness content, tools and services. The Companys services for consumers enable them to obtain information on health and wellness topics or on a particular disease or condition,
to assess their personal health status, to use online trackers, tools and quizzes, to locate physicians, to receive periodic
e-mailed
newsletters and alerts on topics of individual interest, and to participate
in online communities with peers and experts. The Companys services for physicians and healthcare professionals make it easier for them to access clinical reference sources, stay abreast of the latest clinical information, learn about new
treatment options, earn continuing medical education (CME) credit and communicate with peers. The Company does not charge any usage, membership or download fees for access to the Websites and mobile apps included in
The WebMD Health
Network
. The Company generates revenue from
The WebMD Health Network
and mobile platforms primarily through the sale of various types of advertising and sponsorship programs to its clients, which include: pharmaceutical, biotechnology and
medical device companies; hospitals, clinics and other healthcare services companies; health insurance providers; consumer products companies whose products or services relate to health, wellness, diet, fitness, lifestyle, safety and illness
prevention; and various other businesses, organizations and governmental entities. Advertisers and sponsors use the Companys services to reach, educate and inform target audiences of consumers, physicians and other healthcare professionals.
The Company also generates revenue from advertising sold in
WebMD Magazine
, a consumer magazine distributed to physician office waiting rooms.
Health Services
. Under the
WebMD Health Services
brand, the Company markets wellness services and solutions that help employers and health plans improve the health of their employee and plan
participant populations. These services help the Companys clients employees and plan participants make informed decisions about health risks and lifestyle choices. The Company hosts its
WebMD Health Services
platform for its
employer and health plan clients, and its cloud-based online services can be accessed by their employees and plan participants using a computer, a tablet or a smartphone. The Companys
WebMD Health Services
solutions start with an
assessment of individual health and well-being and then work to provide personalized paths for improving or maintaining health. The Company also offers clients the ability to design team-based and individual wellness challenges that help foster a
culture of wellness in the workplace. In addition, the Companys health and wellness coaching programs, available onsite and telephonically and focusing on lifestyle, condition management, weight management and tobacco cessation, help
participants make healthier choices to achieve their health and well-being goals. The
WebMD Digital Health
Assistant
SM
offers online, self-directed health
coaching which enables participants to set and track wellness goals and follow self-paced personal action plans. The Company generates revenue from employer and health plan subscriptions to its
WebMD Health Services
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
10
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
platform, either directly or through distributor relationships. In addition, clients are charged on a
per-participant
basis for its health and wellness
coaching programs.
Information Services.
The Company also generates revenue from the sale of certain information
products and services on a stand-alone basis using
de-identified
data that it licenses from a small number of third-party data sources, of which the principal source is a license retained by HLTH Corporation
(HLTH), the Companys former parent company, in connection with the sale of its Emdeon Business Services (EBS) business. As the successor to HLTH, the Company received this license which provides the Company the rights
to certain
de-identified
data from the operation of the EBS business (which is now known as Change Healthcare) through early February 2018 for use in the development and commercialization of various
information products and services. Customers include data services, informatics and consulting companies. The Company pays a royalty to Change Healthcare in connection with the data it receives through its license with Change Healthcare. The
Companys Information Services revenue is recognized net of this royalty amount.
Basis of Presentation
The accompanying consolidated financial statements include the consolidated accounts of the Company and its wholly-owned subsidiaries and
have been prepared in United States dollars, and in accordance with U.S. generally accepted accounting principles (GAAP). The results of operations for companies acquired or disposed of are included in the consolidated financial
statements from the effective date of acquisition or up to the date of disposal. All material intercompany balances and transactions have been eliminated in consolidation.
2. Summary of Significant Accounting Policies
Accounting
Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and
assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes
are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent liabilities. The Company is subject to uncertainties
such as the impact of future events, economic and political factors, and changes in the Companys business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation
of the Companys financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Companys operating environment changes. Changes in estimates are made when
circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the consolidated financial
statements. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the amortization period of long-lived assets (excluding
goodwill and indefinite-lived intangible assets), the carrying value, capitalization and amortization of software and Website development costs, the carrying value of investments, the provision for income taxes and related deferred tax accounts,
certain accrued liabilities, revenue recognition, contingencies, litigation and related legal accruals and the value attributed to employee stock options and other stock-based awards.
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
11
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Seasonality
The timing of the Companys revenue is affected by seasonal factors. The Companys advertising and sponsorship revenue is seasonal, primarily due to the annual spending patterns of the
Companys advertising and sponsorship clients. This portion of the Companys revenue is usually the lowest in the first quarter of each calendar year, and generally increases during each consecutive quarter throughout the year.
Additionally, the timing of revenue in relation to the Companys expenses, many of which do not vary directly with revenue, has an impact on cost of operations, sales and marketing, and general and administrative expenses as a percentage of
revenue in each calendar quarter.
Cash and Cash Equivalents
All highly liquid investments with an original maturity from the date of purchase of three months or less are considered to be cash equivalents. These investments are stated at cost, which approximates
market. The Companys cash and cash equivalents are generally invested in various money market accounts.
Fair Value
The carrying amount of cash and cash equivalents, accounts receivable, accrued expenses and deferred revenue is deemed to approximate fair
value due to the immediate or short-term maturity of these items. See Note 12 for further information on the fair value of the Companys investments.
Allowance for Doubtful Accounts
The allowance for doubtful accounts
receivable reflects the Companys best estimate of losses inherent in the Companys receivable portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available
evidence.
Long-Lived Assets
Property and Equipment
Property and equipment are stated at cost,
net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets. The useful lives are generally as follows:
|
|
|
Computer equipment
|
|
3 years
|
Office equipment, furniture and fixtures
|
|
4 to 7 years
|
Software
|
|
3 years
|
Website development costs
|
|
3 years
|
Leasehold improvements
|
|
Shorter of useful life or lease term
|
Expenditures for maintenance, repair and renewals of minor items are charged to expense as incurred.
Major improvements are capitalized.
Goodwill and Intangible Assets
Goodwill and intangible assets result from business combinations accounted for under the acquisition method. Goodwill and other intangible
assets with indefinite lives are not amortized and are subjected to
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
12
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
impairment review by applying fair value based tests. Intangible assets with definite lives are amortized on a straight-line basis over the individually estimated useful lives of the related
assets as follows:
|
|
|
Content
|
|
3 to 5 years
|
Customer relationships
|
|
5 to 12 years
|
Acquired technology and patents
|
|
3 years
|
Trade names
|
|
Up to 10 years
|
Recoverability
The Company reviews the carrying value of goodwill and indefinite-lived intangible assets annually and whenever indicators of impairment are present. The Company has one reporting unit and tests goodwill
for impairment at the reporting unit level only when, after completing a qualitative analysis, it is determined that it is more likely than not that the fair value of the reporting unit is less than its carrying value. Fair value is determined using
an income approach valuation method. A reporting unit is defined as an operating segment or one level below an operating segment.
Long-lived assets used in operations are reviewed for impairment whenever events or changes in circumstances indicate that carrying amounts may not be recoverable. For long-lived assets to be held and
used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and the fair value. Long-lived
assets held for sale are reported at the lower of cost or fair value less costs to sell.
Based on the Companys
analysis, there was no impairment of goodwill or indefinite-lived intangible assets during the years ended December 31, 2016, 2015 and 2014.
Internal Use Software
Software development costs that are incurred in the
preliminary project stage and post-implementation stage are expensed as incurred. Once certain criteria have been met, direct costs incurred in developing or obtaining computer software are capitalized. The Company capitalized $3,951 and $6,441
during the years ended December 31, 2016 and 2015, respectively. Capitalized internal use software development costs are included in property and equipment in the accompanying consolidated balance sheets. Training and data conversion costs are
expensed as incurred. Capitalized software costs are depreciated over a three-year period. Depreciation expense related to internal use software was $7,001, $6,403 and $6,449 for the years ended December 31, 2016, 2015 and 2014, respectively.
The remaining balance of internal use software, net of accumulated depreciation, was $8,576 and $11,630 as of December 31, 2016 and 2015, respectively.
Website Development Costs
Costs related to the planning and
post-implementation phases of WebMDs Website development efforts, as well as minor enhancements and maintenance, are expensed as incurred. Direct costs incurred in the development phase are capitalized. The Company capitalized $8,899 and
$4,861 during the years ended December 31, 2016 and 2015, respectively. These capitalized costs are included in property and equipment in the accompanying consolidated balance sheets and are depreciated over a three-year period. Depreciation
expense related to Website development costs was $6,020, $6,580 and $6,421 during the years ended December 31, 2016, 2015 and 2014, respectively. The remaining balance of Website development costs, net of accumulated depreciation, was $12,503
and $9,624 as of December 31, 2016 and 2015, respectively.
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
13
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Restricted Cash
The Companys restricted cash primarily relates to collateral for letters of credit obtained to support the Companys operations. Total restricted cash was $2,116 and $3,547 as of
December 31, 2016 and 2015, respectively, and is included in other assets in the accompanying consolidated balance sheets.
Deferred
Revenue
Deferred revenue consists of invoices sent to customers where the Company has the contractual right to bill or
payments received from customers, in advance of revenue recognition and is recognized as the revenue recognition criteria are met. Deferred revenue is influenced by several factors, including the timing of invoices to our customers and the timing of
payments received from our customers in relation to the timing of the revenue recognition for the related customer contract. Deferred revenue at each balance sheet date is expected to be recognized during the succeeding twelve month period and is
therefore classified as a current liability within the accompanying consolidated balance sheets.
Leases
The Company recognizes rent expense on a straight-line basis, including predetermined fixed escalations, over the initial lease term
including reasonably assured renewal periods, net of lease incentives, from the time that the Company controls the leased property. Leasehold improvements made at the inception of the lease are amortized over the shorter of the useful life of the
asset or the lease term. Lease incentives are recorded as a deferred credit and recognized as a reduction to rent expense on a straight-line basis over the lease term as described above.
Presentation of Segment Information
The Company generates revenue in four
groups, as set forth in the table below. The first group is Advertising and Sponsorship Biopharma and Medical Device and consists of advertising and sponsorship revenue from pharmaceutical, biotechnology and medical device clients
relating to prescription pharmaceutical products or other regulated devices or products or for sponsoring educational programs. The second category is Advertising and Sponsorship OTC, CPG and Other and consists of advertising and
sponsorship revenue relating to
non-Rx
or
over-the-counter
medications and other healthcare products, food and beverages, beauty
products and other consumer products, as well as revenue from clients such as retailers, pharmacies, hospitals, health insurance companies and government agencies and market research companies where the Company provides physician recruitment
services. The combined revenue of the first two groups is sometimes referred to as Advertising and Sponsorship revenue. The third group is Health Services (which the Company previously referred to as Private Portal
Services) and consists of revenue from employers and health plans for subscriptions to the Companys
WebMD Health Services
platform and for related services, including health coaching and condition management services. The change
in the name of this group to Health Services began in the Companys reporting on the quarter ended June 30, 2016 and did not reflect any change in the source of the revenue included in this group from prior periods. The fourth
group is Information Services and consists of revenue from the sale of stand-alone information and data products. Discrete financial information related to a measure of profit or loss for these four revenue groups is not available as
they leverage many common expenses, and the Company does not separately allocate these common expenses in assessing the performance of its business. Accordingly, the Company views its business as one reportable segment.
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
14
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following table presents the revenues recognized from the four revenue groups
described above:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
Advertising and sponsorship
|
|
|
|
|
|
|
|
|
|
|
|
|
Biopharma and medical device
|
|
$
|
428,519
|
|
|
$
|
371,220
|
|
|
$
|
329,329
|
|
OTC, CPG and other
|
|
|
132,754
|
|
|
|
127,805
|
|
|
|
124,636
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
561,273
|
|
|
|
499,025
|
|
|
|
453,965
|
|
Health services
|
|
|
113,937
|
|
|
|
110,441
|
|
|
|
103,182
|
|
Information services
|
|
|
29,836
|
|
|
|
26,933
|
|
|
|
23,302
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
705,046
|
|
|
$
|
636,399
|
|
|
$
|
580,449
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Companys revenue is principally generated in the United States. An adverse change in economic
conditions in the United States could negatively affect the Companys revenue and results of operations. The Company recorded revenue from its international operations of $65,763, $56,979 and $46,095 during the years ended December 31,
2016, 2015 and 2014, respectively.
Sales, Use and Value Added Tax
The Company excludes sales, use and value-added tax from revenue in the accompanying consolidated statements of operations.
Advertising Costs
Advertising costs are generally expensed as incurred and totaled $5,903, $4,359 and $4,196 in 2016, 2015 and 2014, respectively.
Foreign Currency
The functional currency of the Companys foreign operations is the U.S. dollar. Fluctuations in foreign currency monetary assets and liabilities result in gains or losses which are credited or
charged to income. Foreign currency transactional gains or losses are also credited or charged to income. The Company is exposed to fluctuations in foreign currencies primarily through contracts with certain of the Companys customers that are
denominated in foreign currencies. In order to manage this risk, the Company has hedged portions of its foreign currency denominated customer contracts with foreign currency forward contracts. See Note 12 for further information on the
Companys foreign currency forward contracts.
Concentration of Credit Risk
None of the Companys customers individually accounted for more than 10% of the Companys revenue in 2016, 2015 or 2014, or more
than 10% of the Companys accounts receivable as of December 31, 2016 or 2015.
Loss Contingencies
The Company accounts for loss contingencies in accordance with Financial Accounting Standards Board (FASB) ASC No. 450,
Contingencies. Under ASC No. 450, accruals for loss contingencies are recorded
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
15
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
when both (i) the information available indicates that it is probable that a liability has been incurred and (ii) the amount of the loss can be reasonably estimated. The Company records
adjustments to these accruals to reflect the status of negotiations, settlements, advice of counsel and other information and events related to an individual matter.
Income Taxes
Deferred income taxes are recognized for the future tax
consequence of differences between the tax and financial reporting basis of assets and liabilities at each reporting period. A valuation allowance is established to reduce deferred tax assets to the amount expected to be realized.
Tax contingencies are recorded to address potential exposure involving tax positions the Company has taken that could be challenged by
tax authorities. These potential exposures result from applications of various statutes, rules, regulations and interpretations. The Companys estimates of tax contingencies contain assumptions and judgments about potential actions by taxing
jurisdictions. The Company reflects interest and penalties related to uncertain tax positions as part of the income tax provision in the accompanying consolidated statements of operations.
Accounting for Stock-Based Compensation
Stock-based compensation expense
for all share-based payment awards granted is determined based on the grant-date fair value. The grant-date fair value for stock options is estimated using the Black-Scholes Option Pricing Model. The Company recognizes these compensation costs, net
of an estimated forfeiture rate, on a straight-line basis over the requisite service period of the award, which is generally the vesting term of the share-based payment award.
Revenue Recognition
Revenue from advertising is recognized as
advertisements are delivered or as publications are distributed. Revenue from sponsorship arrangements, content syndication and distribution arrangements and subscriptions to our
WebMD Health Services
platform as well as related health
coaching and condition management services is recognized ratably over the term of the applicable agreement. Revenue from information services is recognized as the underlying data is delivered. Revenue from the sponsorship of CME is recognized over
the period the Company substantially completes its contractual deliverables as determined by the applicable agreements.
Contracts that contain multiple deliverables are subject to Accounting Standards Update (ASU)
No. 2009-13
Multiple-Deliverable Revenue Arrangements (ASU
2009-13).
ASU
2009-13
requires the allocation of
revenue to each deliverable of multiple-deliverable revenue arrangements, based on the relative selling price of each deliverable. It also defines the level of evidence of selling price required to separate deliverables and allows a company to make
its best estimate of the selling price of deliverables when more objective evidence of selling price is not available.
Pursuant to the guidance of ASU
2009-13,
when a sales arrangement contains multiple deliverables,
the Company allocates revenue to each deliverable based on relative selling price. The selling price for a deliverable is based on vendor-specific objective evidence (VSOE) if available, third-party evidence (TPE) if VSOE is
not available, or best estimate of selling price if neither VSOE nor TPE is available. The Company then recognizes revenue on each deliverable in accordance with its revenue recognition policies over the period that delivery occurs. VSOE of selling
price is based on the price charged when the deliverable is sold separately. In determining VSOE, GAAP requires that a substantial majority of the selling prices fall within a reasonable range
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
16
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
based on historical pricing trends for specific products and services. TPE is based on competitor prices of similar deliverables when sold separately. The Company is not able to determine TPE of
selling price as it is unable to reliably determine what competitors selling prices are for comparable services, combined with the fact that its services often contain unique features and customizations such that comparable services do not
exist. The determination of best estimate of selling price is a judgmental process that considers multiple factors including, but not limited to, recent selling prices and related discounting practices for each service, market conditions, customer
classes, sales channels and other factors.
Net Income per Common Share
Basic income per common share has been computed using the weighted-average number of shares of Common Stock outstanding during the periods
presented. Diluted income per common share has been computed using the weighted-average number of shares of Common Stock outstanding during the periods, increased to give effect to potentially dilutive securities and assumes that any dilutive
convertible notes were converted, only in the periods in which such effect is dilutive (shares in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations Basic
|
|
$
|
91,304
|
|
|
$
|
64,024
|
|
|
$
|
40,941
|
|
Interest expense on 1.50% Notes, net of tax
|
|
|
3,513
|
|
|
|
3,456
|
|
|
|
3,456
|
|
Interest expense on 2.50% Notes, net of tax
|
|
|
7,307
|
|
|
|
7,189
|
|
|
|
|
|
Interest expense on 2.25% Notes, net of tax
|
|
|
457
|
|
|
|
3,460
|
|
|
|
|
|
Interest expense on 2.625% Notes, net of tax
|
|
|
3,911
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations Diluted
|
|
$
|
106,492
|
|
|
$
|
78,129
|
|
|
$
|
44,397
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations, net of tax Basic and Diluted
|
|
$
|
|
|
|
$
|
|
|
|
$
|
1,122
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares Basic
|
|
|
37,854
|
|
|
|
36,600
|
|
|
|
37,869
|
|
Stock options and restricted stock
|
|
|
1,658
|
|
|
|
1,412
|
|
|
|
2,060
|
|
1.50% Notes
|
|
|
5,695
|
|
|
|
5,694
|
|
|
|
5,685
|
|
2.50% Notes
|
|
|
6,206
|
|
|
|
6,205
|
|
|
|
|
|
2.25% Notes
|
|
|
353
|
|
|
|
2,742
|
|
|
|
|
|
2.625% Notes
|
|
|
2,413
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted weighted-average shares after assumed conversions Diluted
|
|
|
54,179
|
|
|
|
52,653
|
|
|
|
45,614
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic income per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
2.41
|
|
|
$
|
1.75
|
|
|
$
|
1.08
|
|
Income from discontinued operations
|
|
|
|
|
|
|
|
|
|
|
0.03
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
2.41
|
|
|
$
|
1.75
|
|
|
$
|
1.11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted income per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
1.97
|
|
|
$
|
1.48
|
|
|
$
|
0.97
|
|
Income from discontinued operations
|
|
|
|
|
|
|
|
|
|
|
0.03
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
1.97
|
|
|
$
|
1.48
|
|
|
$
|
1.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
17
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The Company has excluded certain of its convertible notes, as well as certain
outstanding stock options and restricted stock, from the calculation of diluted income per common share during the periods in which such securities were anti-dilutive. The following table presents the total weighted-average number of potentially
dilutive common shares that were excluded from the computation of diluted income per common share during the periods presented (shares in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
Options and restricted stock
|
|
|
625
|
|
|
|
3,678
|
|
|
|
2,594
|
|
2.25% Notes
|
|
|
|
|
|
|
|
|
|
|
3,506
|
|
2.50% Notes
|
|
|
|
|
|
|
|
|
|
|
6,195
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
625
|
|
|
|
3,678
|
|
|
|
12,295
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discontinued Operations
A business unit is reported as a discontinued operation if its disposal represents a strategic shift that has, or will have, a major effect on the Companys operations and financial results.
Significant judgments are involved in determining whether a business component meets the criteria for discontinued operation reporting and the period in which these criteria are met.
Reclassifications
Certain reclassifications have been made to the prior
period financial statements to conform with the current period presentation.
Recent Accounting Pronouncements
Accounting Pronouncements Adopted During 2016
In June 2014, the FASB issued ASU
No. 2014-12,
Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be
Achieved after the Requisite Service Period
, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. The revised guidance was effective
for the Company beginning in the quarter ended March 31, 2016. The adoption of the revised guidance did not have any impact on the Companys consolidated financial statements as it did not have any share-based awards with performance
targets outstanding at the time of adoption.
In April 2015, the FASB issued ASU
No. 2015-03,
Interest Imputation of Interest (Subtopic
835-30):
Simplifying the Presentation of Debt Issuance Costs
, which requires that debt issuance
costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The revised guidance was effective for the Company, on a
retrospective basis, beginning in the quarter ended March 31, 2016. The adoption of the revised guidance only affected the balance sheet classification of its debt issuance costs. The impact of this reclassification on the consolidated balance
sheet as of December 31, 2015 was a decrease to other assets of $9,612, a decrease to the carrying amount of the 2.25% Convertible Notes due 2016 (the 2.25% Notes) of $159, a decrease to the carrying amount of the 2.50% Convertible
Notes due 2018 (the 2.50% Notes) of $3,719 and a decrease to the carrying amount of the 1.50% Convertible Notes due 2020 (the 1.50% Notes) of $5,734 (see table below).
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
18
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
In April 2015, the FASB issued ASU
No. 2015-05,
Intangibles Goodwill and Other
Internal-Use
Software (Subtopic
350-40):
Customers
Accounting for Fees Paid in a Cloud Computing Arrangement
, which provides guidance in determining whether a cloud computing arrangement includes a software license. If it is determined that a cloud computing arrangement does include a software
license, the software element should be accounted for consistent with the acquisition of other software licenses. If the arrangement does not include a software license, it should be accounted for as a service contract. The revised guidance was
effective for the Company beginning in the quarter ended March 31, 2016 and will be applied prospectively to all arrangements entered into or materially modified after the effective date. The adoption of this guidance did not have an impact on
the Companys consolidated financial statements.
In September 2015, the FASB issued ASU
No. 2015-16,
Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments
, which requires that the acquirer recognize adjustments to provisional amounts that are
identified during the measurement period in the reporting period in which the adjustment amounts are determined, rather than retrospectively adjusting previously reported amounts. The revised guidance was effective for the Company, on a prospective
basis, beginning in the quarter ended March 31, 2016. The adoption of this guidance did not have an impact on the Companys consolidated financial statements.
In November 2015, the FASB issued ASU
No. 2015-17,
Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes
, which requires that all
deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent in the consolidated balance sheet instead of separating deferred taxes into current and noncurrent. The revised guidance was required to be
effective for the Company beginning in the quarter ending March 31, 2017 and could be applied either prospectively to all deferred tax assets and liabilities or retrospectively to all periods presented. Early adoption was permitted and the
Company elected to early adopt the guidance in the quarter ended March 31, 2016 on a retrospective basis. The adoption of the revised guidance only affected the balance sheet classification of its deferred tax assets and liabilities, and the
related valuation allowance. The impact of this reclassification on the consolidated balance sheet as of December 31, 2015 was a decrease to current deferred tax assets of $16,126, an increase to long-term deferred tax assets of $15,694 and a
decrease to other long-term liabilities of $432 (see table below).
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
19
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following table summarizes the reclassifications made to the consolidated balance
sheet as of December 31, 2015 in connection with the adoption of ASU
No. 2015-03
and ASU
No. 2015-17:
|
|
|
|
|
|
|
|
|
|
|
December 31, 2015
|
|
|
|
As Reported
|
|
|
As Adjusted
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Deferred tax assets
|
|
|
16,126
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
850,602
|
|
|
|
834,476
|
|
Deferred tax assets
|
|
|
|
|
|
|
15,694
|
|
Other assets
|
|
|
20,464
|
|
|
|
10,852
|
|
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
$
|
1,165,967
|
|
|
$
|
1,155,923
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
2.25% convertible notes due 2016
|
|
|
102,682
|
|
|
|
102,523
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
286,061
|
|
|
|
285,902
|
|
2.50% convertible notes due 2018
|
|
|
400,000
|
|
|
|
396,281
|
|
1.50% convertible notes due 2020
|
|
|
300,000
|
|
|
|
294,266
|
|
Other long-term liabilities
|
|
|
23,678
|
|
|
|
23,246
|
|
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY
|
|
$
|
1,165,967
|
|
|
$
|
1,155,923
|
|
|
|
|
|
|
|
|
|
|
Accounting Pronouncements to Be Adopted in the Future
In May 2014, the FASB issued ASU
No. 2014-09,
Revenue from Contracts with Customers (Topic
606)
, to achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under GAAP. Under the new model, recognition of revenue occurs when a customer obtains
control of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the revised guidance requires that reporting companies disclose the
nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. In August 2015, the FASB issued ASU
No. 2015-14,
Revenue from Contracts with Customers (Topic
606): Deferral of the Effective Date
, which delays the effective date of ASU
No. 2014-09
by one year. As a result, the revised guidance is effective for the Company beginning in the quarter ending
March 31, 2018. Early adoption is permitted, but not before the original effective date of the guidance. The revised guidance is required to be applied retrospectively to each prior reporting period presented or retrospectively with the
cumulative effect of initially applying it recognized at the date of initial application. In March, April, May and December 2016, the FASB issued ASU
No. 2016-08,
Revenue from Contracts with
Customers
(Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net)
, ASU
No. 2016-10,
Revenue from Contracts with Customers (Topic 606): Identifying
Performance Obligations and Licensing
, ASU
No. 2016-12,
Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients
, and ASU No. 2016-20,
Technical
Corrections and Improvements to Topic 606, Revenue from Contracts with Customers
, respectively. ASU
No. 2016-08,
ASU
No. 2016-10,
ASU
No. 2016-12
and ASU No. 2016-20 provide supplemental adoption guidance and clarification to ASU
No. 2014-09,
and must be adopted concurrently with the adoption
of ASU
No. 2014-09.
The Company expects that it will adopt the revised guidance under the modified retrospective method; however, the Company has not yet determined the impact the revised guidance will
have on its consolidated financial statements in periods following adoption.
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
20
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
In January 2016, the FASB issued ASU
No. 2016-01,
Financial Instruments Overall (Subtopic
825-10):
Recognition and Measurement of Financial Assets and Financial Liabilities
, which revises
the classification and measurement of investments in certain equity investments and the presentation of certain fair value changes for certain financial liabilities measured at fair value. ASU
No. 2016-01
also requires the change in fair value of many equity investments to be recognized in net income. The revised guidance is effective for the Company beginning in the quarter ending March 31, 2018. The Company has not yet determined the impact
the revised guidance will have on its consolidated financial statements.
In February 2016, the FASB issued ASU
No. 2016-02,
Leases (Topic 842)
, which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a
lessees obligation to make lease payments arising from a lease, measured on a discounted basis; and a
right-of-use
asset, which is an asset that represents the
lessees right to use, or control the use of, a specified asset for the lease term. The revised guidance must be applied on a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the
earliest comparative period presented in the financial statements. The revised guidance is effective for the Company beginning in the quarter ending March 31, 2019. The Company has not yet determined the impact the revised guidance will have on
its consolidated financial statements.
In March 2016, the FASB issued ASU
No. 2016-09,
Compensation Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting
, which simplifies several aspects of the accounting for share-based payment
award transactions, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The revised guidance is effective for the Company
beginning in the quarter ending March 31, 2017. When the Company adopts ASU
No. 2016-09
in the quarter ending March 31, 2017, excess tax benefits and deficiencies generated when stock awards
vest or settle will no longer be recognized in equity but will instead be recognized as a reduction or increase to the income tax provision, cash flows related to excess tax benefits will be required to be presented as an operating activity rather
than a financing activity in the statement of cash flows, and net operating losses related to excess tax benefits will be recognized on the balance sheet. Additionally, the Company also expects to account for forfeitures of stock awards as they
occur, rather than estimate expected forfeitures.
In June 2016, the FASB issued ASU No. 2016-13,
Financial Instruments
Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
, which revises the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. The revised guidance is
effective for the Company beginning in the quarter ending March 31, 2020 and must be adopted using a modified retrospective transition approach. The Company has not yet determined the impact the revised guidance will have on its consolidated
financial statements.
In August 2016, the FASB issued ASU No. 2016-15,
Statement of Cash Flows (Topic 230): Classification
of Certain Cash Receipts and Cash Payments
, which clarifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The revised guidance is effective for the Company beginning in the quarter
ending March 31, 2018 with early adoption permitted and must be applied retrospectively to all periods presented. The Company has not yet determined the impact the revised guidance will have on its consolidated financial statements.
In November 2016, the FASB issued ASU No. 2016-18,
Statement of Cash Flows (Topic 230): Restricted Cash
, which requires that
restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning of period and end of period total amounts shown on the statement of
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
21
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
cash flows. The revised guidance must be applied using a retrospective transition method to each period presented and is effective for the Company beginning in the quarter ending March 31, 2018.
The Company has not yet determined the impact the revised guidance will have on its consolidated financial statements.
In
January 2017, the FASB issued ASU No. 2017-01,
Business Combinations (Topic 805): Clarifying the Definition of a Business
, which clarifies the definition of a business by providing a more robust framework to use in determining when a set of
assets and activities is a business. The revised guidance is effective for the Company beginning in the quarter ending March 31, 2018. The Company has not yet determined the impact the revised guidance will have on its consolidated financial
statements.
In January 2017, the FASB issued ASU No. 2017-04,
Intangibles Goodwill and Other (Topic 350):
Simplifying the Test for Goodwill Impairment
, which eliminates step 2 from the goodwill impairment test. The revised guidance must be applied on a prospective basis and is effective for the Company beginning in the quarter ending March 31, 2020,
with early adoption permitted on January 1, 2017. The Company has not yet determined the impact the revised guidance will have on its consolidated financial statements.
3. Discontinued Operations
On October 19,
2009, the Company completed the sale of its Porex business. In connection with the sale of Porex, the Company agreed to indemnify Porex for certain tax matters. As of December 31, 2013, the remaining estimate of the Companys tax
indemnification liability related to Porex was $1,506. During the year ended December 31, 2014, the Company paid $384 in connection with the completion of the remaining tax audits for all periods covered under the indemnity agreement. The
remaining indemnity liability of $1,122 was adjusted through income from discontinued operations during the year ended December 31, 2014. The Company has no further obligations related to this matter.
4. Convertible Notes
2.50% Convertible Notes due 2018
On January 11, 2011, the
Company issued $400,000 aggregate principal amount of its 2.50% Notes in a private offering. Unless previously converted, the 2.50% Notes will mature on January 31, 2018. Net proceeds from the sale of the 2.50% Notes were
approximately $387,345, after deducting the related offering expenses of $12,655. Approximately $100,000 from the net proceeds was used to repurchase 1,920,490 shares of the Companys Common Stock at a price of $52.07 per share, the last
reported sale price of the Companys Common Stock on January 5, 2011, which repurchase settled on January 11, 2011. Interest on the 2.50% Notes is payable semi-annually on January 31 and July 31 of each year, commencing
July 31, 2011. Under the terms of the 2.50% Notes, holders were able to surrender their 2.50% Notes for conversion into the Companys Common Stock at an initial conversion rate of 15.1220 shares of Common Stock per thousand
dollars principal amount of the 2.50% Notes. This was equivalent to an initial conversion price of approximately $66.13 per share of Common Stock. In the aggregate, the 2.50% Notes were convertible into 6,048,800 shares of the
Companys Common Stock.
Effective April 4, 2012, after giving effect to an adjustment resulting from a tender offer
for the Companys Common Stock that the Company completed on April 3, 2012, the conversion rate was adjusted to 15.3223 shares of Common Stock per thousand dollars principal amount of the 2.50% Notes. This was equivalent to an adjusted
conversion price of approximately $65.26 per share of Common Stock. In the aggregate, the 2.50% Notes were convertible into 6,128,920 shares of Common Stock following the April 4, 2012 adjustment.
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
22
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Effective September 11, 2013, after giving effect to an adjustment resulting from a
tender offer for the Companys Common Stock that the Company completed on September 10, 2013, the conversion rate was adjusted to 15.4764 shares of Common Stock per thousand dollars principal amount of the 2.50% Notes. This was equivalent
to an adjusted conversion price of approximately $64.61 per share of Common Stock. In the aggregate, the 2.50% Notes were convertible into 6,190,560 shares of Common Stock following the September 11, 2013 adjustment.
Effective September 10, 2014, after giving effect to an adjustment resulting from a tender offer for the Companys Common Stock
that the Company completed on September 9, 2014 (see Note 10 for additional discussion), the conversion rate was adjusted to 15.5118 shares of Common Stock per thousand dollars principal amount of the 2.50% Notes. This was equivalent to an
adjusted conversion price of approximately $64.47 per share of Common Stock. In the aggregate, the 2.50% Notes were convertible into 6,204,720 shares of Common Stock following the September 10, 2014 adjustment.
Effective December 16, 2016, after giving effect to an adjustment resulting from a tender offer for the Companys Common Stock
that the Company completed on December 15, 2016 (see Note 10 for additional discussion), the conversion rate was adjusted to 15.5854 shares of Common Stock per thousand dollars principal amount of the 2.50% Notes. This is equivalent to an
adjusted conversion price of approximately $64.16 per share of Common Stock. In the aggregate, the 2.50% Notes are convertible into 6,234,160 shares of Common Stock following the December 16, 2016 adjustment.
Under the terms of the 2.50% Notes, if the Company undergoes certain change of control transactions prior to the maturity date of
the 2.50% Notes, holders of the 2.50% Notes will have the right, at their option, to require the Company to repurchase some or all of their 2.50% Notes at a repurchase price equal to 100% of the principal amount of the
2.50% Notes being repurchased, plus accrued and unpaid interest up to, but excluding, the repurchase date. At the Companys option, and to the extent permitted by the applicable rules of the Nasdaq Global Select Market (or the applicable
rules of such other exchange on which the Companys Common Stock may be listed), instead of paying the repurchase price in cash, the Company may pay the repurchase price in shares of its Common Stock or a combination of cash and shares of its
Common Stock. However, in the case of certain change of control transactions in which the Company is acquired by a public company, the Company may elect to provide for conversion of the 2.50% Notes into acquirer common stock, in which case the
repurchase option would not apply.
2.25% Convertible Notes due 2016
On March 14, 2011, the Company issued $400,000 aggregate principal amount of its 2.25% Notes in a private offering. Net proceeds
from the sale of the 2.25% Notes were approximately $387,400, after deducting the related offering expenses $12,595. Approximately $50,000 from the net proceeds was used to repurchase 868,507 shares of the Companys Common Stock at a
price of $57.57 per share, the last reported sale price of the Companys Common Stock on March 8, 2011, which repurchase settled on March 14, 2011. Interest on the 2.25% Notes was payable semi-annually on March 31 and
September 30 of each year, commencing September 30, 2011. Under the terms of the 2.25% Notes, holders were able to surrender their 2.25% Notes for conversion into the Companys Common Stock at an initial conversion rate of
13.5704 shares of Common Stock per thousand dollars principal amount of the 2.25% Notes. This was equivalent to an initial conversion price of approximately $73.69 per share of Common Stock. In the aggregate, the 2.25% Notes were
convertible into 5,428,160 shares of the Companys Common Stock.
Effective April 4, 2012, after giving effect
to an adjustment resulting from a tender offer for the Companys Common Stock that the Company completed on April 3, 2012, the conversion rate was adjusted to 13.7502
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
23
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
shares of Common Stock per thousand dollars principal amount of the 2.25% Notes. This was equivalent to an adjusted conversion price of approximately $72.73 per share of Common Stock. In the
aggregate, the 2.25% Notes are convertible into 5,500,080 shares of Common Stock following the April 4, 2012 adjustment.
Effective September 11, 2013, after giving effect to an adjustment resulting from a tender offer for the Companys Common Stock
that the Company completed on September 10, 2013, the conversion rate was adjusted to 13.8884 shares of Common Stock per thousand dollars principal amount of the 2.25% Notes. This was equivalent to an adjusted conversion price of approximately
$72.00 per share of Common Stock. In the aggregate, the 2.25% Notes were convertible into 5,555,360 shares of Common Stock following the September 11, 2013 adjustment.
During the year ended December 31, 2013, the Company repurchased $100,000 principal amount of its 2.25% Notes for $101,750 in cash in a privately negotiated transaction. Also during the year ended
December 31, 2013, the Company repurchased $47,768 principal amount of its 2.25% Notes for $48,604 in cash in the open market. The Company recognized a
pre-tax
loss of $4,871 in 2013 related to these
repurchases. The loss included the expensing of the remaining deferred issuance costs outstanding related to the repurchased notes. After these repurchases in 2013, the remaining principal amount of the 2.25% Notes outstanding was $252,232, which,
in the aggregate, was convertible into 3,503,099 shares of Common Stock.
Effective September 10, 2014, after giving
effect to an adjustment resulting from a tender offer for the Companys Common Stock that the Company completed on September 9, 2014 (see Note 10 for additional discussion), the conversion rate was adjusted to 13.9202 shares of Common
Stock per thousand dollars principal amount of the 2.25% Notes. This was equivalent to an adjusted conversion price of approximately $71.84 per share of Common Stock. In the aggregate, the 2.25% Notes were convertible into 3,511,120 shares of Common
Stock following the September 10, 2014 adjustment.
During the year ended December 31, 2015, the Company repurchased
$149,550 principal amount of its 2.25% Notes for $151,038 in cash in privately negotiated transactions. The Company recognized a
pre-tax
loss of $2,058 in 2015 related to these repurchases, which is reflected
within loss on convertible notes in the accompanying consolidated statement of operations. The loss included the expensing of the deferred issuance costs outstanding related to the repurchased notes. After these repurchases, the remaining principal
amount of the 2.25% Notes outstanding was $102,682, which, in the aggregate, was convertible into 1,429,354 shares of Common Stock. The 2.25% Notes matured on March 31, 2016 and the remaining principal amount of $102,682 was repaid to the
holders of the 2.25% Notes.
1.50% Convertible Notes due 2020
On November 26, 2013, the Company issued $300,000 aggregate principal amount of its 1.50% Notes in a private offering. Unless
previously converted, the 1.50% Notes will mature on December 1, 2020. Net proceeds from the sale of the 1.50% Notes were approximately $291,823, after deducting the related offering expenses of $8,177. Interest on the
1.50% Notes is payable semi-annually on June 1 and December 1 of each year, commencing June 1, 2014. Under the terms of the 1.50% Notes, holders were able to surrender their 1.50% Notes for conversion into the
Companys Common Stock at an initial conversion rate of 18.9362 shares of Common Stock per thousand dollars principal amount of the 1.50% Notes. This was equivalent to an initial conversion price of approximately $52.81 per share of
Common Stock. In the aggregate, the 1.50% Notes were convertible into 5,680,860 shares of the Companys Common Stock. The conversion rate may be adjusted under certain circumstances.
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
24
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Effective September 10, 2014, after giving effect to an adjustment resulting from a
tender offer for the Companys Common Stock that the Company completed on September 9, 2014 (see Note 10 for additional discussion), the conversion rate was adjusted to 18.9795 shares of Common Stock per thousand dollars principal amount
of the 1.50% Notes. This was equivalent to an adjusted conversion price of approximately $52.69 per share of Common Stock. In the aggregate, the 1.50% Notes were convertible into 5,693,850 shares of Common Stock following the September 10, 2014
adjustment.
Effective December 16, 2016, after giving effect to an adjustment resulting from a tender offer for the
Companys Common Stock that the Company completed on December 15, 2016 (see Note 10 for additional discussion), the conversion rate was adjusted to 19.0695 shares of Common Stock per thousand dollars principal amount of the 1.50% Notes.
This is equivalent to an adjusted conversion price of approximately $52.44 per share of Common Stock. In the aggregate, the 1.50% Notes are convertible into 5,720,850 shares of Common Stock following the December 16, 2016 adjustment.
Under the terms of the 1.50% Notes, if the Company undergoes certain change of control or other fundamental change transactions
prior to the maturity date of the 1.50% Notes, holders of the 1.50% Notes will have the right, at their option, to require the Company to repurchase some or all of their 1.50% Notes at a repurchase price equal to 100% of the principal
amount of the 1.50% Notes being repurchased, plus accrued and unpaid interest up to, but excluding, the repurchase date. However, the repurchase option will not apply in the case of certain change of control or other fundamental change
transactions in which the Company is acquired by a public company, and (a) not less than 90% of the consideration received or to be received by holders of WebMD Common Stock, excluding cash payments for fractional shares, consists of acquirer
common stock and (b) as a result of the transaction, the 1.50% Notes become convertible into the same consideration.
2.625%
Convertible Notes due 2023
On June 1, 2016, the Company issued $360,000 aggregate principal amount of its 2.625%
Convertible Notes due 2023 (the 2.625% Notes) in a private offering. Unless previously converted, the 2.625% Notes will mature on June 15, 2023. Net proceeds from the sale of the 2.625% Notes were approximately $350,394, after
deducting the related offering expenses of $9,606. Interest on the 2.625% Notes is payable semi-annually on June 15 and December 15 of each year, commencing December 15, 2016. Under the terms of the 2.625% Notes, holders were able to
surrender their 2.625% Notes for conversion into the Companys Common Stock at an initial conversion rate of 11.4845 shares of Common Stock per thousand dollars principal amount of the 2.625% Notes. This was equivalent to an initial conversion
price of approximately $87.07 per share of Common Stock. In the aggregate, the 2.625% Notes were convertible into 4,134,420 shares of the Companys Common Stock.
Effective December 16, 2016, after giving effect to an adjustment resulting from a tender offer for the Companys Common Stock that the Company completed on December 15, 2016 (see Note 10
for additional discussion), the conversion rate was adjusted to 11.5389 shares of Common Stock per thousand dollars principal amount of the 2.625% Notes. This is equivalent to an adjusted conversion price of approximately $86.66 per share of Common
Stock. In the aggregate, the 2.625% Notes are convertible into 4,154,004 shares of Common Stock following the December 16, 2016 adjustment.
Under the terms of the 2.625% Notes, if the Company undergoes certain change of control or other fundamental change transactions prior to the maturity date of the 2.625% Notes, holders of the 2.625% Notes
will have the right, at their option, to require the Company to repurchase some or all of their 2.625% Notes at a repurchase price equal to 100% of the principal amount of the 2.625% Notes being repurchased, plus accrued and
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
25
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
unpaid interest up to, but excluding, the repurchase date. However, the repurchase option will not apply in the case of certain change of control or other fundamental change transactions in which
the Company is acquired by a public company, and (a) not less than 90% of the consideration received or to be received by holders of WebMD Common Stock, excluding cash payments for fractional shares, consists of acquirer common stock and
(b) as a result of the transaction, the 2.625% Notes become convertible into the same consideration.
Costs associated
with the issuance of the Companys convertible notes are presented in the accompanying consolidated balance sheets as direct reductions from the carrying amounts of the corresponding convertible notes, and are amortized to interest expense over
the period from issuance through the earliest date on which holders can demand redemption. The aggregate amortization of these issuance costs, which is included within interest expense in the accompanying consolidated statements of operations, was
$3,906, $4,172 and $4,511 for the years ended December 31, 2016, 2015 and 2014, respectively. During the year ended December 31, 2015, the Company wrote off issuance costs of $571 in connection with the repurchase of a portion of its 2.25%
Notes. The balances of the Companys convertible notes consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2016
|
|
|
December 31, 2015
|
|
|
|
Principal
Amount
|
|
|
Less
Unamortized
Debt Issuance
Costs
|
|
|
Net
Carrying
Amount
|
|
|
Principal
Amount
|
|
|
Less
Unamortized
Debt Issuance
Costs
|
|
|
Net
Carrying
Amount
|
|
2.25% Notes
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
102,682
|
|
|
$
|
(159
|
)
|
|
$
|
102,523
|
|
2.50% Notes
|
|
$
|
400,000
|
|
|
$
|
(1,934
|
)
|
|
$
|
398,066
|
|
|
$
|
400,000
|
|
|
$
|
(3,719
|
)
|
|
$
|
396,281
|
|
1.50% Notes
|
|
$
|
300,000
|
|
|
$
|
(4,568
|
)
|
|
$
|
295,432
|
|
|
$
|
300,000
|
|
|
$
|
(5,734
|
)
|
|
$
|
294,266
|
|
2.625% Notes
|
|
$
|
360,000
|
|
|
$
|
(8,810
|
)
|
|
$
|
351,190
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
5. Long-Lived Assets
Property and Equipment
Property and equipment consist of the following:
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2016
|
|
|
2015
|
|
Software
|
|
$
|
70,622
|
|
|
$
|
66,708
|
|
Computer equipment
|
|
|
77,739
|
|
|
|
69,973
|
|
Web site development costs
|
|
|
71,683
|
|
|
|
62,784
|
|
Leasehold improvements
|
|
|
61,246
|
|
|
|
72,679
|
|
Office equipment, furniture and fixtures
|
|
|
15,844
|
|
|
|
17,398
|
|
Land and buildings
|
|
|
291
|
|
|
|
291
|
|
|
|
|
|
|
|
|
|
|
|
|
|
297,425
|
|
|
|
289,833
|
|
Less: accumulated depreciation
|
|
|
(214,129
|
)
|
|
|
(208,806
|
)
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
$
|
83,296
|
|
|
$
|
81,027
|
|
|
|
|
|
|
|
|
|
|
Depreciation expense was $27,672, $27,200 and $27,010 in 2016, 2015 and 2014, respectively.
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
26
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Goodwill and Intangible Assets
The balance of goodwill was $202,980 as of December 31, 2016 and 2015. Intangible assets consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2016
|
|
|
December 31, 2015
|
|
|
|
Gross
Carrying
Amount
|
|
|
Accumulated
Amortization
|
|
|
Net
|
|
|
Weighted
Average
Remaining
Useful Life
(a)
|
|
|
Gross
Carrying
Amount
|
|
|
Accumulated
Amortization
|
|
|
Net
|
|
|
Weighted
Average
Remaining
Useful Life
(a)
|
|
Content
|
|
$
|
15,954
|
|
|
$
|
(15,954
|
)
|
|
$
|
|
|
|
|
|
|
|
$
|
15,954
|
|
|
$
|
(15,954
|
)
|
|
$
|
|
|
|
|
|
|
Customer relationships
|
|
|
34,057
|
|
|
|
(31,274
|
)
|
|
|
2,783
|
|
|
|
1.9
|
|
|
|
34,057
|
|
|
|
(29,218
|
)
|
|
|
4,839
|
|
|
|
2.7
|
|
Technology and patents
|
|
|
17,882
|
|
|
|
(17,355
|
)
|
|
|
527
|
|
|
|
0.5
|
|
|
|
17,882
|
|
|
|
(16,291
|
)
|
|
|
1,591
|
|
|
|
1.5
|
|
Trade names-definite lives
|
|
|
2,530
|
|
|
|
(2,530
|
)
|
|
|
|
|
|
|
|
|
|
|
2,530
|
|
|
|
(2,530
|
)
|
|
|
|
|
|
|
|
|
Trade names-indefinite lives
|
|
|
4,464
|
|
|
|
|
|
|
|
4,464
|
|
|
|
n/a
|
|
|
|
4,464
|
|
|
|
|
|
|
|
4,464
|
|
|
|
n/a
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
74,887
|
|
|
$
|
(67,113
|
)
|
|
$
|
7,774
|
|
|
|
|
|
|
$
|
74,887
|
|
|
$
|
(63,993
|
)
|
|
$
|
10,894
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
The calculation of the weighted average remaining useful life is based on the net book value and the remaining amortization period of each respective intangible asset.
|
In July 2014, the Company acquired the assets of TheraSim, Inc. for $3,182 in cash. TheraSims
technology provides the content and programming for certain of the Companys sponsorship services. The purchase price was allocated to an intangible asset, Technology, is being amortized over a
three-year
term and is included within Technology and Patents in the above table.
Amortization expense was $3,120, $3,321 and $2,801 in 2016, 2015 and 2014, respectively. Future amortization expense for intangible assets is estimated to be:
|
|
|
|
|
Year Ending December 31:
|
|
|
|
|
2017
|
|
$
|
2,044
|
|
2018
|
|
$
|
1,266
|
|
6. Accrued Expenses
Accrued expenses consist of the following:
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2016
|
|
|
2015
|
|
Accrued compensation
|
|
$
|
43,082
|
|
|
$
|
45,715
|
|
Accrued outside services
|
|
|
11,173
|
|
|
|
10,775
|
|
Accrued marketing and distribution
|
|
|
7,110
|
|
|
|
5,383
|
|
Accrued interest
|
|
|
4,962
|
|
|
|
5,119
|
|
Other accrued liabilities
|
|
|
12,270
|
|
|
|
13,672
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
78,597
|
|
|
$
|
80,664
|
|
|
|
|
|
|
|
|
|
|
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
27
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
7. Commitments and Contingencies
Legal Proceedings and Claims
Dual Diagnosis Treatment Center, et al. v. Blue Cross of California, et al.
On May 8, 2015, six providers of substance abuse and/or mental health treatment services located in the States of California, Arizona and Florida filed an action in the United States District Court
for the Central District of California (the Action) initially against twenty-eight (28) Blue Cross and Blue Shield companies (collectively Blue Cross), as well as at least
forty-one
(41) health and benefit plans, including the WebMD Health and Welfare Plan (the Health Plan). Additional defendants have since been added. Horizon Blue Cross Blue Shield of New
Jersey, one of the Blue Cross companies named as a defendant, serves as third-party claims administrator for the Health Plan, a welfare plan sponsored by the Company under the applicable provisions of the Employee Retirement Income Security Act of
1974, as amended (ERISA). The Company self-insures (up to the deductible amount under the Companys stop loss insurance policy) the group health plan component of the Health Plan. The Company serves as plan administrator
for the Health Plan under ERISA. The plaintiffs,
out-of-network
providers to Blue Cross, claim that Blue Cross improperly ignored assignments of benefits
received by the plaintiffs from the individual plan participants and sent payments directly to such individual participants who then failed to remit those payments to the providers. Plaintiffs claim that defendants failures to honor the
assignments violate ERISA and state law and they seek recovery for benefit claims in unspecified amounts that they claim have been paid to the wrong party together with attorney fees, as well as removal of all fiduciaries who are found to have
breached ERISA-imposed duties under the relevant health and benefit plans on account of such conduct, and injunctive relief to enjoin Blue Cross from alleged unlawful practices regarding assignments of benefits. The Company has not yet filed an
answer to the complaint. On September 14, 2015, most of the named defendants, including the Company, filed an omnibus motion to dismiss the complaint for failure to state a claim. Thereafter, the plaintiffs amended the complaint and added new
parties. Defendants received an extension of time to respond to the amended complaint and on January 25, 2016, 184 defendants, including the Company, renewed the omnibus motion to dismiss after all new parties were served and appeared in the
Action. Opposition papers were filed on the motion on March 21, 2016, and reply papers were filed by the moving defendants on April 4, 2016. Oral argument on the motion was held on May 31, 2016, after which the parties filed
additional submissions at the Courts direction. The motion was granted on November 22, 2016, with leave to amend to the extent there were additional allegations that could overcome the deficiencies of the dismissed complaint. On
December 23, 2016, the plaintiffs filed a second amended complaint which included a claim against the Company. The Company intends to file a motion to dismiss the second amended complaint. The Company is unable to predict the outcome of this
action or to reasonably estimate the possible loss or range of loss, if any, arising from the claims asserted therein.
Other Legal Proceedings and Claims
In the normal course of business, the Company and its subsidiaries are involved in various claims and legal proceedings. While the ultimate resolution of these matters has yet to be determined, the
Company does not believe that their outcomes will have a material adverse effect on the Companys consolidated financial position, results of operations or liquidity.
Leases
The Company leases its offices and other facilities under operating
lease agreements that expire at various dates through 2024. Total rent expense for all operating leases was approximately $13,177, $6,506 and $9,194 in 2016, 2015 and 2014, respectively. Included in other long-term liabilities as of
December 31, 2016 and 2015
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
28
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
were $16,948 and $12,071, respectively, related to lease incentives and the difference between rent expense and the rental amount payable for leases with fixed escalations.
Future minimum lease commitments under
non-cancelable
lease agreements at December 31, 2016
were as follows:
|
|
|
|
|
Year Ending December 31:
|
|
|
|
|
2017
|
|
$
|
15,507
|
|
2018
|
|
|
15,031
|
|
2019
|
|
|
14,128
|
|
2020
|
|
|
14,412
|
|
2021
|
|
|
13,389
|
|
Thereafter
|
|
|
20,306
|
|
|
|
|
|
|
Total minimum lease payments
|
|
$
|
92,773
|
|
|
|
|
|
|
Other Contingencies
The Company provides certain indemnification provisions within its customer agreements to protect the other party from any liabilities or damages resulting from a claim of misappropriation or infringement
by third parties relating to its products and services. The Company has not incurred a liability relating to any of these indemnification provisions in the past and management believes that the likelihood of any future payment relating to these
provisions is unlikely. Therefore, the Company has not recorded a liability during any period for these indemnification provisions.
8. Stock-Based Compensation
The Company has various stock-based compensation plans (collectively, the Plans) that provide for the grant of stock options, restricted stock, and other awards based on WebMD Common Stock.
The 2005 Long-Term Incentive Plan (as amended, the 2005 Plan) is the only existing plan under which future grants
can be made. The maximum number of shares of the Companys Common Stock that may be subject to awards under the 2005 Plan was 24,975,000 as of December 31, 2016, subject to adjustment in accordance with the terms of the 2005 Plan. The
Company had an aggregate of 607,739 shares of Common Stock available for future grants under the 2005 Plan at December 31, 2016, of which 242,700 shares are available for grant only to individuals who are not executive officers of the
Company (other than in the case of a new hire who joins the Company as an executive officer) or members of the Companys Board of Directors.
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
29
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Stock Options
Generally, options under the Plans vest and become exercisable ratably over periods ranging from three to four years based on their individual grant dates, subject to continued employment on the
applicable vesting dates, and expire within ten years from the date of grant. Options are granted at prices not less than the fair market value of the Companys Common Stock on the date of grant. The following table summarizes stock option
activity for the Plans:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
|
|
|
Weighted
Average Exercise
Price Per Share
|
|
|
Weighted
Average
Remaining
Contractual
Life (In Years)
|
|
|
Aggregate
Intrinsic
Value
(a)
|
|
Outstanding at January 1, 2014
|
|
|
11,429,279
|
|
|
$
|
29.12
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
899,200
|
|
|
|
43.03
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(3,875,410
|
)
|
|
|
24.40
|
|
|
|
|
|
|
|
|
|
Cancelled
|
|
|
(905,543
|
)
|
|
|
33.42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at December 31, 2014
|
|
|
7,547,526
|
|
|
|
32.69
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
2,134,900
|
|
|
|
42.75
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(989,993
|
)
|
|
|
24.53
|
|
|
|
|
|
|
|
|
|
Cancelled
|
|
|
(821,998
|
)
|
|
|
38.68
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at December 31, 2015
|
|
|
7,870,435
|
|
|
|
35.81
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
1,975,300
|
|
|
|
49.96
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(3,136,400
|
)
|
|
|
32.66
|
|
|
|
|
|
|
|
|
|
Cancelled
|
|
|
(590,511
|
)
|
|
|
40.53
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at December 31, 2016
|
|
|
6,118,824
|
|
|
$
|
41.55
|
|
|
|
7.5
|
|
|
$
|
51,231
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested and exercisable at the end of the period
|
|
|
2,218,561
|
|
|
$
|
34.44
|
|
|
|
5.3
|
|
|
$
|
33,815
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
The aggregate intrinsic value is based on the market price of the Companys Common Stock on December 30, 2016, the last trading day in December 2016, which
was $49.57, less the applicable exercise price of the underlying option. This aggregate intrinsic value represents the amount that would have been realized if all the option holders had exercised their options on December 30, 2016.
|
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
30
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following table summarizes information with respect to options outstanding and
options exercisable at December 31, 2016:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding
|
|
|
Exercisable
|
|
Exercise Prices
|
|
Shares
|
|
|
Weighted
Average Exercise
Price Per Share
|
|
|
Weighted
Average
Remaining
Contractual
Life (In Years)
|
|
|
Shares
|
|
|
Weighted
Average Exercise
Price Per Share
|
|
$13.15 - $29.89
|
|
|
596,311
|
|
|
$
|
20.32
|
|
|
|
3.9
|
|
|
|
551,011
|
|
|
$
|
20.32
|
|
$30.00 - $36.59
|
|
|
641,889
|
|
|
|
32.90
|
|
|
|
6.0
|
|
|
|
506,856
|
|
|
|
32.65
|
|
$36.62 - $39.46
|
|
|
567,993
|
|
|
|
38.07
|
|
|
|
5.9
|
|
|
|
408,034
|
|
|
|
37.89
|
|
$39.50 - $42.98
|
|
|
689,533
|
|
|
|
39.98
|
|
|
|
7.1
|
|
|
|
274,720
|
|
|
|
39.95
|
|
$42.99
|
|
|
943,675
|
|
|
|
42.99
|
|
|
|
8.0
|
|
|
|
101,994
|
|
|
|
42.99
|
|
$43.05 - $48.75
|
|
|
731,032
|
|
|
|
45.74
|
|
|
|
7.5
|
|
|
|
269,355
|
|
|
|
45.70
|
|
$49.00
|
|
|
1,631,000
|
|
|
|
49.00
|
|
|
|
9.8
|
|
|
|
|
|
|
|
|
|
$49.13 - $63.45
|
|
|
317,391
|
|
|
|
56.29
|
|
|
|
7.3
|
|
|
|
106,591
|
|
|
|
51.90
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,118,824
|
|
|
$
|
41.55
|
|
|
|
7.5
|
|
|
|
2,218,561
|
|
|
$
|
34.44
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The fair value of each option granted is estimated on the date of grant using the Black-Scholes option
pricing model considering the weighted-average assumptions noted in the following table. Expected volatility is based on implied volatility from traded options of the Companys Common Stock combined with historical volatility of the
Companys Common Stock. The expected term represents the period of time that options are expected to be outstanding following their grant date, and was determined using historical exercise data combined with assumptions for future exercise
activity. The risk-free rate is based on the U.S. Treasury yield curve for periods equal to the expected term of the options on the grant date.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
Expected dividend yield
|
|
|
0.0
|
%
|
|
|
0.0
|
%
|
|
|
0.0
|
%
|
Expected volatility
|
|
|
0.35 - 0.44
|
|
|
|
0.41 - 0.48
|
|
|
|
0.47 - 0.49
|
|
Risk-free interest rate
|
|
|
0.86% - 1.71
|
%
|
|
|
1.01% - 1.56
|
%
|
|
|
1.16% - 1.72
|
%
|
Expected term (years)
|
|
|
3.9 - 4.8
|
|
|
|
4.1 - 4.7
|
|
|
|
4.2 - 5.0
|
|
Weighted-average fair value of options granted during the period
|
|
$
|
15.16
|
|
|
$
|
16.26
|
|
|
$
|
17.58
|
|
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
31
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Restricted Stock
The Companys Restricted Stock consists of shares of the Companys Common Stock which have been awarded to employees with restrictions that cause them to be subject to substantial risk of
forfeiture and restrict their sale or other transfer by the employee until they vest. Generally, the Companys Restricted Stock grants vest ratably over periods ranging from three to four years from their individual award dates, subject to
continued employment on the applicable vesting dates. The following table summarizes the activity of the Companys Restricted Stock:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
|
|
Shares
|
|
|
Weighted
Average Grant
Date Fair Value
|
|
|
Shares
|
|
|
Weighted
Average Grant
Date Fair Value
|
|
|
Shares
|
|
|
Weighted
Average Grant
Date Fair Value
|
|
Balance at the beginning of the year
|
|
|
854,845
|
|
|
$
|
39.17
|
|
|
|
904,083
|
|
|
$
|
35.58
|
|
|
|
1,184,961
|
|
|
$
|
33.07
|
|
Granted
|
|
|
457,600
|
|
|
|
50.04
|
|
|
|
441,920
|
|
|
|
42.96
|
|
|
|
177,200
|
|
|
|
43.84
|
|
Vested
|
|
|
(293,967
|
)
|
|
|
34.90
|
|
|
|
(331,558
|
)
|
|
|
35.72
|
|
|
|
(324,453
|
)
|
|
|
32.70
|
|
Forfeited
|
|
|
(138,452
|
)
|
|
|
43.06
|
|
|
|
(159,600
|
)
|
|
|
36.57
|
|
|
|
(133,625
|
)
|
|
|
31.29
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at the end of the year
|
|
|
880,026
|
|
|
$
|
45.97
|
|
|
|
854,845
|
|
|
$
|
39.17
|
|
|
|
904,083
|
|
|
$
|
35.58
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
During November 2016, the Compensation Committee of the Board of Directors granted a total of 55,000
shares of performance-based Restricted Stock to two senior executives that will vest and be earned so long as the executive is employed at the end of the performance period, which is December 31, 2019, and only to the extent that the Committee
determines that the performance criteria have been satisfied; provided, however, that the conditions to vesting and performance criteria may be deemed to have been met in certain circumstances, including in connection with a change in control of the
Company. The performance criteria are based on Average Adjusted EBITDA during the performance period of January 1, 2016 through December 31, 2019. The 55,000 shares of performance-based Restricted Stock are included in the above table.
Proceeds received from the exercise of options to purchase shares of the Companys Common Stock were $65,309, $21,939
and $40,602 for the years ended December 31, 2016, 2015 and 2014, respectively. Additionally, in connection with the exercise of certain stock options and the vesting of restricted stock, the Company made payments of $17,599, $6,438 and $33,385
during the years ended December 31, 2016, 2015 and 2014, respectively, related to employee statutory withholding taxes that were satisfied by withholding shares of Common Stock of equal value from the respective employees. The proceeds and
payments described above are reflected within cash flows from financing activities within the accompanying consolidated statements of cash flows.
The intrinsic value related to stock options that were exercised, combined with the fair value of shares of restricted stock that vested, aggregated $86,080, $34,670 and $100,232 for the years ended
December 31, 2016, 2015 and 2014, respectively.
Other
Each year the Company issues shares of its Common Stock, under the 2005 Plan, to
non-employee
members of its Board of Directors with a value equal to their annual
Board and committee retainers. The Company recorded $467, $467 and $315 of stock-based compensation expense for the years ended December 31, 2016, 2015 and 2014, respectively, in connection with these issuances.
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
32
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Summary of Stock-Based Compensation Expense
The following table summarizes the components and classification of stock-based compensation expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
Stock options
|
|
$
|
18,556
|
|
|
$
|
21,336
|
|
|
$
|
21,117
|
|
Restricted stock
|
|
|
10,306
|
|
|
|
11,940
|
|
|
|
11,114
|
|
Other
|
|
|
467
|
|
|
|
467
|
|
|
|
315
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stock-based compensation expense
|
|
$
|
29,329
|
|
|
$
|
33,743
|
|
|
$
|
32,546
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Included in:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of operations
|
|
$
|
5,216
|
|
|
$
|
5,217
|
|
|
$
|
5,940
|
|
Sales and marketing
|
|
|
5,942
|
|
|
|
7,290
|
|
|
|
7,221
|
|
General and administrative
|
|
|
18,171
|
|
|
|
21,236
|
|
|
|
19,385
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stock-based compensation expense
|
|
$
|
29,329
|
|
|
$
|
33,743
|
|
|
$
|
32,546
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In the table above, stock-based compensation expense included in general and administrative expense for
2016 includes the net reversal of $2,394 of stock-based compensation expense recorded in prior periods for stock-based awards that were forfeited by the Companys former Chief Executive Officer and former Chief Financial Officer upon their
termination of employment in September 2016.
As of December 31, 2016, approximately $62,194 of unrecognized stock-based
compensation expense related to unvested awards (net of estimated forfeitures) is expected to be recognized over a weighted-average period of approximately 2.7 years, related to the Plans.
Tax benefits attributable to stock-based compensation represented approximately 38% of stock-based compensation expense during each of
the years ended December 31, 2016 and 2015 and 39% of stock-based compensation expense during the year ended December 31, 2014.
9. Retirement Plans
The Company maintains certain defined contribution retirement plans covering substantially all of its employees, which provide for matching and discretionary contributions. The Company has recorded
expenses related to these plans of $4,854, $4,495 and $3,971 for 2016, 2015 and 2014, respectively, related to these matching and discretionary contributions.
10. Equity
Treasury Stock
Repurchased shares are recorded under the cost method and are reflected as treasury stock in the accompanying consolidated balance sheets,
unless the shares are cancelled and retired.
Tender Offers
On December 15, 2016, the Company completed a tender offer (the 2016 Tender Offer) through which it repurchased 2,000,000
shares of its Common Stock at a price of $55.00 per share for total consideration of $110,413, which includes $413 of costs directly attributable to the purchase. The shares repurchased through the 2016 Tender Offer are reflected as treasury stock
in the accompanying consolidated balance sheets.
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
33
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
On September 9, 2014, the Company completed a tender offer (the 2014 Tender
Offer) through which it repurchased 2,000,000 shares of its Common Stock at a price of $48.50 per share for total consideration of $97,588, which includes $588 of costs directly attributable to the purchase. The shares repurchased through the
2014 Tender Offer are reflected as treasury stock in the accompanying consolidated balance sheets.
Stock Repurchase
Program
In August 2011, the Board of Directors established a stock repurchase program (the Program)
through which the Company was authorized to use up to $75,000 to purchase shares of WebMD Common Stock, from time to time, in the open market, through block trades or in private transactions, depending on market conditions and other factors. In
October 2011, February 2014, March 2014, April 2014, November 2014 and September 2015, the Companys Board of Directors authorized increases to the Program of $75,000, $50,000, $40,000, $30,000, $23,895 and $27,451, respectively.
Additionally, on September 16, 2016, the Companys Board of Directors authorized an increase in the Program of $35,198, bringing the total then available under the Program to $50,000. During 2016, 2015 and 2014, the Company repurchased
456,218 shares, 688,467 shares and 3,160,070 shares of its Common Stock, respectively, at an aggregate cost of $23,643, $28,406 and $128,748, respectively, under the Program. As of December 31, 2016, $45,611 remained available for repurchases
under the Program.
Accumulated Other Comprehensive Income (AOCI)
The following table summarizes the Companys changes in Accumulated Other Comprehensive Income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized Gains
on Marketable
Securities,
net of tax
|
|
|
Unrealized Gains on
Foreign Currency
Forward Contracts,
net of tax
|
|
|
Total
|
|
Balance at December 31, 2014
|
|
$
|
976
|
|
|
$
|
|
|
|
$
|
976
|
|
Unrealized loss before reclassifications
|
|
|
(536
|
)
|
|
|
|
|
|
|
(536
|
)
|
Amounts reclassified from AOCI to gain on investments
|
|
|
(83
|
)
|
|
|
|
|
|
|
(83
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net current period other comprehensive loss
|
|
|
(619
|
)
|
|
|
|
|
|
|
(619
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2015
|
|
|
357
|
|
|
|
|
|
|
|
357
|
|
Unrealized (loss) gain before reclassifications
|
|
|
(96
|
)
|
|
|
760
|
|
|
|
664
|
|
Amounts reclassified from AOCI to cost of operations
|
|
|
|
|
|
|
(519
|
)
|
|
|
(519
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net current period other comprehensive (loss) income
|
|
|
(96
|
)
|
|
|
241
|
|
|
|
145
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2016
|
|
$
|
261
|
|
|
$
|
241
|
|
|
$
|
502
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
34
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
11. Income Taxes
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for
financial reporting purposes and the amounts used for income tax purposes. Significant components of the Companys deferred tax assets (liabilities) were as follows:
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2016
|
|
|
2015
|
|
Deferred tax assets:
|
|
|
|
|
|
|
|
|
Federal net operating loss carryforwards
|
|
$
|
30,533
|
|
|
$
|
83,071
|
|
State net operating loss carryforwards
|
|
|
31,468
|
|
|
|
33,320
|
|
Capital losses
|
|
|
201
|
|
|
|
292
|
|
Federal tax credits
|
|
|
28,698
|
|
|
|
28,555
|
|
Accrued expenses
|
|
|
20,426
|
|
|
|
19,086
|
|
Stock-based compensation
|
|
|
17,090
|
|
|
|
24,294
|
|
Property and equipment
|
|
|
1,556
|
|
|
|
|
|
Intangible assets
|
|
|
3,603
|
|
|
|
3,610
|
|
Other
|
|
|
3,776
|
|
|
|
3,808
|
|
|
|
|
|
|
|
|
|
|
Total deferred tax assets
|
|
|
137,351
|
|
|
|
196,036
|
|
Valuation allowance
|
|
|
(85,957
|
)
|
|
|
(142,604
|
)
|
|
|
|
|
|
|
|
|
|
Net deferred tax assets
|
|
|
51,394
|
|
|
|
53,432
|
|
|
|
|
|
|
|
|
|
|
Deferred tax liabilities:
|
|
|
|
|
|
|
|
|
Property and equipment
|
|
|
|
|
|
|
(1,466
|
)
|
Goodwill and indefinite-lived intangible asset
|
|
|
(36,548
|
)
|
|
|
(33,465
|
)
|
Other
|
|
|
(302
|
)
|
|
|
(2,807
|
)
|
|
|
|
|
|
|
|
|
|
Total deferred tax liabilities
|
|
|
(36,850
|
)
|
|
|
(37,738
|
)
|
|
|
|
|
|
|
|
|
|
Net deferred tax assets
|
|
$
|
14,544
|
|
|
$
|
15,694
|
|
|
|
|
|
|
|
|
|
|
The income tax provision was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
Current:
|
|
|
|
|
|
|
|
|
|
|
|
|
Federal
|
|
$
|
(4,396
|
)
|
|
$
|
1,076
|
|
|
$
|
(622
|
)
|
State
|
|
|
6,161
|
|
|
|
4,773
|
|
|
|
3,047
|
|
Foreign
|
|
|
99
|
|
|
|
268
|
|
|
|
369
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current income tax provision
|
|
|
1,864
|
|
|
|
6,117
|
|
|
|
2,794
|
|
|
|
|
|
Deferred:
|
|
|
|
|
|
|
|
|
|
|
|
|
Federal
|
|
|
737
|
|
|
|
(8,456
|
)
|
|
|
12,570
|
|
State
|
|
|
729
|
|
|
|
743
|
|
|
|
2,147
|
|
Foreign
|
|
|
(383
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred income tax provision (benefit)
|
|
|
1,083
|
|
|
|
(7,713
|
)
|
|
|
14,717
|
|
Reversal of valuation allowance applied to additional
paid-in
capital
|
|
|
52,583
|
|
|
|
37,443
|
|
|
|
13,196
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total income tax provision
|
|
$
|
55,530
|
|
|
$
|
35,847
|
|
|
$
|
30,707
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
35
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The reconciliation between the federal statutory rate and the effective income tax rate
is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
United States federal statutory rate
|
|
|
35.0
|
%
|
|
|
35.0
|
%
|
|
|
35.0
|
%
|
State income taxes (net of federal benefit)
|
|
|
4.2
|
|
|
|
5.7
|
|
|
|
7.4
|
|
Valuation allowance
|
|
|
(2.7
|
)
|
|
|
(7.1
|
)
|
|
|
(3.3
|
)
|
Non-deductible
officer compensation
|
|
|
0.5
|
|
|
|
1.4
|
|
|
|
2.2
|
|
Other
|
|
|
0.8
|
|
|
|
0.9
|
|
|
|
1.6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective income tax rate
|
|
|
37.8
|
%
|
|
|
35.9
|
%
|
|
|
42.9
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
During 2016, 2015 and 2014, the Company reversed $52,583, $37,443 and $13,196, respectively, of its
valuation allowance through additional
paid-in
capital as a result of the utilization of net operating loss carryforwards generated by excess tax benefits of share-based payments. During 2016, 2015 and 2014,
the Company reversed $1,298, $1,455 and $1,311, respectively, of its deferred tax asset and related valuation allowance through the tax provision as a result of the expiration of state net operating loss carryforwards. In the quarter ended
June 30, 2015, the Company increased its valuation allowance by $24,775 for a correcting adjustment related to the realization of excess tax benefits of share-based payments during the years ended December 31, 2011 and 2010, offset by a
reversal of a valuation allowance originally recorded during the year ended December 31, 2012. During 2014, the Company reversed $1,359 of its deferred tax asset and related valuation allowance through additional
paid-in
capital as a result of the expiration of state net operating loss carryforwards generated by excess tax benefits of share-based payments. The valuation allowance for deferred tax assets decreased by $56,647
and $15,040 in 2016 and 2015, respectively.
At December 31, 2016, the Company had net operating loss carryforwards for
federal income tax purposes of approximately $512,000, primarily all of which expire in 2022 through 2034, and federal tax credits of $63,112, which excludes the impact of any unrecognized tax benefits, of which $44,172 expire in 2017 through 2031
and $18,940 can be carried forward indefinitely.
The Company uses the
with-and-without
approach in determining the order in which tax attributes are utilized. Using the
with-and-without
approach, the Company will only recognize a tax benefit from share-based payments in additional
paid-in
capital if an incremental tax benefit is realized after all other tax attributes currently available to the Company have been utilized. As a result of these ordering rules, the composition of tax
attributes on a tax return and financial statement basis will differ.
The net operating loss carryforwards that are presented
on a tax effected basis within the deferred tax assets include approximately $79,000 of gross excess tax benefits related to share-based payments. Since this amount was recorded through additional
paid-in
capital, the related valuation allowance on these net operating loss carryforwards will be reversed through additional
paid-in
capital when these excess tax benefits are realized. The net operating loss
carryforwards also include gross excess tax benefits related to share-based payments of approximately $499,000 that are not recognized as a deferred tax asset as the amounts would not have resulted in a reduction in current taxes payable if all
other tax attributes currently available to the Company were utilized. The benefit of these deductions will be recognized through additional
paid-in
capital at the time the tax deduction results in a reduction
of current taxes payable.
The tender offer completed on November 25, 2008 resulted in a cumulative change of more than
50% of the ownership of the Companys capital, as determined under rules prescribed by the U.S. Internal Revenue Code
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
36
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
and applicable Treasury regulations. As a result of the ownership change, there is an annual limitation imposed on the Companys net operating loss carryforwards and federal tax credits. The
Company experienced another cumulative change on February 25, 2011. Despite this second ownership change, the Companys net operating loss carryforwards and federal tax credits continue to be limited by the November 25, 2008 annual
limitation.
As of December 31, 2016 and 2015, the Company had unrecognized income tax benefits of $15,516 and $14,815,
respectively, which would result in an income tax benefit if realized. Included in the unrecognized income tax benefits as of December 31, 2016 and 2015 are accrued interest and penalties of $869 and $738, respectively. The Company recognizes
interest and penalties related to unrecognized tax benefits as part of the income tax provision.
The following table
summarizes the activity of unrecognized tax benefits, excluding accrued interest and penalties, for the years ended December 31, 2016, 2015 and 2014:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
Balance at the beginning of the year
|
|
$
|
14,077
|
|
|
$
|
12,972
|
|
|
$
|
13,392
|
|
Increases related to prior year tax positions
|
|
|
76
|
|
|
|
776
|
|
|
|
15
|
|
Increases related to current year tax positions
|
|
|
691
|
|
|
|
394
|
|
|
|
|
|
Decreases related to prior year tax positions
|
|
|
(158
|
)
|
|
|
|
|
|
|
(379
|
)
|
Settlements
|
|
|
|
|
|
|
(15
|
)
|
|
|
|
|
Expiration of the statute of limitations for the assessment of taxes
|
|
|
(39
|
)
|
|
|
(50
|
)
|
|
|
(56
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at the end of the year
|
|
$
|
14,647
|
|
|
$
|
14,077
|
|
|
$
|
12,972
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Although the Company files U.S. federal and various state and other tax returns, the major taxing
jurisdiction is the U.S. The Company is currently under audit in a number of state and local taxing jurisdictions and will have statutes of limitations with respect to certain tax returns expiring within the next twelve months. As a result, it
is reasonably possible that there may be a reduction in the unrecognized income tax benefits, prior to any annual increase, in the range of $100 to $200 within the next twelve months. With the exception of adjusting net operating loss carryforwards
that may be utilized, the Company is no longer subject to federal income tax examinations for tax years before 2013 and for state and local income tax examinations for tax years before 2012.
12. Fair Value of Financial Instruments
The Company
accounts for certain assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
Additionally, the Company uses valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:
|
Level
1:
|
Observable inputs such as quoted market prices in active markets for identical assets or liabilities.
|
|
Level
2:
|
Observable market-based inputs or unobservable inputs that are corroborated by market data.
|
|
Level
3:
|
Unobservable inputs for which there is little or no market data, which require the use of the reporting entitys own assumptions.
|
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
37
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Cash and Marketable Securities
The following table sets forth the Companys Level 1 financial assets that were measured and recorded at fair value on a
recurring basis as of December 31, 2016 and 2015:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value
Estimate Using:
|
|
December 31, 2016
|
|
|
December 31, 2015
|
|
|
|
|
Amortized
Cost Basis
|
|
|
Fair Value
|
|
|
Gross
Unrealized
Gains
|
|
|
Amortized
Cost Basis
|
|
|
Fair Value
|
|
|
Gross
Unrealized
Gains
|
|
Cash and cash equivalents
|
|
Level 1
|
|
$
|
492,424
|
|
|
$
|
492,424
|
|
|
$
|
|
|
|
$
|
641,165
|
|
|
$
|
641,165
|
|
|
$
|
|
|
U.S. Treasury securities
|
|
Level 1
|
|
$
|
498,359
|
|
|
$
|
498,500
|
|
|
$
|
141
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Equity security
|
|
Level 1
|
|
$
|
|
|
|
$
|
278
|
|
|
$
|
278
|
|
|
$
|
|
|
|
$
|
598
|
|
|
$
|
598
|
|
During 2016, the Company invested $948,078 in U.S. Treasury securities that matured on December 22,
2016. Following this maturity, the Company invested $498,332 in U.S. Treasury securities that have a maturity date of June 29, 2017. These securities are reflected within Investments on the accompanying consolidated balance sheet as of
December 31, 2016. The unrealized gain related to these securities, net of tax, is included within accumulated other comprehensive income in the accompanying consolidated balance sheet as of December 31, 2016.
The Companys Level 1 equity security consists of an equity investment in a publicly traded company that completed its initial
public offering in December 2014. During 2015, the Company recorded a gain on investments of $139, which represents the proceeds received by the Company when it sold a portion of this security. The unrealized gain related to this investment, net of
tax, is included within accumulated other comprehensive income in the accompanying consolidated balance sheets as of December 31, 2016 and 2015.
Foreign Currency Forward Contracts
The Company is exposed to fluctuations
in foreign currencies related to contracts with certain of the Companys customers that are denominated in foreign currencies, principally the British Pound and the Euro. In order to manage this risk, the Company has hedged portions of its
foreign currency denominated customer contracts with foreign currency forward contracts. At December 31, 2016, the Company had foreign currency forward contracts with U.S. dollar equivalent notional amounts of $15,401, all of which were
designated as and qualified as cash flow hedges. The Company did not have any foreign currency forward contracts at December 31, 2015. These forward contracts are intended to fix the amount of these foreign currency obligations in terms of the
Companys functional currency, the U.S. dollar. All of the Companys derivative instruments are utilized for risk management purposes, and the Company does not use derivatives for speculative trading purposes.
The Company recognizes the fair value of its foreign currency forward contracts as either assets or liabilities on the consolidated
balance sheets. Changes in the fair value of hedging instruments are recorded each period in accumulated other comprehensive income (loss) as unrealized gains and losses until the forecasted underlying transaction occurs. Realized gains and losses
for the effective portion of such contracts are recognized in cost of operations in the consolidated statement of operations in the period when the forecasted underlying transaction occurs. The Company classifies the cash flows from hedging
instruments in the same category as the cash flows from the hedged items.
The Company assesses, both at inception and on an
ongoing basis, whether the foreign currency forward contracts used in hedging transactions are highly effective in offsetting the changes in cash flows of the hedged
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
38
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
items. The Company also assesses hedge ineffectiveness quarterly and, if determined to be ineffective, records the gain or loss related to the ineffective portion in its consolidated statements
of operations. Gains and losses related to hedge ineffectiveness were not material during the periods presented.
The
following table sets forth the fair values of foreign currency forward contracts, which are valued using Level 2 inputs, and the balance sheet lines in which they are recorded:
|
|
|
|
|
|
|
|
|
|
|
Fair Value Asset (Liability)
|
|
|
|
December 31,
2016
|
|
|
December 31,
2015
|
|
Prepaid expenses and other current assets
|
|
$
|
806
|
|
|
$
|
|
|
Other assets
|
|
$
|
256
|
|
|
$
|
|
|
Accrued expenses
|
|
$
|
(163
|
)
|
|
$
|
|
|
Other long-term liabilities
|
|
$
|
(9
|
)
|
|
$
|
|
|
The impact on accumulated other comprehensive income and net income from foreign currency forward
contracts were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
Gain recognized in AOCI
|
|
$
|
1,226
|
|
|
$
|
|
|
|
$
|
|
|
Gain reclassified from AOCI to cost of operations
|
|
$
|
837
|
|
|
$
|
|
|
|
$
|
|
|
Other
For disclosure purposes, the Company is required to measure the outstanding value of its debt on a recurring basis. The following table presents the principal amount and estimated fair value (based on
Level 2 market price data) of the Companys convertible notes as of December 31, 2016 and 2015:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2016
|
|
|
December 31, 2015
|
|
|
|
Principal
Amount
|
|
|
Fair Value
|
|
|
Principal
Amount
|
|
|
Fair Value
|
|
2.25% Notes
|
|
$
|
|
|
|
$
|
|
|
|
$
|
102,682
|
|
|
$
|
102,618
|
|
2.50% Notes
|
|
$
|
400,000
|
|
|
$
|
409,000
|
|
|
$
|
400,000
|
|
|
$
|
416,000
|
|
1.50% Notes
|
|
$
|
300,000
|
|
|
$
|
338,565
|
|
|
$
|
300,000
|
|
|
$
|
340,566
|
|
2.625% Notes
|
|
$
|
360,000
|
|
|
$
|
341,928
|
|
|
$
|
|
|
|
$
|
|
|
The Company also holds an investment in a privately held company which is carried at cost, and not
subject to fair value measurements. However, if events or circumstances indicate that its carrying amount may not be recoverable, it would be reviewed for impairment. The total amount of the Companys investment in this privately held company
was $3,872 and $6,471 as of December 31, 2016 and 2015, respectively. The decrease in 2016 was due to partial cash redemptions of this investment. Since the Company does not have the ability to exercise significant influence over this company,
the investment is accounted for under the cost method and it is included in other assets on the accompanying consolidated balance sheets as of December 31, 2016 and 2015.
13. Other Expense
For 2016, other expense
represents cash severance and related expenses in connection with the September 2016 departure of the Chief Executive Officer and the Chief Financial Officer of the Company. For 2015, other
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
39
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
expense represents a charge related to the resolution of a patent infringement claim made by International Business Machines Corporation against the Company.
14. Supplemental Disclosures of Cash Flow Information
Supplemental information related to the consolidated statements of cash flows is summarized below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
Supplemental Disclosure of Cash Flow Information:
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest paid
|
|
$
|
20,748
|
|
|
$
|
19,792
|
|
|
$
|
20,225
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxes paid, net
(a)
|
|
$
|
3,809
|
|
|
$
|
2,850
|
|
|
$
|
277
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
As the Company generally files its tax returns on a consolidated basis, taxes paid, net of refunds, includes all taxes paid by the Company, including those of the
Companys discontinued operations.
|
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
40
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
15. Quarterly Financial Data (Unaudited)
The following table summarizes the quarterly financial data for 2016 and 2015. The per common share calculations for each of the quarters
are based on the weighted-average number of common shares for each period; therefore, the sum of the quarters may not necessarily be equal to the full year per common share amount.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2016
|
|
|
|
First
Quarter
|
|
|
Second
Quarter
|
|
|
Third
Quarter
|
|
|
Fourth
Quarter
|
|
Revenue
|
|
$
|
158,553
|
|
|
$
|
167,583
|
|
|
$
|
171,438
|
|
|
$
|
207,472
|
|
Cost of operations
|
|
|
62,513
|
|
|
|
65,788
|
|
|
|
65,458
|
|
|
|
72,895
|
|
Sales and marketing
|
|
|
33,756
|
|
|
|
35,614
|
|
|
|
35,264
|
|
|
|
41,328
|
|
General and administrative
|
|
|
23,756
|
|
|
|
23,983
|
|
|
|
20,005
|
|
|
|
23,397
|
|
Depreciation and amortization
|
|
|
7,487
|
|
|
|
7,672
|
|
|
|
7,912
|
|
|
|
7,721
|
|
Interest income
|
|
|
206
|
|
|
|
367
|
|
|
|
1,034
|
|
|
|
938
|
|
Interest expense
|
|
|
5,100
|
|
|
|
5,265
|
|
|
|
7,065
|
|
|
|
7,066
|
|
Other expense
|
|
|
|
|
|
|
|
|
|
|
1,712
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income tax provision
|
|
|
26,147
|
|
|
|
29,628
|
|
|
|
35,056
|
|
|
|
56,003
|
|
Income tax provision
|
|
|
10,429
|
|
|
|
11,848
|
|
|
|
13,438
|
|
|
|
19,815
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
15,718
|
|
|
$
|
17,780
|
|
|
$
|
21,618
|
|
|
$
|
36,188
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per common share Basic
|
|
$
|
0.42
|
|
|
$
|
0.47
|
|
|
$
|
0.57
|
|
|
$
|
0.95
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per common share Diluted
|
|
$
|
0.36
|
|
|
$
|
0.39
|
|
|
$
|
0.47
|
|
|
$
|
0.73
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income per Common Share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income Basic
|
|
$
|
15,718
|
|
|
$
|
17,780
|
|
|
$
|
21,618
|
|
|
$
|
36,188
|
|
Interest expense on 1.50% Notes, net of tax
|
|
|
878
|
|
|
|
878
|
|
|
|
878
|
|
|
|
878
|
|
Interest expense on 2.50% Notes, net of tax
|
|
|
1,827
|
|
|
|
1,827
|
|
|
|
1,827
|
|
|
|
1,827
|
|
Interest expense on 2.25% Notes, net of tax
|
|
|
457
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense on 2.625% Notes, net of tax
|
|
|
|
|
|
|
|
|
|
|
1,675
|
|
|
|
1,676
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income Diluted
|
|
$
|
18,880
|
|
|
$
|
20,485
|
|
|
$
|
25,998
|
|
|
$
|
40,569
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares Basic
|
|
|
37,267
|
|
|
|
38,041
|
|
|
|
38,103
|
|
|
|
38,006
|
|
Stock options and restricted stock
|
|
|
1,755
|
|
|
|
2,008
|
|
|
|
1,709
|
|
|
|
1,158
|
|
1.50% Notes
|
|
|
5,694
|
|
|
|
5,694
|
|
|
|
5,694
|
|
|
|
5,699
|
|
2.50% Notes
|
|
|
6,205
|
|
|
|
6,205
|
|
|
|
6,205
|
|
|
|
6,210
|
|
2.25% Notes
|
|
|
1,414
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.625% Notes
|
|
|
|
|
|
|
|
|
|
|
4,134
|
|
|
|
4,138
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted weighted-average shares after assumed conversions Diluted
|
|
|
52,335
|
|
|
|
51,948
|
|
|
|
55,845
|
|
|
|
55,211
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
41
WEBMD HEALTH CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2015
|
|
|
|
First
Quarter
|
|
|
Second
Quarter
|
|
|
Third
Quarter
|
|
|
Fourth
Quarter
|
|
Revenue
|
|
$
|
143,343
|
|
|
$
|
148,320
|
|
|
$
|
152,607
|
|
|
$
|
192,129
|
|
Cost of operations
|
|
|
57,877
|
|
|
|
60,407
|
|
|
|
59,552
|
|
|
|
69,475
|
|
Sales and marketing
|
|
|
32,476
|
|
|
|
32,570
|
|
|
|
32,850
|
|
|
|
40,129
|
|
General and administrative
|
|
|
21,453
|
|
|
|
23,002
|
|
|
|
22,942
|
|
|
|
24,183
|
|
Depreciation and amortization
|
|
|
8,245
|
|
|
|
7,592
|
|
|
|
7,266
|
|
|
|
7,418
|
|
Interest income
|
|
|
17
|
|
|
|
9
|
|
|
|
10
|
|
|
|
15
|
|
Interest expense
|
|
|
6,172
|
|
|
|
6,171
|
|
|
|
5,681
|
|
|
|
5,099
|
|
Loss on convertible notes
|
|
|
|
|
|
|
|
|
|
|
2,058
|
|
|
|
|
|
Gain on investments
|
|
|
|
|
|
|
139
|
|
|
|
|
|
|
|
|
|
Other expense
|
|
|
|
|
|
|
4,100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income tax provision
|
|
|
17,137
|
|
|
|
14,626
|
|
|
|
22,268
|
|
|
|
45,840
|
|
Income tax provision
|
|
|
7,133
|
|
|
|
1,255
|
|
|
|
9,080
|
|
|
|
18,379
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
10,004
|
|
|
$
|
13,371
|
|
|
$
|
13,188
|
|
|
$
|
27,461
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per common share Basic
|
|
$
|
0.27
|
|
|
$
|
0.36
|
|
|
$
|
0.36
|
|
|
$
|
0.75
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per common share Diluted
|
|
$
|
0.25
|
|
|
$
|
0.32
|
|
|
$
|
0.32
|
|
|
$
|
0.60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income per Common Share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income Basic
|
|
$
|
10,004
|
|
|
$
|
13,371
|
|
|
$
|
13,188
|
|
|
$
|
27,461
|
|
Interest expense on 1.50% Notes, net of tax
|
|
|
864
|
|
|
|
864
|
|
|
|
864
|
|
|
|
864
|
|
Interest expense on 2.50% Notes, net of tax
|
|
|
|
|
|
|
1,797
|
|
|
|
1,797
|
|
|
|
1,797
|
|
Interest expense on 2.25% Notes, net of tax
|
|
|
|
|
|
|
1,103
|
|
|
|
|
|
|
|
449
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income Diluted
|
|
$
|
10,868
|
|
|
$
|
17,135
|
|
|
$
|
15,849
|
|
|
$
|
30,571
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares Basic
|
|
|
36,393
|
|
|
|
36,705
|
|
|
|
36,721
|
|
|
|
36,583
|
|
Stock options and restricted stock
|
|
|
1,378
|
|
|
|
1,503
|
|
|
|
1,338
|
|
|
|
1,427
|
|
1.50% Notes
|
|
|
5,694
|
|
|
|
5,694
|
|
|
|
5,694
|
|
|
|
5,694
|
|
2.50% Notes
|
|
|
|
|
|
|
6,205
|
|
|
|
6,205
|
|
|
|
6,205
|
|
2.25% Notes
|
|
|
|
|
|
|
3,511
|
|
|
|
|
|
|
|
1,429
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted weighted-average shares after assumed conversions Diluted
|
|
|
43,465
|
|
|
|
53,618
|
|
|
|
49,958
|
|
|
|
51,338
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16. Subsequent event
On February 16, 2017, the Company announced that its Board of Directors, working together with its management team and legal and
financial advisors, had commenced a process to explore and evaluate potential strategic alternatives focused on maximizing shareholder value. These alternatives could include, among other things, the sale of part or all of the Company, a merger with
another party or other strategic transaction, or continuing to execute on WebMDs business plan. The Companys Board of Directors has not set a timetable for this process. There can be no assurance that the exploration of strategic
alternatives will result in a transaction.
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
42
Schedule II. Valuation and Qualifying Accounts
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, 2016, 2015 and 2014
|
|
|
|
Balance at
Beginning
of Year
|
|
|
Charged to
Costs and
Expenses
|
|
|
Write-offs
|
|
|
Other
|
|
|
Balance at
End of Year
|
|
|
|
(in thousands)
|
|
December 31, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for Doubtful Accounts
|
|
$
|
1,040
|
|
|
$
|
571
|
|
|
$
|
(79
|
)
|
|
$
|
|
|
|
$
|
1,532
|
|
Valuation Allowance for Deferred Tax Assets
|
|
|
142,604
|
|
|
|
(3,969
|
)
|
|
|
|
|
|
|
(52,678
|
)
(a)
|
|
|
85,957
|
|
December 31, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for Doubtful Accounts
|
|
|
631
|
|
|
|
874
|
|
|
|
(465
|
)
|
|
|
|
|
|
|
1,040
|
|
Valuation Allowance for Deferred Tax Assets
|
|
|
157,644
|
|
|
|
(7,061
|
)
|
|
|
|
|
|
|
(7,979
|
)
(b)
|
|
|
142,604
|
|
December 31, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for Doubtful Accounts
|
|
|
793
|
|
|
|
577
|
|
|
|
(739
|
)
|
|
|
|
|
|
|
631
|
|
Valuation Allowance for Deferred Tax Assets
|
|
|
174,592
|
|
|
|
(2,350
|
)
|
|
|
|
|
|
|
(14,598
|
)
(a)
|
|
|
157,644
|
|
(a)
|
Primarily represents the valuation allowance released as a result of the utilization during the year ended December 31, 2016, and the utilization and expiration
during the year ended December 31, 2014, of net operating loss carryforwards generated by excess tax benefits of share-based payments.
|
(b)
|
Primarily represents the valuation allowance released as a result of the utilization of net operating loss carryforwards generated by excess tax benefits of share-based
payments, offset by a correcting adjustment, made in the quarter ended June 30, 2015, related to the realization of excess tax benefits of share-based payments during the years ended December 31, 2011 and 2010.
|
W
EB
MD 2016 A
NNUAL
R
EPORT
F
INANCIAL
S
TATEMENTS
A
NNEX
A
NNEX
A P
AGE
S-1
ANNEX B
WEBMD HEALTH CORP. 2016 ANNUAL REPORT
SELECTED HISTORICAL CONSOLIDATED
FINANCIAL DATA
The following selected consolidated financial data should be read in conjunction with
Managements Discussion and Analysis of Financial Condition and Results of Operations in Annex C below and with the Consolidated Financial Statements and notes thereto, which are included in Annex A above.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
|
2013
|
|
|
2012
|
|
|
|
(In thousands, except per share data)
|
|
Consolidated Statements of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
705,046
|
|
|
$
|
636,399
|
|
|
$
|
580,449
|
|
|
$
|
515,293
|
|
|
$
|
469,866
|
|
Cost of operations
|
|
|
266,654
|
|
|
|
247,311
|
|
|
|
224,094
|
|
|
|
209,740
|
|
|
|
216,361
|
|
Sales and marketing
|
|
|
145,962
|
|
|
|
138,025
|
|
|
|
136,160
|
|
|
|
127,997
|
|
|
|
127,659
|
|
General and administrative
|
|
|
91,141
|
|
|
|
91,580
|
|
|
|
94,119
|
|
|
|
93,220
|
|
|
|
97,618
|
|
Depreciation and amortization
|
|
|
30,792
|
|
|
|
30,521
|
|
|
|
29,811
|
|
|
|
26,606
|
|
|
|
28,399
|
|
Interest income
|
|
|
2,545
|
|
|
|
51
|
|
|
|
69
|
|
|
|
76
|
|
|
|
86
|
|
Interest expense
|
|
|
24,496
|
|
|
|
23,123
|
|
|
|
24,686
|
|
|
|
22,826
|
|
|
|
23,334
|
|
Loss on convertible notes
|
|
|
|
|
|
|
2,058
|
|
|
|
|
|
|
|
4,871
|
|
|
|
|
|
Gain on investments
|
|
|
|
|
|
|
139
|
|
|
|
|
|
|
|
|
|
|
|
8,074
|
|
Restructuring
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,579
|
|
Severance and other expense
|
|
|
1,712
|
|
|
|
4,100
|
|
|
|
|
|
|
|
1,353
|
|
|
|
2,297
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations before income tax provision (benefit)
|
|
|
146,834
|
|
|
|
99,871
|
|
|
|
71,648
|
|
|
|
28,756
|
|
|
|
(25,221
|
)
|
Income tax provision (benefit)
|
|
|
55,530
|
|
|
|
35,847
|
|
|
|
30,707
|
|
|
|
13,640
|
|
|
|
(2,134
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations
|
|
|
91,304
|
|
|
|
64,024
|
|
|
|
40,941
|
|
|
|
15,116
|
|
|
|
(23,087
|
)
|
Income from discontinued operations, net of tax
|
|
|
|
|
|
|
|
|
|
|
1,122
|
|
|
|
|
|
|
|
2,743
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
91,304
|
|
|
$
|
64,024
|
|
|
$
|
42,063
|
|
|
$
|
15,116
|
|
|
$
|
(20,344
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic income (loss) per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations
|
|
$
|
2.41
|
|
|
$
|
1.75
|
|
|
$
|
1.08
|
|
|
$
|
0.32
|
|
|
$
|
(0.45
|
)
|
Income from discontinued operations
|
|
|
|
|
|
|
|
|
|
|
0.03
|
|
|
|
|
|
|
|
0.05
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
2.41
|
|
|
$
|
1.75
|
|
|
$
|
1.11
|
|
|
$
|
0.32
|
|
|
$
|
(0.40
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted income (loss) per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations
|
|
$
|
1.97
|
|
|
$
|
1.48
|
|
|
$
|
0.97
|
|
|
$
|
0.31
|
|
|
$
|
(0.45
|
)
|
Income from discontinued operations
|
|
|
|
|
|
|
|
|
|
|
0.03
|
|
|
|
|
|
|
|
0.05
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
1.97
|
|
|
$
|
1.48
|
|
|
$
|
1.00
|
|
|
$
|
0.31
|
|
|
$
|
(0.40
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares outstanding used in computing per share amounts:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
37,854
|
|
|
|
36,600
|
|
|
|
37,869
|
|
|
|
46,830
|
|
|
|
50,862
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
54,179
|
|
|
|
52,653
|
|
|
|
45,614
|
|
|
|
48,398
|
|
|
|
50,862
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
W
EB
MD 2016 A
NNUAL
R
EPORT
S
ELECTED
F
INANCIAL
D
ATA
A
NNEX
A
NNEX
B P
AGE
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2016
|
|
|
2015
(a)
|
|
|
2014
(a)
|
|
|
2013
(a)
|
|
|
2012
(a)
|
|
|
|
(In thousands)
|
|
Consolidated Balance Sheet Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash, cash equivalents and investments
|
|
$
|
990,924
|
|
|
$
|
641,165
|
|
|
$
|
706,776
|
|
|
$
|
824,880
|
|
|
$
|
991,835
|
|
Working capital (excluding assets and liabilities of discontinued operations)
|
|
|
1,001,765
|
|
|
|
548,574
|
|
|
|
695,016
|
|
|
|
803,468
|
|
|
|
955,907
|
|
Total assets
|
|
|
1,501,186
|
|
|
|
1,155,923
|
|
|
|
1,183,202
|
|
|
|
1,306,762
|
|
|
|
1,473,459
|
|
Long-term convertible notes
|
|
|
1,044,688
|
|
|
|
690,547
|
|
|
|
937,877
|
|
|
|
933,366
|
|
|
|
782,834
|
|
Stockholders equity
|
|
|
243,860
|
|
|
|
156,228
|
|
|
|
61,589
|
|
|
|
190,900
|
|
|
|
509,989
|
|
(a)
|
On January 1, 2016, we adopted Accounting Standards Update (ASU) No. 2015-03 and ASU No. 2015-17 on a retrospective basis. As a result of the adoption of ASU No.
2015-03, debt issuance costs related to our convertible notes that were included in other assets in prior year Consolidated Balance Sheets, are now reflected as a direct deduction from the carrying amount of each respective convertible note. As a
result of the adoption of ASU No. 2015-17, deferred tax assets and liabilities, along with any related valuation allowance, that were separately classified as current and noncurrent in prior year Consolidated Balance Sheets, are now all presented as
noncurrent. In Consolidated Balance Sheet Data above as of December 31, 2015, 2014, 2013 and 2012, the balances for Working Capital, Total Assets and Long-term Convertible Notes reflect the retrospective application of the new authoritative
guidance.
|
W
EB
MD 2016 A
NNUAL
R
EPORT
S
ELECTED
F
INANCIAL
D
ATA
A
NNEX
A
NNEX
B P
AGE
2
ANNEX C
WEBMD HEALTH CORP. 2016 ANNUAL REPORT
MANAGEMENTS DISCUSSION AND
ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Annex C contains forward-looking statements that involve risks and uncertainties. Please see Forward-Looking
Statements on page ii of the Proxy Statement for a discussion of the uncertainties, risks and assumptions associated with these statements. The results of operations for the periods reflected herein are not necessarily indicative of results
that may be expected for future periods, and our actual results may differ materially from those discussed in our forward-looking statements as a result of various factors, including but not limited to those listed as Risk Factors in
Annex F below. In this Annex C, dollar amounts (other than per share amounts) are stated in thousands, unless otherwise noted.
Except for adjustments to references to where to find our Consolidated Financial Statements, the text of this Annex C is taken directly from Item 7 of our Annual Report on Form 10-K for the year ended
December 31, 2016, which was filed on March 1, 2017, and does not reflect any events occurring after that filing date.
Overview
Managements discussion and analysis of financial condition and results of operations, or MD&A, is provided as a
supplement to the Consolidated Financial Statements and notes thereto included in Annex A above and is intended to provide an understanding of our results of operations, financial condition and changes in our results of operations and financial
condition. Our MD&A is organized as follows:
|
|
|
Introduction
. This section provides: a general description of our company and its business; background information on
certain trends, transactions and other developments affecting our company; and a discussion of how seasonal factors may impact the timing of our revenue.
|
|
|
|
Critical Accounting Estimates and Policies
. This section discusses those accounting policies that are considered
important to the evaluation and reporting of our financial condition and results of operations, and whose application requires us to exercise subjective and often complex judgments in making estimates and assumptions. In addition, all of our
significant accounting policies, including our critical accounting policies, are summarized in Note 2 to the Consolidated Financial Statements included in Annex A above.
|
|
|
|
Results of Operations and Supplemental Financial and Operating Information
. These sections provide our analysis and
outlook for the significant line items on our statements of operations, as well as other information that we deem meaningful to understand our results of operations on a consolidated basis.
|
|
|
|
Liquidity and Capital Resources
. This section provides an analysis of our liquidity and cash flows, as well as a
discussion of our commitments that existed as of December 31, 2016.
|
|
|
|
Recent Accounting Pronouncements
. This section provides a summary of the most recent authoritative accounting standards
and guidance that have either been recently adopted by our company or may be adopted in the future.
|
Introduction
Our Company.
WebMD Health Corp. is a Delaware corporation that was incorporated on
May 3, 2005. We completed an initial public offering on September 28, 2005. Our Common Stock trades under the symbol WBMD on the Nasdaq Global Select Market.
Our Business.
We generate revenue from the advertising and sponsorship services of
The WebMD
Health Network
and related operations, from the services we market to employers and health plans under the
WebMD Health Services
brand and from certain information services, each of which is described below and discussed further under
Supplemental Financial and Operating Information below.
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
1
Advertising and Sponsorship. The WebMD Health Network
includes:
www.WebMD.com
, our primary Website for consumers and related mobile apps;
www.Medscape.com
, our primary Website for physicians and other healthcare professionals and related mobile apps; and other sites and apps through which
we provide our branded health and wellness content, tools and services. Our services for consumers enable them to obtain information on health and wellness topics or on a particular disease or condition, to assess their personal health status, to
use online trackers, tools and quizzes, to locate physicians, to receive periodic
e-mailed
newsletters and alerts on topics of individual interest, and to participate in online communities with peers and
experts. Our services for physicians and healthcare professionals make it easier for them to access clinical reference sources, stay abreast of the latest clinical information, learn about new treatment options, earn continuing medical education
(which we refer to as CME) credit and communicate with peers. We do not charge any usage, membership or download fees for access to the Websites and mobile apps included in
The WebMD Health Network
. We generate revenue from
The WebMD
Health Network
primarily through the sale of various types of advertising and sponsorship programs to our clients, which include: pharmaceutical, biotechnology and medical device companies; hospitals, clinics and other healthcare services
companies; health insurance providers; consumer products companies whose products or services relate to health, wellness, diet, fitness, lifestyle, safety and illness prevention; and various other businesses, organizations and governmental entities.
Advertisers and sponsors use our services to reach, educate and inform target audiences of consumers, physicians and other healthcare professionals. We also generate revenue from advertising sold in
WebMD Magazine
, a consumer magazine
distributed to physician office waiting rooms.
Health Services.
Under the
WebMD Health Services
brand, we market wellness services and solutions that help employers and health plans improve the health and well-being of their employee and plan participant populations. We host our
WebMD Health Services
platform for our employer and health plan clients. Our cloud-based online services can be accessed by their employees and plan participants using a computer, a tablet or a smartphone. Our flexible architecture allows us to integrate with the
clients existing programs, websites and intranets. Our services help our clients employees and plan participants make informed decisions about health risks and lifestyle choices. Our solutions start with an assessment of individual
health and well-being and then work to provide personalized paths for improving or maintaining health. We also offer clients the ability to design team-based and individual wellness challenges that help foster a culture of wellness in the workplace.
In addition, our health and wellness coaching programs, available onsite and telephonically and focusing on lifestyle, condition management, weight management and tobacco cessation, help participants make healthier choices to achieve their health
and well-being goals. Our
WebMD Digital Health
Assistant
SM
offers online, self-directed health coaching which enables participants to set and track wellness goals and follow self-paced personal action plans. We generate Health Services revenue from employer and
health plan subscriptions to our
WebMD Health Services
platform, either directly or through distributor relationships. In addition, clients are charged on a per participant basis for our health and wellness coaching programs.
Information Services.
We generate revenue from the sale of certain information products and services on a
stand-alone basis using
de-identified
data that we license from a small number of third-party data sources, of which the principal source is a license from Change Healthcare to HLTH Corporation (or HLTH), our
former parent company. As the successor to HLTH, this license provides us the rights to certain
de-identified
data from Change Healthcare through early February 2018 for use in the development and
commercialization of various information products and services. Customers for these information services include data services, informatics and consulting companies. Our revenue from the products and services that utilize data under the current
Change Healthcare license is highly profitable and is reported net of the royalties and commissions that we pay to Change Healthcare or others. We do not expect that the current license agreement with Change Healthcare will continue after February
2018, and expect that if such agreement is renewed or is replaced with new third-party data sources, the terms of any such renewal or replacement license would not be as favorable to us as those in the current agreement. Change Healthcare is in the
process of merging with McKesson Corporation and, as a result, discussions around extending our agreement with Change Healthcare have stalled. We are exploring other sources of third-party data and uses of our first party data to generate additional
revenue streams, but we are early in that process. Accordingly, we expect that the sales of, and the profits generated by, our information services
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
2
business will be materially adversely affected by the expiration, in early February 2018, of our license agreement with Change Healthcare.
Background Information on Certain Trends and Developments Affecting Our Business.
Key trends and
developments affecting the use of healthcare information services of the types we provide or are developing and our ability to generate revenue from those services include the following:
|
|
|
Online Marketing and Education Spending for Healthcare Products.
Pharmaceutical, biotechnology and medical device
companies spend large amounts each year marketing their products and educating consumers and physicians about them; however, only a small portion is currently spent on online services. We believe that these companies, which represented approximately
76% of our advertising and sponsorship revenue in 2016, are aware of the effectiveness of the Internet relative to traditional media in providing health, clinical and product-related information to consumers and physicians. In addition, in an effort
to improve operating efficiencies, some pharmaceutical companies have been reducing their field sales forces in the past several years.
|
|
|
|
We believe that we are well-positioned to provide advertising solutions for pharmaceutical products that are currently being marketed as well as those
in the pipeline for Food and Drug Administration (FDA) approval. Many of these pharmaceutical products are expensive therapies that treat complex conditions affecting relatively small patient populations, for which we believe that our online
services provide an efficient way to reach target audiences.
|
|
|
|
However, notwithstanding our general expectation for increased future demand, we cannot predict the extent or the pace of any shift by pharmaceutical,
biotechnology and medical device companies of their marketing expenditures to online services or to what extent they will choose WebMD to provide such services. In addition, some of our pharmaceutical company customers have experienced patent
expirations for certain of their products in the past several years and some are expected to experience patent expirations over the next several years. In the pharmaceutical industry, patent expirations allow for competition from lower-priced
generic versions of the patented drugs and generally result in the termination of marketing efforts for the drug and, in certain instances, have resulted in reductions in the overall online advertising budgets for some of our customers.
|
|
|
|
Trends Affecting the Pharmaceutical Industry
. The pharmaceutical industry is highly regulated and is subject to changing
political, legislative, regulatory and other influences. The expectations of pharmaceutical companies regarding pending or potential industry developments may affect their budgeting processes and spending plans with respect to services of the types
we provide. Since 2016, there has been increasing scrutiny regarding pricing and profitability for pharmaceutical products, which could lead to additional regulation of such pricing or other changes in how those products are distributed and the
roles played by various industry participants in that distribution, including significant changes in how drugs are procured for government-funded programs, such as Medicare and Medicaid. Our pharmaceutical company customers are assessing the
implications of potential changes for their businesses and we believe that some may, in light of the uncertainty regarding the nature and timing of any such changes, be delaying or deferring deployment of their marketing budgets. We cannot predict
the effect that any resulting changes may have on the marketing plans of our customers in future periods or their future use of our services. For additional discussion, see Healthcare Reform below.
|
|
|
|
Healthcare Reform
. Political, economic, regulatory and enforcement influences are subjecting the healthcare industry in
the U.S. to fundamental changes. There have been, and we expect there will continue to be, legislative and regulatory proposals to change the healthcare system in ways that could impact the various healthcare entities with which we do
business. In particular, we anticipate that the U.S. Executive Branch, U.S. Congress, state legislatures and the private sector will continue to consider and may adopt healthcare policies intended to curb rising healthcare costs, particularly
given the ongoing scrutiny regarding healthcare pricing in the U.S. generally, and prescription drug pricing specifically. Such policies could limit the prices our advertisers and sponsors charge for their healthcare-related
|
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
3
|
products or services, limit the commercial opportunities of our advertisers and sponsors and negatively impact revenues collected by our advertisers and sponsors. However, the nature and
timing of any specific changes is uncertain. Our advertisers and sponsors may, in response to any such changes or the uncertainty regarding potential changes, reduce their expenditures or postpone expenditure decisions, including expenditures for
our services, which could have a material adverse effect on our business.
|
One law with a significant impact
on the healthcare industry is the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (which we refer to as the Affordable Care Act). The Affordable Care Act made extensive changes to
the system of healthcare insurance and benefits in the U.S. While we do not currently anticipate any significant adverse effects as a direct result of the application of the Affordable Care Act, as currently enacted or as it may be amended, to our
business or on our company in its capacity as an employer, we are unable to predict what the indirect impacts will be on WebMDs business through its effects on other healthcare industry participants, including pharmaceutical and medical device
companies that are advertisers and sponsors of
The WebMD Health Network
and employers and health plans that license our
WebMD Health Services
platform. Healthcare industry participants may respond to uncertainties created by the
potential statutory and regulatory changes to the Affordable Care Act by reducing their expenditures or postponing expenditure decisions, including expenditures for our services.
|
|
|
Factors That May Cause Our Advertising and Sponsorship Revenue to Vary from Quarter to Quarter
. Our advertising and
sponsorship revenue may vary significantly from quarter to quarter due to a number of other factors, many of which are outside our control, including economic and regulatory conditions generally and those specifically affecting healthcare industry
participants, as well as the following:
|
|
|
|
The majority of our advertising and sponsorship commitments are for terms of approximately four to twelve months. We have relatively few longer term
advertising and sponsorship commitments.
|
|
|
|
The time between the date of initial contact with a potential advertiser or sponsor regarding a specific program and the execution of a contractual
commitment with the advertiser or sponsor for that program, as well as the additional time period before our services are delivered, may be longer than expected, especially for
medium-sized
and larger
contracts, and may be subject to delays over which we have little or no control, including as a result of budgetary constraints of the advertiser or sponsor or their need for internal approvals, including internal approvals relating to compliance
with the laws and regulations applicable to the marketing of healthcare products. We have experienced, from time to time in the past, a lengthening of this internal review process by pharmaceutical and biotechnology companies, which has resulted in
delays in contracting, as well as delays in recognizing expected revenue under executed contracts, and we cannot predict whether similar delays may occur in future periods.
|
Additional factors that may affect the timing of contracting for specific programs with advertisers and sponsors, or receipt of revenue
under such contracts, include: the timing of FDA approval for new products or for new approved uses for existing products; the timing of FDA approval of generic products that compete with existing brand name products and any increase in the number
or significance of such approvals or of withdrawals of products from the market; consolidation of companies in the pharmaceutical and biotechnology industries; the timing of roll-outs of new or enhanced services for
The WebMD Health Network
;
seasonal factors relating to the prevalence of specific health conditions and other seasonal factors that may affect the timing of promotional campaigns for specific products; and the scheduling of conferences for physicians and other healthcare
professionals.
|
|
|
Other Factors Affecting the Demand for Our Advertising and Sponsorship Services.
Advertiser and sponsor clients of
The
WebMD Health Network
also include companies that provide
over-the-counter
drugs and other healthcare products, food and beverages, beauty products and other consumer
products, particularly for products and services that relate to health, wellness, diet, fitness, lifestyle, safety and
|
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
4
|
illness prevention, as well as clients such as retailers, pharmacies, hospitals, health insurance companies and government agencies. Revenues from these clients are more likely to reflect trends
in general economic conditions than revenues from pharmaceutical, biotechnology and medical device companies. Accordingly, revenues from these clients may be subject to significant
quarter-to-quarter
variations and we may not be able to forecast those variations accurately. Our advertising and sponsorship services are subject to competition from
numerous alternatives, including other Internet sites that focus on health-related content, Internet search engines, social media Internet sites, general interest consumer sites and traditional media. Such competition may result in smaller customer
commitments or pressure to reduce prices, both of which could reduce our revenues and profit margins.
|
|
|
|
Considerations Regarding Traffic to The WebMD Health Network
.
The WebMD Health Network
reached an average of
approximately 193.4 million unique users per month in 2016 and delivered an aggregate of approximately 16.1 billion page views during 2016, representing a 7% decrease in unique users and a 1% decrease in page views compared to the prior year.
Traffic to Medscape properties from physicians averaged approximately 7.9 million physician sessions per month in 2016, an increase of approximately 12% over the prior year.
The WebMD Health Network
reached an average of approximately
179.5 million unique users per month in the fourth quarter of 2016 and delivered an aggregate of approximately 3.63 billion page views during the quarter, representing an 11% decrease in users and a 9% decrease in page views, when compared
to the prior year period. Traffic to Medscape properties from physicians averaged approximately 8.3 million physician sessions per month in the fourth quarter of 2016, an increase of approximately 14% over the prior year period.
|
|
|
|
Starting in the third quarter of 2015, we began to experience slower growth in the overall traffic to
The WebMD Health Network
than in the prior
several years and, in the second half of 2016, the traffic was lower than in the prior year period. In 2016, we saw declines in the number of search referrals we received from Google and this impacted our aggregate traffic. In 2016, 58% of our
traffic came from search engines, compared to 66% in the prior year. We offset much of the decline with growth in direct sources of traffic. In 2016, we grew
non-search-related
traffic by approximately 21%
over the prior year.
|
|
|
|
In the fourth quarter of 2016, our advertising and sponsorship revenue grew by 8% over the prior year period, even though the aggregate number of page
views delivered by
The WebMD Health Network
declined by 9%; and, for all of 2016, our advertising and sponsorship revenue grew by 12% over the prior year, even though the aggregate number of pages views delivered declined by 1%. Overall
traffic to
The WebMD Health Network
is not correlated to our advertising and sponsorship revenue, which can continue to grow even when overall traffic is reduced. We create content on specific topics and program various parts of
The WebMD
Health Network
to build and maintain traffic in the areas most important to both our audience and our advertising and sponsorship clients. For example, the total
Medscape
audience is small compared to the total audience of
The WebMD
Health Network
, but
Medscape
Websites and mobile apps contributed approximately 60% of our advertising and sponsorship revenue in 2016 because of the high value our clients place on being able to reach the
Medscape
audience of
physicians and other healthcare professionals or to reach targeted portions of that
Medscape
audience.
|
|
|
|
Advertising and Sponsorship Revenue from Mobile.
We remain focused on delivering a multi-screen platform that engages
users on their personal computers, tablet devices and smartphones. While we offer mobile as a stand-alone purchase, our advertising and sponsorship clients are generally interested in reaching a targeted audience, regardless of what device the user
is engaging on, and choose multi-platform advertising and sponsorship programs. Of the 3.63 billion page views that we served in the fourth quarter of 2016, 40% was from a U.S. smartphone; 20% was from a US personal computer; 6% was from a U.S.
tablet device; and 34% was international. The percentage of our advertising revenue from programs delivered on mobile devices closely approximated our traffic distribution during the year. This includes stand-alone mobile advertising and sponsorship
revenue as well as the allocation of multi-platform advertising and sponsorship
|
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
5
|
revenue for the portion delivered on smartphone or tablet. With our significant scale in both desktop and mobile audience engagement and our ability to reach targeted portions of our audience, we
believe that
The WebMD Health Network
is well-positioned to meet the needs of our advertising and sponsorship clients.
|
|
|
|
Social Media and Video Initiatives
. Given the increasing prominence of social networks as important platforms for finding
and consuming content, WebMD is working to enable users to more easily discover, share and interact with content from WebMD, not just on our own Websites, but also in other online locations. Some of our initiatives are directed toward the creation
of new content offerings that are tailored for specific social networks and platforms. Our strategy to extend our content and brand beyond
The WebMD Health Network
will, in some cases, allow us to drive people back to WebMDs sites,
where we can monetize that traffic as we do today; in other cases, we may be able to take advantage of new monetization opportunities as we engage with users outside of WebMDs sites. Another key aspect of these initiatives is to create video
content that is both highly engaging and easily sharable across social networks. We are also continuing to develop longer-form video offerings, such as our multi-episode clinical series,
Medscape TV
, which utilizes nationally recognized
thought leaders to discuss important topics in medicine for a physician audience.
|
|
|
|
Trends Affecting Our Services for Employers and Health Plans.
In response to increasing healthcare costs, public and
private sector employers and health plans have been changing benefit plan designs to increase deductibles,
co-payments
and other
out-of-pocket
costs and taking other steps to motivate employees and plan participants to live healthier lives and use healthcare in a cost-effective manner. In
connection with shifting greater responsibility for healthcare costs to employees and plan participants, employers and health plans are making available more health and benefits information and decision- support applications to help their employees
and plan participants make informed decisions about treatment options, health risks, lifestyle choices and healthcare providers. Since lifestyle choices, including choices regarding nutrition, exercise and tobacco use, are key drivers of health and
can dramatically impact risks for acquiring chronic, costly health conditions, employers and health plans seek to reduce demand for healthcare services by focusing on health and wellness initiatives for their employees and plan participants. We
believe that, through our
WebMD Health Services
platform and related coaching and condition management services, we are well-positioned to play a role in this environment. Our services help employees and plan participants make more informed
health and benefit decisions, positively change health behaviors, manage health conditions and lead healthier lives. Our strategy depends, in part, on increasing usage of our services by our employer and health plan clients employees and plan
participants and being able to demonstrate a sufficient return on investment and other benefits for our clients from those services. Increasing such usage requires us to continue to develop new and updated applications, features and services.
|
|
|
|
International.
Physicians and healthcare professionals from around the world access our content in English through
Medscape
. In addition, we publish Spanish, French, Portuguese and German language editions of
Medscape
through which healthcare professionals can access our content in those languages. We have also entered into collaborations with
companies having expertise in a specific country or region to extend our reach. We plan to continue to pursue opportunities to expand the reach of our brands outside the United States, particularly with respect to our healthcare professionals
audience. In certain markets outside the United States, we expect to accomplish this through partnerships or joint ventures with other companies having expertise in the specific country or region, while in other such markets we expect to rely
primarily on our own internal resources.
|
|
|
|
Other Initiatives
. We are pursuing, and intend to continue to identify, new business opportunities where our consumer and
physician audiences and our resources can be leveraged to develop additional products and services. We may pursue initiatives to create new or enhanced revenue streams or, alternatively, to increase audience engagement even when we have not
identified any potential related revenue stream. New business initiatives present risks and challenges that may be different from the ones we have faced in the past. In addition, later events may alter the risks that were evaluated at the time
decisions are made on
|
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
6
|
specific initiatives. Failure to effectively identify and assess new business initiatives and to successfully implement them may adversely affect our company and its prospects.
|
The healthcare industry in the United States and relationships among healthcare payers, providers and
consumers are very complicated. In addition, the Internet and the market for online and mobile services are relatively new and still evolving. Accordingly, there can be no assurance that the trends identified above will continue or that the expected
benefits to our business from our responses to those trends will be achieved. In addition, the market for healthcare information services is highly competitive and not only are our existing competitors seeking to benefit from these same trends, but
the trends may also attract additional competitors.
Background Information on Certain Significant Developments and
Transactions
Exploration of Strategic Alternatives
. On February 16, 2017, we
announced that our Board of Directors, working together with our management team and legal and financial advisors, had commenced a process to explore and evaluate potential strategic alternatives focused on maximizing shareholder value. These
alternatives could include, among other things, the sale of part or all of our company, a merger with another party or other strategic transaction, or continuing to execute on WebMDs business plan. Our Board has not set a timetable for this
process. There can be no assurance that the exploration of strategic alternatives will result in a transaction.
As described
under Convertible Notes below, WebMD has outstanding convertible notes in an aggregate principal amount of $1.06 billion. The effect on the convertible notes of any potential transaction relating to the exploration of strategic
alternatives would depend on the specific timing, structure and terms of such transaction, including (among other things) the type and amount of any consideration received, and may also depend on specific information regarding the other party to a
transaction, including whether and where its securities are publicly traded. Under the respective indentures applicable to each of the convertible notes, a holder of the convertible notes may, depending on the specific terms of any transaction, have
certain rights, such as: the right to require WebMD (or its successor) to repurchase the holders convertibles notes at 100% of their principal amount plus accrued interest; the right to an adjustment of the respective conversion rates
applicable to the convertible notes; and, in connection with a conversion of notes within a specified period of time, the right to receive additional shares of WebMD Common Stock, above what the holder would be entitled to pursuant to the applicable
conversion rate (sometimes referred to as a make-whole adjustment). The convertible notes do not permit their holders to vote, as noteholders, on any potential transaction relating to the exploration of strategic alternatives.
Tender Offers.
On September 9, 2014, we completed a tender offer (which we refer to as the
2014 Tender Offer) for our Common Stock and repurchased 2,000,000 shares at a price of $48.50 per share for a total cost of $97,588, which includes $588 of costs directly attributable to the purchase. On December 15, 2016, we completed a tender
offer (which we refer to as the 2016 Tender Offer and, collectively with the 2014 Tender Offer, as the Tender Offers) for our Common Stock and repurchased 2,000,000 shares at a price of $55.00 per share for a total cost of $110,413, which includes
$413 of costs directly attributable to the purchase. Each of the Tender Offers represented an opportunity for WebMD to return capital to stockholders who elected to tender their shares of WebMD Common Stock, while stockholders who chose not to
participate in the Tender Offers automatically increased their relative percentage interest in our company at no additional cost to them.
Stock Repurchases.
During 2014, we repurchased 3,160,070 shares of our Common Stock at an aggregate cost of $128,748 through our stock repurchase program.
During 2015, we repurchased 688,467 shares of our Common Stock at an aggregate cost of $28,406 through our stock repurchase program.
During 2016, we repurchased 456,218 shares of our Common Stock at an aggregate cost of $23,643 through our stock repurchase
program. On September 16, 2016, our Board of Directors authorized an increase to our stock repurchase program of $35,198. As of December 31, 2016, $45,611 remained available for repurchases under our stock repurchase program.
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
7
Convertible Notes.
On January 11, 2011, we issued
$400,000 aggregate principal amount of 2.50% Convertible Notes due 2018 (which we refer to as the 2.50% Notes) in a private offering. Unless previously converted, the 2.50% Notes will mature on January 31, 2018. Net proceeds from the sale of
the 2.50% Notes were approximately $387,345, after deducting the related offering expenses, of which approximately $100,000 was used by us to repurchase 1,920,490 shares of WebMD Common Stock at a price of $52.07 per share, the last reported sale
price of WebMD Common Stock on January 5, 2011, which repurchase settled on January 11, 2011. Interest on the 2.50% Notes is payable semi-annually on January 31 and July 31 of each year, commencing July 31, 2011. Under the
terms of the 2.50% Notes, as adjusted in December 2016 following completion of the 2016 Tender Offer, holders may surrender their 2.50% Notes for conversion into WebMD Common Stock at a conversion rate of 15.5854 shares of WebMD Common Stock per
thousand dollars principal amount of the 2.50% Notes. This is equivalent to a conversion price of approximately $64.16 per share of Common Stock. In the aggregate, the 2.50% Notes were convertible into 6,234,160 shares of Common Stock as of
December 31, 2016. The conversion rate may be adjusted further under certain circumstances.
On March 14, 2011, we
issued $400,000 aggregate principal amount of 2.25% Convertible Notes due 2016 (which we refer to as the 2.25% Notes) in a private offering. The 2.25% Notes matured on March 31, 2016 and the remaining outstanding principal amount of $102,682
was repaid.
On November 26, 2013, we issued $300,000 aggregate principal amount of 1.50% Convertible Notes due 2020
(which we refer to as the 1.50% Notes) in a private offering. Unless previously converted, the 1.50% Notes will mature on December 1, 2020. Net proceeds from the sale of the 1.50% Notes were approximately $291,823, after deducting the related
offering expenses. Interest on the 1.50% Notes is payable semi-annually on June 1 and December 1 of each year, commencing June 1, 2014. Under the terms of the 1.50% Notes, as adjusted in December 2016 following completion of the 2016
Tender Offer, holders may surrender their 1.50% Notes for conversion into WebMD Common Stock at a conversion rate of 19.0695 shares of Common Stock per thousand dollars principal amount of the 1.50% Notes. This is equivalent to a conversion price of
approximately $52.44 per share of Common Stock. In the aggregate, the 1.50% Notes were convertible into 5,720,850 shares of Common Stock as of December 31, 2016. The conversion rate may be adjusted further under certain circumstances.
On June 1, 2016, we issued $360,000 aggregate principal amount of 2.625% Convertible Notes due 2023 (which we refer to as
the 2.625% Notes) in a private offering. Unless previously converted, the 2.625% Notes will mature on June 15, 2023. Net proceeds from the sale of the 2.625% Notes were approximately $350,394, after deducting the related offering expenses.
Interest on the 2.625% Notes is payable semi-annually on June 15 and December 15 of each year, commencing December 15, 2016. Under the terms of the 2.625% Notes, as adjusted in December 2016 following completion of the 2016 Tender
Offer, holders may surrender their 2.625% Notes for conversion into WebMD Common Stock at a conversion rate of 11.5389 shares of Common Stock per thousand dollars principal amount of the 2.625% Notes. This is equivalent to a conversion price of
approximately $86.66 per share of Common Stock. In the aggregate, the 2.625% Notes were convertible into 4,154,004 shares of Common Stock as of December 31, 2016. The conversion rate may be adjusted further under certain circumstances.
Seasonality
The timing of our revenue is affected by seasonal factors. Our advertising and sponsorship revenue is seasonal, primarily due to the annual spending patterns of our advertising and sponsorship clients.
This portion of our revenue is usually the lowest in the first quarter of each calendar year, and generally increases during each consecutive quarter throughout the year. Additionally, the timing of revenue in relation to our expenses, many of which
do not vary directly with revenue, has an impact on cost of operations, sales and marketing, and general and administrative expenses as a percentage of revenue in each calendar quarter.
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
8
Critical Accounting Estimates and Policies
Critical Accounting Estimates
Our MD&A is based upon our Consolidated Financial Statements and Notes to Consolidated Financial Statements, which were prepared in conformity with U.S. generally accepted accounting principles
(GAAP). The preparation of the Consolidated Financial Statements requires us to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. We base our estimates on historical
experience, current business factors, and various other assumptions that we believe are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses and
the disclosure of contingent assets and liabilities. We are subject to uncertainties such as the impact of future events, economic and political factors, and changes in our business environment; therefore, actual results could differ from these
estimates. Accordingly, the accounting estimates used in the preparation of our financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as our operating environment changes.
Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the
Notes to our Consolidated Financial Statements.
We evaluate our estimates on an ongoing basis, including those related to
revenue recognition, the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and indefinite-lived intangible assets), the amortization period of long-lived assets (excluding goodwill and indefinite-lived
intangible assets), the carrying value, capitalization and amortization of software and Website development costs, the carrying value of investments, the provision for income taxes and related deferred tax accounts, certain accrued expenses,
contingencies, litigation and related legal accruals and the value attributed to employee stock options and other stock-based awards.
Critical Accounting Policies
We believe the following reflects our
critical accounting policies and our more significant judgments and estimates used in the preparation of our Consolidated Financial Statements:
|
|
|
Revenue Recognition.
Revenue from advertising is recognized as advertisements are delivered or as publications are distributed. Revenue
from sponsorship arrangements, content syndication and distribution arrangements and subscriptions to our
WebMD Health Services
platform as well as related health coaching and condition management services is recognized ratably over the term
of the applicable agreement. Revenue from information services is recognized as the underlying data is delivered. Revenue from the sponsorship of CME is recognized over the period that we substantially complete our contractual deliverables as
determined by the applicable agreements.
|
Contracts that contain multiple deliverables are subject to
Accounting Standards Update (ASU) No. 2009-13 Multiple-Deliverable Revenue Arrangements (ASU 2009-13). ASU 2009-13 requires the allocation of revenue to each deliverable of multiple-deliverable revenue arrangements, based on the relative
selling price of each deliverable. It also defines the level of evidence of selling price required to separate deliverables and allows a company to make its best estimate of the selling price of deliverables when more objective evidence of selling
price is not available.
Pursuant to the guidance of ASU 2009-13, when a sales arrangement contains multiple
deliverables, we allocate revenue to each deliverable based on relative selling price. The selling price for a deliverable is based on vendor-specific objective evidence (VSOE) if available, third-party evidence (TPE) if VSOE is not available, or
best estimate of selling price if neither VSOE nor TPE is available. We then recognize revenue on each deliverable in accordance with our revenue recognition policies over the period that delivery occurs. VSOE of selling price is based on the price
charged when the deliverable is sold separately. In determining VSOE, GAAP
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
9
requires that a substantial majority of the selling prices fall within a reasonable range based on historical pricing trends for specific products and services. TPE is based on competitor prices
of similar deliverables when sold separately. We are generally not able to determine TPE of selling price as we are unable to reliably determine what competitors selling prices are for comparable services, combined with the fact that our
services often contain unique features and customizations such that comparable services do not exist. The determination of best estimate of selling price is a judgmental process that considers multiple factors including, but not limited to, recent
selling prices and related discounting practices for each service, market conditions, customer classes, sales channels and other factors.
|
|
|
Long-Lived Assets.
Our long-lived assets consist of property and equipment, goodwill and other intangible assets. Goodwill and other
intangible assets arise from the acquisitions we have made. The amount assigned to intangible assets is subjective and based on fair value using exit price and market participant view, such as discounted cash flow and replacement cost models. Our
long-lived assets, excluding goodwill and indefinite-lived intangible assets, are amortized over their estimated useful lives, which we determine based on the consideration of several factors including the period of time the asset is expected to
remain in service. We evaluate the carrying value and remaining useful lives of long-lived assets, excluding goodwill and indefinite-lived intangible assets, whenever indicators of impairment are present. We evaluate the carrying value of goodwill
and indefinite-lived intangible assets annually, or whenever indicators of impairment are present. We test goodwill for impairment at the reporting unit level only when, after completing a qualitative analysis, it is determined that it is more
likely than not that the fair value of the reporting unit is less than its carrying value. Long-lived assets held for sale are reported at the lower of cost or fair value less cost to sell. There was no impairment of goodwill or indefinite-lived
intangible assets in 2016, 2015 or 2014.
|
|
|
|
Stock-Based Compensation.
Stock-based compensation expense for all share-based payment awards granted is determined based on the grant date fair
value. The grant date fair value for stock options is estimated using the Black-Scholes Option Pricing Model. We recognize these compensation costs net of an estimated forfeiture rate on a straight-line basis over the requisite service period of the
award, which is generally the vesting term of the share-based payment awards. As of December 31, 2016, there was approximately $62,194 of unrecognized stock-based compensation expense (net of estimated forfeitures) related to unvested stock options
and restricted stock held by employees, which is expected to be recognized over a weighted-average period of approximately 2.7 years, related to our stock-based compensation plans. Effective January 1, 2017, we will adopt ASU No. 2016-09, which will
modify the way we account for stock-based compensation. For a more detailed discussion, see Recent Accounting Pronouncements Accounting Pronouncements to Be Adopted in the Future below.
|
|
|
|
Deferred Taxes.
Our deferred tax assets are comprised primarily of net operating loss carryforwards and federal tax credits. These net operating
loss carryforwards and federal tax credits may be used to offset taxable income in future periods, reducing the amount of taxes we might otherwise be required to pay. A significant portion of our net deferred tax assets, including the portion
related to excess tax benefits of stock-based awards, are reserved for by a valuation allowance as required by relevant accounting literature. Management determines the need for a valuation allowance by assessing the probability of realizing
deferred tax assets, taking into consideration factors including historical operating results, expectations of future earnings and taxable income. Management will continue to evaluate the need for a valuation allowance in the future.
|
|
|
|
Tax Contingencies.
Our tax contingencies are recorded to address potential exposures involving tax positions we have taken that could be
challenged by tax authorities. These potential exposures result from applications of various statutes, rules, regulations and interpretations. Our estimates of
|
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
10
|
tax contingencies reflect assumptions and judgments about potential actions by taxing jurisdictions. We believe that these assumptions and judgments are reasonable. However, our accruals may
change in the future due to new developments in each matter and the ultimate resolution of these matters may be greater or less than the amount that we have accrued. Consistent with our historical financial reporting, we have elected to reflect
interest and penalties related to uncertain tax positions as part of the income tax provision.
|
Results of Operations
The following table sets forth our Consolidated Statements of Operations data and expresses that data as a percentage of
revenue for the periods presented:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
|
|
$
|
|
|
% (a)
|
|
|
$
|
|
|
% (a)
|
|
|
$
|
|
|
% (a)
|
|
Revenue
|
|
$
|
705,046
|
|
|
|
100.0
|
|
|
$
|
636,399
|
|
|
|
100.0
|
|
|
$
|
580,449
|
|
|
|
100.0
|
|
Cost of operations
|
|
|
266,654
|
|
|
|
37.8
|
|
|
|
247,311
|
|
|
|
38.9
|
|
|
|
224,094
|
|
|
|
38.6
|
|
Sales and marketing
|
|
|
145,962
|
|
|
|
20.7
|
|
|
|
138,025
|
|
|
|
21.7
|
|
|
|
136,160
|
|
|
|
23.5
|
|
General and administrative
|
|
|
91,141
|
|
|
|
12.9
|
|
|
|
91,580
|
|
|
|
14.4
|
|
|
|
94,119
|
|
|
|
16.2
|
|
Depreciation and amortization
|
|
|
30,792
|
|
|
|
4.4
|
|
|
|
30,521
|
|
|
|
4.8
|
|
|
|
29,811
|
|
|
|
5.1
|
|
Interest income
|
|
|
2,545
|
|
|
|
0.4
|
|
|
|
51
|
|
|
|
|
|
|
|
69
|
|
|
|
|
|
Interest expense
|
|
|
24,496
|
|
|
|
3.5
|
|
|
|
23,123
|
|
|
|
3.6
|
|
|
|
24,686
|
|
|
|
4.3
|
|
Loss on convertible notes
|
|
|
|
|
|
|
|
|
|
|
2,058
|
|
|
|
0.3
|
|
|
|
|
|
|
|
|
|
Gain on investments
|
|
|
|
|
|
|
|
|
|
|
139
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other expense
|
|
|
1,712
|
|
|
|
0.2
|
|
|
|
4,100
|
|
|
|
0.6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before income tax provision
|
|
|
146,834
|
|
|
|
20.8
|
|
|
|
99,871
|
|
|
|
15.7
|
|
|
|
71,648
|
|
|
|
12.3
|
|
Income tax provision
|
|
|
55,530
|
|
|
|
7.9
|
|
|
|
35,847
|
|
|
|
5.6
|
|
|
|
30,707
|
|
|
|
5.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
91,304
|
|
|
|
13.0
|
|
|
|
64,024
|
|
|
|
10.1
|
|
|
|
40,941
|
|
|
|
7.1
|
|
Income from discontinued operations, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,122
|
|
|
|
0.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
91,304
|
|
|
|
13.0
|
|
|
$
|
64,024
|
|
|
|
10.1
|
|
|
$
|
42,063
|
|
|
|
7.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
Amounts may not add due to rounding.
|
Revenue is derived from four groups. The first group is Advertising and Sponsorship Biopharma and Medical Device and consists of advertising and sponsorship revenue from pharmaceutical,
biotechnology and medical device clients relating to prescription pharmaceutical products or other regulated devices or products or for sponsoring educational programs. The second category is Advertising and Sponsorship OTC, CPG and
Other and consists of advertising and sponsorship revenue relating to non-Rx or over-the-counter medications and other healthcare products, food and beverages, beauty products and other consumer products, as well as revenue from clients such
as retailers, pharmacies, hospitals, health insurance companies and government agencies and market research companies where we provide physician recruitment services. The combined revenue of the first two groups is sometimes referred to as
Advertising and Sponsorship revenue. The third group is Health Services (which we previously referred to as Private Portal Services) and consists of revenue from employers and health plans for subscriptions to our
WebMD Health Services
platform and related services, including health coaching and condition management services. The change in the name of this group to Health Services does not reflect any change in the source of the revenue
included in this group from prior periods. The fourth group is Information Services and consists of revenue from the sale of stand-alone information and data products.
Cost of operations consists of salaries and related expenses, and non-cash stock-based compensation expense related to providing and
distributing services and products we provide to customers and costs associated
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
11
with the operation and maintenance of our Websites, mobile applications and our
WebMD Health Services
platform. Cost of operations also consists of editorial and production costs, Website
operations costs, non-capitalized Website development costs, costs we pay to our distribution partners, costs associated with our health and condition management programs and personalized health coaching services, and costs related to the production
and distribution of our publications, including costs related to creating and licensing content, telecommunications, leased properties and printing and distribution.
Sales and marketing expense consists primarily of salaries and related expenses, and non-cash stock-based compensation for account executives, account management and marketing personnel, as well as costs
and expenses for marketing programs, and fees for professional marketing and advertising services.
General and administrative
expense consists primarily of salaries and related expenses and non-cash stock-based compensation expense for administrative, finance, legal, information technology, human resources and executive personnel. Also included in general and
administrative expense are costs of general insurance and professional services expenses.
Our discussions throughout this
MD&A make references to certain non-cash expenses. Our principal non-cash expenses are related to the awards of all share-based payments to employees and non-employee directors, such as grants of employee stock options and restricted stock.
Non-cash stock-based compensation expense is reflected in the same expense captions as the related salary cost of the respective employee.
The following table is a summary of our non-cash expenses included in the respective statements of operations captions.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
Stock-based compensation expense included in:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of operations
|
|
$
|
5,216
|
|
|
$
|
5,217
|
|
|
$
|
5,940
|
|
Sales and marketing
|
|
|
5,942
|
|
|
|
7,290
|
|
|
|
7,221
|
|
General and administrative
|
|
|
18,171
|
|
|
|
21,236
|
|
|
|
19,385
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stock-based compensation expense
|
|
$
|
29,329
|
|
|
$
|
33,743
|
|
|
$
|
32,546
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2016 and 2015
The following discussion is a comparison of our results of operations for the year ended December 31, 2016 to the year ended December 31, 2015.
Revenue.
Our total revenue increased 10.8% to $705,046 in 2016 from $636,399 in 2015. The increase was due to an increase
in advertising and sponsorship revenue of $62,248, an increase in health services revenue of $3,496 and an increase in information services revenue of $2,903. A more detailed discussion regarding changes in these revenue groupings is
included below under Supplemental Financial and Operating Information.
Cost of
Operations.
Cost of operations was $266,654 in 2016, compared to $247,311 in 2015. Our cost of operations represented 37.8% of revenue in 2016, compared to 38.9% of revenue in 2015. Included in cost of operations were non-cash expenses related
to stock-based compensation of $5,216 in 2016, compared to $5,217 in 2015.
Cost of operations, excluding the non-cash
stock-based compensation expense discussed above, was $261,438, or 37.1% of revenue in 2016, compared to $242,094, or 38.0% of revenue in 2015. The increase in absolute dollars in 2016, compared to 2015, was primarily attributable to the increased
expense associated with the delivery of our advertising and sponsorship programs and the operations of our Websites. The decrease as a percentage of revenue, both with and without the non-cash expenses discussed above, for 2016 compared to 2015, was
primarily due to the increase in our revenue of 10.8% without a commensurate increase in cost of operations expenses as many of these expenses are fixed in nature.
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
12
Sales and Marketing
. Sales and marketing expense was $145,962 in 2016, compared to
$138,025 in 2015. Our sales and marketing expense represented 20.7% of revenue in 2016, compared to 21.7% of revenue in 2015. Included in sales and marketing expense were non-cash expenses related to stock-based compensation of $5,942 in 2016,
compared to $7,290 in 2015.
Sales and marketing expense, excluding the non-cash stock-based compensation expense discussed
above, was $140,020, or 19.9% of revenue, in 2016, compared to $130,735, or 20.5% of revenue, in 2015. The decrease as a percentage of revenue, both with and without the non-cash expenses discussed above, for 2016 compared to 2015, was primarily due
to the increase in our revenue of 10.8% without a commensurate increase in our sales and marketing expenses as certain of these expenses are fixed in nature.
General and Administrative.
General and administrative expense was $91,141 in 2016, compared to $91,580 in 2015. Our general and administrative expenses represented 12.9% of revenue in 2016,
compared to 14.4% of revenue in 2015. Included in general and administrative expense was non-cash stock-based compensation expense of $18,171 in 2016, compared to $21,236 in 2015. The decrease in non-cash stock-based compensation expense in 2016,
compared to 2015, was primarily due to the net reversal of $2,394 of stock-based compensation expense recorded in prior periods for stock-based awards that were forfeited by our former Chief Executive Officer and our former Chief Financial Officer
upon their termination of employment in September 2016.
General and administrative expense, excluding the non-cash stock-based
compensation expense discussed above, was $72,970, or 10.3% of revenue, in 2016, compared to $70,344, or 11.1% of revenue in 2015. The decrease in general and administrative expense as a percentage of revenue, both with and without the non-cash
expenses discussed above, for 2016 compared to 2015, was primarily due to the increase in our revenue of 10.8% without a commensurate increase in our general and administrative expenses as many of these expenses are fixed in nature.
Depreciation and Amortization.
Depreciation and amortization expense was $30,792, or 4.4% of revenue in 2016, compared to $30,521,
or 4.8% of revenue in 2015.
Interest Income.
Interest income was $2,545 in 2016 and $51 in 2015. The increase resulted
from higher average rates of return on our investments, investments we made in U.S. Treasury securities in 2016, as well as higher average investment balances during 2016 due to the net proceeds from the issuance of our 2.625% Notes on June 1, 2016.
Interest Expense.
Interest expense was $24,496 in 2016 compared to $23,123 in 2015. These amounts included non-cash
interest expense, related to the amortization of the debt issuance costs for our convertible notes, of $3,906 and $4,172 for 2016 and 2015, respectively. The increase in interest expense for 2016, compared to 2015, was primarily due to the issuance
of $360,000 principal amount of our 2.625% Notes on June 1, 2016.
Loss on Convertible Notes.
During 2015, we recorded a
loss on convertible notes of $2,058 related to the repurchase of $149,550 principal amount of our 2.25% Notes.
Gain on
Investments.
Gain on investments of $139 for 2015 represents the gain from the sale of a portion of our investment in an equity security.
Other Expense.
Other expense of $1,712 for 2016 represents cash severance and related expenses in connection with the termination of employment of our former Chief Executive Officer and our former
Chief Financial Officer in September 2016. Other expense of $4,100 for 2015 represents a charge related to the resolution of a patent infringement claim made against us by International Business Machines Corporation.
Income Tax Provision.
The income tax provision of $55,530 in 2016 related to pre-tax income of $146,834, compared to the income tax
provision of $35,847 in 2015, which related to pre-tax income of $99,871. The income tax provision represented 37.8% and 35.9% of pre-tax income in 2016 and 2015, respectively. The effective tax rate was lower than our statutory tax rate for 2015 as
the income tax provision included a non-cash income tax benefit of $4,724 due to the reversal of an income tax valuation allowance. This benefit reflects a
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
13
correcting adjustment, made in the quarter ended June 30, 2015, to the income tax valuation allowance originally recorded during the year ended December 31, 2012, which increased our net loss in
that year.
Net Income.
Net income was $91,304 in 2016, compared to $64,024 in 2015. As a percentage of revenue, net
income was 13.0% of revenue in 2016, compared to 10.1% of revenue in 2015. The increase as a percentage of revenue was primarily due to the higher revenue in 2016. Many of our expenses are fixed in nature and do not vary directly with revenue and,
accordingly, our net income as a percentage of revenue will fluctuate primarily as a result of changes in our revenue.
2015 and 2014
The following discussion is a comparison of our results of operations for the year ended December 31, 2015 to the year ended December 31, 2014.
Revenue.
Our total revenue increased 9.6% to $636,399 in 2015 from $580,449 in 2014. The increase was due to an increase in
advertising and sponsorship revenue of $45,060, an increase in health services revenue of $7,259 and an increase in information services revenue of $3,631. A more detailed discussion regarding changes in these revenue groupings is included below
under Supplemental Financial and Operating Information.
Cost of Operations.
Cost of operations was
$247,311 in 2015, compared to $224,094 in 2014. Our cost of operations represented 38.9% of revenue in 2015, compared to 38.6% of revenue in 2014. Included in cost of operations were non-cash expenses related to stock-based compensation of $5,217 in
2015, compared to $5,940 in 2014.
Cost of operations, excluding the non-cash stock-based compensation expense discussed above,
was $242,094, or 38.0% of revenue in 2015, compared to $218,154, or 37.6% of revenue in 2014. The increase in absolute dollars in 2015, compared to 2014, was primarily attributable to the increased expense associated with the delivery of our
advertising and sponsorship programs and the operations of our Websites, as well as the increased expense attributable to the timing of certain discretionary services delivered to our health services clients during 2015.
Sales and Marketing
. Sales and marketing expense was $138,025 in 2015, compared to $136,160 in 2014. Our sales and marketing
expense represented 21.7% of revenue in 2015, compared to 23.5% of revenue in 2014. Included in sales and marketing expense were non-cash expenses related to stock-based compensation of $7,290 in 2015, compared to $7,221 in 2014.
Sales and marketing expense, excluding the non-cash expenses discussed above, was $130,735, or 20.5% of revenue, in 2015, compared to
$128,939, or 22.2% of revenue, in 2014. The decrease as a percentage of revenue, both with and without the non-cash expenses discussed above, for 2015 compared to 2014, was primarily due to the increase in our revenue of 9.6% without a commensurate
increase in our sales and marketing expenses as certain of these expenses are fixed in nature.
General and
Administrative.
General and administrative expense was $91,580 in 2015, compared to $94,119 in 2014. Our general and administrative expenses represented 14.4% of revenue in 2015, compared to 16.2% of revenue in 2014. Included in general and
administrative expense was non-cash stock-based compensation expense of $21,236 in 2015, compared to $19,385 in 2014.
General
and administrative expense, excluding the non-cash stock-based compensation expense discussed above, was $70,344, or 11.1% of revenue, in 2015, compared to $74,734, or 12.9% of revenue in 2014. The decrease in general and administrative expense as a
percentage of revenue, both with and without the non-cash expenses discussed above, for 2015 compared to 2014, was primarily due to the increase in our revenue of 9.6% without a commensurate increase in our general and administrative expenses as
many of these expenses are fixed in nature.
Depreciation and Amortization.
Depreciation and amortization expense was
$30,521, or 4.8% of revenue in 2015, compared to $29,811, or 5.1% of revenue in 2014.
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
14
Interest Income.
Interest income was $51 in 2015, which was relatively consistent
when compared to $69 in 2014.
Interest Expense.
Interest expense was $23,123 in 2015 compared to $24,686 in 2014. These
amounts included non-cash interest expense, related to the amortization of the debt issuance costs for our convertible notes, of $4,172 and $4,511 for 2015 and 2014, respectively. The decrease in interest expense for 2015 compared to 2014, was due
to the repurchase of $149,550 principal amount of our 2.25% Notes during 2015.
Loss on Convertible Notes.
During 2015,
we recorded a loss on convertible notes of $2,058 related to the repurchase of $149,550 principal amount of our 2.25% Notes.
Gain on Investments.
Gain on investments of $139 for 2015 represents the gain from the sale of a portion of our investment in an
equity security.
Other Expense.
Other expense of $4,100 for 2015 represents a charge related to the resolution of a
patent infringement claim made against us by International Business Machines Corporation.
Income Tax Provision.
The
income tax provision of $35,847 in 2015 related to pre-tax income of $99,871, compared to the income tax provision of $30,707 in 2014, which related to pre-tax income of $71,648. The income tax provision represented 35.9% and 42.9% of pre-tax income
in 2015 and 2014, respectively. The effective tax rate was lower than our statutory tax rate for 2015 as the income tax provision included a non-cash income tax benefit of $4,724 due to the reversal of an income tax valuation allowance. This benefit
reflects a correcting adjustment, made in the quarter ended June 30, 2015, to the income tax valuation allowance originally recorded during the year ended December 31, 2012, which increased our net loss in that year. The effective tax rate exceeded
our statutory tax rate for 2014 as a result of certain expenses that are non-deductible for income tax purposes.
Income
from Discontinued Operations, Net of Tax.
Income from discontinued operations, net of tax, was $1,122 in 2014. During 2014, we paid $384 in connection with the completion of the remaining tax audits for all periods covered under a tax
indemnification agreement related to our Porex business which was sold in 2009. The remaining balance in the indemnity liability of $1,122 was adjusted through income from discontinued operations during 2014.
Net Income.
Net income was $64,024 in 2015, compared to $42,063 in 2014. As a percentage of revenue, net income was 10.1% of
revenue in 2015, compared to 7.2% of revenue in 2014. The increase as a percentage of revenue was primarily due to the higher revenue in 2015. Many of our expenses are fixed in nature and do not vary directly with revenue and, accordingly, our net
income as a percentage of revenue will fluctuate primarily as a result of changes in our revenue.
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
15
Supplemental Financial and Operating Information
The following table and the discussion that follows present information for groups of revenue based on similar services we provide, as
well as information related to a non-GAAP performance measure that we use to monitor the performance of our business and which we refer to as Earnings before interest, taxes, non-cash and other items or Adjusted EBITDA. Due
to the fact that Adjusted EBITDA is a non-GAAP measure, we have also included a reconciliation from net income to Adjusted EBITDA.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
Advertising and sponsorship
|
|
|
|
|
|
|
|
|
|
|
|
|
Biopharma and medical device
|
|
$
|
428,519
|
|
|
$
|
371,220
|
|
|
$
|
329,329
|
|
OTC, CPG and other
|
|
|
132,754
|
|
|
|
127,805
|
|
|
|
124,636
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
561,273
|
|
|
|
499,025
|
|
|
|
453,965
|
|
Health services
|
|
|
113,937
|
|
|
|
110,441
|
|
|
|
103,182
|
|
Information services
|
|
|
29,836
|
|
|
|
26,933
|
|
|
|
23,302
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
705,046
|
|
|
$
|
636,399
|
|
|
$
|
580,449
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
91,304
|
|
|
$
|
64,024
|
|
|
$
|
40,941
|
|
Income from discontinued operations, net of tax
|
|
|
|
|
|
|
|
|
|
|
1,122
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
91,304
|
|
|
$
|
64,024
|
|
|
$
|
42,063
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest, taxes, non-cash and other items
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations, net of tax
|
|
|
|
|
|
|
|
|
|
|
(1,122
|
)
|
Interest income
|
|
|
(2,545
|
)
|
|
|
(51
|
)
|
|
|
(69
|
)
|
Interest expense
|
|
|
24,496
|
|
|
|
23,123
|
|
|
|
24,686
|
|
Income tax provision
|
|
|
55,530
|
|
|
|
35,847
|
|
|
|
30,707
|
|
Depreciation and amortization
|
|
|
30,792
|
|
|
|
30,521
|
|
|
|
29,811
|
|
Non-cash stock-based compensation
|
|
|
29,329
|
|
|
|
33,743
|
|
|
|
32,546
|
|
Loss on convertible notes
|
|
|
|
|
|
|
2,058
|
|
|
|
|
|
Gain on investments
|
|
|
|
|
|
|
(139
|
)
|
|
|
|
|
Other expense
|
|
|
1,712
|
|
|
|
4,100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before interest, taxes, non-cash and other items
(Adjusted EBITDA)
|
|
$
|
230,618
|
|
|
$
|
193,226
|
|
|
$
|
158,622
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2016 and 2015
The following is a discussion of the results of operations for our groups of revenue and our Adjusted EBITDA for the year ended December 31, 2016, as compared to the year ended December 31, 2015.
Advertising and Sponsorship.
Advertising and sponsorship revenue was $561,273 in 2016, an increase of $62,248, or
12.5%, from 2015. The increase in revenue was primarily attributable to the increased adoption of our advertising and sponsorship offerings by biopharma and medical device companies, as well as our OTC, CPG and other customers, which represented
increases of $57,299 and $4,949, respectively. In general, pricing remained relatively stable for our advertising and sponsorship offerings and was not a significant source of the revenue increase. For a more detailed discussion, see
Introduction Background Information on Certain Trends and Developments Affecting Our Business.
Health
Services.
Health services revenue was $113,937 in 2016, an increase of $3,496, or 3.2%, from 2015. This slight increase in revenue was primarily attributable to an increase in the services provided. In general,
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
16
pricing remained relatively stable for our
WebMD Health Services
platform and related services and was not a significant source of the revenue increase. The number of customers using our
WebMD Health Services
platform at December 31, 2016 was 84, compared to 91 customers using our
WebMD Health Services
platform at December 31, 2015.
Information Services.
Information services revenue was $29,836 in 2016, an increase of $2,903, or 10.8%, from 2015. This increase was attributable to an increase in the rates charged for our
information services and an increase in the number of customers licensing our information services.
Adjusted EBITDA.
Adjusted EBITDA increased to $230,618 in 2016 compared to $193,226 in 2015. As a percentage of revenue, Adjusted EBITDA was 32.7% of revenue in 2016, compared to 30.4% of revenue in 2015. This increase as a percentage of revenue was primarily due to
higher revenue in 2016. Many of our expenses are fixed in nature and do not vary directly with revenue, and accordingly, our Adjusted EBITDA as a percentage of revenue has fluctuated primarily as a result of changes in our revenue.
2015 and 2014
The following is a discussion of the results of operations for our groups of revenue and our Adjusted EBITDA for the year ended December 31, 2015, as compared to the year ended December 31, 2014.
Advertising and Sponsorship.
Advertising and sponsorship revenue was $499,025 in 2015, an increase of $45,060, or
9.9%, from 2014. The increase in revenue was primarily attributable to the increased adoption of our advertising and sponsorship offerings by biopharma and medical device companies as well as our OTC, CPG and other customers, which represented
increases of $41,891 and $3,169, respectively. In general, pricing remained relatively stable for our advertising and sponsorship offerings and was not a significant source of the revenue increase.
Health Services.
Health services revenue was $110,441 in 2015, an increase of $7,259, or 7.0%, from 2014. This increase was
primarily attributable to an increase in the services delivered during 2015 for certain client programs. In general, pricing remained relatively stable for our
WebMD Health Services
platform and related services and was not a significant
source of the revenue increase. The number of customers using our
WebMD Health Services
platform at December 31, 2015 was 91, compared to 102 customers using our
WebMD Health Services
platform at December 31, 2014.
Information Services.
Information services revenue was $26,933 in 2015, an increase of $3,631, or 15.6%, from 2014. This increase
was attributable to an increase in the rates charged to our customers for our information services and an increase in the number of customers licensing our information services.
Adjusted EBITDA.
Adjusted EBITDA increased to $193,226 in 2015 compared to $158,622 in 2014. As a percentage of revenue, Adjusted
EBITDA was 30.4% of revenue in 2015, compared to 27.3% of revenue in 2014. This increase as a percentage of revenue was primarily due to higher revenue in 2015. Many of our expenses are fixed in nature and do not vary directly with revenue, and
accordingly, our Adjusted EBITDA as a percentage of revenue has fluctuated primarily as a result of changes in our revenue.
*
* * *
Explanatory Note Regarding Adjusted EBITDA. Adjusted EBITDA is a non-GAAP financial measure and should be viewed as
supplemental to, and not as an alternative for, income (loss) from continuing operations or net income (loss) calculated in accordance with GAAP. Our management uses Adjusted EBITDA as an additional measure of performance for
purposes of business decision-making, including developing budgets, managing expenditures, and evaluating potential acquisitions or divestitures. Period-to-period comparisons of
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
17
Adjusted EBITDA help our management identify additional trends in financial results that may not be shown solely by period-to-period comparisons of income (loss) from continuing operations or net
income (loss). In addition, we may use Adjusted EBITDA in the incentive compensation programs applicable to some of our employees in order to evaluate our companys performance. We believe that the presentation of Adjusted EBITDA is useful to
investors in their analysis of our results for reasons similar to the reasons why our management finds it useful and because it helps facilitate investor understanding of decisions made by our management in light of the performance metrics used in
making those decisions. In addition, we believe that providing Adjusted EBITDA, together with a reconciliation of income (loss) from continuing operations or net income (loss) to Adjusted EBITDA helps investors make comparisons between us and other
companies that may have different capital structures, different effective income tax rates and tax attributes, different capitalized asset values and/or different forms of employee compensation. Please see the Explanation of Non-GAAP Financial
Measures included as Annex G below for additional background information regarding our use of Adjusted EBITDA. Annex G is incorporated in this MD&A by reference.
Liquidity and Capital Resources
Cash Flows
As of December 31, 2016, we had $492,424 of cash and cash equivalents, investments of $498,500 and working capital of $1,001,765. Our
operating cash flows are affected by the timing of each period end in relation to items such as payments received from customers, payments made to vendors, the timing of interest payments related to our convertible notes and internal payroll and
billing cycles, as well as the seasonality within our business. Accordingly, our working capital, and its impact on cash flow from operations, can fluctuate materially from period to period.
Cash provided by operating activities in 2016 was $161,153, which related to net income of $91,304, adjusted for a non-cash income tax
provision of $1,083 related to deferred income taxes, and other non-cash expenses of $64,027, which include depreciation and amortization expense, non-cash interest expense and non-cash stock-based compensation expense. Additionally, changes in
operating assets and liabilities increased operating cash flow by $4,739, primarily due to a decrease in prepaid expenses and other assets of $4,039, an increase in accrued expenses and other long-term liabilities of $3,246 and an increase in
deferred revenue of $2,595, which were offset by an increase in accounts receivable of $5,141.
Cash provided by operating
activities in 2015 was $107,563, which related to net income of $64,024, adjusted for a loss on convertible notes of $2,058, a gain on investments of $139, a non-cash income tax benefit of $7,713 related to deferred income taxes, and other non-cash
expenses of $68,436, which include depreciation and amortization expense, non-cash interest expense and non-cash stock-based compensation expense. Additionally, changes in operating assets and liabilities decreased operating cash flow by $19,103,
primarily due to an increase in accounts receivable of $37,507 and an increase in prepaid expenses and other assets of $4,132, which were offset by an increase in accrued expenses and other long-term liabilities of $9,606 and an increase in deferred
revenue of $12,930.
Cash used in investing activities was $525,518 in 2016, compared to $48,233 in 2015. In 2016, we used
$1,446,410 in cash to purchase short-term investments. During 2016 and 2015, we received $948,078 and $139, respectively, in cash proceeds from the maturities and sales of our investments. We used $29,785 in connection with purchases of property and
equipment in 2016, compared to $48,372 of property and equipment purchases in 2015, which included approximately $8,000 and $28,000, respectively, related to the relocation and expansion of our corporate offices. Also included in investing
activities in 2016 was the receipt of $2,599 related to the partial redemption of a cost-method investment.
Cash provided by
financing activities was $215,624 in 2016, compared to cash used in financing activities of $124,941 in 2015. Cash provided by financing activities in 2016 primarily related to the issuance of $360,000
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
18
principal amount of our 2.625% Notes for which we received $350,394 in net proceeds, after deducting the related issuance costs. In 2016, we used cash of $102,682 to repay our 2.25% Notes which
matured on March 31, 2016 and we used cash of $151,038 in 2015 to repurchase a portion of our 2.25% Notes. During 2016, we used cash of $110,413 to repurchase shares of our Common Stock through the 2016 Tender Offer. We used cash of $23,643 in 2016
and $28,406 in 2015 to repurchase shares of our Common Stock through our authorized stock repurchase program. During 2016 and 2015, we received cash proceeds of $65,309 and $21,939, respectively, related to the exercise of stock options, and used
cash of $17,599 and $6,438, respectively, for withholding taxes due on stock-based awards. Also included in cash flows from financing activities in 2016 and 2015 were excess tax benefits on stock-based awards of $54,258 and $39,002, respectively.
Contractual Obligations and Commitments
The following table summarizes our principal commitments as of December 31, 2016 for future specified contractual obligations, as well as
the estimated timing of the cash payments associated with these obligations. Managements estimates of the timing of future cash flows are largely based on historical experience, and accordingly, actual timing of cash flows may vary from these
estimates.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
Less Than
1 Year
|
|
|
2-3 Years
|
|
|
4-5 Years
|
|
|
More Than
5 Years
|
|
Leases (a)
|
|
$
|
92,773
|
|
|
$
|
15,507
|
|
|
$
|
29,159
|
|
|
$
|
27,801
|
|
|
$
|
20,306
|
|
2.50% Notes due 2018 (b)
|
|
$
|
410,833
|
|
|
$
|
10,000
|
|
|
$
|
400,833
|
|
|
$
|
|
|
|
$
|
|
|
1.50% Notes due 2020 (b)
|
|
$
|
317,625
|
|
|
$
|
4,500
|
|
|
$
|
9,000
|
|
|
$
|
304,125
|
|
|
$
|
|
|
2.625% Notes due 2023 (b)
|
|
$
|
421,031
|
|
|
$
|
9,450
|
|
|
$
|
18,900
|
|
|
$
|
18,900
|
|
|
$
|
373,781
|
|
(a)
|
Represents leases of office facilities and data centers
|
(b)
|
Amounts include contractual interest payments
|
The above table excludes $15,516 of uncertain tax positions, including interest and penalties, as we are unable to reasonably estimate the timing of the settlement of these items. See Note 11,
Income Taxes located in the Notes to Consolidated Financial Statements included in Annex A above.
Outlook
on Future Liquidity
As of December 31, 2016, we had $991 million in investments and cash and cash equivalents.
Potential future uses of cash include repurchases of our Common Stock, payments related to the January 2018 maturity of our
2.50% Notes and our anticipated 2017 capital expenditure requirements. Our capital expenditure requirements for 2017, which we estimate to be approximately $25 million to $30 million, primarily relate to improvements that will be deployed across our
Websites in order to enable us to service future growth in unique users and page views, as well as to create new sponsorship areas for our customers, and to improve the systems used to provide our
WebMD Health Services
platform.
Based on our plans and expectations, we believe that our available cash resources and future cash flow from operations will provide
sufficient cash resources to meet the cash commitments of our convertible notes and to fund our currently anticipated working capital and capital expenditure requirements, for at least the next 24 months. Our future liquidity and capital
requirements will depend upon numerous factors, including retention of customers at current volume and revenue levels, implementation of new or updated application and service offerings, competing technological and market developments and potential
future acquisitions. In addition, our ability to generate cash flow is subject to numerous factors beyond our control, including general economic, regulatory and other matters affecting us and our customers. We plan to continue to enhance our online
services and to continue to invest in acquisitions, strategic relationships, facilities and technological infrastructure and product development. We intend to grow each of our existing businesses and enter into complementary ones
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
19
through both internal investments and acquisitions. We may need to raise additional funds to support expansion, develop new or enhanced applications and services, respond to competitive
pressures, acquire complementary businesses or technologies or take advantage of unanticipated opportunities. If required, we may raise such additional funds through public or private debt or equity financing, strategic relationships or other
arrangements. We cannot assure that such financing will be available on acceptable terms, if at all, or that such financing will not be dilutive to our stockholders. Future indebtedness may impose various restrictions and covenants on us that could
limit our ability to respond to market conditions, to provide for unanticipated capital investments or to take advantage of business opportunities.
Off-Balance Sheet Arrangements
We have no material off-balance
sheet arrangements.
Recent Accounting Pronouncements
Accounting Pronouncements Adopted During 2016
In June 2014, the
Financial Accounting Standards Board (FASB) issued ASU No. 2014-12,
Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved
after the Requisite Service Period,
which requires
that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. The revised guidance was effective for us beginning in the quarter ended March 31, 2016. The adoption
of the revised guidance did not have any impact on our consolidated financial statements as we did not have any share-based awards with performance targets outstanding at the time of the adoption.
In April 2015, the FASB issued ASU No. 2015-03,
Interest Imputation of Interest (Subtopic 835-30): Simplifying the Presentation
of Debt Issuance Costs
, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The
revised guidance was effective for us, on a retrospective basis, beginning in the quarter ended March 31, 2016. The adoption of the revised guidance only affected the balance sheet classification of our debt issuance costs.
In April 2015, the FASB issued ASU No. 2015-05,
Intangibles Goodwill and Other
Internal-Use Software (Subtopic
350-40): Customers Accounting for Fees Paid in a Cloud Computing Arrangement
, which provides guidance in determining whether a cloud computing arrangement includes a software license. If it is determined that a cloud computing arrangement
does include a software license, the software element should be accounted for consistent with the acquisition of other software licenses. If the arrangement does not include a software license, it should be accounted for as a service contract. The
revised guidance was effective for us beginning in the quarter ended March 31, 2016 and will be applied prospectively to all arrangements entered into or materially modified after the effective date. The adoption of this guidance did not have an
impact on our consolidated financial statements.
In September 2015, the FASB issued ASU No. 2015-16,
Business Combinations
(Topic 805): Simplifying the Accounting for Measurement-Period Adjustments
, which requires that the acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the
adjustment amounts are determined, rather than retrospectively adjusting previously reported amounts. The revised guidance was effective for us beginning in the quarter ended March 31, 2016. The adoption of this guidance did not have an impact on
our consolidated financial statements.
In November 2015, the FASB issued ASU No. 2015-17,
Income Taxes (Topic 740):
Balance Sheet Classification of Deferred Taxes
, which requires that all deferred tax assets and liabilities, along with any related
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
20
valuation allowance, be classified as noncurrent in the consolidated balance sheet instead of separating deferred taxes into current and noncurrent. The revised guidance was required to be
effective for us beginning in the quarter ending March 31, 2017 and could be applied either prospectively to all deferred tax assets and liabilities or retrospectively to all periods presented. Early adoption was permitted and we elected to early
adopt the guidance in the quarter ended March 31, 2016 on a retrospective basis. The adoption of the revised guidance only affected the balance sheet classification of our deferred tax assets and liabilities, and the related valuation allowance.
Accounting Pronouncements to Be Adopted in the Future
In May 2014, the FASB issued ASU No. 2014-09,
Revenue from Contracts with Customers (Topic 606)
, to achieve a consistent
application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under GAAP. Under the new model, recognition of revenue occurs when a customer obtains control of promised goods or services
in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the revised guidance requires that reporting companies disclose the nature, amount, timing, and uncertainty
of revenue and cash flows arising from contracts with customers. In August 2015, the FASB issued ASU No. 2015-14,
Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,
which delays the effective date of ASU No.
2014-09 by one year. As a result, the revised guidance is effective for us beginning in the quarter ending March 31, 2018. Early adoption is permitted, but not before the original effective date of the guidance. The revised guidance is required to
be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. In March, April, May and December 2016, the FASB issued
ASU No. 2016-08,
Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net)
, ASU No. 2016-10,
Revenue from Contracts with Customers (Topic 606): Identifying Performance
Obligations and Licensing
, ASU No.
2016-12,
Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients
, and ASU No.
2016-20,
Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers
, respectively. ASU No. 2016-08, ASU No. 2016-10, ASU No.
2016-12
and ASU No.
2016-20
provide supplemental adoption guidance and clarification to ASU No. 2014-09, and must be adopted concurrently with the adoption of ASU
No. 2014-09. We expect that we will adopt the revised guidance under the modified retrospective method; however, we have not yet determined the impact the revised guidance will have on our consolidated financial statements in periods following
adoption.
In January 2016, the FASB issued ASU No. 2016-01,
Financial Instruments Overall (Subtopic 825-10):
Recognition and Measurement of Financial Assets and Financial Liabilities
, which revises the classification and measurement of investments in certain equity investments and the presentation of certain fair value changes for certain financial
liabilities measured at fair value. ASU No. 2016-01 also requires the change in fair value of many equity investments to be recognized in net income. The revised guidance is effective for us beginning in the quarter ending March 31, 2018. We have
not yet determined the impact that the revised guidance will have on our consolidated financial statements.
In February 2016,
the FASB issued ASU No. 2016-02,
Leases (Topic 842)
, which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessees obligation
to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessees right to use, or control the use of, a specified asset for the lease term. The revised
guidance must be applied on a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The revised guidance is effective for us
beginning in the quarter ending March 31, 2019. We have not yet determined the impact the revised guidance will have on our consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09,
Compensation Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting
, which simplifies several aspects of the
accounting
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
21
for share-based payment award transactions, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash
flows. The revised guidance is effective for us beginning in the quarter ending March 31, 2017. When we adopt ASU No. 2016-09 in the quarter ending March 31, 2017, excess tax benefits and deficiencies generated when stock awards vest or settle will
no longer be recognized in equity but will instead be recognized as a reduction or increase to the income tax provision, cash flows related to excess tax benefits will be required to be presented as an operating activity rather than a financing
activity in the statement of cash flows, and net operating losses related to excess tax benefits will be recognized on the balance sheet. Additionally, we also expect to account for forfeitures of stock awards as they occur, rather than estimate
expected forfeitures.
In June 2016, the FASB issued ASU No. 2016-13,
Financial Instruments Credit Losses (Topic
326): Measurement of Credit Losses on Financial Instruments
, which revises the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. The revised guidance is effective for us beginning
in the quarter ending March 31, 2020 and must be adopted using a modified retrospective transition approach. We have not yet determined the impact the revised guidance will have on our consolidated financial statements.
In August 2016, the FASB issued ASU No. 2016-15,
Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash
Payments
, which clarifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The revised guidance is effective for us beginning in the quarter ending March 31, 2018, with early adoption
permitted, and must be applied retrospectively to all periods presented. We have not yet determined the impact the revised guidance will have on our consolidated financial statements.
In November 2016, the FASB issued ASU No. 2016-18,
Statement of Cash Flows (Topic 230): Restricted Cash
, which requires that
restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning of period and end of period total amounts shown on the statement of cash flows. The revised guidance must be applied using a
retrospective transition method to each period presented and is effective for us beginning in the quarter ending March 31, 2018. We have not yet determined the impact the revised guidance will have on our consolidated financial statements.
In January 2017, the FASB issued ASU No. 2017-01,
Business Combinations (Topic 805): Clarifying the Definition of a
Business
, which clarifies the definition of a business by providing a more robust framework to use in determining when a set of assets and activities is a business. The revised guidance is effective for us beginning in the quarter ending March
31, 2018. We have not yet determined the impact the revised guidance will have on our consolidated financial statements.
In
January 2017, the FASB issued ASU No. 2017-04,
Intangibles Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment
, which eliminates step 2 from the goodwill impairment test. The revised guidance must be applied on
a prospective basis and is effective for us beginning in the quarter ending March 31, 2020, with early adoption permitted on January 1, 2017. We have not yet determined the impact the revised guidance will have on our consolidated financial
statements.
W
EB
MD 2016 A
NNUAL
R
EPORT
MD&A A
NNEX
A
NNEX
C P
AGE
22
ANNEX D
WEBMD HEALTH CORP. 2016 ANNUAL REPORT
PERFORMANCE GRAPH AND OTHER MARKET
INFORMATION
Performance Graph
The following graph compares the cumulative total stockholder return on WebMD Common Stock with the comparable cumulative return of:
|
|
|
the NASDAQ Composite Index;
|
|
|
|
the Research Data Group (RDG) Internet Composite Index; and
|
|
|
|
a customized peer group of 15 companies that includes Advisory Board Co, Angies List Inc., Athenahealth Inc., Bankrate Inc., Blucora Inc., Costar
Group Inc., DHI Group Inc., E. W. Scripps Co., Media General Inc., Meredith Corp, Nexstar Broadcasting Group Inc., Pandora Media Inc., Tivity Health, Inc., Yelp Inc. and Zillow Group Inc.
|
The companies in our peer group are publicly-traded Internet, publishing, media and healthcare information services companies that share
business model characteristics with WebMD. These companies are also used by the Compensation Committee for purposes of compensation benchmarking. The graph assumes that, on December 31, 2011, $100 was invested in WebMD Common Stock, in each
index and in the peer group and tracks the value of those investments (including reinvestment of dividends) through December 31, 2016. The stock price performance on the following graph is not necessarily indicative of future stock price
performance.
W
EB
MD 2016 A
NNUAL
R
EPORT
M
ARKET
I
NFORMATION
A
NNEX
A
NNEX
D
P
AGE
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12/11
|
|
|
12/12
|
|
|
12/13
|
|
|
12/14
|
|
|
12/15
|
|
|
12/16
|
|
WebMD Health Corp.
|
|
|
100.00
|
|
|
|
38.19
|
|
|
|
105.19
|
|
|
|
105.33
|
|
|
|
128.63
|
|
|
|
132.01
|
|
NASDAQ Composite
|
|
|
100.00
|
|
|
|
116.41
|
|
|
|
165.47
|
|
|
|
188.69
|
|
|
|
200.32
|
|
|
|
216.54
|
|
RDG Internet Composite
|
|
|
100.00
|
|
|
|
119.34
|
|
|
|
195.83
|
|
|
|
192.42
|
|
|
|
264.96
|
|
|
|
277.56
|
|
Peer Group
|
|
|
100.00
|
|
|
|
109.96
|
|
|
|
217.96
|
|
|
|
195.49
|
|
|
|
181.80
|
|
|
|
176.00
|
|
The Performance Graph shall not be deemed filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the Exchange Act), or incorporated by reference into any filing of WebMD under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent we specifically incorporate it by reference into any such
filing.
Market Information
Our Common Stock trades on the Nasdaq Global Select Market. The high and low prices of our Common Stock for each quarterly period during the last two fiscal years are as follows:
|
|
|
|
|
|
|
|
|
|
|
High
|
|
|
Low
|
|
2015
|
|
|
|
|
|
|
|
|
First quarter
|
|
$
|
44.94
|
|
|
$
|
37.62
|
|
Second quarter
|
|
|
48.91
|
|
|
|
41.53
|
|
Third quarter
|
|
|
46.28
|
|
|
|
37.57
|
|
Fourth quarter
|
|
|
49.88
|
|
|
|
39.67
|
|
2016
|
|
|
|
|
|
|
|
|
First quarter
|
|
$
|
63.14
|
|
|
$
|
45.46
|
|
Second quarter
|
|
|
67.55
|
|
|
|
56.41
|
|
Third quarter
|
|
|
62.45
|
|
|
|
48.18
|
|
Fourth quarter
|
|
|
54.99
|
|
|
|
48.26
|
|
The market price of our Common Stock has fluctuated in the past and is likely to fluctuate in the future.
Changes in the market price of our Common Stock may result from, among other things:
|
|
|
quarter-to-quarter
variations in operating results or other financial
or operational metrics;
|
|
|
|
operating results or other financial or operational metrics being different from our previously announced guidance or from analysts estimates or
opinions;
|
|
|
|
changes in analysts or financial commentators earnings estimates, ratings or opinions;
|
|
|
|
changes in financial guidance or other forward-looking information;
|
|
|
|
new products, services or pricing policies introduced by us or our competitors;
|
|
|
|
acquisitions by us or our competitors;
|
|
|
|
developments in existing customer relationships;
|
|
|
|
actual or perceived changes in our business strategy;
|
|
|
|
developments in new or pending litigation and claims;
|
|
|
|
sales of large amounts of our Common Stock;
|
|
|
|
changes in general business or regulatory conditions affecting the healthcare, information technology or Internet industries;
|
|
|
|
changes in general economic conditions; and
|
|
|
|
fluctuations in the securities markets in general.
|
W
EB
MD 2016 A
NNUAL
R
EPORT
M
ARKET
I
NFORMATION
A
NNEX
A
NNEX
D
P
AGE
2
In addition, the market prices of our Common Stock and of the stock of other Internet-related companies have
experienced large fluctuations, sometimes quite rapidly. These fluctuations often may be unrelated to or disproportionate to operating performance.
Dividends
We have never declared or paid any cash dividends on our Common
Stock, and we do not anticipate paying cash dividends in the foreseeable future.
W
EB
MD 2016 A
NNUAL
R
EPORT
M
ARKET
I
NFORMATION
A
NNEX
A
NNEX
D
P
AGE
3
ANNEX E
WEBMD HEALTH CORP. 2016 ANNUAL REPORT
QUANTITATIVE AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISK
Interest Rate Sensitivity
The primary objective of our investment activities is to preserve principal and maintain adequate liquidity.
The value of our cash and cash equivalents, which was $492.4 million at December 31, 2016, is not subject to changes in interest rates.
The value of our investments, which was $498.5 million at December 31, 2016, is subject to changes in interest rates; however, due to the short-term nature of these investments, any changes are not expected to be material.
The 2.50% Notes, the 1.50% Notes and the 2.625% Notes have fixed interest rates; therefore, changes in interest rates will not impact our
results of operations or financial position.
Exchange Rate Sensitivity
Substantially all of our revenues and expenses are denominated in United States dollars; however, a portion of the revenue from our
international operations was contracted in foreign currencies. The impact of changes in exchange rates for each of the three years in the period ended December 31, 2016 has been reflected in our results of operations and was not material, and future
changes in exchange rates are not expected to have a material impact on our results of operations or financial position.
ANNEX F
WEBMD HEALTH CORP. 2016 ANNUAL REPORT
RISK FACTORS
This Annex F includes the risk factors from Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2016 and
describes circumstances or events that could have a negative effect on our financial results or operations or that could change, for the worse, existing trends in some or all of our businesses. The occurrence of one or more of the circumstances or
events described below could have a material adverse effect on our financial condition, results of operations and cash flows or on the trading prices of our Common Stock and Convertible Notes or of securities that we may issue in the future. The
risks and uncertainties described in this Annex F are not the only ones facing us. Additional risks and uncertainties that are not currently known to us, or that we currently believe are immaterial, may also adversely affect our business and
operations.
Risks Related to Our Operations and the Healthcare Content We Provide
If we are unable to provide content and services that attract users to The WebMD Health Network, our advertising and sponsorship
revenue could be reduced
Users of
The WebMD Health Network
have numerous other online and offline sources of
healthcare information and related services. Our ability to compete for user traffic on
The WebMD Health Network
depends upon our ability to make available a variety of health, wellness and medical content, decision-support applications and
other services that meet the needs of a variety of types of users, including consumers, physicians and other healthcare professionals, with a variety of reasons for seeking information. Our ability to do so depends, in turn, on:
|
|
|
our ability to hire and retain qualified authors, journalists and independent writers and healthcare professionals;
|
|
|
|
our ability to license quality content from third parties; and
|
|
|
|
our ability to monitor and respond to increases and decreases in user interest in specific topics.
|
If consumers and healthcare professionals do not perceive our content, applications and tools to be useful, reliable and trustworthy, we
may not be able to attract or retain users or otherwise maintain or increase the frequency and duration of their engagement with our health information services. We cannot assure you that we will be able to continue to develop or acquire needed
content, applications and tools at a reasonable cost. In addition, since consumers may be attracted to
The WebMD Health Network
as a result of a specific condition or for a specific purpose, it is difficult for us to predict the rate at which
they will return. Because we generate revenue by, among other things, selling sponsorships of specific pages, sections or events on
The WebMD Health Network
, a decline in user traffic levels or a reduction in the number of pages viewed by
users could cause our advertising and sponsorship revenue to decrease and could have a material adverse effect on our results of operations. However, overall traffic to
The WebMD Health Network
does not have a direct correlation to our
advertising and sponsorship revenue, which can continue to grow even if overall traffic remains constant or goes down. Our ability to generate advertising and sponsorship revenue depends primarily on our ability to create content on specific topics
and to program various parts of
The WebMD Health Network
to build and maintain traffic in areas most important to both our audience and our advertising and sponsorship clients. If we are unable to do that, our advertising and sponsorship
revenue could decrease even if our overall traffic remains the same or increases.
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
1
A significant portion of the traffic to The WebMD Health Network is directed to us
through algorithmic search results on Internet search engines and, if we are listed less prominently in search result listings or our traffic from search is otherwise reduced, our business and operating results could be harmed
A significant portion of the traffic to
The WebMD Health Network
is directed to us through the algorithmic search results on
Internet search engines. In addition to providing quality content and tools, we seek to produce and deliver our content and tools in ways that will cause them to rank well in algorithmic search engine results, which makes it more likely that search
engine users will visit our Websites. This is commonly referred to as search engine optimization, or SEO. However, there can be no assurance that our SEO efforts will succeed in improving the ranking of our content or, even if they do result in such
improvement, that the improved ranking will result in increased numbers of users and page views for our Websites. In addition, search engines frequently change the criteria that determine site rankings in their search results or make other changes
and our SEO efforts may not be successful if we do not respond to those changes appropriately and on a timely basis. Search engine providers may also prioritize search results generated by certain types of queries, including health-related queries,
based on criteria they select, which could, in some circumstances, reduce the ranking that would otherwise be provided to our Websites and increase the ranking of other sites. If we are unable to respond effectively to changes made by search engine
providers in their algorithms and other processes or to respond effectively to other factors and challenges that may impair our ability to attract traffic through search, a substantial decrease in traffic to
The WebMD Health Network
could
occur, which could cause our revenue to decrease and could have a material adverse effect on our results of operations. We cannot predict if, or how long, efforts to improve SEO or otherwise increase traffic may take to mitigate any such declines.
Search engine providers also typically display, together with algorithmic search results, content and links that may divert
traffic from the pages referenced in the algorithmic search results, including: advertisements that are presented with the algorithmic search results for which the search engine provider receives compensation (sometimes referred to as paid search
results); and health-related or other content and links that the search engine provider selects and displays in response to the specific search queries in a format determined by the search engine provider. Accordingly, even if we rank highly in
algorithmic search results, traffic to our Websites may be reduced as a result of paid search results and other content included on the search results page generated by a search query. We cannot control the amount, quality or presentation of such
paid search results and other content and, accordingly, we cannot predict any reductions in our traffic that may occur from time to time as search engine providers make changes in their policies and procedures regarding paid search results or
regarding any other content they provide. In addition, to the extent that there is a reduction in the total volume of health-related searches on Internet search engines, traffic to
The WebMD Health Network
could also be reduced and we may
have little or no ability to take steps to mitigate the effect on our traffic. In addition, we have experienced in the past, and may experience in the future, declines in traffic to
The WebMD Health Network
from search for reasons that we are
unable to identify. Any resulting reduction in our traffic for any of the reasons described above, if significant, could cause our revenue to decrease and could have a material adverse effect on our results of operations.
If we fail to maintain successful monetization strategies for smartphone traffic, our financial results could be adversely affected
The number of people, including the number of physicians and other healthcare professionals, who access online content
and services through smartphones has increased rapidly and is expected to continue to increase. Accordingly, the portion of our page views from smartphones has increased rapidly and is expected to continue to increase. The monetization of smartphone
page views can be challenging because of the smaller screen size. If we are unable to maintain successful monetization strategies for smartphone traffic, our financial results could be negatively affected.
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
2
Our initiative to provide content in online locations outside The WebMD Health Network
may not increase our audience and, even if it does, may not be profitable
We are in the process of working to enable
users to more easily discover, share and interact with content from WebMD not just on our Websites but also in other online locations and, in support of this initiative, we are creating new content offerings tailored for specific social networks and
platforms and building our capabilities to create video content. If we are not successful in creating content offerings that support this initiative, our ability to compete for advertising and sponsorship revenue may be reduced. Even if we are
successful in creating such content offerings and users respond favorably, there can be no assurance that we will be able to adequately monetize audience usage of such content or to drive sufficient traffic to our own Websites to make this
initiative profitable.
We face significant competition for our healthcare information products and services
The markets for healthcare information products and services are intensely competitive, continually evolving and, in
some cases, subject to rapid change.
|
|
|
The WebMD Health Network
faces competition from numerous other companies, both in attracting users and in generating revenue from advertisers
and sponsors. We compete for users with Websites and mobile applications that provide health-related information, including both commercial ones and
not-for-profit
ones.
We compete for advertisers and sponsors with: health-related Websites and mobile applications; general interest consumer Websites that offer specialized health
sub-channels
or functions; other high-traffic
Websites that include both healthcare-related and
non-healthcare-related
content and services, including social media Websites; search engines; and advertising networks that aggregate traffic from multiple
sites.
The WebMD Health Network
also faces competition from: traditional media and offline publications and information services; and manufacturers and distributors of activity trackers, heart rate monitors, blood pressure monitors and
similar devices relating to health and wellness that can download data to a PC, tablet or smartphone, as well as numerous other companies developing applications and tools for use with those devices.
|
|
|
|
Our
WebMD Health Services
platform and related services, including health coaching and condition management services compete with: providers of
online health management applications, including personal health records; wellness and disease management vendors; and competing services provided by health insurance companies, employee benefits services companies, and their affiliates. Employers
may also decide to develop similar solutions for their own populations rather than obtaining solutions from
WebMD Health Services
or its competitors.
|
Many of our competitors have greater financial, technical, product development, marketing and other resources than we do. These organizations may be better known than we are and may have more customers or
users than we do. We cannot provide assurance that we will be able to compete successfully against these organizations. In addition, we expect that competitors will continue to enter these markets. The competition we face for our services may result
in fewer or smaller customer commitments or pressure to reduce prices, which could reduce our profit margins.
Developing and implementing new and updated services may be more difficult than expected and may not result in sufficient increases
in revenue to justify the costs
In order to attract and retain users of our Websites and mobile applications and
clients for our
WebMD Health Services
platform and related services, we must continue to improve the technology underlying our services and continue to develop new and updated offerings. If we are unable to do so on a timely basis or if we
are unable to implement new offerings without disruption to our existing ones, we may lose potential users and clients.
We
rely on a combination of internal development, strategic relationships, licensing and acquisitions to develop our Websites, mobile applications and related features and services. Our development and/or implementation of new technologies, features
and services may cost more than expected, may take longer than
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
3
originally expected, may require more testing than originally anticipated and may require the acquisition of additional personnel and other resources. There can be no assurance that the revenue
opportunities from any new or updated technologies, applications, features or services will justify the amounts spent.
Failure to effectively identify, assess and pursue new business initiatives could adversely affect our company and its prospects
We are working to broaden our portfolio of services and taking steps to diversify our client base and revenue streams.
The development of new products and services in response to evolving trends in healthcare and evolving technologies for Internet-based and mobile services, as well as the identification of new business opportunities in this dynamic environment,
requires significant time and resources. We may not be able to respond quickly enough or in a cost-effective manner, appropriately time the introduction of new products and services to the market or identify new business opportunities in a timely
manner. In addition, while evolving technologies may offer new opportunities, they may also present additional challenges, including challenges relating to security and privacy.
Some of the business initiatives we are working on have challenges that are different from those associated with our existing products and
services and could strain our financial, operational and management resources. Furthermore, there can be no assurance that the potential revenue streams from any investments that we may make in pursuing new business opportunities will justify the
amounts spent. Failure to effectively identify, assess and pursue new business initiatives may adversely affect our company and its prospects.
Failure to continue to enhance the analytic capabilities we use to demonstrate the value of our services to advertisers and sponsors could adversely affect our ability to market our services
We continue to work to enhance the analytic capabilities we use to demonstrate to advertisers and sponsors how
promotional strategies implemented through
The WebMD Health Network
impact physician and consumer behaviors and preferences. Our ability to demonstrate the value of advertising and sponsorship on
The WebMD Health Network
depends, in
part, on our ability to provide accurate and reliable analytics and measurement capabilities and to continue to improve such capabilities. If we are unable to demonstrate such analytic capabilities, it could adversely affect our ability to market
our services or to satisfy client expectations and commitments that rely on analytics to measure performance and, as a result, we may lose business to competitors even if our advertising and sponsorship services are superior to theirs.
Restrictions on our ability to access or use various forms and sources of data could adversely impact our business
We are increasingly using data analytics based on information that we collect regarding usage of
The WebMD Health
Network
, as well as other third-party sources of data. Our use of data regarding users of
The WebMD Health Network
is governed by the privacy policies posted on those sites and is designed to comply with applicable laws and regulations as
is our use of any third-party data. In addition, we sell certain information products and services on a stand-alone basis using
de-identified
data that we license from a small number of third-party data
sources, of which the principal source is a license from Change Healthcare to HLTH Corporation (HLTH). As the successor to HLTH, this license provides us the rights to certain
de-identified
data from Change
Healthcare through early February 2018 for use in the development and commercialization of various information products and services as to which we pay Change Healthcare a royalty. To date, these stand-alone information products and services do not
include any data derived from the operation of our Websites. We are seeking to acquire additional third-party data sources and to develop data generated from our Website operations in order to diversify our data product offerings.
Our revenue from the stand-alone products and services that utilize data under the current Change Healthcare license is highly profitable
and is reported net of the royalties and commissions that we pay to Change Healthcare or others. We do not expect that the current license agreement with Change Healthcare will continue after February 2018, and expect that if such agreement is
renewed or is replaced with new third-party data sources, the terms of any such renewal or replacement license would not be as favorable to us as those in the
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
4
current agreement. Change Healthcare is in the process of merging with McKesson Corporation and, as a result, discussions around extending our agreement with Change Healthcare have stalled. We
are exploring other sources of third-party data and uses of our first party data to generate additional revenue streams, but we are early in that process. Accordingly, we expect that the sales of, and the profits generated by, our information
services business will be materially adversely affected by the expiration, in early February 2018, of our license agreement with Change Healthcare.
Changes to our ability to access or use data could adversely affect our ability to implement improved analytics or to offer information products on a stand-alone basis. Accordingly, our business could be
adversely impacted if, for any reason (including, but not limited to, changes in applicable laws and regulations) the data we use becomes unavailable or the conditions on its availability are not commercially reasonable or are inconsistent with our
planned usage. In addition, the quality of our data analytics depends on the reliability of the information that we are able to obtain. If the information we use contains errors or is otherwise unreliable, analyses we create and actions we take
based on those analyses could be wrong, which could hurt our reputation and business.
Failure to maintain and enhance
the WebMD and Medscape brands and our other brands could have a material adverse effect on our business
We believe that the WebMD and Medscape brand identities that we have developed have contributed to the success of our business and have helped us achieve recognition as a trusted
source of health and wellness information and tools for consumers and of online content for physicians and other healthcare professionals. We also believe that maintaining and enhancing those brands, as well as our other brands, is important to
expanding the user base for
The WebMD Health Network
and to our relationships with sponsors and advertisers. The WebMD brand is also important to our ability to gain additional employer and healthcare payer clients for our
WebMD Health Services
platform and related services. We have expended considerable resources on establishing and enhancing the WebMD and Medscape brands and our other brands, and we have developed policies and
procedures designed to preserve and enhance our brands, including editorial procedures designed to provide quality control of the information we publish. We expect to continue to devote resources and efforts to maintain and enhance our brands.
However, we may not be able to successfully maintain or enhance our brands, and events outside of our control may have a negative effect on our brands. If we are unable to maintain or enhance our brands, and do so in a cost-effective manner, our
business could be adversely affected.
The markets we participate in are relatively new and continue to change
We participate in relatively new markets. These markets, and our business, have undergone significant changes during
their short history and can be expected to continue to change. Many companies with business plans based on providing healthcare information and related services online and through mobile platforms have failed to be profitable and some have filed for
bankruptcy or ceased operations. Even if demand from users exists, we cannot assure you that our business will be profitable.
The standards that our advertising and sponsorship clients apply to our services continue to evolve, including standards for ad delivery,
placement and frequency and for measuring the effectiveness of our services as compared to other alternatives available to our clients. Our ability to meet such standards as they change in the future will be important to our ability to compete for
business, and we cannot provide assurance that we will be able to do so or estimate what the costs for doing so may be. For example, standards are continuing to evolve in the online advertising marketplace regarding the viewability of online
advertising, or the length of time an advertisement is visible to a user as determined by a third-party verification source. We cannot predict how the requirements of advertisers will continue to evolve. If we fail to meet the standards that our
advertisers require, our advertising revenues could be reduced.
Our failure to attract and retain qualified executives
and employees may have a material adverse effect on our business
Our business depends largely on the skills,
experience and performance of key members of our management team and other key employees. We also depend, in part, on our ability to attract and retain qualified writers and
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
5
editors, software developers and other technical personnel, healthcare professionals, and sales and marketing personnel. Competition for qualified personnel in the healthcare information services
and Internet industries is intense. We cannot assure you that we will be able to hire or retain a sufficient number of qualified personnel to meet our requirements, or that we will be able to do so at costs that are acceptable to us. Failure to do
so may have an adverse effect on our business.
Our advertising and sponsorship revenue may vary significantly from
quarter to quarter and its amount and timing may be subject to factors beyond our control, including regulatory changes
Our advertising and sponsorship revenue may vary significantly from quarter to quarter due to a number of factors, many of which are not
within our control, and some of which may be difficult to forecast accurately, including potential effects on demand for our services as a result of regulatory changes affecting advertising and promotion of drugs and medical devices and general
economic conditions. The majority of our advertising and sponsorship programs are for terms of approximately four to twelve months. We have relatively few longer term advertising and sponsorship programs. We cannot assure you that our current
advertisers and sponsors will continue to use our services beyond the terms of their existing commitments or that they will enter into any additional commitments.
The time between the date of initial contact with a potential advertiser or sponsor regarding a specific program and the execution of a commitment with the advertiser or sponsor for that program, as well
as the additional time period before our services are delivered, may be longer than expected, especially for
medium-sized
and larger contracts, and may be subject to delays over which we have little or no
control, including as a result of budgetary constraints of the advertiser or sponsor or their need for internal approvals, including internal approvals relating to compliance with the laws and regulations applicable to the marketing of healthcare
products. We have experienced, from time to time, a lengthening of this internal review process by pharmaceutical and biotechnology companies, which has resulted in delays in contracting as well as delays in recognizing expected revenue under
executed commitments. Other factors that could affect the timing of contracting for specific programs with advertisers and sponsors, or receipt of revenue under such contracts, include the timing of:
|
|
|
U.S. Food and Drug Administration (FDA) approval for new products or for new indications or uses for approved products;
|
|
|
|
any adverse determinations by the FDA affecting products previously approved or expected to be approved or the permitted uses of such products or their
marketing;
|
|
|
|
FDA approval of generic products that compete with existing brand name products and any increase in the number or significance of such approvals;
|
|
|
|
recalls, withdrawals or shortages of products from the market;
|
|
|
|
consolidation of companies in the pharmaceutical and biotechnology industries;
|
|
|
|
rollouts of new or enhanced services on
The WebMD Health Network
;
|
|
|
|
seasonal factors relating to the prevalence of specific health conditions and other seasonal factors that may affect the timing of promotional
campaigns for specific products; and
|
|
|
|
the scheduling of conferences for physicians and other healthcare professionals.
|
Some of our pharmaceutical company customers have experienced patent expirations for certain of their products in the past several years
and some are expected to experience patent expirations over the next several years. In the pharmaceutical industry, patent expirations allow for competition from lower-priced generic versions of the patented drugs and generally result in the
termination of marketing efforts for the drug (unless the FDA awards regulatory exclusivities beyond the patent term). In addition, expirations of patents that result in a significant reduction in revenue for a pharmaceutical company can lead to
reductions in their advertising and sponsorship expenditures for other drugs in their product portfolios or for their entire product portfolio.
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
6
Applications and other software that can block advertisements could reduce demand for
our advertising and sponsorship products and decrease our revenue
We derive a significant portion of our revenue from
advertising and sponsorship on
The WebMD Health Network
. Applications and software are available that can block or obscure the display of advertisements or block the cookies used to deliver such advertisements, or shift the location in which
advertising appears on pages. While the use of
ad-blocking
programs by visitors to
The WebMD Health Network
has been limited to date and our audience consists primarily of individuals who have not
typically adopted
ad-blocking
programs so far, if these programs gain acceptance among our users in the future, they could reduce our ability to deliver advertisements to our audience which, in turn, could
reduce demand for our advertising and sponsorship products and cause our revenue from those products to decrease.
Mergers and acquisitions among our clients may reduce the volume of our services purchased by the consolidated company following
such a transaction, which could harm our operating results
Mergers and acquisitions among our pharmaceutical,
biotechnology and medical device company clients have in the past and could in the future reduce the number of our clients and potential clients. Similarly, mergers and acquisitions among health insurance company clients of our WebMD Health Services
platform could reduce the number of those clients. In addition, when companies consolidate, the number of vendors used for services, or the amount spent, by the separate companies may be reduced by the consolidated entity and some vendors and
services may no longer be used at all. Any such event could have a negative effect on our revenue and profitability and we cannot provide assurance that we would be able to mitigate any such negative effect.
We may be unsuccessful in our efforts to generate advertising and sponsorship revenue from consumer products companies
Much of our advertising and sponsorship revenue has, in the past, come from pharmaceutical, biotechnology and medical
device companies. We also seek to generate advertising and sponsorship revenue from consumer products companies that are interested in communicating health-related or safety-related information about their products to our audience. However, while
many consumer products companies are increasing the portion of their promotional spending used on the Internet, we cannot assure you that these advertisers and sponsors will find our consumer Websites to be as effective for promoting their products
and services as competing channels, which include traditional media, Internet search engines, social media Internet sites, general interest consumer sites, and numerous other alternatives. Competition for this business may also result in smaller
customer commitments or pressure to reduce prices, both of which could reduce our profit margins even if we are able to generate revenue.
In addition, revenues from consumer products companies are more likely to reflect general economic conditions, and to be reduced to a greater extent during economic downturns, than revenues from
pharmaceutical, biotechnology and medical device companies. Accordingly, revenues from this portion of our business may be subject to significant
quarter-to-quarter
variations and we may be unsuccessful in our efforts to develop it further.
Lengthy sales and implementation cycles for
our WebMD Health Services platform and certain contractual rights of our clients make it difficult to forecast our revenues and may have an adverse impact on our results of operations
The period from our initial contact with a potential client for our
WebMD Health Services
platform and entry into a contract for a
subscription to our solution by the client is difficult to predict. In the past, this period has generally ranged from six to twelve months, but in some cases has been longer. Potential contracts may be subject to delays or cancellations due to a
clients internal procedures for approving large expenditures and other factors beyond our control, including the effect of general economic conditions on the willingness of potential clients to subscribe to our
WebMD Health Services
solution. The time it takes to implement our
WebMD Health Services
platform is also difficult to predict and has lasted as long as six months from contract execution to the commencement of live operation. Implementation may be subject to
delays based on the availability of the
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
7
internal resources of the client that are needed and other factors outside of our control. As a result, we have limited ability to forecast the timing of revenue from clients. This, in turn,
makes it more difficult to forecast our financial performance for future periods and may have an adverse impact on our results of operations.
During the contracting cycle and the implementation period, we may expend substantial time, effort and money preparing contract proposals, negotiating contracts and implementing our
WebMD Health
Services
platform without receiving any related revenue. In addition, many of the expenses related to providing our platform are relatively fixed in the short term, including personnel costs and technology and infrastructure costs. If our health
services revenue is lower than expected, we may not be able to reduce related short-term spending in response. Any shortfall in such revenue would have a direct impact on our results of operations.
In addition, some of our client contracts permit termination, by the client, prior to the end of the stated contract term for some or all
of the services to be provided, which can make it more difficult to forecast our future financial performance and may have an adverse impact on our results of operations.
Our ability to renew existing agreements with employers and health plans will depend, in part, on our ability to continue to develop and update our offerings and to increase usage of our services by
their employees and plan members
In a healthcare market where a greater share of the responsibility for healthcare
costs and decision-making has been shifting to consumers, use of information technology (including personal health records) to assist consumers in making informed decisions about healthcare has also increased. We believe that through our
WebMD
Health Services
platform as well as our health coaching programs and our targeted condition management programs, we are well positioned to play a role in this environment. However, our strategy depends, in part, on increasing usage of our
services by our employer and health plan clients employees and plan participants and being able to demonstrate a sufficient return on investment and other benefits for our clients from those services. Increasing usage of our platform and
related services requires us to continue to develop new and updated applications, features and services. In addition, there are numerous competitors for the services we provide, many of which have greater financial, technical, product development,
marketing and other resources than we do, and may be better known than we are. We cannot provide assurance that we will be able to meet our development and implementation goals or that we will be able to compete successfully against other vendors
offering competitive services and, if we are unable to do so, we may experience static or diminished usage of our platform and related services, possible
non-renewals
of our customer agreements and, since some
customers have the right to terminate or modify existing agreements before the end of the full contract term, possible terminations for some or all of the services to be provided.
The condition management programs that we provide to clients of our WebMD Health Services platform involve risk and challenges with
which we have limited experience and may not be profitable
We provide condition management services to clients of our
WebMD Health Services
platform and plan to continue to expand that portion of our business. Our current offerings include programs targeting individuals struggling with coronary artery disease, congestive heart failure, diabetes, chronic
obstructive pulmonary disease and asthma. Our condition management programs include ongoing, intensive
one-on-one
coaching by condition specialists, along with targeted
online resources and progress tracking tools. Providing condition management services involves new risks and challenges for us, including: potential requirements to obtain and retain licenses, permits and regulatory clearances and approvals related
to these services; difficulty in quantifying the costs savings and other benefits for our clients from these services; and difficulty in differentiating our condition management services from those of competitors, some of whom may be able to provide
such services at a lower cost. We cannot predict the demand among our existing
WebMD Health Services
clients and other potential clients for our condition management services and cannot provide assurance that the revenue opportunities from
providing our current offerings or ones for additional conditions will justify the costs involved in maintaining or developing the required capabilities and delivering the services to clients.
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
8
Contractual relationships with governmental customers may impose special burdens on us
and provide special benefits to those customers, including the right to change or terminate the contract in response to budgetary constraints or policy changes
A portion of our revenues come from customers that are governmental agencies or vendors to such agencies. Government contracts and subcontracts may be subject to some or all of the following:
|
|
|
termination when appropriated funding for the current fiscal year is exhausted or becomes unavailable;
|
|
|
|
termination for the governmental customers convenience, subject to a negotiated settlement for costs incurred and profit on work completed, along
with the right to place contracts out for bid before the full contract term, as well as the right to make unilateral changes in contract requirements, subject to negotiated price adjustments;
|
|
|
|
most-favored pricing disclosure requirements that are designed to ensure that the government can negotiate and receive pricing akin to that
offered commercially and requirements to submit proprietary cost or pricing data to ensure that government contract pricing is fair and reasonable;
|
|
|
|
commercial customer price tracking requirements that require contractors to monitor pricing offered to a specified class of customers and to extend
price reductions offered to that class of customers to the government;
|
|
|
|
reporting and compliance requirements related to, among other things: equal employment opportunity, affirmative action for veterans and for workers
with disabilities, and accessibility for the disabled;
|
|
|
|
broader audit rights than we would usually grant to
non-governmental
customers; and
|
|
|
|
specialized remedies for breach and default or failure to meet service level commitments, including setoff rights, retroactive price adjustments, and
civil or criminal fraud penalties, as well as mandatory administrative dispute resolution procedures instead of state contract law remedies.
|
In addition, certain violations of federal law may subject government contractors to having their contracts terminated and, under certain circumstances, suspension and/or debarment from future government
contracts.
Expansion to markets outside the United States subjects us to additional risks
One element of our growth strategy is to seek to expand our online services to markets outside the United States. In certain markets
outside the United States, we expect to accomplish this through partnerships or joint ventures with other companies having expertise in the specific country or region, while in other such markets we expect to rely primarily on our own internal
resources. In certain markets outside of the United States, we are providing some of our online services in the local language directly to healthcare professionals. We also provide our online services in English to healthcare professionals outside
the United States. Our participation in international markets is subject to certain risks beyond those applicable to our operations in the United States, such as:
|
|
|
challenges caused by cultural differences;
|
|
|
|
difficulties in staffing and managing operations from a distance;
|
|
|
|
uncertainty regarding liability for services and content;
|
|
|
|
potential burdens of complying with a wide variety of legal, regulatory and market requirements, as well as uncertainty as to the applicability of
non-U.S.
laws to operations based in the United States and regarding the interpretation of such laws by local authorities;
|
|
|
|
potential regulation or interpretation of existing regulation that could limit or eliminate our ability to distribute one or more of our products in
one or more countries;
|
|
|
|
variability of economic and political conditions, including the extent of the impact of adverse economic conditions in markets outside the United
States;
|
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
9
|
|
|
exposure to applicable anti-corruption laws, including but not limited to the U.S. Foreign Corrupt Practices Act;
|
|
|
|
tariffs or other trade barriers;
|
|
|
|
fluctuations in currency exchange rates;
|
|
|
|
potentially adverse tax consequences, including restrictions on repatriation of earnings; and
|
|
|
|
difficulties in protecting intellectual property.
|
In addition, outside the United States, we face competition from locally based companies that have experience doing business in their home countries or regions and familiarity with local business
practices, customs and laws and, as a result, generally do not face, or are better positioned to face, the risks described above.
Risks Related
to the Internet and Our Technological Infrastructure
Any service interruption or failure in the systems that we use
to provide online services could harm our business
Our online services are designed to operate 24 hours a day, seven
days a week, without interruption. However, we have experienced and expect that we will in the future experience interruptions and delays in services and availability from time to time. We rely on internal systems as well as third-party vendors,
including data center providers, bandwidth providers and mobile carriers, to provide our online services. We may not maintain redundant systems or facilities for some of these services. In the event of a catastrophic event with respect to one or
more of these systems or facilities, we may experience an extended period of system unavailability, which could negatively impact our relationship with users. In addition, system failures may result in loss of data, including user registration data,
business intelligence data, content, and other data critical to the operation of our online services, which could cause significant harm to our business and our reputation.
To operate without interruption or loss of data, both we and our service providers must guard against:
|
|
|
damage from fire, power loss and other natural disasters;
|
|
|
|
communications failures;
|
|
|
|
software and hardware errors, failures and crashes;
|
|
|
|
security breaches, computer viruses, distributed
denial-of-service
attacks and similar disruptive problems; and
|
|
|
|
other potential service interruptions.
|
Any disruption in the network access or
co-location
services provided by third-party providers to us or any failure by these third-party providers or our own
systems to handle current or higher volume of use could significantly harm our business. We exercise little control over these third-party vendors, which increases our vulnerability to problems with services they provide. Any errors, failures,
interruptions or delays experienced in connection with these third-party technologies and information services or our own systems could negatively impact our relationships with users and adversely affect our brand and our business and could expose
us to liabilities to third parties. Although we maintain insurance for our business, the coverage under our policies may not be adequate to compensate us for all losses that may occur. In addition, we cannot provide assurance that we will continue
to be able to obtain adequate insurance coverage at an acceptable cost.
Failure to update our technology infrastructure
could adversely affect our business
Evolving technologies could require us to modify our technology infrastructure and
any failure to do so on a timely basis may limit the types of services we can provide or the quality of those services, and may put us in a
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
10
weaker position relative to our competitors. Competitors with newer technology infrastructure may also have greater flexibility and be in a position to respond more quickly than us to new
opportunities, which may impact our competitive position in certain markets and adversely affect our business.
Implementation of updates to our technology infrastructure may result in performance problems and may not provide the additional
functionality that was expected
From time to time, we implement additions to or changes in the hardware and software
platforms we use for providing our online services. During and after the implementation of additions or changes, a platform may not perform as expected, which could result in interruptions in operations, an increase in response time or an inability
to track performance metrics. In addition, in connection with integrating acquired businesses, we may move their operations to our hardware and software platforms or make other changes, any of which could result in interruptions in those operations.
Any significant interruption in our ability to operate any of our online services could have an adverse effect on our relationships with users and clients and, as a result, on our financial results. We rely on a combination of purchasing, licensing,
internal development, and acquisitions to develop our hardware and software platforms. Our implementation of additions to or changes in these platforms may cost more than originally expected, may take longer than originally expected, and may require
more testing than originally anticipated. In addition, we cannot provide assurance that additions to or changes in these platforms will provide the additional functionality and other benefits that were originally expected.
If the systems we use to provide our online services experience security breaches or are otherwise perceived to be insecure, our
business could suffer
We retain and transmit confidential information, including personal health records, in the
processing centers and other facilities we use to provide our online services. It is critical that these facilities and infrastructure remain secure and be perceived by the marketplace as secure. A security breach could damage our reputation or
result in liability. We may be required to expend significant capital and other resources to protect against security breaches and hackers or to alleviate problems caused by breaches. Despite the implementation of security measures, this
infrastructure or other systems that we interface with, including the Internet and related systems, may be vulnerable to physical
break-ins,
hackers, improper employee or contractor access, computer viruses,
programming errors,
denial-of-service
attacks or other attacks by third parties or similar disruptive problems. Because the techniques used by hackers to sabotage or to
obtain unauthorized access to computer systems change frequently, we may be unable to anticipate specific types of attacks or to implement adequate preventative measures. If an actual or perceived breach of our security occurs, the market perception
of the effectiveness of our security measures could be harmed and we could lose users, customers, advertisers or publishers. Any compromise of our security, whether as a result of breaches or failures of our own systems or the systems with which
they interface, could reduce demand for our services and could subject us to legal claims from our clients and users, including for breach of contract or breach of warranty.
Our online services are dependent on the development and maintenance of the Internet infrastructure
Our ability to deliver our online services is dependent on the development and maintenance of the infrastructure of the Internet by third parties. The Internet has experienced a variety of outages and
other delays as a result of damages to portions of its infrastructure, and it could face outages and delays in the future. The Internet has also experienced, and is likely to continue to experience, significant growth in the number of users and the
amount of traffic. If the Internet continues to experience increased usage, the Internet infrastructure may be unable to support the demands placed on it. In addition, the reliability and performance of the Internet may be harmed by increased usage
or by
denial-of-service
attacks. Any resulting interruptions in our services or increases in response time could, if significant, result in a loss of potential or
existing users of and advertisers and sponsors on our Websites and, if sustained or repeated, could reduce the attractiveness of our services.
Customers who utilize our online services depend on Internet service providers and other Website operators for access to our Websites. Many of these providers have experienced significant outages in the
past and they
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
11
could experience outages, delays and other difficulties in the future due to system failures unrelated to our systems. Any such outages or other failures on their part could reduce traffic to our
Websites.
Third parties may challenge the enforceability of our online agreements
The law governing the validity and enforceability of online agreements and other electronic transactions is evolving. We could be subject
to claims by third parties that the online terms and conditions for use of our Websites, including disclaimers or limitations of liability, are unenforceable. A finding by a court that these terms and conditions or other online agreements are
invalid could harm our business.
We could be subject to breach of warranty or other claims by clients of our online
services if the software and systems we use to provide them contain errors or experience failures
Errors in the
software and systems we use could cause serious problems for clients of our online services. We may fail to meet contractual performance standards or client expectations. Clients of our online services may seek compensation from us or may seek to
terminate their agreements with us, withhold payments due to us, seek refunds from us of part or all of the fees charged under those agreements or initiate litigation or other dispute resolution procedures. In addition, we could face breach of
warranty or other claims by clients, or additional development costs. Our software and systems are inherently complex and, despite testing and quality control, we cannot be certain that they will perform as planned.
We attempt to limit, by contract, our liability to our clients for damages arising from our negligence, errors or mistakes. However,
contractual limitations on liability may not be enforceable in certain circumstances or may otherwise not provide sufficient protection to us from liability for damages. We maintain liability insurance coverage, including coverage for errors and
omissions. However, it is possible that claims could exceed the amount of our applicable insurance coverage, if any, or that this coverage may not continue to be available on acceptable terms or in sufficient amounts. Even if these claims do not
result in liability to us, investigating and defending against them would be expensive and time consuming and could divert managements attention away from our operations. In addition, negative publicity caused by these events may delay or
hinder market acceptance of our services, including unrelated services.
Risks Related
to the Healthcare Industry, Healthcare Regulation and Internet Regulation
Developments in the healthcare industry
that reduce spending by healthcare industry participants generally could adversely affect our business
Our business
could be adversely impacted by changes in the structure of the healthcare industry and other changes that reduce healthcare spending. We are particularly dependent on pharmaceutical, biotechnology and medical device companies for our advertising and
sponsorship revenue. General reductions in expenditures by healthcare industry participants could result from, among other things:
|
|
|
changes in government regulation or private initiatives that affect the manner in which healthcare industry participants interact with patients, payers
(including governmental payers) or other healthcare industry participants, including any such regulations or initiatives that seek to control the pricing or means of delivery of healthcare products and services or that create restrictions on the
advertising or promotion of healthcare products and services;
|
|
|
|
consolidation of healthcare industry participants;
|
|
|
|
reductions in governmental funding for healthcare; and
|
|
|
|
adverse changes in business or economic conditions affecting healthcare payers or providers, pharmaceutical, biotechnology or medical device companies
or other healthcare industry participants.
|
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
12
Developments in the healthcare industry that reduce spending in the specific market
segments that we participate in could adversely affect our business
Even if overall expenditures by industry
participants remain the same or increase, developments in the healthcare industry may result in reduced spending in some or all of the specific market segments that we serve or are planning to serve. For example, use of our products and services
could be affected by:
|
|
|
changes in the design of health insurance plans or governmental programs that pay for healthcare products and services;
|
|
|
|
the timing of FDA (or European or other national regulatory authority) approvals for new products or for new approved indications or uses for existing
products and any decrease in the number or significance of new drugs or medical devices coming to market or new approved uses for existing products;
|
|
|
|
the timing of FDA (or European or other national regulatory authority) approvals of generic products that compete with existing brand name products and
any increase in the number or significance of such approvals or of withdrawals of brand name products from the market;
|
|
|
|
the timing of FDA (or European or other national regulatory authority) approvals of biosimilars to approved biological products and any increase in the
number or significance of such approvals or of withdrawals of biological products from the market; and
|
|
|
|
decreases in marketing expenditures by pharmaceutical or medical device companies, including as a result of governmental regulation or private
initiatives that discourage, restrict or prohibit advertising, sponsorship or educational activities by pharmaceutical or medical device companies or that discourage, restrict or prohibit their use of online services for some or all such activities.
|
In addition, our customers expectations regarding pending or potential industry developments may also
affect their budgeting processes and spending plans with respect to products and services of the types we provide. Since 2016, there has been increasing scrutiny regarding pricing increases for pharmaceutical products, which could lead to additional
regulation of pharmaceutical pricing or other changes in how those products are distributed and the roles played by various industry participants in that distribution. We cannot predict the effect that such scrutiny or any resulting changes may have
on the marketing plans of our customers in future periods or their future use of our services.
The healthcare industry has
changed significantly in recent years, and we expect that significant changes will continue to occur. However, the timing and impact of developments in the healthcare industry are difficult to predict. We cannot assure you that the markets for our
products and services will continue to exist at current levels or that we will have adequate technical, financial and marketing resources to react to changes in those markets.
Changes to the Affordable Care Act and other healthcare reform efforts could affect some of our healthcare industry customers and clients
Political, economic, regulatory and enforcement influences are subjecting the healthcare industry in the U.S. to fundamental
changes. There have been, and we expect there will continue to be, legislative and regulatory proposals to change the healthcare system in ways that could impact the various healthcare entities with which we contract. In particular, we
anticipate that the U.S. Executive Branch, U.S. Congress, state legislatures and the private sector will continue to consider and may adopt healthcare policies intended to curb rising healthcare costs, particularly given the ongoing scrutiny
regarding healthcare pricing in the U.S. generally, and prescription drug pricing specifically. Such policies could limit the prices our advertisers and sponsors charge for their healthcare-related products or services, limit the commercial
opportunities of our advertisers and sponsors and/or negatively impact revenues collected by our advertisers and sponsors. We are particularly dependent on our healthcare clients, which primarily include pharmaceutical, biotechnology, and
medical device companies, for our advertising and sponsorship revenue. Our advertisers and sponsors may face cost reduction measures and, in
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
13
response, reduce their expenditures or postpone expenditure decisions, including expenditures for our services, which could have material adverse effects on our business.
One law in particular with a significant impact on the healthcare industry is the Patient Protection and Affordable Care Act, as amended
by the Health Care and Education Reconciliation Act of 2010 (which we refer to as the Affordable Care Act), which was signed into law in March 2010. The Affordable Care Act made extensive changes to the system of healthcare insurance and benefits in
the U.S. While we do not currently anticipate any significant adverse effects on WebMD as a direct result of the application of the Affordable Care Act, as currently enacted or as it may be amended, to our business or on our company in its capacity
as an employer, we are unable to predict what the indirect impacts will be on WebMDs business through its effects on other healthcare industry participants, including pharmaceutical and medical device companies that are advertisers and
sponsors of The WebMD Health Network and employers and health plans that license our
WebMD Health Services
platform. Healthcare industry participants may respond to the Affordable Care Act or to uncertainties created by the potential
statutory and regulatory changes by reducing their expenditures or postponing expenditure decisions, including expenditures for our services, which could have a material adverse effect on our business.
Government regulation of healthcare creates risks and challenges with respect to our compliance efforts and our business strategies
The healthcare industry is highly regulated and is subject to changing political, legislative, regulatory and other
influences. Existing and new laws and regulations affecting the healthcare industry could create unexpected liabilities for us, could cause us to incur additional costs and could restrict our operations. Many healthcare laws are complex, and their
application to specific products, services, and business arrangements may not be clear. In particular, many existing healthcare laws and regulations, when enacted, did not anticipate the healthcare information services that we provide. However,
these laws and regulations may nonetheless be applied to our products, services, and business arrangements. Our failure to accurately anticipate the application of these laws and regulations, or other failure to comply, could create liability for
us, result in adverse publicity and negatively affect our business. Even in areas where we are not subject to healthcare regulation directly, we may become involved in governmental actions or investigations through our relationships with customers
that are regulated, and participation in such actions or investigations, even if we are not a party and not the subject of an investigation, may cause us to incur significant expenses. Some of the risks we face from healthcare regulation are as
follows:
|
|
|
U.S. Regulation of Drug and Medical Device Advertising and Promotion. The WebMD Health Network
provides services
involving advertising and promotion of prescription and
over-the-counter
drugs and medical devices and claims of nutritional supplements. If the FDA or the Federal Trade
Commission (FTC) finds that any of our products and services or any information on
The WebMD Health Network
, in our mobile applications, or in
WebMD Magazine
violates applicable regulations and guidance documents, they may take
regulatory or judicial action against us and/or the advertiser or sponsor of that information. State attorneys general may take similar action based on their respective states consumer protection statutes. Any increase or change in regulation
of drug or medical device advertising and promotion, especially if it relates to promotional activities involving the Internet or social media, could make it more difficult for us to contract for sponsorships and advertising and could have a
material adverse effect on our revenues and results of operations. We cannot predict how our customers or others in the industry might implement regulations or guidance in the future or how its implementation might affect our business. Private
industry initiatives have resulted in voluntary restrictions, which advertisers and sponsors have agreed to follow.
|
In December 2016, Congress passed the 21st Century Cures Act (the Cures Act) which contained a number of provisions designed to speed development of innovative therapies, to provide public science
funding, and to adjust how the FDA evaluates new medical products and new indications for existing prescription drugs and devices. We cannot predict what effect, if any, the Cures Act might have on our business but we will closely monitor the
changes.
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
14
|
|
|
Non-U.S.
Regulation of Drug and Medical Device Advertising and Promotion.
To the
extent that
The WebMD Health Network
reaches users outside of the United States, our Websites may be required to comply with the national laws of the respective countries whose users they address. In many countries, the advertising of
prescription drugs to the general public is not allowed and, accordingly, these countries generally require access restrictions for Websites that contain such advertisements, which are only allowed to be addressed to healthcare professionals. In
addition, there are laws and regulations regarding the use of indirect or disguised marketing, and regarding the offering and providing of gifts or benefits with promotional purpose that are not of minor value.
|
|
|
|
Anti-Kickback Laws.
There are federal and state laws that govern patient referrals, physician financial relationships and
inducements to healthcare providers and patients. The federal anti-kickback law prohibits any person or entity from offering, paying, soliciting or receiving anything of value, directly or indirectly, in exchange for the referral of patients for
items or services reimbursed by Medicare, Medicaid and other federal healthcare programs, or to induce or reward the leasing, purchasing, ordering or arranging for or recommending the lease, purchase or order of any item, good, facility or service
reimbursed by these programs. Many states and European countries also have similar anti-kickback laws that are not necessarily limited to items or services for which payment is made by a government healthcare program. These laws are applicable to
any person or entity, including manufacturers and distributors and, therefore, may restrict how we and some of our customers market products to healthcare providers. We carefully review our practices with regulatory experts in an effort to ensure
that we comply with all applicable laws. However, the laws in this area are both broad and vague, and it is often difficult or impossible to determine precisely how the laws will be applied, particularly to new services. Penalties for violating the
federal anti-kickback law include imprisonment, fines and exclusion from participating, directly or indirectly, in Medicare, Medicaid and other federal healthcare programs. Any determination by a state, federal, or foreign regulatory agency that any
of our practices violate any of these laws could subject us to civil or criminal penalties and require us to change or terminate some portions of our business and could have an adverse effect on our business. Even an unsuccessful challenge by
regulatory authorities of our practices could cause us to incur significant costs or cause adverse publicity. In addition, enforcement or the potential for enforcement of these laws against some of our customers may influence the services we are
able to offer and/or our customers willingness to continue to use our services.
|
|
|
|
False Claims Laws.
The Federal False Claims Act imposes liability on any person or entity who, among other things,
knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a Federal healthcare program. The whistleblower (or
qui tam
) provisions of the Federal False Claims Act allow a private individual to bring
actions on behalf of the Federal government alleging that the defendant has submitted a false claim to the federal government and to share in any monetary recovery. After the filing of a
qui tam
suit, the Federal government may intervene and
control the case; if it does not, the private individual may pursue the claim on his or her own. In addition, various states and European countries have enacted false claim laws analogous to the Federal False Claims Act, and many of these laws apply
where a claim is submitted to any third-party payor and not merely a federal healthcare program. When an entity is determined to have violated the Federal False Claims Act, it may be required to pay up to three times the actual damages sustained by
the government plus civil penalties. In recent years an increasing number of Federal False Claims Act cases have been brought against drug manufacturers and resulted in significant monetary settlements and imposition of federally supervised
corporate integrity agreements in circumstances that include allegations that company-sponsored continuing medical education (or CME) was unlawful
off-label
promotion. It is not clear whether there is a basis
for the application of the Federal False Claims Act to the types of services that WebMD provides. However, plaintiffs have in the past, and may in the future, seek to name us as defendants in these types of cases. Any action against us for violation
of these laws could cause us to incur significant legal expenses and may adversely affect our ability to operate our business. Similarly, False Claims Act actions and resulting corporate integrity agreements involving our customers may reduce the
use of our services by our advertising and sponsorship clients.
|
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
15
|
|
|
Medical Professional Regulation.
The practice of most healthcare professions requires licensing under applicable state
law. In addition, the laws in some states prohibit business entities from practicing medicine. If a state determines that some portion of our business violates these laws, it may seek to have us discontinue those portions or subject us to penalties
or licensure requirements.
|
|
|
|
Regulation of Mobile Medical Applications and Other Mobile Health Technology.
The FDA has issued guidance regarding
mobile medical applications and other mobile health technology, clarifying the agencys intent to regulate only those applications that meet the agencys definition of device and could pose a risk to patients safety if
they fail to work as intended. The FDA is exercising enforcement discretion with respect to certain lower risk mobile applications that meet the device definition, such as those that maintain or encourage a general state of health or a healthy
activity. Mobile applications that do not meet the device definition are beyond the FDAs jurisdiction and, accordingly, are not subject to the agencys oversight. In February 2015, the FDA issued guidance stating it would refrain from
exercising enforcement over certain products that promote health or healthy lifestyles that reduce the risk or impact of certain diseases or conditions. In light of FDA guidance, we believe that none of our existing online services and mobile
applications are subject to regulation as a medical device under applicable FDA regulations. We are required to determine whether FDA regulations would apply to any of our applications and the FDA could disagree with our determination. It is also
possible that products or services that we may offer in the future could subject us to such regulation or that current rules could change or be interpreted to apply to some of our existing online services or mobile applications. In addition, it is
possible that our mobile health offerings could fall under the scope of the FTC Act or the Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended by the Health Information Technology for Economic and Clinical Health (HITECH)
Act of 2009. In April 2016, the FTC released a
web-based
tool in conjunction with the U.S. Department of Health and Human Services (HHS), Office of National Coordinator for Health Information Technology (ONC)
and Office for Civil Rights (OCR), and the FDA, to help mobile application developers determine which federal privacy laws might apply to their applications. At the same time, the FTC released guidance aimed at mobile health developer compliance
with the FTC Act. In February 2016, OCR posted guidance on its mHealth Developer Portal regarding scenarios in which HIPAA might apply to mobile health applications. Complying with such rules and regulations could be burdensome and expensive and
could delay our introduction of new services or applications.
|
We may be subject to claims brought
against us as a result of content we provide
Consumers access health-related information through our online services,
including information regarding particular medical conditions and possible adverse reactions or side effects from medications. Physicians and other healthcare professionals use our services to access clinical reference sources, commentary from
leading medical experts, medical news, and coverage of professional meetings and conferences. If our content, or content we obtain from third parties, contains inaccuracies, it is possible that physicians, consumers, employees, health plan members
or others may sue us for various causes of action. Although our Websites and mobile applications contain terms and conditions, including disclaimers of liability, that are intended to reduce or eliminate our liability, the law governing the validity
and enforceability of online agreements and other electronic transactions is evolving. We could be subject to claims by third parties that our online agreements with consumers and physicians that provide the terms and conditions for use of our
Websites and mobile applications are unenforceable. A finding by a court that these agreements are invalid and that we are subject to liability could harm our business and require costly changes to our business.
We have editorial procedures in place to provide quality control of the information that we publish or provide. However, we cannot assure
you that our editorial and other quality control procedures will be sufficient to ensure that there are no errors or omissions in particular content. Even if potential claims do not result in liability to us, investigating and defending against
these claims could be expensive and time-consuming and could divert managements attention away from our operations. In addition, our business is based on establishing
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
16
the reputation of our Websites as trustworthy and dependable sources of healthcare information. Allegations of impropriety or inaccuracy, even if unfounded, could harm our reputation and
business.
Government regulation of the Internet could adversely affect our business
The Internet and its associated technologies are subject to various laws and government regulation. Our failure, or the failure of our
business partners or third-party service providers, to accurately anticipate the application of these laws and regulations to our products and services and the manner in which we deliver them, or any other failure to comply with such laws and
regulations, could create liability for us, result in adverse publicity and negatively affect our business. In addition, new laws and regulations, or new interpretations of existing laws and regulations, may be adopted with respect to online
services, including in areas such as user privacy, confidentiality, consumer protection, marketing, pricing, content, copyrights and patents, and characteristics and quality of products and services. For example, in 2015, the Federal Communications
Commission (FCC) altered a long-standing regulatory regime by classifying broadband Internet access services as common carrier telecommunications services. While this decision appears to most directly impact broadband Internet service providers, how
associated FCC rulemakings may affect our business is difficult to predict.
Internet and mobile user privacy, personal data
security and the use of consumer information to track online activities are major issues both in the United States and abroad. The FTC and state attorneys general continue to pay close attention to Internet privacy issues and, under their current
unfair or deceptive trade practices authority, have been active in investigating and entering into consent decrees with companies because of the online privacy and data security practices of those companies. The FTCs evolving privacy
enforcement activities, as reflected in its workshops, reports and enforcement actions, may be relevant to services we offer. In the U.S., there is a possibility of new legislation and regulation and increased enforcement activities relating to
privacy and behavioral advertising. In addition, changes in industry practice (whether on their own or when combined with regulatory changes) could adversely impact our ability to deliver advertisements based on online behavior. For example, it is
possible that at some point in the future, it will be a common Internet practice for Websites to honor Do Not Track settings in Internet browsers that are turned on by default. Whether through industry practice or in combination with
government regulation, such a development could limit our ability to serve advertisements to consumers based on online behavior on third-party sites or on our sites, which could adversely affect our revenue.
In Europe, Directive 2009/136/EC of the European Parliament and of the Council requires the users full information and consent prior
to the installation and use of any
so-called
cookie on a users computer. This Directive has been implemented differently, if at all, in member states of the European Union and national
requirements to remain compliant with the respective laws may vary. Nevertheless, the provisions of this directive, whether or not effectively implemented in national laws, are now applicable in all the member states of the European Union and
enforcement actions are now being considered by local data protection authorities. In January 2017, the European Commission proposed a new
EU-wide
regulation to replace Directive 2009/136/EC, which if enacted,
may impose new privacy requirements for electronic communications, including the use of cookies and similar technologies on a users computer or mobile device.
Separately, under the General Data Protection Regulation (GDPR), a European-wide regulation that will be fully enforceable by May 25, 2018, various new requirements relating to Internet privacy will
apply, including for users consent for offline and online marketing. European privacy regulators will continue to publish guidance on GDPR requirements throughout 2017. In addition, the GDPR and recent case law in some European countries will
increase the likelihood of the applicability of European law to entities established outside the European Union but processing data of European data subjects.
We have privacy policies posted on our Websites that we believe comply with existing applicable laws requiring notice to users about our information collection, use and disclosure practices. We also
notify users about our information collection, use and disclosure practices relating to data we receive through offline means such as paper health risk assessments. Moreover, we take steps to reasonably protect certain sensitive personal
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
17
information we hold. We cannot assure you that the privacy policies and other statements we provide to users of our products and services, or our practices, will sufficiently protect us from
liability or adverse publicity in this area. A determination by a state or federal agency or court, or European data protection authority or competent court, that any of our practices do not meet applicable standards, or the implementation of new
standards or requirements, including, but not limited to the GDPR or a new cookie regulation in the EU, could adversely affect our business.
Failure to comply with laws relating to privacy and security of personal information, including personal health information, could result in liability to us, and concerns about privacy-related
issues could damage our reputation and our business
Privacy and security of personal information stored or transmitted
electronically, including personal health information, are a major issue in the United States and abroad. While we strive to comply with all applicable privacy and security laws and regulations, as well as our own posted privacy policies, legal
standards for privacy (including, but not limited to, unfairness and deception as enforced by the FTC and state attorneys general) continue to evolve, and any failure or perceived failure to comply may result in private party
litigation against us or proceedings or actions against us by government entities, or could cause us to lose users and customers, which could have a material adverse effect on our business. There has recently been an increase in the number of
privacy-related lawsuits filed against companies. In addition, we are unable to predict what additional legislation or regulation in the area of privacy of personal information, including personal health information, could be enacted and what effect
that could have on our operations and business. Concerns about our practices with regard to the collection, use, disclosure, or security of personal information or other privacy-related matters, even if unfounded and even if we are in compliance
with applicable laws, could damage our reputation and harm our business.
The Privacy Standards and Security Standards under
HIPAA establish a set of national privacy and security standards for the handling of protected health information by health plans, healthcare clearinghouses and healthcare providers (referred to as covered entities) and their
business associates, which are persons or entities that perform certain services for, or functions or activities on behalf of, a covered entity (or another business associate) that involve the creation, receipt, maintenance, or
transmission of protected health information. Certain portions of our business, such as those managing employee or plan member health information for employers or health plans, are subject to HIPAA as business associates of covered entities. In
addition to imposing privacy and security requirements, HIPAA also creates obligations for us to report any unauthorized acquisition, access, use or disclosure of protected health information, known as a breach, to our covered entity customers. The
2013 final HITECH rule modified the breach reporting standard in a manner that made more data security incidents qualify as reportable breaches. In addition, HITECH and its implementing regulations imposed similar data breach notification
requirements on vendors of personal health records that require us to notify affected individuals, the FTC, and, in some cases, the media in the event of a data breach involving the unsecured personal information of users of
The WebMD Health
Network
. Violations of HIPAA may result in civil and criminal penalties and could damage our reputation and harm our business. HITECH increased civil penalty amounts for violations of HIPAA and significantly strengthened enforcement by requiring
HHS to conduct periodic audits to confirm compliance and authorizing state attorneys general to bring civil actions seeking either injunctions or damages in response to violations of HIPAA Privacy Standards and Security Standards that threaten the
privacy of state residents. In July 2016, OCR announced a new phase of the HIPAA Audit Program, which for the first time targets business associates. Audits may, in certain circumstances, lead to full compliance reviews with the potential for
civil or criminal penalties. We cannot assure you that we will adequately address the risks created by these amended HIPAA Privacy Standards and Security Standards. In addition, we are unable to predict what changes to these Standards might be made
in the future or how those changes, or other changes in applicable laws and regulations, could affect our business.
In Europe,
transfers of EU individuals personal data from EU member states to countries not recognized as having adequate protections for personal data, which includes the U.S., are regulated by the Directive 95/46/EC
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
18
and its national implementations. The
U.S.-EU
Safe Harbor Framework, previously used widely to legitimize transfers of personal data from the EU to the
U.S, was declared invalid in 2015. On July 12, 2016, the European Commission adopted the
EU-U.S.
Privacy Shield to replace the
U.S.-EU
Safe Harbor Framework. The
Privacy Shield is intended to protect the fundamental rights of anyone in the EU whose personal data are transferred to the U.S. to a Privacy-Shield certified organization. U.S. companies that self-certify to meeting the requirements of the new
framework, are required to among other things post a privacy policy on their Websites, and are required to reply promptly to any complaints. We are continuing to assess the need for, and form of any transfer mechanism we may use.
Criminal sanctions in Europe for violations of national implementations of the data protection Directive 95/46/EC and of the
e-Privacy
Directive 2002/58/EC are rarely imposed, though national implementations provide for both criminal and administrative sanctions. For example, France provides for administrative fines of up to 3,000,000
Euros in case of illegal collection or processing of personally identifiable information. Under the General Data Protection Regulation, there will be fines of up to 10,000,000 Euros or up to 2% of the global sales for certain comparatively minor
offenses, or up to 20,000,000 Euros or up to 4% of the global sales for more serious offenses.
Failure to maintain CME
accreditation could adversely affect Medscape, LLCs ability to provide online CME offerings
Medscape, LLCs
continuing education activities for physicians and other healthcare professionals are planned and implemented in accordance with the current Essential Areas and Elements and the Policies of the Accreditation Council for Continuing Medical Education
(or ACCME), which oversees providers of CME credit, and other applicable accreditation standards. The ACCMEs standards for commercial support of CME are intended to assure, among other things, that CME activities of ACCME-accredited providers,
such as Medscape, LLC, are independent of commercial interests, which are defined as entities that produce, market,
re-sell
or distribute healthcare goods and services, excluding certain
organizations. Commercial interests and entities owned or controlled by commercial interests are ineligible for accreditation by the ACCME. Medscape, LLCs accreditation is a Joint Accreditation from the ACCME, the Accreditation Council for
Pharmacy Education (as a provider of continuing education for pharmacy) and the American Nurses Credentialing Center (as a provider of continuing education for nurses).
Medscape, LLCs current ACCME accreditation expires in August 2022. If Medscape, LLC
fails to maintain its status as an accredited ACCME provider (whether at the time of such renewal or at an
earlier time as a result of a failure to comply with existing or additional ACCME standards), it will not be permitted to certify CME activities for physicians and other healthcare professionals. Instead, Medscape, LLC would be required to use third
parties to provide such
CME-related
services. That, in turn, could discourage potential supporters from engaging Medscape, LLC to develop CME activities, which could have a material adverse effect on our
business.
Government regulation and industry initiatives could adversely affect the volume of CME programming available
on Medscape Education
CME activities may be subject to government oversight or regulation by Congress, the FDA, HHS,
and local regulatory authorities, both in the United States and abroad. Medscape, LLC, WebMD Global LLC and the financial supporters of their medical education activities may be subject to enforcement actions if any of these activities are deemed
improperly promotional, potentially leading to the termination of financial support. Additionally, Supporters of CME activities could be affected by industry initiatives regarding funding for CME which may cause them to decrease funding for CME
activities.
Government authorities continue to examine pharmaceutical companies financial support of CME including
public reporting requirements as they relate to payments and transfers of value made to physician speakers and faculty involved in CME activities. These authorities interpretation of these reporting requirements, which has been evolving and
may continue to change, could affect pharmaceutical companies
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
19
views of their reporting obligations with respect to payments in support of physician speakers and faculty for CME activities. In implementing internal controls and procedures that promote
adherence to applicable regulations and requirements, supporters of CME may interpret the regulations and requirements differently and may implement varying procedures or requirements. These regulations and requirements which are subject to change,
and the related internal controls and procedures:
|
|
|
may discourage pharmaceutical and medical device companies from providing grants for independent educational activities;
|
|
|
|
may slow their internal approval for such grants;
|
|
|
|
may reduce the volume of third-party supported educational programming on
Medscape Education
to levels that are lower than in the past, thereby
reducing revenue; and
|
|
|
|
may require Medscape, LLC and WebMD Global LLC to make changes to how they offer or provide educational programming.
|
If we are not able to comply with applicable regulations and requirements, then our ability to provide medical education programming will
be limited, which could have an adverse effect on our business.
Failure to comply with applicable anti-corruption laws
could subject us to penalties and other adverse consequences
The United States and other countries have adopted
anti-corruption laws that generally prohibit directly or indirectly giving, offering or promising inducements to public officials to elicit an improper commercial advantage. Under applicable U.S., U.K., German, and most European laws, this
prohibition has been interpreted to apply to doctors and other medical professionals who work in
state-run
hospitals and
state-run
healthcare systems. Some of these laws
broadly prohibit bribery in both the private and public sectors, even to self-employed HCPs. In recent years, several global anti-corruption enforcement actions led to significant monetary penalties against several companies operating in the global
healthcare industry for providing illegal inducements to medical professionals.
As our business expands globally, we (and
others acting on our behalf) increasingly interact with public officials, including with doctors and other medical professionals, at least some of whom work in
state-run
hospitals or healthcare systems. Such
interactions inherently increase the risk of violating applicable anti-corruption laws. While we have implemented compliance policies and procedures to mitigate such risk, our personnel and others acting on our behalf could engage in conduct that
violates such laws, for which we could be held responsible. Under such circumstances, we could be subject to civil and/or criminal penalties and other consequences that could have a material adverse effect on our business, reputation, brand,
financial condition and results of operations.
Other Risks
Applicable to Our Company and to Ownership of Our Securities
We cannot assure you that our exploration of strategic
alternatives will result in us pursuing a transaction or that any such transaction would be successfully completed, and there may be negative impacts on our business as a result of the process of exploring strategic alternatives
On February 16, 2017, we announced that our Board of Directors, working together with our management team and legal and financial
advisors, had commenced a process to explore and evaluate potential strategic alternatives focused on maximizing shareholder value. These alternatives could include, among other things, the sale of part or all of the company, a merger with another
party or other strategic transaction or continuing to execute on WebMDs business plan. Our Board has not set a timetable for this process. There can be no assurance that the exploration of strategic alternatives will result in a transaction or
that any transaction that is agreed to will be completed. Our ability to complete a transaction, if our Board decides to pursue one, will
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
20
depend on numerous factors, some of which are outside of our control, including factors affecting the availability of financing for transactions and the financial markets in general. Even if a
transaction is completed, there can be no assurance that it will be successful or have a positive effect on shareholder value.
Our financial results and operations may be adversely affected by the diversion of management resources to the process of exploring
strategic alternatives and by uncertainty regarding the outcome of the process. For example, the process could lead us to lose or fail to attract employees, customers or business partners. Although we have taken steps to address those risks, there
can be no assurance that any such losses or distractions will not adversely affect our operations or financial results.
Provisions in our organizational documents and Delaware law may inhibit a takeover, which could adversely affect the value of our
Common Stock
Our Restated Certificate of Incorporation and
By-laws,
as well as
Delaware corporate law, contain provisions that could delay or prevent a change of control or changes in our management and board of directors that holders of our common stock might consider favorable and may prevent them from receiving a takeover
premium for their shares. These provisions include, for example, our classified board structure and the authorization of our board of directors to issue up to 50 million shares of preferred stock without a stockholder vote. In addition, our
Restated Certificate of Incorporation provides that stockholders may not act by written consent and may not call special meetings. These provisions apply even if an offer to purchase our company may be considered beneficial by some of our
stockholders. If a change of control or change in management is delayed or prevented, the market price of our common stock could decline.
If certain transactions occur with respect to our capital stock, limitations may be imposed on our ability to utilize net operating loss carryforwards and tax credits to reduce our income taxes
WebMD has substantial accumulated net operating loss (NOL) carryforwards and tax credits available to offset taxable
income in future tax periods. If certain transactions occur with respect to WebMDs capital stock (including issuances, redemptions, recapitalizations, exercises of options, conversions of convertible debt, purchases or sales by
5%-or-greater
shareholders and similar transactions) that result in a cumulative change of more than 50% of the ownership of capital stock over a three-year period (as
determined under rules prescribed by Section 382 of the U.S. Internal Revenue Code and applicable Treasury regulations), an annual limitation would be imposed with respect to the ability to utilize WebMDs NOL carryforwards and federal tax
credits that existed at the time of the ownership change.
In November 2008, HLTH repurchased shares of its common stock in a
tender offer. The tender offer resulted in a cumulative change of more than 50% of the ownership of HLTHs capital, as determined under rules prescribed by Section 382 of the Code and applicable Treasury regulations. As a result of this
ownership change, there is an annual limitation imposed on the amount of the NOL carryforwards and federal tax credits existing at the time of the ownership change that we may use to offset income in each tax year following the ownership change.
In September 2014 and December 2016, WebMD repurchased shares of its common stock in tender offers (collectively, the
Tender Offers). Completion of the Tender Offers may increase the possibility of another ownership change, which could decrease the existing annual limitation and would apply to all NOL carryforwards and tax credits generated prior to
this potential new ownership change.
We may not be successful in protecting our intellectual property and proprietary
rights
Our intellectual property and proprietary rights are important to our businesses. The steps that we take to
protect our intellectual property, proprietary information and trade secrets may prove to be inadequate and, whether or not adequate, may be expensive. We rely on a combination of trade secret, patent and other intellectual property laws and
confidentiality procedures and
non-disclosure
contractual provisions to protect our intellectual property. We cannot assure you that we will be able to detect potential or actual misappropriation or
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
21
infringement of our intellectual property, proprietary information or trade secrets. Even if we detect misappropriation or infringement by a third party, we cannot assure you that we will be able
to enforce our rights at a reasonable cost, or at all. In addition, our rights to intellectual property, proprietary information and trade secrets may not prevent independent third-party development and commercialization of competing products or
services.
Third parties may claim that we are infringing their intellectual property, and we could suffer significant
litigation or licensing expenses or be prevented from providing certain services
We have been, and may continue to be,
subject to claims that we are misappropriating or infringing intellectual property or other proprietary rights of others. These claims, even if not meritorious, may be expensive to defend and divert managements attention from our operations.
If we become liable to third parties for infringing these rights, we could be required to pay a substantial damage award and to develop
non-infringing
technology, obtain a license or cease selling the products
or services that use or contain the infringing intellectual property. We may be unable to develop
non-infringing
products or services or obtain a license on commercially reasonable terms, or at all. We may
also be required to indemnify our customers if they become subject to third-party claims relating to intellectual property that we license or otherwise provide to them, which could be costly.
Acquisitions, business combinations and other transactions may be difficult to complete and, if completed, may have negative
consequences for our business and our security holders
We may seek to acquire or to engage in business combinations
with companies engaged in complementary businesses. In addition, we may enter into joint ventures, strategic alliances or similar arrangements with third parties. These transactions may result in changes in the nature and scope of our operations and
changes in our financial condition. Our success in completing these types of transactions will depend on, among other things, our ability to locate suitable candidates and negotiate mutually acceptable terms with them, and to obtain adequate
financing. Significant competition for these opportunities exists, which may increase the cost of and decrease the opportunities for these types of transactions. Financing for these transactions may come from several sources, including:
|
|
|
cash and cash equivalents on hand and marketable securities;
|
|
|
|
proceeds from the incurrence of indebtedness; and
|
|
|
|
proceeds from the issuance of common stock, preferred stock, convertible debt or of other securities.
|
The issuance of additional equity or debt securities could:
|
|
|
cause substantial dilution of the percentage ownership of our stockholders at the time of the issuance;
|
|
|
|
cause substantial dilution of our earnings per share;
|
|
|
|
subject us to the risks associated with increased leverage, including a reduction in our ability to obtain financing or an increase in the cost of any
financing we obtain;
|
|
|
|
subject us to restrictive covenants that could limit our flexibility in conducting future business activities; and
|
|
|
|
adversely affect the prevailing market price for our outstanding securities.
|
We do not intend to seek security holder approval for any such acquisition or security issuance unless required by applicable law,
regulation or the terms of then-existing securities.
Our business will suffer if we fail to successfully integrate
acquired businesses and technologies or to assess the risks in particular transactions
We have in the past acquired,
and may in the future acquire, businesses, technologies, services, product lines and other assets. The successful integration of the acquired businesses and assets into our operations, on a
cost-
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
22
effective basis, can be critical to our future performance. The amount and timing of the expected benefits of any acquisition, including potential synergies between our company and the acquired
business, are subject to significant risks and uncertainties. These risks and uncertainties include, but are not limited to, those relating to:
|
|
|
our ability to maintain relationships with the customers of the acquired business;
|
|
|
|
our ability to retain or replace key personnel of the acquired business;
|
|
|
|
potential conflicts in sponsor or advertising relationships or in relationships with strategic partners;
|
|
|
|
our ability to coordinate organizations that are geographically diverse and may have different business cultures; and
|
|
|
|
compliance with regulatory requirements.
|
We cannot guarantee that any acquired businesses will be successfully integrated with our operations in a timely or cost-effective manner, or at all. Failure to successfully integrate acquired businesses
or to achieve anticipated operating synergies, revenue enhancements or cost savings could have a material adverse effect on our business, financial condition and results of operations.
Although our management attempts to evaluate the risks inherent in each transaction and to value acquisition candidates appropriately, we
cannot assure you that we will properly ascertain all such risks or that acquired businesses and assets will perform as we expect or enhance the value of our company as a whole. In addition, acquired companies or businesses may have larger than
expected liabilities that are not covered by the indemnification, if any, that we are able to obtain from the sellers.
We may not be able to raise additional funds when needed for our business or to exploit opportunities
Our future liquidity and capital requirements will depend upon numerous factors, including the success of our service offerings, market
developments, and repurchases of our common stock. We may need to raise additional funds to support expansion, develop new or enhanced applications and services, respond to competitive pressures, acquire complementary businesses or technologies or
take advantage of unanticipated opportunities. If required, we may raise such additional funds through public or private debt or equity financing, strategic relationships or other arrangements. There can be no assurance that such financing will be
available on acceptable terms, if at all, or that such financing will not be dilutive to our stockholders.
W
EB
MD 2016 A
NNUAL
R
EPORT
R
ISK
F
ACTORS
A
NNEX
A
NNEX
F
P
AGE
23
ANNEX G
WEBMD HEALTH CORP. 2016 ANNUAL REPORT
EXPLANATION OF NON-GAAP FINANCIAL MEASURES
Annex C above (the MD&A) includes both financial measures in accordance with U.S. generally accepted accounting principles, or
GAAP, as well as non-GAAP financial measures. The non-GAAP financial measures represent earnings before interest, taxes, non-cash and other items (which we refer to as Adjusted EBITDA) and related per share amounts. Adjusted EBITDA
should be viewed as supplemental to, and not as an alternative for net income or loss calculated in accordance with GAAP (referred to below as net income) or income or loss from continuing operations calculated in accordance with GAAP
(referred to below as income from continuing operations). The MD&A also includes reconciliations of non-GAAP financial measures to GAAP financial measures.
Adjusted EBITDA is used by our management as an additional measure of our companys performance for purposes of business decision-making,
including developing budgets, managing expenditures, and evaluating potential acquisitions or divestitures. Period-to-period comparisons of Adjusted EBITDA help our management identify additional trends in our companys financial results that
may not be shown solely by period-to-period comparisons of net income or income from continuing operations. In addition, we may use Adjusted EBITDA in the incentive compensation programs applicable to some of our employees in order to evaluate our
companys performance. Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items, particularly those items that are recurring in nature. In order to compensate for those limitations, management also
reviews the specific items that are excluded from Adjusted EBITDA, but included in net income or income from continuing operations, as well as trends in those items. The amounts of those items are set forth, for the applicable periods, in the
reconciliations of Adjusted EBITDA to net income or income from continuing operations that accompany our press releases and disclosure documents containing non-GAAP financial measures, including the reconciliations contained in the MD&A.
We believe that the presentation of Adjusted EBITDA is useful to investors in their analysis of our results for reasons similar to the reasons
why our management finds it useful and because it helps facilitate investor understanding of decisions made by management in light of the performance metrics used in making those decisions. In addition, as more fully described below, we believe that
providing Adjusted EBITDA, together with a reconciliation of Adjusted EBITDA to net income or income from continuing operations, helps investors make comparisons between our company and other companies that may have different capital structures,
different effective income tax rates and tax attributes, different capitalized asset values and/or different forms of employee compensation. However, Adjusted EBITDA is intended to provide a supplemental way of comparing our company with other
public companies and is not intended as a substitute for comparisons based on net income or income from continuing operations. In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to
evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measures and the corresponding GAAP measures provided by each company under applicable SEC rules.
The following is an explanation of the items excluded by us from Adjusted EBITDA but included in net income and income from continuing
operations:
|
|
|
Depreciation and Amortization
. Depreciation and amortization expense is a non-cash expense relating
to capital expenditures and intangible assets arising from acquisitions that are expensed on a straight-line basis over the estimated useful life of the related assets. We exclude depreciation and amortization expense from Adjusted EBITDA because we
believe that (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and
|
W
EB
MD
2016 A
NNUAL
R
EPORT
E
XPLANATION
OF
N
ON
-GAAP F
INANCIAL
M
EASURES
A
NNEX
G P
AGE
1
|
(ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired tangible and intangible assets. Accordingly, we believe
that this exclusion assists management and investors in making period-to-period comparisons of operating performance. Investors should note that the use of tangible and intangible assets contributed to revenue in the periods presented and will
contribute to future revenue generation and should also note that such expense will recur in future periods.
|
|
|
|
Stock-Based Compensation Expense
. Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards to employees. We believe that excluding the effect of stock-based
compensation from Adjusted EBITDA assists management and investors in making period-to-period comparisons in our companys operating performance because (i) the amount of such expenses in any specific period may not directly correlate to
the underlying performance of our business operations and (ii) such expenses can vary significantly between periods as a result of the timing of grants of new stock-based awards, including grants in connection with acquisitions. Additionally,
we believe that excluding stock-based compensation from Adjusted EBITDA assists management and investors in making meaningful comparisons between our companys operating performance and the operating performance of other companies that may use
different forms of employee compensation or different valuation methodologies for their stock-based compensation. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating
results in the periods presented and are expected to contribute to operating results in future periods. Investors should also note that such expenses will recur in the future.
|
|
|
|
Interest Income and Expense.
Interest income is associated with the level of marketable debt securities and other interest bearing accounts in which we invest, and interest expense is related to our
companys capital structure (including non-cash interest expense relating to our convertible notes). Interest income and expense varies over time due to a variety of financing transactions and due to acquisitions and divestitures that we have
entered into or may enter into in the future. We have, in the past, issued convertible debentures, repurchased shares in cash tender offers and repurchased shares and convertible debentures through other repurchase transactions, and completed the
divestiture of certain businesses. We exclude interest income and interest expense from Adjusted EBITDA (i) because these items are not directly attributable to the performance of our business operations and, accordingly, their exclusion
assists management and investors in making period-to-period comparisons of operating performance and (ii) to assist management and investors in making comparisons to companies with different capital structures. Investors should note that
interest income and expense will recur in future periods.
|
|
|
|
Income Tax Provision (Benefit).
We maintain a valuation allowance on a portion of our net deferred tax assets (including our net operating
loss carryforwards), the amount of which may change from quarter to quarter based on factors that are not directly related to our results for the quarter. The valuation allowance is either adjusted through the statement of operations or additional
paid-in capital. The timing of such adjustments has not been consistent and as a result, our income tax expense can fluctuate significantly from period to period in a manner not directly related to our operating performance. We exclude the income
tax provision (benefit) from Adjusted EBITDA (i) because we believe that the income tax provision (benefit) is not directly attributable to the underlying performance of our business operations and, accordingly, its exclusion assists management
and investors in making period-to-period comparisons of operating performance and (ii) to assist management and investors in making comparisons to companies with different tax attributes. Investors should note that income tax provision
(benefit) will recur in future periods.
|
|
|
|
Other Items.
We engage in other activities and transactions that can impact our net income or
income from continuing operations. In recent periods, these other items included, but were not limited to: (i) gain or loss on investments; (ii) settlement of litigation or claims; (iii) severance expense; and
|
W
EB
MD
2016 A
NNUAL
R
EPORT
E
XPLANATION
OF
N
ON
-GAAP F
INANCIAL
M
EASURES
A
NNEX
G P
AGE
2
|
(iv) loss on repurchases of our convertible notes. We exclude these other items from Adjusted EBITDA because we believe these activities or transactions are not directly attributable to the
performance of our business operations and, accordingly, their exclusion assists management and investors in making period-to-period comparisons of operating performance. Investors should note that some of these other items may recur in future
periods.
|
W
EB
MD
2016 A
NNUAL
R
EPORT
E
XPLANATION
OF
N
ON
-GAAP F
INANCIAL
M
EASURES
A
NNEX
G P
AGE
3
ANNEX H
W
EB
MD H
EALTH
C
ORP
.
A
MENDED
AND
R
ESTATED
A
UDIT
C
OMMITTEE
C
HARTER
Effective as of October 30, 2015
A. Purpose and Role
|
1.
|
General
. The Audit Committee (the Committee) has been established by the Board of Directors (the Board) of WebMD Health Corp. (the
Corporation) to oversee:
|
|
|
|
the accounting and financial reporting processes of the Corporation,
|
|
|
|
the effectiveness of the Corporations internal control over financial reporting,
|
|
|
|
the performance of the Corporations internal audit function and independent auditor,
|
|
|
|
the audits of the Corporations financial statements and internal control over financial reporting, and
|
|
|
|
related matters, including administration of the Corporations Code of Business Conduct and compliance with legal and regulatory requirements;
|
with such oversight responsibilities being delegated by the Board to the Committee to the full extent
contemplated by the requirements applicable to audit committees of companies listed for quotation on The NASDAQ Global Market under applicable law and under the listing standards of The NASDAQ Stock Market.
|
2.
|
Oversight Role
. The Committees role is one of oversight, recognizing that the Corporations management is responsible for preparing the
Corporations financial statements and that the Corporations registered public accounting firm is responsible for auditing those financial statements. In carrying out its oversight responsibilities, the Committee is not providing any
expert or professional certification as to the Corporations financial statements or the registered public accounting firms work.
|
|
3.
|
Reporting Relationships; Retention Authority
. The Corporations registered public accounting firm shall report directly to the Committee and the Committee
shall have the sole authority to appoint and terminate the Corporations registered public accounting firm and to approve the amount of their compensation and shall have the authority to cause its payment by the Corporation. The
Corporations internal audit function shall also report directly to the Committee. The Committee shall have the sole authority to appoint and terminate any outside parties retained by the Corporation to provide internal audit services and to
approve the amount of their compensation and shall have the authority to cause its payment by the Corporation.
|
B.
Composition
|
1.
|
Members
. The Committee shall consist of as many members as the Board shall determine, but in any event not fewer than three members. Members of the Committee
shall be appointed by the Board in accordance with the
By-laws
of the Corporation. Committee members shall serve until the earliest of their resignation or their replacement or removal by the Board in
accordance with this Charter and the
By-laws
of the Corporation.
|
|
2.
|
Qualifications
. Each member of the Committee shall, in the judgment of the Board (or an appropriate committee of the Board), meet the following requirements (the
Independence Requirements):
|
|
|
|
all independence requirements, under applicable laws, rules and regulations, for members of audit committees of companies listed for quotation on The
NASDAQ Global Market;
|
|
|
|
all applicable independence requirements of The NASDAQ Stock Market for members of audit committees of companies listed for quotation on The NASDAQ
Global Market; and
|
|
|
|
being free from any relationship that, in the opinion of the Board (or an appropriate committee of the Board), would interfere with the exercise of
independent judgment as a member of the Committee.
|
In addition, the following additional requirements
(together with the Independence Requirements, the Qualification Requirements) shall also apply:
|
|
|
each member of the Committee shall, in the judgment of the Board (or an appropriate committee of the Board), meet the basic financial literacy
requirements, under applicable law, for members of audit committees of companies listed for quotation on The NASDAQ Global Market;
|
|
|
|
each member of the Committee shall, in the judgment of the Board (or an appropriate committee of the Board), meet the basic financial literacy
requirements under applicable listing standards of the NASDAQ Stock Market for members of audit committees of companies listed for quotation on The NASDAQ Global Market;
|
|
|
|
each member of the Committee must not have participated in the preparation of the financial statements of the Corporation (or any subsidiary of the
Corporation) at any time during the three years prior to appointment as a member of the Committee;
|
|
|
|
at least one member of the Committee shall, in the judgment of the Board (or an appropriate committee of the Board), have previous employment
experience in finance or accounting, requisite professional certification in accounting, or any other comparable experience or background which results in the individuals financial sophistication, including being or having been a chief
executive officer, chief financial officer, or other senior officer with financial oversight responsibilities (which member may be the one who is also an audit committee financial expert under applicable rules promulgated by the
Securities and Exchange Commission); and
|
|
|
|
at least one member of the Committee shall, in the judgment of the Board (or an appropriate committee of the Board), be an audit committee
financial expert under the applicable rules promulgated by the Securities and Exchange Commission.
|
In
the event that the Board (or an appropriate committee of the Board) determines that a member ceases to meet the Qualification Requirements applicable to individual members, the Board shall consider the removal and replacement of such member;
provided, however, that the Board may, if necessary or appropriate in its judgment, appoint or retain Committee members in reliance on any available exceptions to any of the Qualification Requirements for the time period such exceptions are
available. A failure by one or more Committee members to meet any of the Qualification Requirements (or of there to be an audit committee financial expert or a Committee member meeting other qualifications required of one or more
Committee members) shall not invalidate decisions made, or actions taken, by the Committee.
A
MENDED
AND
R
ESTATED
A
UDIT
C
OMMITTEE
C
HARTER
E
FFECTIVE
AS
OF
O
CTOBER
30, 2015
A
NNEX
H P
AGE
2
|
3.
|
Chairperson
. A Chairperson of the Committee shall be appointed by the Board or by the Committee. If the Board does not do so, the Committee members shall elect a
Chairperson by vote of a majority of the full Committee.
|
|
4.
|
Removal and Replacement
. The members of the Committee may be removed or replaced, and any vacancies on the Committee shall be filled by the Board in accordance
with the
By-laws
of the Corporation.
|
C. Operations
|
1.
|
Meetings
. The Committee shall determine the schedule and frequency of the Committee meetings, provided that the Committee shall meet at least four times per
year. Minutes of these meetings shall be kept and filed with the Secretary of the Corporation.
|
|
2.
|
Agenda; Reports
. The Committee shall determine the agenda for its meetings. The Committee may invite other Board members, members of management and others to
attend meetings and provide pertinent information and reports, as it deems necessary; provided, however, that the Committee members shall meet regularly: with appropriate representatives of the Corporations registered public accounting firm
without any members of management present; and with the Corporations head of internal audit without any other members of management present. Nothing in this Charter shall be construed to restrict the reliance by any member of the Committee, to
the full extent permitted by law, on information, opinions, reports or statements presented to the Committee by any of the Corporations officers or employees, or other committees of the Board, or by any other person selected with reasonable
care by or on behalf of the Corporation or the Committee as to matters the Committee member reasonably believes are within such other persons professional or expert competence.
|
|
3.
|
Report to Board
. The Committee shall report its actions and recommendations to the Board at the next Board meeting after each Committee meeting or, if so
determined by the Committee, by distribution to the members of the Board of the minutes of a meeting, a unanimous written consent or other relevant documents.
|
D. Authority and Responsibilities Delegated to the Committee
|
1.
|
The Committee shall assess the adequacy of this Charter and the procedures developed by the Committee to implement this Charter on at least an annual basis and shall
submit any proposed amendments to this Charter that the Committee recommends be made to the Board for its approval.
|
|
2.
|
The Committee shall review and discuss with corporate management and the Corporations registered public accounting firm:
|
|
|
|
the unaudited quarterly financial results prior to the release of earnings and/or the quarterly financial statements prior to filing or distribution;
|
|
|
|
the audited financial results for the year and the proposed footnotes to the financial statements prior to filing or distribution, including
disclosures of related party transactions;
|
|
|
|
other financial information to be included in the Corporations SEC filings, including in Managements Discussion and Analysis of
Financial Condition and Results of Operations section;
|
A
MENDED
AND
R
ESTATED
A
UDIT
C
OMMITTEE
C
HARTER
E
FFECTIVE
AS
OF
O
CTOBER
30, 2015
A
NNEX
H P
AGE
3
|
|
|
the Report of Management on Internal Control Over Financial Reporting and the registered public accounting firms attestation of the
Report prior to filing or distribution;
|
|
|
|
all major accounting policy matters involved in the preparation of interim and annual financial reports and any deviations from prior practice; and
|
|
|
|
the application of significant accounting and auditing policies, including new pronouncements, to the Corporations financial reports.
|
|
3.
|
In consultation with corporate management, the Corporations registered public accounting firm and the internal auditors, the Committee shall review the
Corporations accounting procedures, internal controls, financial reporting processes and disclosure controls and procedures, and shall take such action with respect to any of those matters as the Committee may determine to be necessary or
appropriate. The Committee shall annually obtain and review a report from the Corporations registered public accounting firm, which shall be delivered prior to and within 90 days of the filing of the audit report with the SEC, which sets
forth:
|
|
|
|
all critical accounting policies and practices used by the Corporation,
|
|
|
|
all alternative accounting treatments of financial information within GAAP related to material items that have been discussed with management,
including the ramifications of the use of such alternative treatments and disclosures and the treatment preferred by the accounting firm, and
|
|
|
|
other material written communications between the Corporations registered public accounting firm and management.
|
|
4.
|
The Committee shall oversee the work of the Corporations registered public accounting firm and evaluate their performance at least annually and shall receive and
review:
|
|
|
|
a report by the Corporations registered public accounting firm describing the firms internal quality-control procedures and any material
issues raised by the most recent internal quality-control review, or peer review, of the registered public accounting firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five years, respecting
one or more independent audits carried out by the firm, and any steps taken to deal with any such issues; and
|
|
|
|
any other required reports from the registered public accounting firm.
|
|
5.
|
At least annually, the Committee shall consider the independence of the registered public accounting firm, including whether the provision by the firm of permitted
non-audit
services is compatible with independence, and obtain and review a report from, and discuss with, the registered public accounting firm describing all relationships between the auditor and the Corporation.
|
|
6.
|
The Committee shall determine whether to
pre-approve,
to the extent required by applicable law, all potential audit engagements
and any permitted
non-audit
engagements and the related fees and terms with the Corporations registered public accounting firm. The Committee may establish policies and procedures for the engagement of
the Corporations registered public accounting firm to provide permitted
non-audit
services. The Committee shall review with management and the registered public accounting firm, at a time when the annual
audit plan is being developed, the plans timing, scope, staffing, locations, foreseeable issues, priorities and procedures, and the engagement team.
|
A
MENDED
AND
R
ESTATED
A
UDIT
C
OMMITTEE
C
HARTER
E
FFECTIVE
AS
OF
O
CTOBER
30, 2015
A
NNEX
H P
AGE
4
|
7.
|
The Committee shall review with the Corporations registered public accounting firm, on completion of the annual audit, their experience, any restrictions on their
work, cooperation received, significant disagreements with corporate management, their findings and their recommendations. The Committee shall oversee the resolution of any disagreements between corporate management and the registered public
accounting firm. The Committee shall discuss with the registered public accounting firm those matters required to be communicated to audit committees by the registered public accounting firm in accordance with law and with professional standards
applicable to the registered public accounting firm.
|
|
8.
|
The Committee shall recommend to the Board, based on the reviews performed by the Committee, whether the annual financial statements should be included in the Annual
Report on Form
10-K.
|
|
9.
|
The Committee shall oversee the Corporations internal auditing program, shall receive regular reports from the Corporations internal auditors regarding the
results of their procedures and shall receive corporate managements response and
follow-up
to those reports. The Committee shall evaluate the Corporations internal auditors, including any outside
parties retained by the Corporation to provide internal audit services.
|
|
10.
|
To the extent requested by the Board from time to time, the Committee shall review the Corporations policies with respect to risk assessment and risk management,
and review contingent liabilities and risks that may be material to the Corporation and major legislative and regulatory developments which could materially impact the Corporations contingent liabilities and risks.
|
|
11.
|
The Committee shall review and monitor any programs or procedures that the Corporation has instituted to correct any control deficiencies noted by the
Corporations registered public accounting firm or the internal auditors in their reviews.
|
|
12.
|
The Committee shall oversee and confirm the rotation, in accordance with applicable law, of the lead audit partner of the Corporations registered public
accounting firm.
|
|
13.
|
The Committee shall establish policies with respect to hiring by the Corporation of current or former employees of the Corporations registered public accounting
firm.
|
|
14.
|
The Committee shall administer the Corporations Code of Business Conduct in accordance with its terms, shall have authority to construe all terms, provisions,
conditions and limitations of the Code and to make factual determinations required for the administration of the Code and, in connection with such administration shall:
|
|
|
|
establish procedures for (a) the receipt, retention and treatment of complaints received by the Corporation regarding accounting, internal
accounting controls, or auditing matters and (b) the confidential, anonymous submission by employees of the Corporation of concerns regarding questionable accounting or auditing matters; and
|
|
|
|
review with management proposed related party transactions (as such term is used in Item 404 of SEC Regulation
S-K)
and approve any such transactions the Committee determines to be appropriate for the Corporation to enter into.
|
The Committee shall coordinate with the full Board and the Nominating & Governance Committee on matters relating to the Corporations compliance programs, implementation of the Code of
Business Conduct, corporate governance, compliance with legal requirements, pending litigation, regulatory proceedings and claims and such other matters as the Committee may determine to be appropriate.
A
MENDED
AND
R
ESTATED
A
UDIT
C
OMMITTEE
C
HARTER
E
FFECTIVE
AS
OF
O
CTOBER
30, 2015
A
NNEX
H P
AGE
5
|
15.
|
The Committee shall annually prepare a report to stockholders as required to be included in the Corporations annual proxy statement filed with the Securities and
Exchange Commission.
|
The foregoing list is not intended to be exhaustive, and the Committee shall, in addition,
have such powers as may be necessary or appropriate in furtherance of the objectives set forth in this Charter or as may, from time to time, be delegated by the Board. The adoption of this Charter and any amendments hereto shall not be construed to
reduce any power or authority previously delegated to the Committee by the Board.
The Committee shall have the power to
delegate its authority to subcommittees or individual members of the Committee as it deems appropriate, to the full extent permitted under applicable law and applicable listing standards of The NASDAQ Stock Market; provided, however, that any
decision made pursuant to the foregoing delegation of authority with respect to the Committee authority under Paragraph 6 of this Section D shall be presented to the Committee at its next regularly-scheduled meeting. In addition, the Committee shall
have the power to delegate its authority to other members of the Board who meet the Independence Requirements as it deems appropriate, to the full extent permitted by applicable law and the listing standards of The NASDAQ Stock Market applicable to
the Corporation; provided, however, that in no event may it delegate its authority to such other members of the Board under Paragraphs 1 through 8 or Paragraph 15 of this Section D. The Committee shall have the power to delegate its authority under
Paragraph 14 of this Section D with respect to administration of the Corporations Code of Business Conduct to the General Counsel of the Corporation and the Compliance Officer referred to in the Code, except with respect to the authority to
amend the Code and to grant waivers to the Corporations directors, executive officers and senior financial officers.
The Committee shall have the power to conduct or authorize investigations into any matters within the scope of its responsibilities. The
Committee shall have direct access to management of the Corporation and may obtain advice and assistance from the Corporations Legal, Human Resources, Tax, Finance, Accounting and Internal Audit Departments and other specialists. The Committee
shall have the power to retain consultants, accountants and other outside advisors to advise and assist it in any manner it deems appropriate. The Committee may also retain outside legal counsel, as it deems appropriate. The Committee shall have the
sole authority to retain and terminate such consultants, accountants, advisors and counsel and to review and approve their fees and other retention terms and shall have the authority to cause the payment of such fees by the Corporation.
A
MENDED
AND
R
ESTATED
A
UDIT
C
OMMITTEE
C
HARTER
E
FFECTIVE
AS
OF
O
CTOBER
30, 2015
A
NNEX
H P
AGE
6
ANNEX I
W
EB
MD H
EALTH
C
ORP
.
A
MENDED
AND
R
ESTATED
C
OMPENSATION
C
OMMITTEE
C
HARTER
Effective as of October 30, 2013
A. Purpose
|
1.
|
General
. The Compensation Committee (the Committee) has been established by the Board of Directors (the Board) of WebMD Health Corp. (the Corporation) to determine the
compensation arrangements of the executive officers of the Corporation, to assist the Board in providing oversight of the compensation programs applicable to other employees of the Corporation and to provide assistance and recommendations to the
Board with respect to various other aspects of the Corporations compensation policies and practices and related matters.
|
|
2.
|
Equity Compensation Plans
. The Committee has the authority under the Corporations existing equity compensation plans (and shall have the authority under any future equity compensation plans that so provide)
to make awards in any form permitted under the respective plans. All option grants and other stock-based awards to executive officers or Board members shall require Committee approval.
|
B. Composition
|
1.
|
Members
. The Committee shall consist of as many members as the Board shall determine, but in any event not fewer than three members. Members of the Committee shall be appointed by the Board in accordance with the
By-laws
of the Corporation. Committee members shall serve until the earliest of their resignation or their replacement or removal by the Board in accordance with this Charter and the
By-laws
of the Corporation.
|
|
2.
|
Qualifications
. Each member of the Committee shall, in the judgment of the Board (or an appropriate committee of the Board), meet the following requirements (the Independence Requirements):
|
|
|
|
all independence requirements, under applicable laws, rules and regulations, for members of compensation committees of companies listed for quotation on the NASDAQ Global Market;
|
|
|
|
all applicable independence requirements of The NASDAQ Stock Market for members of compensation committees of companies listed for quotation on the NASDAQ Global Market; and
|
|
|
|
being free from any relationship that, in the opinion of the Board (or an appropriate committee of the Board), would interfere with the exercise of independent judgment as a member of the Committee.
|
In addition, each member shall, in the judgment of the Board (or an appropriate committee of the Board), also meet the following additional
requirements (together with the Independence Requirements, the Qualification Requirements):
|
|
|
being non-employee directors (within the meaning of Rule
16b-3
promulgated under the Securities Exchange Act of 1934, as amended); and
|
|
|
|
being outside directors (within the meaning of Section 162(m) of the Internal Revenue Code of 1986, as amended, and the regulations thereunder) (Section 162(m)).
|
In the event that the Board (or an appropriate committee of the Board) determines that a member ceases to meet the Qualification Requirements,
the Board shall consider the removal and replacement of such member; provided, however, that the Board may, if necessary or appropriate in its judgment, appoint or retain Committee members in reliance on any available exceptions to any of the
Qualification Requirements for the time period such exceptions are available. A failure by one or more Committee members to meet any of the Qualification Requirements shall not invalidate decisions made, or actions taken, by the Committee.
|
3.
|
Chairperson
. A Chairperson of the Committee shall be appointed by the Board or by the Committee. If the Board does not do so, the Committee members shall elect a Chairperson by vote of a majority of the full
Committee.
|
|
4.
|
Removal and Replacement
. The members of the Committee may be removed or replaced, and any vacancies on the Committee shall be filled, by the Board in accordance with the
By-laws
of the Corporation.
|
C. Operations
|
1.
|
Meetings
. The Committee shall determine the schedule and frequency of the Committee meetings, provided that the Committee shall meet at least twice per year. Minutes of these meetings shall be kept and filed with
the Secretary of the Corporation.
|
|
2.
|
Agenda; Reports
. The Committee shall determine the agenda for its meetings. The Committee may invite other Board members, members of management and others to attend meetings and provide pertinent information and
reports, as it deems necessary; provided, however, that the Chief Executive Officer of the Corporation may not be present during voting or deliberations with respect to his or her own compensation arrangements. Nothing in this Charter shall be
construed to restrict the reliance by any member of the Committee, to the full extent permitted by law, on information, opinions, reports or statements presented to the Committee by any of the Corporations officers or employees, or other
committees of the Board, or by any other person selected with reasonable care by or on behalf of the Corporation or the Committee as to matters the Committee member reasonably believes are within such other persons professional or expert
competence.
|
|
3.
|
Report to Board
. The Committee shall report its actions and recommendations to the Board at the next Board meeting after each Committee meeting or, if so determined by the Committee, by distribution to the
members of the Board of the minutes of a meeting, a unanimous written consent or other relevant documents.
|
D. Authority and
Responsibilities Delegated to the Committee
|
1.
|
The Committee shall review and approve compensation arrangements for the Corporations Chief Executive Officer and other executive officers and shall have the sole authority to make any determinations and take any
actions it determines to be necessary or appropriate in administering any such compensation arrangements.
|
|
2.
|
The Committee shall provide general oversight with respect to compensation policies relating to the Corporations other officers and employees and make recommendations to the Board for any changes to such policies
that the Committee determines to be necessary or appropriate.
|
|
3.
|
The Committee shall review and approve compensation arrangements for
non-employee
directors in their capacity as directors and members of the standing committees of the Board. The
Committee shall review and approve compensation arrangements for any
non-employee
directors who provide services to the Corporation other than in their capacity as directors.
|
|
4.
|
The Committee shall evaluate the Chief Executive Officers performance in light of the Corporations goals and objectives and have the sole authority to determine and approve the compensation level of the
Companys Chief Executive Officer based on this evaluation.
|
|
5.
|
The Committee shall assist the Board and the Nominating & Governance Committee of the Board in overseeing the development of executive succession plans.
|
|
6.
|
The Committee shall administer the Corporations equity compensation plans and such other compensation plans as the Board may determine (the Plans) in accordance with their terms, shall
|
A
MENDED
AND
R
ESTATED
C
OMPENSATION
C
OMMITTEE
C
HARTER
E
FFECTIVE
AS
OF
O
CTOBER
30, 2013
A
NNEX
I
P
AGE
2
|
construe all terms, provisions, conditions and limitations of the Plans and shall make factual determinations required for the administration of the Plans.
|
|
7.
|
The Committee shall have, to the full extent permitted by applicable law, the Certification of Incorporation of the Corporation, the
By-laws
of the Corporation and the listing
standards of The NASDAQ Stock Market applicable to the Corporation, all of the power and authority of the Board with respect to the adoption and amendment of Plans.
|
|
8.
|
The Committee shall review the Plans from time to time, as it deems appropriate, and may recommend to the Board any changes in such Plans that the Committee determines to be necessary or appropriate or, to the full
extent permitted by Paragraph 7 of this Section D, use the authority delegated to the Committee by the Board to approve any such changes it determines to be necessary or appropriate.
|
|
9.
|
The Committee shall oversee the Corporations policies on structuring compensation for executive officers to preserve tax deductibility and, as and when required, establish and certify the attainment of performance
goals pursuant to Section 162(m).
|
|
10.
|
The Committee shall assess the adequacy of this Charter and the procedures developed by the Committee to implement this Charter on at least an annual basis and shall submit any proposed amendments to this Charter that
the Committee recommends be made to the Board for its approval.
|
|
11.
|
The Committee shall oversee disclosure, pursuant to the applicable rules of the Securities and Exchange Commission (the SEC), of compensation matters relating to the Corporation, including by:
(a) reviewing and discussing with the Corporations management the Compensation Discussion and Analysis (CD&A) to be included in the Corporations annual proxy statement and Annual Report on Form
10-K
(whether directly or by incorporation by reference) and determining whether to recommend to the Board that the CD&A be included in those filings with the SEC; and (b) providing a Compensation
Committee Report, for inclusion in those filings, that complies with the rules and regulations applicable to those filings.
|
|
12.
|
The Committee shall, to the full extent permitted by applicable law and the listing standards of The NASDAQ Stock Market applicable to the Corporation, have the power to make all decisions and determinations relating
to: (a) (1) the advisory votes at WebMDs Annual Meetings of Stockholders regarding WebMDs executive compensation contemplated by the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and related SEC rules and
(2) the form and content of proposals to be included in the Corporations proxy materials regarding such advisory votes, including any recommendations to stockholders regarding voting on such proposals; and (b) (1) the frequency
of such advisory votes and (2) the form and content of proposals regarding such frequency to be included in the Corporations proxy materials, including any recommendations to stockholders regarding voting on such frequency.
|
|
13.
|
The Committee shall oversee the evaluation and management of risks arising from the Companys compensation plans and practices and, in connection with fulfilling its duties under this Charter, shall consider
potential opportunities for mitigation of those risks. In addition, the Committee shall oversee disclosure, pursuant to the applicable rules of the SEC, of such risks and efforts to mitigate such risks.
|
The foregoing list is not intended to be exhaustive, and the Committee shall, in addition, have such powers as may be necessary or appropriate
in furtherance of the objectives set forth in this Charter or as may, from time to time, be delegated by the Board. The adoption of this Charter and any amendments hereto shall not be construed to reduce any power or authority previously delegated
to the Committee by the Board.
The Committee shall, to the full extent permitted by applicable law and the listing standards of The NASDAQ
Stock Market applicable to the Corporation, have the power to delegate its authority to
A
MENDED
AND
R
ESTATED
C
OMPENSATION
C
OMMITTEE
C
HARTER
E
FFECTIVE
AS
OF
O
CTOBER
30, 2013
A
NNEX
I
P
AGE
3
subcommittees or individual members of the Committee as it deems appropriate. In addition, the Committee shall have the power to delegate its authority to other members of the Board and to
members of management as it deems appropriate, to the full extent permitted by applicable law and the listing standards of The NASDAQ Stock Market applicable to the Corporation; provided, however, that in no event may it delegate its authority under
Paragraphs 1, 3, 4, 6, 7 and 9 of this Section D.
The Committee shall have direct access to management of the Corporation and may obtain
advice and assistance from the Corporations Legal, Human Resources, Tax, Finance, Accounting and Internal Audit Departments and other specialists.
The Committee shall have the power to retain compensation consultants to assist the Committee in evaluating executive and director compensation
or to provide other advice and assistance to the Committee in any manner it deems appropriate. The Committee may also retain outside legal counsel, accountants or other advisors as it deems appropriate to discharge its duties and responsibilities.
The Committee has the sole authority to retain and terminate such compensation consultants or advisors (collectively, Outside Advisors) and to review and approve their fees and other retention terms and shall have the authority to cause
the Company to pay such Outside Advisors. The Committee shall be responsible for the oversight of any such Outside Advisors work. Nothing contained in this Charter shall require the Committee to consult with or receive advice from an Outside
Advisor, nor shall the Committee be required to accept the advice of any Outside Advisor.
The Committee shall consider the independence of
any Outside Advisor in its decision to retain the advisor or when otherwise receiving advice from an advisor and at least annually thereafter. The Committee shall determine whether Outside Advisors are independent in light of the applicable
requirements of The NASDAQ Stock Market, considering all factors prescribed under those requirements and any such other factors the Committee determines to be relevant.
Notwithstanding anything to the contrary contained in this Charter, the Committee shall not engage the Companys independent auditors to
perform any services without prior approval of the Audit Committee.
A
MENDED
AND
R
ESTATED
C
OMPENSATION
C
OMMITTEE
C
HARTER
E
FFECTIVE
AS
OF
O
CTOBER
30, 2013
A
NNEX
I
P
AGE
4
ANNEX J
W
EB
MD H
EALTH
C
ORP
.
A
MENDED
AND
R
ESTATED
N
OMINATING
& G
OVERNANCE
C
OMMITTEE
C
HARTER
Effective
as of October 30, 2014
A. Purpose
|
1.
|
General
. The Nominating & Governance Committee (the Committee) has been established by the Board of Directors (the Board) of WebMD Health Corp. (the Corporation) by
combining the responsibilities of the Boards Nominating Committee and its Governance & Compliance Committee. The Committee shall:
|
|
|
|
assist the Board by actively identifying individuals qualified to become Board members and making recommendations to the Board regarding (a) the persons to be nominated by the Board for election as director at each
annual meeting of stockholders, (b) appointments of directors to fill vacancies occurring between annual meetings and (c) appointments of directors to fill newly created directorships, if any, created by expansion of the size of the Board
between annual meetings;
|
|
|
|
to evaluate and make recommendations to the Board regarding matters relating to the governance of the Corporation;
|
|
|
|
to assist the Board in coordinating the activities of the Boards other standing committees, including with respect to the Corporations compliance programs; and to provide additional oversight of those
compliance programs.
|
|
2.
|
Diversity
. The Board believes that diversity is a critical attribute of a well-functioning board. It is the responsibility of the Committee to seek qualified candidates to fill vacancies on the Board that
contribute distinctive and useful perspectives to governance that best serves the interests of the Corporation and its stockholders. The Committee shall advise the Board on matters of diversity, including gender, race, culture, thought and
geography, and recommend, as necessary, procedures for achieving diversity of viewpoint, background, skills, types of experience, and areas of expertise on the Board.
|
B. Composition
|
1.
|
Members
. The Committee shall consist of as many members as the Board shall determine, but in any event not fewer than two members. Members of the Committee shall be appointed by the Board in accordance with the
By-laws
of the Corporation. Committee members shall serve until the earliest of their resignation or their replacement or removal by the Board in accordance with this Charter and the
By-laws
of the Corporation.
|
|
2.
|
Qualifications
. Each member of the Committee shall, in the judgment of the Board (or the Committee or another appropriate committee of the Board), meet the following requirements (the Independence
Requirements):
|
|
|
|
all independence requirements, under applicable laws, rules and regulations, for members of nominating committees of companies listed for quotation on the NASDAQ Global Market;
|
|
|
|
all applicable independence requirements of The NASDAQ Stock Market for members of nominating committees of companies listed for quotation on the NASDAQ Global Market; and
|
|
|
|
being free from any relationship that, in the opinion of the Board (or the Committee or another appropriate committee of the Board), would interfere with the exercise of independent judgment as a member of the
Committee.
|
In the event that the Board (or the Committee or another appropriate committee of the Board)
determines that a member ceases to meet the Independence Requirements, the Board shall consider the removal and replacement of such member; provided, however, that the Board may, if necessary or appropriate in its judgment, appoint or retain
Committee members in reliance on any available exceptions to any of the Independence Requirements for the time period such exceptions are available. A failure by one or more Committee members to meet any of the Independence Requirements shall not
invalidate decisions made, or actions taken, by the Committee.
|
3.
|
Chairperson
. A Chairperson of the Committee shall be appointed by the Board or by the Committee. If the Board does not do so, the Committee members shall elect a Chairperson by vote of a majority of the full
Committee.
|
|
4.
|
Removal and Replacement
. The members of the Committee may be removed or replaced, and any vacancies on the Committee shall be filled, by the Board in accordance with the
By-laws
of the Corporation.
|
C. Operations
|
1.
|
Meetings
. The Committee shall determine the schedule and frequency of the Committee meetings, provided that the Committee shall meet at least twice per year, one of which shall be in advance of the Boards
nomination of directors for election at the Corporations annual meeting and consideration of other matters relating to the annual meeting. Minutes of these meetings shall be kept and filed with the Secretary of the Corporation.
|
|
2.
|
Agenda; Reports
. The Committee shall determine the agenda for its meetings. The Committee may invite other Board members, members of management and others to attend meetings and provide pertinent information and
reports, as it deems necessary. Nothing in this Charter shall be construed to restrict the reliance by any member of the Committee, to the full extent permitted by law, on information, opinions, reports or statements presented to the Committee by
any of the Corporations officers or employees, or other committees of the Board, or by any other person selected with reasonable care by or on behalf of the Corporation or the Committee as to matters the Committee member reasonably believes
are within such other persons professional or expert competence.
|
|
3.
|
Report to Board
. The Committee shall report its actions and recommendations to the Board at the next Board meeting after each Committee meeting or, if so determined by the Committee, by distribution to the
members of the Board of the minutes of a meeting, a unanimous written consent or other relevant documents.
|
D. Authority and
Responsibilities Delegated to the Committee
|
1.
|
The Committee shall establish and review with the Board the qualifications and characteristics that it determines should be sought with respect to individual Board members and the Board as a whole and shall review with
the Board any changes thereto that it may, from time to time, determine to be appropriate. These qualifications and characteristics shall be designed to assist the Board in meeting the objectives set forth in Section A.2 of this Charter with respect
to diversity.
|
|
2.
|
The Committee shall assess the adequacy of this Charter and the procedures developed by the Committee to implement this Charter on at least an annual basis and shall submit any proposed amendments to this Charter that
the Committee recommends be made to the Board for its approval. This assessment shall include a review of procedures developed to assist the Board in meeting the objectives set forth in Section A.2 of this Charter with respect to diversity.
|
|
3.
|
In order to assist the Board in meeting the objectives set forth in Section A.2 of this Charter with respect to diversity, the Committee shall develop director search processes that identify qualified Board
|
A
MENDED
AND
R
ESTATED
N
OMINATING
& G
OVERNANCE
C
OMMITTEE
C
HARTER
E
FFECTIVE
AS
OF
O
CTOBER
30, 2014
A
NNEX
J
P
AGE
2
|
candidates both in the corporate environment as well as other enterprises, such as government, academia, private enterprise, complex
non-profit
organizations, and professions that serve them, such as accounting, human resources, and legal services. The search process will be designed so that candidates are not systematically eliminated from the search process due solely to background or
organizational affiliation and so that each director search affirmatively seeks to include candidates with diverse backgrounds and skills.
|
|
4.
|
The Committee shall, in accordance with (a) the policies and principles set forth in this Charter and (b) the relevant requirements of applicable law and requirements applicable to companies listed for
quotation on the NASDAQ Global Market, identify and recommend to the Board
|
|
i.
|
the persons to be nominated by the Board for election as director at each annual meeting of stockholders,
|
|
ii.
|
persons to be appointed as directors to fill vacancies occurring between annual meetings, and
|
|
iii.
|
persons to be appointed as directors to fill newly created directorships, if any, created by expansion of the size of the Board between annual meetings.
|
|
5.
|
The Committee shall review candidates for the Board recommended by stockholders pursuant to policies and procedures established by the Committee from time to time.
|
|
6.
|
The Committee shall consider whether to recommend to the Board increases or decreases in the size of the Board. The Committee shall consider whether to recommend to the Board (a) changes in the Board committee
assignments of existing directors, (b) committee assignments for new directors and (c) the formation of additional Board committees.
|
|
7.
|
The Committee shall evaluate and make recommendations to the Board regarding (a) the governance of the Corporation; (b) Board procedures; and (c) related matters. Recommendations may include possible
changes to the Corporations Certificate of Incorporation,
By-laws,
Board committee charters and other relevant constitutive documents, policy statements or similar materials.
|
|
8.
|
The Committee shall evaluate and make recommendations to the Board regarding any proposals for which a stockholder has provided required notice that such stockholder intends to make at the Annual Meeting of
Stockholders, including recommendations regarding the Boards response and regarding whether to include such proposal in the Corporations proxy statement.
|
|
9.
|
The Committee may, if it deems it appropriate to do so, develop and present to the Board for its adoption a set of Corporate Governance Guidelines, which shall set forth guidelines in areas such as the
function and operations of the Board and its committees.
|
|
10.
|
The Committee shall, to the full extent permitted by applicable law and the listing standards of The NASDAQ Stock Market applicable to the Corporation, be responsible for making any required determinations regarding the
independence of the members of the Board.
|
|
11.
|
The Committee shall assist the Board in coordinating the activities of the Boards other standing committees, including with respect to the Corporations compliance programs, and shall provide additional
oversight of those compliance programs and related matters.
|
|
12.
|
The Committee shall provide oversight with respect to matters relating to recruitment of senior executives of the Corporation, development of management talent and executive succession planning.
|
The foregoing list is not intended to be exhaustive, and the Committee shall, in addition, have such powers as may be necessary or appropriate
in furtherance of the objectives set forth in this Charter, including the objectives set forth in Section A.2 of this Charter with respect to diversity, or as may, from time to time, be delegated by the Board. The adoption of this Charter and any
amendments hereto shall not be construed to reduce any power or authority previously delegated to the Committee by the Board.
A
MENDED
AND
R
ESTATED
N
OMINATING
& G
OVERNANCE
C
OMMITTEE
C
HARTER
E
FFECTIVE
AS
OF
O
CTOBER
30, 2014
A
NNEX
J
P
AGE
3
The Committee shall, to the full extent permitted by applicable law and the listing standards of
The NASDAQ Stock Market applicable to the Corporation, have the power to delegate its authority to subcommittees or individual members of the Committee, as it deems appropriate.
The Committee shall have direct access to management of the Corporation and may obtain advice and assistance from the Corporations Legal,
Human Resources, Tax, Finance, Accounting and Internal Audit Departments and other specialists. The Committee shall have the power to retain search firms or other advisors to identify director candidates. The Committee may also retain counsel or
other advisors, as it deems appropriate. The Committee shall have the sole authority to retain and terminate such search firms, advisors or counsel and to review and approve their fees and other retention terms and shall have the authority to cause
the payment of such fees by the Corporation.
A
MENDED
AND
R
ESTATED
N
OMINATING
& G
OVERNANCE
C
OMMITTEE
C
HARTER
E
FFECTIVE
AS
OF
O
CTOBER
30, 2014
A
NNEX
J
P
AGE
4
ANNEX K
WEBMD HEALTH CORP.
AMENDED AND RESTATED
2005 LONG-TERM INCENTIVE PLAN
(AS AMENDED
AND RESTATED AS OF FEBRUARY 13, 2017)
ARTICLE 1
PURPOSE
1.1
General.
The purpose of the WebMD Health Corp. 2005 Long-Term Incentive Plan (as it may
be amended from time to time, the Plan) is to promote the success, and enhance the value, of WebMD Health Corp., a Delaware Corporation (the Corporation), by linking the personal interests of its employees, officers,
directors and consultants to those of Corporation shareholders and by providing such persons with an incentive for outstanding performance. The Plan is further intended to provide flexibility to the Corporation in its ability to motivate, attract
and retain the services of employees, officers, directors and consultants upon whose judgment, interest and special effort the successful conduct of the Corporations operation is largely dependent. Accordingly, the Plan permits the grant of
incentive awards from time to time to selected employees and officers, directors and consultants.
ARTICLE 2
EFFECTIVE DATE
2.1
Effective Date.
The Plan became effective on the date upon which it was initially approved by the
Board and the shareholders of the Corporation, which was September 26, 2005 (the Effective Date). This amendment and restatement of the Plan is effective as of February 13, 2017 and reflects all prior amendments.
ARTICLE 3
DEFINITIONS
3.1
Definitions.
When a word or phrase appears in this Plan with the initial letter capitalized, and
the word or phrase does not commence a sentence and is not otherwise defined in the Plan, the word or phrase shall generally be given the meaning ascribed to it in this Section. The following words and phrases shall have the following meanings:
(a) 1933 Act means the Securities Act of 1933, as amended from time to time.
(b) 1934 Act means the Securities Exchange Act of 1934, as amended from time to time.
(c) Affiliate means any Parent or Subsidiary and any person that directly, or indirectly through one or
more intermediaries, controls, is controlled by, or is under common control with, the Corporation.
(d)
[intentionally
omitted]
(e) Award means any Option, Stock Appreciation Right, Restricted Stock Award,
Performance Share Award, Dividend Equivalent Award or Other Stock-Based Award, or any other right or interest relating to Stock or cash, granted to a Participant under the Plan.
(f) Award Agreement means any written agreement, contract or other instrument or document evidencing an
Award.
(g) Board means the Board of Directors of the Corporation.
(h) Cause as a reason for a Participants termination
of employment or service shall have the meaning assigned such term in the employment agreement, if any, between such Participant and the Corporation or an affiliated company,
provided
,
however
, that if there is no such employment
agreement in which such term is defined, Cause shall mean any of the following acts by the Participant, as determined by the Board: gross neglect of duty, prolonged absence from duty without the consent of the Corporation, intentionally
engaging in any activity that is in conflict with or adverse to the business or other interests of the Corporation, or willful misconduct, misfeasance or malfeasance of duty which is reasonably determined to be detrimental to the Corporation.
(i) Change of Control means and includes the occurrence of any one of the following events:
(i) individuals who, at the effective date of the Initial Public Offering, constitute the Board (the Incumbent
Directors) cease for any reason to constitute at least a majority of the Board,
provided
that any person becoming a director after the Effective Date and whose election or nomination for election was approved by a vote of at least a
majority of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Corporation in which such person is named as a nominee for director, without written objection to such nomination) shall be
an Incumbent Director;
provided
,
however
, that no individual initially elected or nominated as a director of the Corporation as a result of an actual or threatened election contest (as described in
Rule 14a-11
under the 1934 Act (Election Contest)) or other actual or threatened solicitation of proxies or consents by or on behalf of any person (as such term is defined in
Section 3(a)(9) of the 1934 Act and as used in Section 13(d)(3) and 14(d)(2) of the 1934 Act) other than the Board (Proxy Contest), including by reason of any agreement intended to avoid or settle any Election Contest
or Proxy Contest, shall be deemed an Incumbent Director;
(ii) any person becomes a beneficial owner
(as defined in
Rule 13d-3
under the 1934 Act), directly or indirectly, of securities of the Corporation representing 50% or more of the combined voting power of the Corporations then
outstanding securities eligible to vote for the election of the Board (the Corporation Voting Securities);
provided
,
however
, that the event described in this paragraph (ii) shall not be deemed to be a Change of
Control of the Corporation by virtue of any of the following acquisitions: (A) any acquisition by a person who is on the Effective Date the beneficial owner of 50% or more of the outstanding Corporation Voting Securities, (B) an
acquisition by the Corporation which reduces the number of Corporation Voting Securities outstanding and thereby results in any person acquiring beneficial ownership of more than 50% of the outstanding Corporation Voting Securities,
provided
that if after such acquisition by the Corporation such person becomes the beneficial owner of additional Corporation Voting Securities that increase the percentage of outstanding Corporation Voting Securities beneficially owned by such person, a
Change of Control of the Corporation shall then occur, (C) an acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Corporation or any Parent or Subsidiary, (D) an acquisition by an underwriter
temporarily holding securities pursuant to an offering of such securities or (E) an acquisition pursuant to a Non-Qualifying Transaction (as defined in paragraph (iii)); or
(iii) the consummation of a reorganization, merger, consolidation, statutory share exchange or similar form of
corporate transaction involving the Corporation that requires the approval of the Corporations stockholders, whether for such transaction or the issuance of securities in the transaction (a Reorganization), or the sale or other
disposition of all or substantially all of the Corporations assets to an entity that is not an affiliate of the Corporation (a Sale), unless immediately following such Reorganization or Sale: (A) more than 50% of the total
voting power of (x) the corporation resulting from such Reorganization or the corporation which has acquired all or substantially all of the assets of the Corporation (in either case, the Surviving Corporation) or (y) if
applicable, the ultimate parent corporation that directly or indirectly has beneficial ownership of 100% of the voting securities eligible to elect directors of the Surviving Corporation (the Parent Corporation), is represented by the
W
EB
MD 2005 L
ONG
-T
ERM
I
NCENTIVE
P
LAN
A
S
A
MENDED
AND
R
ESTATED
AS
OF
F
EBRUARY
13, 2017
A
NNEX
K
P
AGE
2
Corporation Voting Securities that were outstanding immediately prior to such Reorganization or Sale (or, if applicable, is represented by shares into which such Corporation Voting Securities
were converted pursuant to such Reorganization or Sale), and such voting power among the holders thereof is in substantially the same proportion as the voting power of such Corporation Voting Securities among the holders thereof immediately prior to
the Reorganization or Sale, (B) no person (other than (x) the Corporation, (y) any employee benefit plan (or related trust) sponsored or maintained by the Surviving Corporation or the Parent Corporation or (z) a person who
immediately prior to the Reorganization or Sale was the beneficial owner of 25% or more of the outstanding Corporation Voting Securities) is the beneficial owner, directly or indirectly, of 25% or more of the total voting power of the outstanding
voting securities eligible to elect directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation) and (C) at least a majority of the members of the board of directors of the Parent Corporation (or, if
there is no Parent Corporation, the Surviving Corporation) following the consummation of the Reorganization or Sale were Incumbent Directors at the time of the Boards approval of the execution of the initial agreement providing for such
Reorganization or Sale (any Reorganization or Sale which satisfies all of the criteria specified in (A), (B) and (C) above shall be deemed to be a Non-Qualifying Transaction).
Notwithstanding the foregoing, with respect to an Award that is subject to Section 409A of the Code, and payment or
settlement of such Award is to be accelerated in connection with an event that would otherwise constitute a Change of Control, no event set forth in clause (i), (ii) or (iii) will constitute a Change of Control for purposes of the
Plan and any Award Agreement unless such event also constitutes a change in the ownership, change in the effective control or change in the ownership of a substantial portion of the assets of the Corporation as
defined under Section 409A of the Code and the Treasury guidance promulgated thereunder.
(j) Code means the Internal Revenue Code of 1986, as amended from time to time, and the rulings and
regulations promulgated thereunder.
(k) Committee means, subject to the last sentence of
Section 4.1, the committee of the Board described in Article 4.
(l) Covered Employee
means a covered employee as defined in Section 162(m)(3) of the Code,
provided
that no employee shall be a Covered Employee until the deduction limitations of Section 162(m) of the Code are applicable to the Corporation and any
reliance period under Treasury Regulation Section 1.162-27(f) has expired.
(m) Disability
has the meaning ascribed under the long-term disability plan applicable to the Participant. Notwithstanding the above, (i) with respect to an Incentive Stock Option, Disability shall mean Permanent and Total Disability as defined in
Section 22(e)(3) of the Code and (ii) to the extent an Award is subject to Section 409A of the Code, and payment or settlement of the Award is to be accelerated solely as a result of the Participants Disability, Disability shall
have the meaning ascribed thereto under Section 409A of the Code and the Treasury guidance promulgated thereunder.
(n) Dividend Equivalent means a right granted to a Participant under Article 11.
(o) Effective Date has the meaning assigned such term in Section 2.1.
(p) Fair Market Value, on any date, means (i) if the Stock is listed on a securities exchange or is
traded over the Nasdaq National Market, the closing sales price on such exchange or over such system on such date or, in the absence of reported sales on such date, the closing sales price on the immediately preceding date on which sales were
reported or (ii) if the Stock is not listed on a securities exchange or traded over the Nasdaq National Market, Fair Market Value will be determined by such other method as the Committee determines in good faith to be reasonable; provided,
however, that if the Stock underlying an Award is sold on the same day as the date of exercise or settlement or the date on which the restrictions
W
EB
MD 2005 L
ONG
-T
ERM
I
NCENTIVE
P
LAN
A
S
A
MENDED
AND
R
ESTATED
AS
OF
F
EBRUARY
13, 2017
A
NNEX
K
P
AGE
3
lapse applicable to Restricted Stock or similar Award through a broker approved by the Corporation, Fair Market Value shall be the actual sale price of the Stock in such transaction or
transactions. With respect to awards granted on the effective date of the Corporations Initial Public Offering, Fair Market Value shall mean the price at which the Stock is initially offered in the Initial Public Offering.
(q) HLTH Corporation means HLTH Corporation, a Delaware corporation (which was formerly known as Emdeon
Corporation).
(r) Incentive Stock Option means an Option that is intended to meet the requirements
of Section 422 of the Code or any successor provision thereto.
(s) Initial Public Offering
means the underwritten initial public offering of equity securities of the Corporation pursuant to an effective registration statement under the 1933 Act.
(t) Non-Employee Director means a member of the Board who is not an employee of the Corporation or any
Parent or Affiliate.
(u) Non-Qualified Stock Option means an Option that is not an Incentive Stock Option.
(v) Option means a right granted to a Participant under Article 7 to purchase Stock at a specified
price during specified time periods. An Option may be either an Incentive Stock Option or a Non-Qualified Stock Option.
(w) Other Stock-Based Award means a right, granted to a Participant under Article 12, that relates
to or is valued by reference to Stock or other Awards relating to Stock.
(x) Parent means a
corporation which owns or beneficially owns a majority of the outstanding voting stock or voting power of the Corporation. Notwithstanding the above, with respect to an Incentive Stock Option, Parent shall have the meaning set forth in
Section 424(e) of the Code.
(y) Participant means a person who, as an employee, officer,
consultant or director of the Corporation or any Parent, Subsidiary or Affiliate, has been granted an Award under the Plan.
(z) Performance Share means a right granted to a Participant under Article 9, to receive cash,
Stock, or other Awards, the payment of which is contingent upon achieving certain performance goals established by the Committee.
(aa) Restricted Stock Award means Stock granted to a Participant under Article 10 that is subject
to certain restrictions and to risk of forfeiture.
(bb) Stock means the $.01 par value common stock
of the Corporation (which, beginning immediately following the completion of the merger of HLTH Corporation into the Corporation on October 23, 2009, was no longer referred to as Class A and, while otherwise unchanged, began being
referred to as $.01 par value common stock of the Corporation) and such other securities of the Corporation as may be substituted for Stock pursuant to Article 15.
(cc) Stock Appreciation Right or SAR means a right granted to a Participant under
Article 8 to receive a payment equal to the difference between the Fair Market Value of a share of Stock as of the date of exercise of the SAR over the grant price of the SAR, all as determined pursuant to Article 8.
(dd) Subsidiary means any corporation, limited liability company, partnership or other entity of which a
majority of the outstanding voting equity securities or voting power is beneficially owned directly or indirectly by the Corporation. Notwithstanding the above, with respect to an Incentive Stock Option, Subsidiary shall have the meaning set forth
in Section 424(f) of the Code.
W
EB
MD 2005
L
ONG
-T
ERM
I
NCENTIVE
P
LAN
A
S
A
MENDED
AND
R
ESTATED
AS
OF
F
EBRUARY
13, 2017
A
NNEX
K
P
AGE
4
ARTICLE 4
ADMINISTRATION
4.1
Committee.
The Plan shall be administered by a committee (the Committee) appointed by
the Board (which Committee shall consist of two or more directors) or, at the discretion of the Board from time to time, the Plan may be administered by the Board. It is intended that the directors appointed to serve on the Committee shall be
non-employee directors (within the meaning of
Rule 16b-3
promulgated under the 1934 Act) and outside directors (within the meaning of Section 162(m) of the Code) to the
extent that
Rule 16b-3
and, if necessary for relief from the limitation under Section 162(m) of the Code and such relief is sought by the Corporation, Section 162(m) of the Code, respectively,
are applicable. However, the mere fact that a Committee member shall fail to qualify under either of the foregoing requirements shall not invalidate (a) any Award made by the Committee which Award is otherwise validly made under the Plan or
(b) any other action taken by the Committee which action is otherwise validly taken under the Plan. The members of the Committee shall be appointed by, and may be changed at any time and from time to time in the discretion of, the Board. During
any time that the Board is acting as administrator of the Plan, it shall have all the powers of the Committee hereunder, and any reference herein to the Committee (other than in this Section 4.1) shall include the Board.
4.2
Action by the Committee.
For purposes of administering the Plan, the following rules of procedure
shall govern the Committee. A majority of the Committee shall constitute a quorum. The acts of a majority of the members present at any meeting at which a quorum is present, and acts approved unanimously in writing by the members of the Committee in
lieu of a meeting, shall be deemed the acts of the Committee. Each member of the Committee is entitled to, in good faith, rely or act upon any report or other information furnished to that member by any officer or other employee of the Corporation
or any Parent or Affiliate, the Corporations independent certified public accountants, or any executive compensation consultant or other professional retained by the Corporation to assist in the administration of the Plan.
4.3
Authority of Committee.
Except as provided below, the Committee has the exclusive power, authority
and discretion to:
(a) Designate Participants;
(b) Determine the type or types of Awards to be granted to each Participant;
(c) Determine the number of Awards to be granted and the number of shares of Stock to which an Award will relate;
(d) Determine the terms and conditions of any Award granted under the Plan, including, but not limited to, the
exercise price, grant price or purchase price, any restrictions or limitations on the Award, any schedule for lapse of forfeiture restrictions or restrictions on the exercisability of an Award, and accelerations or waivers thereof, based in each
case on such considerations as the Committee in its sole discretion determines; provided, however that any Awards of (i) Restricted Stock or Other Stock-Based Award for which no purchase or exercise price is payable will be scheduled to vest
over a period of no less than three years where such vesting is not tied to the attainment of performance goals and (ii) Performance Share Awards, Restricted Stock or Other Stock-Based Awards for which no purchase or exercise price is payable
will be scheduled to vest over a period of no less than one year where such vesting is tied to the attainment of performance goals; provided, that, notwithstanding the foregoing, such vesting schedule will not be required for grants of Stock to
Non-Employee Directors made to satisfy applicable Board of Director or Committee retainers or fees;
(e) Accelerate the vesting or lapse of restrictions of any outstanding Award, based in each case on such
considerations as the Committee in its sole discretion determines;
(f) Determine whether, to what extent, and
under what circumstances an Award may be settled in, or the exercise price of an Award may be paid in, cash, Stock, other Awards or other property, or an Award may be canceled, forfeited or surrendered;
W
EB
MD 2005 L
ONG
-T
ERM
I
NCENTIVE
P
LAN
A
S
A
MENDED
AND
R
ESTATED
AS
OF
F
EBRUARY
13, 2017
A
NNEX
K
P
AGE
5
(g) Prescribe the form of each Award Agreement, which need not be
identical for each Participant, or amend any Award Agreement;
(h) Decide all other matters that must be determined in
connection with an Award;
(i) Establish, adopt or revise any rules and regulations as it may deem necessary or
advisable to administer the Plan;
(j) Make all other decisions and determinations that may be required under
the Plan or as the Committee deems necessary or advisable to administer the Plan; and
(k) Amend the Plan as provided
herein.
Notwithstanding the foregoing authority, except as provided in or pursuant to Article 15, the Committee shall
not authorize, generally or in specific cases only, for the benefit of any Participant, any adjustment in the exercise price of an Option or the base price of a Stock Appreciation Right, or in the number of shares subject to an Option or Stock
Appreciation Right granted hereunder by (i) cancellation of an outstanding Option or Stock Appreciation Right and a subsequent regranting of an Option or Stock Appreciation Right, (ii) amendment to an outstanding Option or Stock
Appreciation Right, (iii) substitution of an outstanding Option or Stock Appreciation Right or (iv) any other action that would be deemed to constitute a repricing of such an Award under applicable law, in each case, without prior approval
of the Corporations stockholders.
4.4
Delegation of Authority.
To the extent not prohibited
by applicable laws, rules and regulations, the Board or the Committee may, from time to time, delegate some or all of its authority under the Plan to a subcommittee or subcommittees thereof or to one or more directors or executive officers of the
Corporation as it deems appropriate under such conditions or limitations as it may set at the time of such delegation or thereafter, except that neither the Board nor the Committee may delegate its authority pursuant to Article 16 to amend the
Plan. For purposes of the Plan, references to the Committee shall be deemed to refer to any subcommittee, subcommittees, directors or executive officers to whom the Board or the Committee delegates authority pursuant to this Section 4.4.
4.5
Decisions Binding.
The Committees interpretation of the Plan, any Awards granted under the
Plan, any Award Agreement and all decisions and determinations by the Committee with respect to the Plan are final, binding and conclusive on all parties.
ARTICLE 5
SHARES
SUBJECT TO THE PLAN
5.1
Number of Shares.
Subject to adjustment as provided in
Article 15, the aggregate number of shares of Stock reserved and available for Awards or which may be used to provide a basis of measurement for or to determine the value of an Award (such as with a Stock Appreciation Right or Performance Share
Award) shall be 24,975,000 shares (the Maximum Number). Not more than the Maximum Number of shares of Stock shall be granted in the form of Incentive Stock Options. Subject to Section 5.2, (a) not more than 20% of the shares of
Stock available for issuance under the Plan on October 21, 2010 were available for the grant of Restricted Stock Awards, Performance Share Awards and similar Awards for which no purchase or exercise price is paid (Full Value
Awards); and (b) not more than 20% of the 6,775,000 shares of Stock added to the Plan since July 24, 2012 may be granted as Full Value Awards (the sum of the amounts remaining available for Full Value Awards under clauses (a) and (b) of this
sentence, as of any date after July 24, 2012, being referred to as the Full Value Award Limit).
5.2
Lapsed
Awards.
To the fullest extent permissible under Section 422 of the Code and any other applicable laws, rules and regulations, (i) if an Award is canceled, terminates, expires, is forfeited or lapses for any
reason without having been exercised or settled, any shares of Stock subject to the Award will be added back into the Maximum Number and will again be available for the grant of an Award under the Plan and (ii) shares of
W
EB
MD 2005 L
ONG
-T
ERM
I
NCENTIVE
P
LAN
A
S
A
MENDED
AND
R
ESTATED
AS
OF
F
EBRUARY
13, 2017
A
NNEX
K
P
AGE
6
Stock subject to SARs or other Awards settled in cash shall be added back into the Maximum Number and will be available for the grant of an Award under the Plan;
provided,
however,
that any shares of Stock underlying Full Value Awards that are added back into the Maximum Number pursuant to this Section 5.2 shall increase the Full Value Award Limit. For the sake of clarity, shares tendered or withheld to
satisfy the exercise price or tax withholding obligations arising in connection with the exercise or vesting of an Award (including in connection with a net exercise as contemplated by Section 7.1(c)) shall not be added back into
the Maximum Number and shall not be available for further grant.
5.3
Stock Distributed.
Any Stock
distributed pursuant to an Award may consist, in whole or in part, of authorized and unissued Stock, treasury Stock or Stock purchased on the open market.
5.4
Limitation on Awards.
Notwithstanding any provision in the Plan to the contrary (but subject to
adjustment as provided in Article 15), the maximum number of shares of Stock with respect to one or more Options and/or SARs that may be granted during any one calendar year under the Plan to any one Participant shall be 412,500 (all of which
may be granted as Incentive Stock Options);
provided
,
however
, that in connection with his or her initial employment with the Corporation, a Participant may be granted Options or SARs with respect to up to an additional
412,500 shares of Stock (all of which may be granted as Incentive Stock Options), which shall not count against the foregoing annual limit. The maximum Fair Market Value (measured as of the date of grant) of any Awards other than Options and
SARs that may be received by any one Participant (less any consideration paid by the Participant for such Award) during any one calendar year under the Plan shall be $5,000,000. The maximum number of shares of Stock that may be subject to one or
more Performance Share Awards (or used to provide a basis of measurement for or to determine the value of Performance Share Awards) in any one calendar year to any one Participant (determined on the date of grant) shall be 412,500.
ARTICLE 6
ELIGIBILITY
6.1
General.
Awards may be granted only to individuals who are employees, officers, directors or
consultants of the Corporation or a Parent or an Affiliate. In the discretion of the Committee, Awards may be made to Covered Employees which are intended to constitute qualified performance-based compensation under Section 162(m) of the Code.
ARTICLE 7
STOCK OPTIONS
7.1
General.
The Committee is authorized to grant Options to Participants on the following terms and
conditions:
(a)
Exercise Price.
The exercise price per share of Stock under an
Option shall be determined by the Committee at the time of the grant but in no event shall the exercise price be less than 100% of the Fair Market Value of a share of Stock on the date of grant.
(b)
Time and Conditions of Exercise.
The Committee shall determine the time or times
at which an Option may be exercised in whole or in part, subject to Section 7.1(e) and 7.3. The Committee also shall determine the performance or other conditions, if any, that must be satisfied before all or part of an Option may be exercised.
The Committee may waive any exercise provisions at any time in whole or in part based upon factors as the Committee may determine in its sole discretion so that the Option becomes exerciseable at an earlier date.
(c)
Payment.
Unless otherwise determined by the Committee, the exercise price of an
Option may be paid (i) in cash, (ii) by actual delivery or attestation to ownership of freely transferable shares of stock
W
EB
MD 2005 L
ONG
-T
ERM
I
NCENTIVE
P
LAN
A
S
A
MENDED
AND
R
ESTATED
AS
OF
F
EBRUARY
13, 2017
A
NNEX
K
P
AGE
7
already owned; (iii) by a combination of cash and shares of Stock equal in value to the exercise price or (iv) by such other means as the Committee, in its discretion, may authorize. In
accordance with the rules and procedures authorized by the Committee for this purpose, an Option may, if the Committee so determines also be exercised through either or both of the following: (i) a cashless exercise procedure authorized
by the Committee that permits Participants to exercise Options by delivering a properly executed exercise notice to the Corporation together with a copy of irrevocable instructions to a broker to deliver promptly to the Corporation the amount of
sale or loan proceeds necessary to pay the exercise price and the amount of any required tax or other withholding obligations or (ii) a net exercise arrangement pursuant to which the Corporation will reduce the number of
shares of Stock issued upon exercise by that number of shares of Stock having a Fair Market Value equal to the aggregate exercise price.
(d)
Evidence of Grant.
All Options shall be evidenced by a written Award Agreement
between the Corporation and the Participant. The Award Agreement shall include such provisions not inconsistent with the Plan as may be specified by the Committee.
(e)
Exercise Term.
In no event may any Option be exercisable for more than ten years
from the date of its grant.
7.2
Incentive Stock Options.
The terms of any Incentive Stock Options
granted under the Plan must comply with the following additional rules:
(a)
Lapse of
Option.
An Incentive Stock Option shall lapse under the earliest of the following circumstances;
provided
,
however
, that the Committee may, prior to the lapse of the Incentive Stock Option under the
circumstances described in paragraphs (3), (4) and (5) below, provide in writing that the Option will extend until a later date, but if an Option is exercised after the dates specified in paragraphs (3), (4) and
(5) below, it will automatically become a Non-Qualified Stock Option:
(1) The Incentive Stock Option shall
lapse as of the option expiration date set forth in the Award Agreement.
(2) The Incentive Stock Option shall
lapse ten years after it is granted, unless an earlier time is set in the Award Agreement.
(3) If the
Participant terminates employment for any reason other than as provided in paragraph (4) or (5) below, the Incentive Stock Option shall lapse, unless it is previously exercised, three months after the Participants termination of
employment;
provided
,
however
, that if the Participants employment is terminated by the Corporation for Cause, the Incentive Stock Option shall (to the extent not previously exercised) lapse immediately.
(4) If the Participant terminates employment by reason of his Disability, the Incentive Stock Option shall lapse,
unless it is previously exercised, one year after the Participants termination of employment.
(5) If the
Participant dies while employed, or during the three-month period described in paragraph (3) or during the one-year period described in paragraph (4) and before the Option otherwise lapses, the Option shall lapse one year after
the Participants death. Upon the Participants death, any exercisable Incentive Stock Options may be exercised by the Participants beneficiary, determined in accordance with Section 14.5.
Unless the exercisability of the Incentive Stock Option is accelerated as provided in Article 14, if a Participant exercises an Option
after termination of employment, the Option may be exercised only with respect to the shares that were otherwise vested on the Participants termination of employment.
(b)
Individual Dollar Limitation.
The aggregate Fair Market Value (determined as of
the time an Award is made) of all shares of Stock with respect to which Incentive Stock Options are first exercisable by a Participant in any calendar year may not exceed $100,000.00.
W
EB
MD 2005 L
ONG
-T
ERM
I
NCENTIVE
P
LAN
A
S
A
MENDED
AND
R
ESTATED
AS
OF
F
EBRUARY
13, 2017
A
NNEX
K
P
AGE
8
(c)
Ten Percent Owners.
No Incentive
Stock Option shall be granted to any individual who, at the date of grant, owns stock possessing more than ten percent of the total combined voting power of all classes of stock of the Corporation or any Parent or Affiliate unless the exercise price
per share of such Option is at least 110% of the Fair Market Value per share of Stock at the date of grant and the Option expires no later than five years after the date of grant.
(d)
Expiration of Incentive Stock Options.
No Award of an Incentive Stock Option may
be made pursuant to the Plan after the day immediately prior to the tenth anniversary of the Effective Date.
(e)
Right to Exercise.
During a Participants lifetime, an Incentive Stock Option
may be exercised only by the Participant or, in the case of the Participants Disability, by the Participants guardian or legal representative.
(f)
Directors.
The Committee may not grant an Incentive Stock Option to a non-employee
director. The Committee may grant an Incentive Stock Option to a director who is also an employee of the Corporation or any Parent or Affiliate but only in that individuals position as an employee and not as a director.
7.3
Options Granted to Non-Employee Directors.
Notwithstanding the foregoing, Options granted to
Non-Employee Directors under this Article 7 shall be subject to the following additional terms and conditions:
(a)
Lapse of Option.
An Option granted to a Non-Employee Director under this
Article 7 shall lapse under the earliest of the following circumstances:
(1) The Option shall lapse as of
the option expiration date set forth in the Award Agreement.
(2) If the Participant ceases to serve as a member
of the Board for any reason other than as provided in the proviso to this paragraph (2), the Option shall lapse, unless it is previously exercised, three years after the Participants termination as a member of the Board; provided,
however, that if the Participant is removed for cause (determined in accordance with the Corporations bylaws, as amended from time to time), the Option shall (to the extent not previously exercised) lapse immediately. If the Participant dies
during the post termination exercise period specified above and before the Option otherwise lapses, the Option shall lapse one year after the Participants death, if later than the end of the three year period. Upon the Participants
death, any exercisable Options may be exercised by the Participants beneficiary, determined in accordance with Section 14.5.
If a Participant exercises Options after termination of his service on the Board, he may exercise the Options only with respect
to the shares that were otherwise exercisable on the date of termination of his service on the Board. Such exercise otherwise shall be subject to the terms and conditions of this Article 7.
(b)
Acceleration Upon Change of Control.
Notwithstanding Section 7.1(b), in the
event of a Change of Control, each Option granted to a Non-Employee Director under this Article 7 that is then outstanding immediately prior to such Change of Control shall become immediately vested and exercisable in full on the date of such
Change of Control.
ARTICLE 8
STOCK APPRECIATION RIGHTS
8.1
Grant of Stock Appreciation Rights.
The Committee is authorized to grant Stock Appreciation
Rights to Participants on the following terms and conditions:
(a)
Right to
Payment.
Upon the exercise of a Stock Appreciation Right, the Participant to whom it is granted has the right to receive the excess, if any, of:
(1) The Fair Market Value of one share of Stock on the date of exercise; over
W
EB
MD 2005 L
ONG
-T
ERM
I
NCENTIVE
P
LAN
A
S
A
MENDED
AND
R
ESTATED
AS
OF
F
EBRUARY
13, 2017
A
NNEX
K
P
AGE
9
(2) The grant price of the Stock Appreciation Right as determined by
the Committee, which shall not be less than the Fair Market Value of one share of Stock on the date of grant.
(b)
Other Terms.
All awards of Stock Appreciation Rights shall be evidenced by an
Award Agreement. The terms, the period in which the Stock Appreciation Right may be exercised (subject to Section 8.1(c) below), the methods of exercise, the methods of settlement, the form of consideration payable in settlement, and any other terms
and conditions of any Stock Appreciation Right shall be determined by the Committee at the time of the grant of the Award and shall be reflected in the Award Agreement.
(c)
Exercise Period
. In no event may a Stock Appreciation Right be exercisable for
more than ten years from the date of its grant.
ARTICLE 9
PERFORMANCE SHARES
9.1
Grant of Performance Shares.
The Committee is authorized to grant Performance Shares to Participants on such
terms and conditions as may be selected by the Committee, subject to Section 4.3(d). The Committee shall have the complete discretion to determine the number of Performance Shares granted to each Participant, subject to Section 5.4. All
Awards of Performance Shares shall be evidenced by an Award Agreement.
9.2
Right to Payment.
A
grant of Performance Shares gives the Participant rights, valued as determined by the Committee, and payable to, or exercisable by, the Participant to whom the Performance Shares are granted, in whole or in part, as the Committee shall establish at
grant or thereafter. The Committee shall set performance goals and other terms or conditions to payment of the Performance Shares in its discretion which, depending on the extent to which they are met, will determine the number and value of
Performance Shares that will be paid to the Participant.
9.3
Other Terms.
Performance Shares may
be payable in cash, Stock or other property, and have such other terms and conditions as determined by the Committee and reflected in the Award Agreement.
ARTICLE 10
RESTRICTED STOCK AWARDS
10.1
Grant of Restricted Stock.
The Committee is authorized to make Awards of Restricted Stock to
Participants in such amounts and subject to such terms and conditions as may be selected by the Committee, subject to Section 4.3(d). All Awards of Restricted Stock shall be evidenced by a Restricted Stock Award Agreement.
10.2
Issuance and Restrictions.
Restricted Stock shall be subject to such restrictions on transferability and
other restrictions as the Committee may impose (including, without limitation, limitations on the right to vote Restricted Stock or the right to receive dividends on the Restricted Stock). These restrictions may lapse separately or in combination at
such times, under such circumstances, in such installments, upon the satisfaction of performance goals or otherwise, as the Committee determines at the time of the grant of the Award or thereafter.
10.3
Forfeiture.
Except as otherwise determined by the Committee at the time of the grant of the Award
or thereafter, upon termination of employment during the applicable restriction period or upon failure to satisfy a performance goal during the applicable restriction period, Restricted Stock that is at that time subject to restrictions shall be
forfeited and reacquired by the Corporation;
provided
,
however
, that the Committee may provide in any Award Agreement that restrictions or forfeiture conditions relating to Restricted Stock will be waived in whole or in part in the
event of terminations resulting from specified causes, and the Committee may in other cases waive in whole or in part restrictions or forfeiture conditions relating to Restricted Stock.
W
EB
MD 2005 L
ONG
-T
ERM
I
NCENTIVE
P
LAN
A
S
A
MENDED
AND
R
ESTATED
AS
OF
F
EBRUARY
13, 2017
A
NNEX
K
P
AGE
10
10.4
Certificates for Restricted Stock.
Restricted Stock
granted under the Plan may be evidenced in such manner as the Committee shall determine. If certificates representing shares of Restricted Stock are registered in the name of the Participant, certificates must bear an appropriate legend referring to
the terms, conditions and restrictions applicable to such Restricted Stock.
ARTICLE 11
DIVIDEND EQUIVALENTS
11.1
Grant of Dividend Equivalents.
The Committee is authorized to grant Dividend Equivalents to
Participants subject to such terms and conditions as may be selected by the Committee. Dividend Equivalents shall entitle the Participant to receive payments (in cash, Stock or other property) equal to dividends with respect to all or a portion of
the number of shares of Stock subject to an Award, as determined by the Committee. The Committee may provide that Dividend Equivalents be paid or distributed when accrued, or be deemed to have been reinvested in additional shares of Stock or
otherwise reinvested. The terms of any reinvestment of Dividend Equivalents shall comply with Section 409A of the Code.
ARTICLE 12
OTHER
STOCK-BASED AWARDS
12.1 Grant of Other Stock-based Awards.
The Committee is authorized, subject to
limitations under applicable law and Section 4.3(d), to grant to Participants such other Awards that are payable in, valued in whole or in part by reference to, or otherwise based on or related to shares of Stock, as deemed by the Committee to
be consistent with the purposes of the Plan, including, without limitation, shares of Stock awarded purely as a bonus and not subject to any restrictions or conditions, convertible or exchangeable debt securities, other rights
convertible or exchangeable into shares of Stock, stock units, phantom stock and other Awards valued by reference to book value of shares of Stock or the value of securities of or the performance of specified Parents or Subsidiaries. The Committee
shall determine the terms and conditions of such Awards.
ARTICLE 13
ANNUAL AWARDS TO NON-EMPLOYEE DIRECTORS
13.1
Grant of Options.
Each Non-Employee Director who is serving in such capacity as of January 1 of
each year that the Plan is in effect shall be granted a Non-Qualified Option to purchase 13,200 shares of Stock, subject to adjustment as provided in Article 15. In addition, each Non-Employee Director who is serving in such capacity
as of the effective date of the Initial Public Offering shall be granted a Non-Qualified Stock Option to purchase 13,200 shares of Stock on such date. Each such date that Options are to be granted under this Article 13 is referred to
hereinafter as a Grant Date. In addition, the Committee may, in its sole discretion, permit or require each Non-Employee Director to receive all or any portion of his or her compensation for services as a director in the form of an Award
under the Plan with such term and conditions as may be determined by the Committee in its sole discretion.
If on any Grant Date, shares of
Stock are not available under the Plan to grant to Non-Employee Directors the full amount of a grant contemplated by the immediately preceding paragraph, then each Non-Employee Director shall receive an Option (a Reduced Grant) to
purchase shares of Stock in an amount equal to the number of shares of Stock then available under the Plan divided by the number of Non-Employee Directors as of the applicable Grant Date. Fractional shares shall be ignored and not granted.
If a Reduced Grant has been made and, thereafter, during the term of the Plan, additional shares of Stock become available for grant, then each
person who was a Non-Employee Director both on the Grant Date on
W
EB
MD 2005 L
ONG
-T
ERM
I
NCENTIVE
P
LAN
A
S
A
MENDED
AND
R
ESTATED
AS
OF
F
EBRUARY
13, 2017
A
NNEX
K
P
AGE
11
which the Reduced Grant was made and on the date additional shares of Stock become available (a Continuing Non-Employee Director) shall receive an additional Option to purchase shares
of Stock. The number of newly available shares shall be divided equally among the Options granted to the Continuing Non-Employee Directors;
provided
,
however
, that the aggregate number of shares of Stock subject to a Continuing
Non-Employee Directors additional Option plus any prior Reduced Grant to the Continuing Non-Employee Director on the applicable Grant Date shall not exceed 13,200 shares (subject to adjustment pursuant to Article 15). If more than
one Reduced Grant has been made, available Options shall be granted beginning with the earliest such Grant Date.
13.2
Option
Price.
The option price for each Option granted under this Article 13 shall be the Fair Market Value on the date of grant of the Option.
13.3
Term.
Each Option granted under this Article 13 shall, to the extent not previously
exercised, terminate and expire on the date ten (10) years after the date of grant of the Option, unless earlier terminated as provided in Section 13.4.
13.4
Lapse of Option.
An Option granted under this Article 13 shall not automatically lapse by
reason of the Participant ceasing to qualify as a Non-Employee Director but remaining as a member of the Board. An Option granted under this Article 13 shall lapse under the earliest of the following circumstances:
(1) The Option shall lapse ten years after it is granted.
(2) If the Participant ceases to serve as a member of the Board for any reason other than as provided in the proviso
to this paragraph (2), the Option shall lapse, unless it is previously exercised, three years after the Participants termination as a member of the Board; provided, however, that if the Participant is removed for cause (determined in
accordance with the Corporations bylaws, as amended from time to time), the Option shall (to the extent not previously exercised) lapse immediately. If the Participant dies during the post termination exercise period specified above and before
the Option otherwise lapses, the Option shall lapse one year after the Participants death, if later than the end of the three year period. Upon the Participants death, any exercisable Options may be exercised by the Participants
beneficiary, determined in accordance with Section 14.5.
If a Participant exercises Options after termination of his or her service
on the Board, he or she may exercise the Options only with respect to the shares that were otherwise exercisable on the date of termination of his service on the Board. Such exercise otherwise shall be subject to the terms and conditions of this
Article 13.
13.5
Cancellation of Options.
Upon a Participants termination of service
for any reason other than death or Disability, all Options that have not vested in accordance with the Plan shall be cancelled immediately.
13.6
Exercisability.
Subject to Section 13.7, each Option grant under this Article 13 shall
be exercisable as to twenty-five percent (25%) of the Option shares on each of the first, second, third and fourth anniversaries of the Grant Date, such that the Options will be fully exercisable after four years from the Grant Date.
13.7
Acceleration Upon Change of Control.
Notwithstanding Section 13.6, in the event of a Change
of Control, each Option granted under this Article 13 that is then outstanding immediately prior to such Change of Control shall become immediately exercisable in full on the date of such Change in Control.
13.8
Termination of Article 13.
No Options shall be granted under this Article 13 after
January 1, 2015.
13.9
Non-exclusivity.
Nothing in this Article 13 shall prohibit the
Committee from making discretionary Awards to Non-Employee Directors pursuant to the other provisions of the Plan before or after January 1, 2015. Options granted pursuant to this Article 13 shall be governed by the provisions of this
Article 13 and by other provisions of the Plan to the extent not inconsistent with the provisions of this Article 13.
W
EB
MD 2005 L
ONG
-T
ERM
I
NCENTIVE
P
LAN
A
S
A
MENDED
AND
R
ESTATED
AS
OF
F
EBRUARY
13, 2017
A
NNEX
K
P
AGE
12
ARTICLE 14
PROVISIONS APPLICABLE TO AWARDS
14.1
Stand-alone, Tandem, and Substitute Awards.
Awards granted under the Plan may, in the discretion
of the Committee, be granted either alone or in addition to, in tandem with, (subject to the last sentence of Section 4.3) or in substitution for, any other Award granted under the Plan. If an Award is granted in substitution for another Award,
the Committee may require the surrender of such other Award in consideration of the grant of the new Award. Awards granted in addition to or in tandem with other Awards may be granted either at the same time as or at a different time from the grant
of such other Awards.
14.2
Term of Award.
The term of each Award shall be for the period as
determined by the Committee,
provided
that in no event shall the term of any Incentive Stock Option or a Stock Appreciation Right granted in tandem with the Incentive Stock Option exceed a period of ten years from the date of its grant (or,
if Section 7.2(c) applies, five years from the date of its grant).
14.3
Form of Payment for
Awards.
Subject to the terms of the Plan and any applicable law or Award Agreement, payments or transfers to be made by the Corporation or a Parent or Affiliate on the grant or exercise of an Award may be made in such form
as the Committee determines at or after the time of grant, including, without limitation, cash, Stock, other Awards or other property, or any combination thereof, and may be made in a single payment or transfer, in installments or on a deferred
basis, in each case determined in accordance with rules adopted by, and at the discretion of, the Committee.
14.4
Limits on
Transfer.
No right or interest of a Participant in any unexercised or restricted Award may be pledged, encumbered or hypothecated to or in favor of any party other than the Corporation or a Parent or Affiliate, or shall be
subject to any lien, obligation, or liability of such Participant to any other party other than the Corporation or a Parent or Affiliate. No unexercised or restricted Award shall be assignable or transferable by a Participant other than by will or
the laws of descent and distribution or, except in the case of an Incentive Stock Option, pursuant to a domestic relations order that would satisfy Section 414(p)(1)(A) of the Code if such Section applied to an Award under the Plan;
provided
,
however
, that the Committee may (but need not) permit other transfers where the Committee concludes that such transferability (i) does not result in accelerated taxation or other adverse tax consequences, (ii) does
not cause any Option intended to be an Incentive Stock Option to fail to be described in Section 422(b) of the Code, and (iii) is otherwise appropriate and desirable, taking into account any factors deemed relevant, including, without
limitation, state or federal tax or securities laws applicable to transferable Awards. In furtherance of the foregoing, with the consent of the Committee or its designee, a Participant may transfer Awards to such Participants family members or
trusts or other entities in which the Participant or his or her family members hold 50% or more of the voting or beneficial ownership interest in such trust or entity for estate planning or other tax purpose. Any such permitted transfer shall be
subject to such conditions as the Committee or its designee may impose and compliance with applicable federal and state securities laws.
14.5
Beneficiaries.
Notwithstanding Section 14.4, a Participant may, in the manner determined by
the Committee, designate a beneficiary to exercise the rights of the Participant and to receive any distribution with respect to any Award upon the Participants death. A beneficiary, legal guardian, legal representative or other person
claiming any rights under the Plan is subject to all terms and conditions of the Plan and any Award Agreement applicable to the Participant, except to the extent the Plan and such Award Agreement otherwise provide, and to any additional restrictions
deemed necessary or appropriate by the Committee. If no beneficiary has been designated or survives the Participant, payment shall be made to the Participants estate. Subject to the foregoing, a beneficiary designation may be changed or
revoked by a Participant at any time,
provided
the change or revocation is filed with the Committee.
14.6
Stock
Certificates.
All Stock issuable under the Plan is subject to any stop-transfer orders and other restrictions as the Committee deems necessary or advisable to comply with federal or state securities laws, rules
W
EB
MD 2005 L
ONG
-T
ERM
I
NCENTIVE
P
LAN
A
S
A
MENDED
AND
R
ESTATED
AS
OF
F
EBRUARY
13, 2017
A
NNEX
K
P
AGE
13
and regulations and the rules of any national securities exchange or automated quotation system on which the Stock is listed, quoted or traded. The Committee may place legends on any Stock
certificate or issue instructions to the transfer agent to reference restrictions applicable to the Stock.
14.7
Acceleration
Upon Death or Disability.
Unless otherwise set forth in an Award Agreement, upon the Participants death or Disability during his employment or service as a director, all outstanding Options, Stock Appreciation
Rights, Restricted Stock Awards and other Awards in the nature of rights that may be exercised shall become fully exercisable and all restrictions on outstanding Awards shall lapse. Any Option or Stock Appreciation Rights Awards shall thereafter
continue or lapse in accordance with the other provisions of the Plan and the Award Agreement. To the extent that this provision causes Incentive Stock Options to exceed the dollar limitation set forth in Section 7.2(b), the excess Options
shall be deemed to be Non-Qualified Stock Options.
14.8
Acceleration of Vesting and Lapse of
Restrictions.
Subject to Sections 7.3(b) and 13.7, the Committee may, in its sole discretion, at any time (including, without limitation, prior to, coincident with or subsequent to a Change of Control) determine that
(a) all or a portion of a Participants Options, Stock Appreciation Rights and other Awards in the nature of rights that may be exercised shall become fully or partially exercisable, and/or (b) all or a part of the restrictions on all
or a portion of the outstanding Awards shall lapse, in each case, as of such date as the Committee may, in its sole discretion, declare;
provided
,
however
, that, with respect to Awards that are subject to Section 409A of the Code,
the Committee shall not have the authority to accelerate or postpone the timing of payment or settlement of an Award in a manner that would cause such Award to become subject to the interest and penalty provisions under Section 409A of the
Code. The Committee may discriminate among Participants and among Awards granted to a Participant in exercising its discretion pursuant to this Section 14.8. All Awards made to Non-Employee Directors shall become fully vested and, in the case
of Options, Stock Appreciation Rights and other Awards in the nature of rights that may be exercised, fully exercisable in the event of the occurrence of a Change of Control as of the date of such Change of Control.
14.9
Other Adjustments.
If (i) an Award is accelerated under Sections 7.3(b), 13.7 and/or
14.8 or (ii) a Change of Control occurs (regardless or whether acceleration under Sections 7.3(b), 13.7 and/or 14.8 occurs), the Committee may, in its sole discretion, provide (a) that the Award will expire after a designated period
of time after such acceleration or Change of Control, as applicable, to the extent not then exercised, (b) that the Award will be settled in cash rather than Stock, (c) that the Award will be assumed by another party to a transaction
giving rise to the acceleration or a party to the Change of Control, (d) that the Award will otherwise be equitably converted or adjusted in connection with such transaction or Change of Control, or (e) any combination of the foregoing.
The Committees determination need not be uniform and may be different for different Participants whether or not such Participants are similarly situated;
provided
,
however
, that, with respect to Awards that are subject to
Section 409A of the Code, the Committee shall not have the authority to accelerate or postpone the timing of payment or settlement of an Award in a manner that would cause such Award to become subject to the interest and penalty provisions
under Section 409A of the Code.
14.10
Performance Goals.
In order to preserve the
deductibility of an Award under Section 162(m) of the Code, the Committee may determine that any Award granted pursuant to this Plan to a Participant that is or is expected to become a Covered Employee shall be determined solely on the basis of
(a) the achievement by the Corporation or Subsidiary of a specified target return, or target growth in return, on equity or assets, (b) the Corporations stock price, (c) the Corporations total shareholder return (stock
price appreciation plus reinvested dividends) relative to a defined comparison group or target over a specific performance period, (d) the achievement by the Corporation or a Parent or Subsidiary, or a business unit of any such entity, of a
specified target, or target growth in, net income, revenues, earnings per share, earnings before income and taxes, and earnings before income, taxes, depreciation and amortization, or (e) any combination of the goals set forth in
(a) through (d) above. If an Award is made on such basis, the Committee shall establish goals prior to the beginning of the period for which such performance goal relates (or such later date as may be permitted under Section 162(m) of
the Code), and the Committee has the right for any reason to reduce (but not increase) the Award, notwithstanding the achievement of a specified goal. Any payment of an Award granted with
W
EB
MD 2005 L
ONG
-T
ERM
I
NCENTIVE
P
LAN
A
S
A
MENDED
AND
R
ESTATED
AS
OF
F
EBRUARY
13, 2017
A
NNEX
K
P
AGE
14
performance goals shall be conditioned on the written certification of the Committee in each case that the performance goals and any other material conditions were satisfied.
14.11
Termination of Employment.
Whether military, government or other service or other leave of
absence shall constitute a termination of employment shall be determined in each case by the Committee at its discretion, and any determination by the Committee shall be final and conclusive. A termination of employment shall not occur (i) in a
circumstance in which a Participant transfers from the Corporation to one of its Parents or Subsidiaries, transfers from a Parent or Affiliate to the Corporation, or transfers from one Parent or Affiliate to another Parent or Affiliate, or
(ii) in the discretion of the Committee as specified at or prior to such occurrence, in the case of a split-off, spin-off, sale or other disposition of the Participants employer from the Corporation or any Parent or Affiliate. To the
extent that this provision causes Incentive Stock Options to extend beyond three months from the date a Participant is deemed to be an employee of the Corporation, a Parent or Affiliate for purposes of Section 424(f) of the Code, the Options
held by such Participant shall be deemed to be Non-Qualified Stock Options.
ARTICLE 15
CHANGES IN CAPITAL STRUCTURE
15.1
General.
Upon or in contemplation of (a) any reclassification, recapitalization, stock
split (including a stock split in the form of a stock dividend) or reverse stock split, (b) any merger, combination, consolidation, or other reorganization, (c) any spin-off, split-up, or similar extraordinary dividend distribution in
respect of the Stock (whether in the form of securities or property), (d) any exchange of Stock or other securities of the Corporation, or any similar, unusual or extraordinary corporate transaction in respect of the Stock, or (e) a sale
of all or substantially all the business or assets of the Corporation as an entirety, then the Committee shall, in such manner, to such extent (if any) and at such time as it deems appropriate and equitable in the circumstances in order to preserve,
but not increase, the benefits or potential benefits intended to be made available under the Plan or an outstanding Award:
(i) proportionately adjust any or all of (A) the number and type of shares of Stock (or other securities) that
thereafter may be made the subject of Awards (including the specific share limits, maximums and numbers of shares set forth elsewhere in this Plan), (B) the number, amount and type of shares of Stock (or other securities or property) subject to
any or all outstanding Awards, (C) the grant, purchase, or exercise price (which term includes the base price of any SAR or similar right) of any or all outstanding Awards, (D) the securities, cash or other property deliverable upon
exercise or payment of any outstanding Awards, or (E) the performance standards applicable to any outstanding Awards, or
(ii) make provision for a cash payment or for the assumption, substitution or exchange of any or all outstanding
share-based Awards or the cash, securities or property deliverable to the holder of any or all outstanding share-based Awards, based upon the distribution or consideration payable to holders of the Stock upon or in respect of such event.
The Committee may adopt such valuation methodologies for outstanding Awards as it deems reasonable in the event of a cash or property
settlement and, in the case of Options, SARs or similar rights, but without limitation on other methodologies, may base such settlement solely upon the excess if any of the per share amount payable upon or in respect of such event over the exercise
or base price of the Award. With respect to any Award of an Incentive Stock Option, the Committee may make such an adjustment that causes the option to cease to qualify as an Incentive Stock Option without the consent of the affected Participant.
Notwithstanding the foregoing, to the extent possible, all adjustments shall be made in a manner to avoid: (i) an Award that is not already subject to Section 409A of the Code from becoming subject to Section 409A of the Code; and
(ii) the imposition of penalties pursuant to Section 409A of the Code.
In any of such events, the Committee may take such action
prior to such event to the extent that the Committee deems the action necessary to permit the Participant to realize the benefits intended to be conveyed
W
EB
MD 2005 L
ONG
-T
ERM
I
NCENTIVE
P
LAN
A
S
A
MENDED
AND
R
ESTATED
AS
OF
F
EBRUARY
13, 2017
A
NNEX
K
P
AGE
15
with respect to the underlying shares in the same manner as is or will be available to stockholders generally. In the case of any stock split or reverse stock split, if no action is taken by the
Committee, the proportionate adjustments contemplated by clause (i) above shall nevertheless be made.
ARTICLE 16
AMENDMENT, MODIFICATION AND TERMINATION
16.1
Amendment, Modification and Termination.
The Board or the Committee may, at any time and from
time to time, amend, modify or terminate the Plan; provided, however, that the Board or the Committee may condition any amendment or modification on the approval of shareholders of the Corporation if such approval is necessary or deemed advisable
with respect to tax, securities or other applicable laws, policies or regulations.
16.2
Awards Previously
Granted.
At any time and from time to time, but subject to Section 4.3, the Committee may amend, modify or terminate any outstanding Award or Award Agreement without approval of the Participant; provided, however,
that, subject to the terms of the applicable Award Agreement, such amendment, modification or termination shall not, without the Participants consent, reduce or diminish the value of such Award determined as if the Award had been exercised,
vested, cashed in or otherwise settled on the date of such amendment or termination; provided further, however, that the original term of any Option may not be extended. No termination, amendment, or modification of the Plan shall adversely affect
any Award previously granted under the Plan, without the written consent of the Participant. Notwithstanding any provision herein to the contrary, the Committee shall have broad authority to amend the Plan or any outstanding Award under the Plan
without approval of the Participant to the extent necessary or desirable (i) to comply with, or take into account changes in or interpretations of, applicable tax laws, securities laws, accounting rules and other applicable laws, rules and
regulations or (ii) to ensure that an Award is not subject to interest and penalties under Section 409A of the Code.
ARTICLE 17
GENERAL
PROVISIONS
17.1
No Rights to Awards.
No Participant or any eligible participant shall have
any claim to be granted any Award under the Plan, and neither the Corporation nor the Committee is obligated to treat Participants or eligible participants uniformly.
17.2
No Stockholder Rights.
No Award gives the Participant any of the rights of a shareholder of the
Corporation unless and until shares of Stock are in fact issued to such person in connection with the exercise, payment or settlement of such Award.
17.3
Withholding.
The Corporation or any Subsidiary, Parent or Affiliate shall have the authority and
the right to deduct or withhold, or require a Participant to remit to the Corporation, an amount sufficient to satisfy federal, state, local and other taxes (including the Participants FICA obligation) required by law to be withheld with
respect to any taxable event arising as a result of the Plan. With respect to withholding required upon any taxable event under the Plan, the Committee may, at the time the Award is granted or thereafter, require or permit that any such withholding
requirement be satisfied, in whole or in part, by (i) withholding from the Award shares of Stock or (ii) delivering shares of Stock that are already owned, having a Fair Market Value on the date of withholding equal to the amount required
to be withheld for tax purposes, all in accordance with such procedures as the Committee establishes. The Corporation or any Subsidiary, Parent or Affiliate may permit tax withholding in shares of Stock in excess of the statutory minimum if such
withholding will not result in liability classification of the Awards pursuant to the accounting rules under ASC 718. The Corporation or any Subsidiary, Parent or Affiliate, as appropriate, shall also have the right to deduct from all cash payments
made to a Participant (whether or not such payment is made in connection with an Award) any applicable taxes required to be withheld with respect to such payments.
W
EB
MD 2005 L
ONG
-T
ERM
I
NCENTIVE
P
LAN
A
S
A
MENDED
AND
R
ESTATED
AS
OF
F
EBRUARY
13, 2017
A
NNEX
K
P
AGE
16
17.4
No Right to Continued Service.
Nothing in the Plan
or any Award Agreement shall interfere with or limit in any way the right of the Corporation or any Parent or Affiliate to terminate any Participants employment or status as an officer, director or consultant at any time, nor confer upon any
Participant any right to continue as an employee, officer, director or consultant of the Corporation or any Parent or Affiliate. In its sole discretion, the Board or the Committee may authorize the creation of trusts or other arrangements to meet
the obligations created under the Plan to deliver shares of Stock with respect to awards hereunder.
17.5
Unfunded Status of
Awards.
The Plan is intended to be an unfunded plan for incentive and deferred compensation. With respect to any payments not yet made to a Participant pursuant to an Award, nothing contained in the Plan or any
Award Agreement shall give the Participant any rights that are greater than those of a general creditor of the Corporation or any Parent or Affiliate.
17.6
Indemnification.
To the extent allowable under applicable law, each member of the Committee shall
be indemnified and held harmless by the Corporation from any loss, cost, liability or expense that may be imposed upon or reasonably incurred by such member in connection with or resulting from any claim, action, suit or proceeding to which such
member may be a party or in which he may be involved by reason of any action or failure to act under the Plan and against and from any and all amounts paid by such member in satisfaction of judgment in such action, suit or proceeding against him;
provided such member shall give the Corporation an opportunity, at its own expense, to handle and defend the same before such member undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification shall not be
exclusive of any other rights of indemnification to which such persons may be entitled under the Corporations Certificate of Incorporation or Bylaws, as a matter of law, or otherwise, or any power that the Corporation may have to indemnify
them or hold such persons harmless.
17.7
Relationship to Other Benefits.
No Award shall
constitute salary, recurrent compensation or contractual compensation for the year of grant, any later year or any other period of time. No payment under the Plan shall be taken into account in determining any benefits under any pension, retirement,
savings, profit sharing, group insurance, welfare or other benefit plan of the Corporation or any Parent or Affiliate unless provided otherwise in such other plan.
17.8
Expenses; Application of Funds.
The expenses of administering the Plan shall be borne by the
Corporation and its Parents or Subsidiaries. The proceeds received by the Corporation from the sale of shares of Stock pursuant to Awards will be used for general corporate purposes.
17.9
Titles and Headings.
The titles and headings of the Sections in the Plan are for convenience of
reference only, and in the event of any conflict, the text of the Plan, rather than such titles or headings, shall control.
17.10
Gender and Number.
Except where otherwise indicated by the context, any masculine term used
herein also shall include the feminine; the plural shall include the singular and the singular shall include the plural.
17.11
Fractional Shares.
No fractional shares of Stock shall be issued and the Committee shall
determine, in its discretion, whether cash shall be given in lieu of fractional shares or whether such fractional shares shall be eliminated by rounding up or down.
17.12
Government and Other Regulations.
The obligation of the Corporation to make payment of awards in
Stock or otherwise shall be subject to all applicable laws, rules and regulations, and to such approvals by government agencies as may be required. To the extent that Awards under the Plan are awarded to individuals who are domiciled or resident
outside of the United States or to persons who are domiciled or resident in the United States but who are subject to the tax laws of a jurisdiction outside of the United States, the Committee may adjust the terms of the Awards granted hereunder to
such person (i) to comply with the laws of such jurisdiction and (ii) to avoid adverse tax consequences relating to an Award. The authority granted under the previous sentence shall include the discretion for the Committee to adopt, on
behalf of the Corporation, one or
W
EB
MD 2005
L
ONG
-T
ERM
I
NCENTIVE
P
LAN
A
S
A
MENDED
AND
R
ESTATED
AS
OF
F
EBRUARY
13, 2017
A
NNEX
K
P
AGE
17
more sub-plans applicable to separate classes of Participants who are subject to the laws of jurisdictions outside of the United States.
17.13
Securities Law Restrictions.
An Award may not be exercised or settled and no shares of Stock may
be issued in connection with an Award unless the issuance of such shares of Stock has been registered under the 1933 Act and qualified under applicable state blue sky laws and any applicable foreign securities laws, or the
Corporation has determined that an exemption from registration and from qualification under such state blue sky laws is available. The Corporation shall be under no obligation to register under the 1933 Act, or any state securities
act, any of the shares of Stock issued in connection with the Plan. The shares issued in connection with the Plan may in certain circumstances be exempt from registration under the 1933 Act, and the Corporation may restrict the transfer of such
shares in such manner as it deems advisable to ensure the availability of any such exemption. The Committee may require each Participant purchasing or acquiring shares of Stock pursuant to an Award under the Plan to represent to and agree with the
Corporation in writing that such Participant is acquiring the shares of Stock for investment purposes and not with a view to the distribution thereof. All certificates for shares of Stock delivered under the Plan shall be subject to such
stock-transfer orders and other restrictions as the Committee may deem advisable under the rules, regulations and other requirements of the Securities and Exchange Commission, any exchange upon which the Stock is then listed, and any applicable
securities law, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.
17.14
Satisfaction of Obligations.
Subject to applicable law, the Corporation may apply any cash,
shares of Stock, securities or other consideration received upon exercise or settlement of an Award to any obligations a Participant owes to the Corporation and its Parents, Subsidiaries or Affiliates in connection with the Plan or otherwise,
including, without limitation, any tax obligations or obligations under a currency facility established in connection with the Plan.
17.15
Section 409A of the Code.
Notwithstanding any contrary provisions of the Plan or an Award
Agreement, if any provision of the Plan or an Award Agreement contravenes the requirements of any regulations or Treasury guidance promulgated under Section 409A of the Code or could cause an Award to be subject to additional taxes, accelerated
taxation, interest and/or penalties under Section 409A of the Code, such provision of the Plan or any Award Agreement shall be modified to maintain, to the maximum extent practicable, the original intent of the applicable provision without
violating the provisions of Section 409A of the Code. Moreover, any discretionary authority that the Board or the Committee may have pursuant to the Plan shall not be applicable to an Award that is subject to Section 409A of the Code to
the extent such discretionary authority will contravene Section 409A of the Code or the Treasury guidance promulgated thereunder.
17.16
Governing Law.
To the extent not governed by federal law, the Plan and all Award Agreements
shall be construed in accordance with and governed by the laws of the State of Delaware.
17.17
Additional
Provisions.
Each Award Agreement may contain such other terms and conditions as the Board or the Committee may determine,
provided
that such other terms and conditions are not inconsistent with the provisions of
this Plan. In the event of any conflict or inconsistency between the Plan and an Award Agreement, the Plan shall govern and the Award Agreement shall be interpreted to minimize or eliminate such conflict or inconsistency. Nothing contained in the
Plan shall be construed: (a) to prevent the Company or any Subsidiary from taking any corporate action, whether or not it would have an adverse effect on any Awards made under the Plan; or (b) to provide any rights, not otherwise provided under
applicable law, to any participant, beneficiary or other person with respect to the taking of any corporate action by the Company or any Subsidiary.
W
EB
MD 2005 L
ONG
-T
ERM
I
NCENTIVE
P
LAN
A
S
A
MENDED
AND
R
ESTATED
AS
OF
F
EBRUARY
13, 2017
A
NNEX
K
P
AGE
18
WEBMD HEALTH CORP.
ANNUAL MEETING OF STOCKHOLDERS
June 1, 2017